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Abstract 
The size of the upper airway is critical during oral inhalation of drugs. Mandibular advancement 
through oral appliances has been introduced in the treatment of subjects with obstructive sleep 
apnoea (OSA) as a method to increase the size of the upper airway but has not been extended to 
subjects using inhalers.  
The main objectives of the 4 studies were to correlate upper airway cross-sectional areas (CSA) 
and volumes measured with acoustic pharyngometry with oropharyngeal and lung depositions, to 
evaluate the impact of mandibular advancement and incisor opening achieved with stepped 
mouthpieces on the upper airways, and to investigate in vitro the impact of an open velum on the 
acoustic pharyngogram. 
Statistically significant correlations between oropharyngeal and lung depositions, and upper 
airway CSA at glottis and volume between epiglottis and glottis, were shown in 9 healthy subjects.  
Four healthy subjects were included in a proof-of-concept study of a new stepped mouthpiece 
(without tongue depressor) with which different mandibular advancements (-3 to +6 mm) and 
incisal openings (10, 15 and 20 mm) were achieved. The upper airway CSA and volume was 
shown to increase in all 4 subjects. 
Sixty subjects (30 healthy and 30 with OSA) were included in a study of the impact of mandibular 
advancement (0 to 5 mm) and incisal opening (18 mm) achieved with a stepped mouthpiece (with 
tongue depressor) on the size of the upper airways. Statistically significant effects were shown 
following both incisal opening and mandibular advancement, and the effects were larger for the 
healthy subjects. In the in vitro study the effect of an open velum on the acoustic pharyngogram 
was investigated through a cast of a human upper airway. The results showed that during acoustic 
pharyngometry an open velum would pass acoustic impulses into the nasal airways which would 
create an overestimation of the volume of the upper airways from the pharynx to the glottis.  
The thesis highlights the possibility to increase the size of the upper airways during inhalation of 
drugs. 
 
Keys words: acoustic pharyngometry, mandibular advancement, incisal opening, stepped 
mouthpiece, tongue depressor, and nebuliser. 
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Chapter 1 Introduction 
1.1 Background 
There are several advantages of the delivery of locally acting drugs through the pulmonary route 
for treatment of diseases of the lungs. The inhaled drugs are targeted directly to the airway 
surfaces, avoid inactivation through hepatic first pass metabolism, relatively small amounts are 
required, and onset of action is relatively rapid in comparison with swallowed drug (Newman et 
al., 2009). The mouth, the pharynx and the larynx are, however, potential sites of aerosol 
deposition in the upper airways during oral inhalation.  
The right angle bend of the lumen at the back of the mouth, the variable position of the tongue 
during inhalation, the variable size and shape of the lumen in the pharynx and larynx, a number of 
diseases of the upper airways, and the breathing pattern could – in addition to aerosol 
characteristics - promote upper airway deposition and restrict lung deposition (Kumazawa et al., 
1997; Borgström et al., 2006; Newman et al., 2009; Nikander et al., 2010c;  Scheuch et al., 2010; 
Diaz et al., 2012; van Velzen et al., 2015). The part of the pharynx (oropharynx) located behind 
the tongue, and mainly between the oropharyngeal junction (OPJ) and the epiglottis (EG), seems 
to present the narrowest part of the upper airways (Fajdiga, 2005). Mandibular advancement has 
in the past been practiced as a means to open up the upper airway behind the tongue during 
inhalation (Tissier, 1903). 
Tissier discusses the opposition of the EG through its “oblique position over the entrance to the 
larynx” to the penetration of atomised liquids into the larynx. He also describes an interesting 
“general method” of practicing inhalation of atomised liquid, gas or vapour, as follows: 
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“In the more general method, patients are first instructed to project the tongue as far as possible. 
It is then grasped with a cloth held in the fingers, preferably between the thumb and forefinger of 
the patient’s right hand, and pulled downward as far as possible. Lazarus recommends that the 
organ be rolled, as it were, around the lower lip. In this way is prevented the arching of the base 
of the tongue that often causes a narrowing of the ostium of the pharynx, while the lingual traction 
causes the epiglottis to be lifted up and well forward. The patient throws his head slightly forward, 
at the same time tilting it a trifle backward and upward, bringing his lower jaw as far as possible. 
These manoeuvres have for their object the greatest possible widening out of the angle between 
the axes of the buccal and laryngeal cavities. In this position the medication may be made to reach 
the vestibule of the larynx, even in the most difficult cases.” 
 
Mandibular advancement was already used during the late 1800s in cases of mandibular retrusion 
and is still used as a means to prevent collapse up the upper airway during sleep in subjects with 
obstructive sleep apnoea (OSA) (Bailey, 2005; Fleetham et al., 2010; Wee, 2012; Friedman et al., 
2014). There are presently a number of different oral appliances available for the treatment of 
OSA, which are used to increase the size - and prevent a collapse - of the upper airway by either 
advancing the mandible or the tongue (Fleetham et al., 2010). There is a wide variety among the 
oral appliances in terms of design, material, location of coupling mechanism, and amount of 
possible horizontal (advancement or protrusion) and vertical jaw movement (Hoekema et al., 2004; 
Viviano, 2004; Bailey, 2005; Chan et al., 2007; Hoffstein, 2007; Fleetham et al., 2010; Wee, 2012; 
Friedman et al., 2014; Sutherland et al., 2014). The terminology regarding the oral appliances is 
somewhat variable and some of the labels in English include: oral appliances, functional 
appliances, mandibular advancement devices, mandibular advancement splints, mandibular 
repositioning devices, anterior mandibular positioners, oral airway dilators and airway orthotic 
devices (Viviano, 2002a; Bailey, 2005; Horchover, 2007; Fleetham et al., 2010; Friedman et al., 
2014). Two of the main proposed mechanisms of action during sleep for these devices are 
increasing the size of the upper airway (Ryan et al., 1999), and decreasing the collapsibility of the 
upper airway (Ng et al., 2003; Hoekema et al., 2004; Viviano, 2004; Bailey, 2005; Hoffstein, 2007; 
Fleetham et al., 2010).  
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A number of airway-imaging studies have been performed in both healthy subjects and in patients 
with OSA using oral appliances. The imaging techniques used included cephalometry, CT, MRI 
and videoendoscopy (Fleetham et al., 2010). Mandibular and tongue advancement have been 
shown to increase the size of the upper airway and alter the shape of the upper airways – 
particularly in the velopharynx in healthy subjects and in subjects with OSA (Ferguson et al., 
1997a). The use of oral appliances have in other studies been shown to increase the anteroposterior 
diameter of the upper airway (Ng et al., 2003), to increase the total volume of the upper airway 
and CSAs of the retropalatal and retroglossal regions (Sam et al., 2006; Kyung et al., 2005) and to 
increase the lateral dimensions of the velopharynx (Zhao et al., 2008; Chan et al., 2010a). The 
Tissier described method and the results achieved with oral appliances in subjects with OSA 
indicate that mandibular advancement might expand the upper airway during inhalation. 
During the analysis of the study presented in Chapter 3 the question regarding the size of the upper 
airways and the impact of the anatomy of the upper airways on lung deposition was discussed. The 
possibility to enlarge the upper airway through mandibular advancement was suggested, and a new 
stepped mouthpiece was developed as a tool in order to achieve mandibular advancement. The 
newly developed stepped mouthpieces without (patent US 2011/0240015 A1) and with a tongue 
depressor (patent US 2012/0240922 A1) are shown in Figure 1.1 (without a tongue depressor) and 
in Figure 1.2 (with tongue depressor). 
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Figure 1.1: Schematic presentation of the new stepped mouthpiece without tongue depressor and 
the mandibular protrusion achieved with it. The numbers in the schematic presentation refer to the 
“Method and apparatus comprising stepped mouthpiece for aerosol drug delivery” section in the 
patent. From patent US 2011/0240015 A1. 
 
The stepped mouthpiece without a tongue depressor was tested in the proof-of-concept study 
presented in Chapter 4. It was designed in several configurations with front ends with 10 mm, 15 
mm and 20 mm orifices (vertical diameters). These front orifices were also designed with a single 
protrusion on the upper side for the upper incisors and 4 protrusions on the lower side at different 
distances (-3 mm, ±0 mm, +3 mm and +6 mm) in relation to the protrusion on the upper side for 
horizontal movement of the mandible (Figure 1.1). The horizontal offsets were -3 mm (lower jaw 
moved back from an incisal edge-to-edge position), ±0 (incisal edge-to-edge position), + 3 mm 
and +6 mm (mandible moved forward from an incisal edge-to-edge position). The stepped 
mouthpiece was 40 mm long.  
The stepped mouthpiece with a tongue depressor was developed based on the experience from the 
proof-of-concept study presented in Chapter 4. The new stepped mouthpiece was 81 mm long fully 
extended including tongue depressor, and the external horizontal and vertical diameters were 34 
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mm and 24 mm, respectively. The tongue depressor and the related part of the mouthpiece to be 
held in the mouth were 33 mm long, and the external horizontal and vertical diameters 34 mm and 
18 mm, respectively.  
 
 
Figure 1.2: Schematic presentation of the stepped mouthpiece with tongue depressor (left end). 
The numbers in the schematic presentation refer to the “Apparatus and method comprising 
adjustable stepped mouthpiece for aerosol drug delivery” section in the patent. From patent US 
2012/0240922 A1. 
 
The 18 mm vertical external diameter was chosen partly based on the results of the previous proof-
of-concept study in which the largest mouthpiece had an external vertical mouthpiece diameter of 
20 mm, and partly as this is a common vertical size of a jet nebuliser mouthpiece. The length of 
the stepped mouthpiece from the round end to the position for the upper incisors was 52 mm 
(Figure 1.2). 
1.2 Aim and objectives 
1.2.1 Aim 
The aim of this research work was to: 
- Investigate through acoustic pharyngometry the effects of mandibular advancement and 
incisal opening, achieved with a novel stepped mouthpiece, on the upper airways during 
inhalation. 
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- Investigate the open velum (soft palate) effect on the pharyngogram in an in vitro study 
design using a cast of the human upper airways and a surrogate open velum. 
1.2.2 Objectives 
1. To develop and evaluate a new stepped mouthpiece without and with tongue depressor using 
acoustic pharyngometry. 
2. To evaluate the impact of the mandibular advancement achieved with the stepped mouthpiece 
on the upper airways in healthy subjects, and in subjects with OSA, using acoustic 
pharyngometry. 
3. To evaluate the impact of the incisal opening achieved with the stepped mouthpiece on the 
upper airways in healthy subjects, and in subjects with OSA, using acoustic pharyngometry. 
4. To develop an automatic procedure for analysis of large amounts of pharyngograms in order 
to identify deviating pharyngograms within each measurement consisting of 4 pharyngograms. 
A measure of “Goodness of Fit” (GOF) was required for the process, and each of the 4 
pharyngograms was compared to the median pharyngogram and those deviating too much were 
removed. GOF was calculated as the square root of the average squared vertical distance 
between the median curve and the curve under study. The region over which the GOF-
calculation was performed was limited to the region from the start of the pharyngogram to the 
glottis (GL).  
5. To develop a method for the analysis of pharyngograms in terms of cross-sectional areas 
(CSAs) at the landmarks (OPJ, EG, and GL), and volume (area under the curve, AUC) between 
the incisors and the OPJ, between the OPJ and the EG, and between the EG and the GL. 
6. To evaluate through an in vitro study design the impact of leakage through an open velum (soft 
palate) on the pharyngogram. 
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1.3 Thesis structure 
The work in this thesis is as follows: 
Chapter 1: a general introduction with a brief summary of work. 
Chapter 2: an overview of literature related to the areas of study. 
Chapter 3: describes the measurement of the upper airways of 9 healthy subjects by means of 
acoustic reflection (AR) using an acoustic pharyngometer (Kamal, 2001; Kamal, 2002; Jung et al., 
2004; Kamal, 2004a; Kamal, 2004b; Monahan et al., 2005; Gelardi et al., 2007; Shiota et al., 2007; 
Kumar et al., 2015). The subjects had been included in a previous lung deposition study (Nikander 
et al., 2010c). The measurements were performed with the subjects seated in the same position as 
when they were inhaling through an I-neb nebuliser in the previous lung deposition study. The 
subjects were also instructed to inhale with the same inspiratory flow as in the previous study. 
Chapter 4: describes a proof-of-concept study in 4 healthy subjects. The study was designed to 
evaluate the impact of mandibular advancement and incisal opening, achieved with a newly 
invented stepped mouthpiece, on the size of the upper airways of the subjects. The measurements 
of the upper airways were performed by means of AR using an acoustic pharyngometer. The upper 
airway included the oral cavity, the OPJ, the oropharynx, the EG, the hypopharynx, and the GL. 
These were analysed in terms of CSAs and the AUCs.  
Chapter 5: describes a clinical study in 60 subjects without (30 subjects) and with OSA (30 
subjects), in which the primary objective was to measure through acoustic pharyngometry the 
impact of different horizontal mandibular advancements - achieved with a new stepped 
mouthpiece with a tongue depressor - on the size of the upper airways. The upper airways included 
the area from the incisors to the GL. The measurements were performed while the subjects were 
seated in a chair and inhaled room air during tidal breathing through the stepped mouthpiece. The 
secondary objectives included assessment of the most protrusive and most retrusive positions of 
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the mandible, measurement of the upper airways through acoustic pharyngometry during slow and 
deep breathing while the subjects used a stepped mouthpiece, and assessment of the most 
comfortable mandibular advancement position for the subjects when using the stepped mouthpiece 
during tidal breathing and during slow and deep breathing, 
Chapter 6: describes an in vitro study, in which the primary objective was to measure through 
acoustic pharyngometry the impact of leakage through an open velum (soft palate) on the 
pharyngogram. The in vitro study was designed to investigate the possible artefact found in 
Chapter 3, which was related to the use of nose clips during the acoustic pharyngometer 
measurements. Based on published data on the open velum effect, this was a plausible reason for 
the observed increases in the CSAs and AUCs (Molfino et al., 1990; Marshall et al., 1993). An in 
vitro study design was chosen as it would allow controlled acoustic pharyngometer measurements 
to be made through a cast of the human upper airways with a surrogate for a closed or an open 
velum (Cheng et al., 1990).  
Chapter 7: describes a general conclusion from these studies and suggestions for future work. 
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Chapter 2 Literature review 
2.1 The human respiratory system 
Ventilation of the lungs is the major function of the respiratory system as the normal cellular 
metabolism requires a continuous supply of oxygen and disposal of carbon dioxide. The 
respiratory system can be divided into two main parts: the upper respiratory (nasal airways, 
pharynx and larynx) and the lower respiratory tracts (trachea, primary bronchi and lungs) (Figure 
2.1). From a functional perspective the lower respiratory tract can be divided into three distinct 
zones: the conducting, the transitional and the respiratory zones (Forrest, 1993). The conducting 
zone is involved in the movement of air and includes bronchi with cartilage and bronchioles 
without cartilage, but no alveoli. The transitional zone is a transition between the conducting and 
the respiratory parts of the airway – from bronchioles to the gas exchanging tissue - and includes 
occasional alveoli.  
 
Figure 2.1: A sagittal view of the respiratory system with upper and lower respiratory tracts 
(Respiratory System Upper Tracts at www.yahoo.com).  
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Gas exchange occurs in the respiratory zone (Forrest, 1993). In adults the CSA of the trachea is 2-
3 cm2, the diameter of the alveoli ~200 µm and the area of the gas exchange 40-100 m2 (Merkus, 
1993). Inspiration is based on contractions of the major inspiratory muscles (the diaphragm and 
the intercostal muscles) which expand the chest and inflate the lungs, whereas expiration occurs 
passively through an elastic recoil of the lungs and the chest wall (Berne et al., 1988). 
2.2 The upper airways 
Multiple terms have been used for the description of the upper airways between the nasal airways 
and the larynx which tend to cause confusion. For this thesis the terminology presented by Fogel 
et al (2004) and Tung (2007), and highlighted in Figure 2.2 (Fogel et al., 2004), will be used.  
 
Figure 2.2: A sagittal view of the upper respiratory tract including the airway from the nose to the 
trachea. The pharynx has been divided into the nasopharynx, the velopharynx, the oropharynx and 
the hypopharynx (Fogel et al., 2004). An almost identical figure has been published by Ayappa et 
al (2003), with reference to Kuna et al in “Anatomy and Physiology of Upper Airway Obstruction” 
(MH Kryger, T Roth and WC Dement (Eds). Principles and Practice of Sleep Medicine, 3rd Edn. 
W.B. Saunders Company). 
 
Fogel et al (2004) and Tung (2007) divided the upper airway between the nasal airways and the 
larynx into the nasopharynx, the velopharynx, the oropharynx, and the hypopharynx (Figure 2.2; 
Fogel et al., 2004; Tung, 2007). Tung (2007) defined the upper airway as the passage for gas and 
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food with mouth and nose as starting points, and EG and vocal cords as end points. The anatomy 
could be described with an “X” shape as there are two distinct entry points (mouth and nose), a 
common middle part (pharynx) and two exit points (larynx and esophagus). The functions of the 
upper airway covers breathing, mastication, communication, swallowing, taste and smell (Tung, 
2007).  
The swallowing reflex has been divided into an oral or voluntary phase, a pharyngeal phase and 
an esophageal phase. During the oral phase a bolus of food is moved by the tongue upward and 
backward in the mouth, forcing the bolus into the pharynx stimulating tactile receptors that initiate 
the swallowing reflex. The pharyngeal phase consists of a series of events: the nasopharynx is 
closed by the soft palate which is moved upward, the trachea is closed by the EG which covers the 
larynx, and the vocal cords are pulled together, the upper esophageal sphincter is relaxed to receive 
the bolus of food. A peristaltic wave is finally activated with contraction of the pharyngeal 
constrictor muscles which forces the bolus through the esophageal sphincter (Berne et al., 1988). 
2.2.1 The nose 
In the nose the airway is both double and convoluted, whereas there is a single airway from the 
nasopharynx to the trachea. The nasal cavity is located directly above the oral cavity and the hard 
palate separates the two cavities. Data on the CSA of the nasal valve indicate that it would be ~0.4 
cm2 and the CSA of the nasal cavity ~1.5 cm2 (Sahin-Yilmaz et al., 2011).  The inspired air is 
warmed, moistened and filtered during the passage through the nose and the relative humidity is 
close to 100% in the nasopharynx. The heat and moisture is recovered during expiration. The 
velocity of the inspired air is high past the middle turbinate (18 m/s) and slows down through the 
main part of the nasal cavity (2-3 m/s). Inspiratory airflows up to 20-30 L/min can be nasal, 
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whereas higher flows during for example exercise are oral (Chang et al., 1993; Tung, 2007, Sahin-
Yilmaz et al., 2011) 
2.2.2 The nasopharynx 
The nasopharynx is located below the nasal cavity and at this junction the hard palate changes to 
form the soft palate and the upper airway lumen makes a 90° turn downwards behind the posterior 
part of the soft palate. The soft palate is a muscular flap that hangs almost vertically and terminates 
in the uvula. The length of the soft palate in 8 healthy subjects was shown to be 30.5 mm (range 
28-34 mm), whereas the area of the soft palate was 3.2 cm2 (range 3.0-3.6 cm2) (Ciscar et al., 
2001). The nasopharynx is “closed” by the soft palate when it is moved upward and thus changes 
position. The soft palate directs the flow or air to pass either through the nose or the mouth (Tung, 
2007). 
2.2.3 The oral cavity 
In the oral cavity the hard and soft palates form the “roof”, the lingual mucosa the “floor” and the 
buccal mucosa the “walls”. The anterior palatine tonsils mark the junction between the oral cavity 
and the oropharynx, the OPJ. The pharynx is a 12-15 cm long muscular tube stretching vertically 
downward from the level of the soft palate to the cricoid cartilage. In healthy subjects the 
pharyngeal tube is oval in cross section with the long dimension oriented from medial to lateral 
(Chang et al., 1993; Tung, 2007, Sahin-Yilmaz et al., 2011).  
2.2.4 The velopharynx and the oropharynx 
The terms retropalatal region of the oropharynx and velopharynx both refer to the same area behind 
the soft palate, below the nasopharynx and posterior to the oral cavity. The velopharynx forms the 
part of the “X” where the oral and nasal cavities meet (Tung, 2007). The retroglossal region of the 
oropharynx extends from the tip of the soft palate superiorly to the base of the EG inferiorly. The 
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CSA of the oropharynx is generally larger than the CSA of the velopharynx. Any reduction of 
CSA in the velopharynx and the oropharynx seems to mainly occur through a thickening of the 
lateral pharyngeal walls, and the shape of the lumen seems to change from an oval with the long 
axis oriented laterally to a more circular shape with the long axis oriented anteroposteriorly (Tung, 
2007). 
2.2.5 The hypopharynx 
The term hypopharynx is often used for the lower boundary of the retroglossal region of the 
oropharynx, and the area is bounded anteriorly by the base of the tongue and the EG, and 
posteriorly/laterally by the inferior pharyngeal constrictor muscle. Below the EG the hypopharynx 
runs parallel with the esophagus, and the larynx splits off anteriorly with the vocal cords below 
the EG (Tung, 2007).  
2.2.6 The larynx and the glottis (GL) 
The upper airway branches into the trachea (anteriorly) and the esophagus (posteriorly) below the 
EG. The larynx covers the area bounded superiorly by the EG, inferiorly by the vocal cords, and 
laterally by the aryepiglottic folds (Tung, 2007). The GL is located within the larynx in the space 
between the vocal folds with an elliptical and triangular shape (Brouns et al., 2007; Scheinherr et 
al., 2015, Boiron et al., 2015; Figure 2.3).  
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Figure 2.3: A frontal view of the GL between the vocal folds. (Boiron et al., 2015; from poster 
presented at the ISAM congress 2015).  
 
2.2.7 The shape of the lumen of the upper airways 
The pharyngeal lumen is deformable whereas the nose, the larynx and the trachea have a 
framework of cartilage. The narrowest section of the pharynx is located behind the soft palate at 
the level of the velopharynx (Suratt et al., 1983). There are more than 20 muscles surrounding the 
upper airway which either constrict or dilate the upper airway lumen. The muscles that interact to 
determine the patency of the upper airway can be divided into four groups: muscles regulating the 
position of the soft palate, the tongue, the hyoid apparatus and the posterolateral pharyngeal walls. 
The tonsils, the soft palate, the uvula, the tongue and the lateral pharyngeal walls are all soft tissues 
that form the walls of the upper airway. The mandible and the hyoid bone are the main craniofacial 
bony structures that determine the upper airway size and presumably provide anchoring for 
muscles and soft tissue (Ayappa et al., 2003). The shape of the lumen of the upper airway is quite 
variable from the nasal valve to the trachea (Figure 2.4).  
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Figure 2.4: A sagittal view of the upper airway which highlights the shape and comparative size 
of the airway lumen and the location of the nasal, velopharyngeal, glottal or laryngeal valves 
(Proctor, 1983; Strohl et al., 2012).  
 
The nostrils, the lips, the palate and the larynx are narrow parts of the upper airways that limit the 
lumen calibre and contributes to the overall airflow resistance (Proctor, 1983; Strohl et al., 2012). 
A fall in pressure in the pharynx tends to collapse the pharyngeal airway but can be prevented by 
the contraction of pharyngeal muscles (Suratt et al., 1983). 
2.2.8 Impact of breathing on the size of the upper airways 
Inhalation of an aerosol is the preferred mode of administration of a number of drugs in the 
treatment of different respiratory disorders. The size of the lumen in the upper airways is therefore 
of interest, especially since breathing related motion of soft tissue in the pharynx (the retropalatal 
and retroglossal regions), and related bony structures has been shown to create dimensional 
changes in this part of the upper airways (Figure 2.5; Schwab et al., 1993a; Schwab et al., 1993b; 
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Schwab, 1998).  Schwab highlighted 4 distinct phases during breathing which affected the size of 
the pharynx (Figure 2.5): 
1) At the beginning of inspiration an increase in pharynx from resting position. 
2) During the rest of inspiration the size of the pharynx is relatively constant. 
3) At the beginning of expiration the pharynx is enlarged. 
4) During end of expiration the size of the pharynx returns to the resting position. 
 
Figure 2.5: The figure illustrates changes in the pharynx (the retropalatal and retroglossal regions) 
as a function of tidal volume during breathing in an apnoeic subject. 1 = early inspiration; 2 = 
inspiration; 3 = early expiration; 4 = late expiration (Schwab, 1998). 
 
Schwab et al concluded that most imaging studies of the upper airways have indicated that airway 
narrowing was greatest in the velopharyngeal region and that the changes occurred mainly in the 
lateral dimension (Schwab et al., 1993a; Schwab et al., 1993b; Schwab, 1998). Interestingly, a 
breathing dependent movement of the glottal area has also been shown to occur through studies 
with fibreoptic bronchoscope and (Brancatisano et al., 1983) nasofibroscope (Scheinherr et al., 
2015). In contrast to the results of the Schwab et al studies on pharyngeal movement, Brancatisano 
and colleagues (1983) showed in healthy subjects that both GL width and area increased during 
inspiration, and decreased during expiration. These results have been supported by the late 
Scheinherr et al study (2015). Thus different parts of the upper airways seem to move in opposite 
directions during the breathing cycle.  
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2.2.9 The cross-sectional area (CSA) of the upper airways 
The size of the upper airways has been shown to be larger in men than in women, and to decrease 
with increasing age (Martin et al., 1997). A number of authors have published data on the CSAs 
(centimetre or millimetre square; cm2 or mm2) of the velopharynx, the pharynx, the OPJ, the EG, 
the GL, and the larynx measured with an acoustic pharyngometer (Eccovision; Table 2.1) (in 
alphabetical order: Allen et al., 2014, Busetto et al., 2009; Jung et al., 2004, Kamal., 2001, Kamal., 
2002; Kamal, 2004b; Monahan et al., 2005; Shiota et al., 2007).  
Table 2.1: The size of different parts of the upper airway lumen in adult healthy subjects expressed 
as mean CSA and/or range (maximum to minimum) in cm2. Results from studies using the 
Eccovision ARP have been included. The measurements were performed during (end) expiration 
while the subjects were seated - if supine, this has been highlighted specifically. 
 
1st author, 
year published 
Subjects 
(male)  
CSA (cm2, mean and range) 
Allen et al., 
2014 
80 (no data), 
20/ethnic 
group 
Mouth to larynx: Caucasian = 2.7 cm2 ; Chinese = 2.9 cm2 ; 
Japanese = 2.6 cm2 ; Korean = 2.9 cm2  
Busetto et al., 
2009 
145 (no male) Seated: Pharynx = 2.6 cm2 (0.7-5.8);  OPJ = 1.6 cm2  
(0.3-4.0); GL = 2.2 cm2 (0.5-4.4) 
Supine: Pharynx = 2.2 cm2 (0.7-4.4); OPJ = 1.2 cm2  
(0.5-2.0); GL = 2.0 cm2 (0.5-3.9) 
Jung et al., 
2004 
16 (14) 
 
Seated: Pharynx = 2.5 cm2; OPJ = 1.6 cm2; GL = 1.8 cm2 
Supine: Pharynx = 1.9 cm2; OPJ = 1.3 cm2; GL = 1.4 cm2  
Kamal, 2001 350 (271)  
 
Pharynx: Men = 2.7 - 3.8 cm2; Women = 2.1 - 3.4 cm2 
GL: Men = 0.9 - 1.2 cm2; Women = 0.8 - 1.1 cm2 
Kamal, 2002 40 (29) Pharynx: Men = 3.2 cm2, Women = 2.8 cm2 
Kamal, 2004b 20 (16) Pharynx: Test 1 = 3.2 cm2, Test 2 = 3.2 cm2, Test 3 = 3.2 cm2 
Monahan et al., 
2005 
75 (36) white 
62 (23) black 
Oropharynx: White = 2.7 cm2, (1.9 - 3.8); Black = 2.4 cm2 , (1.7 - 
3.3) 
OPJ: White = 2.4 cm2; Black = 2.0 cm2  
EG : White = 2.2 cm2; Black = 2.6 cm2 
Shiota et al., 
2007 
27 (16) Supine: Velum to GL = 2.7 cm2 (baseline) 
 
 
The CSAs of the upper airways were somewhat larger in men than in women, and also larger when 
measured in a seated position in comparison with in a supine position. When seated the OPJ CSAs 
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ranged from 0.3 to 4.0 cm2, the EG CSAs from 2.2 to 2.6 cm2, the GL CSAs from 0.5 to 4.4 cm2, 
the oropharynx CSAs from 1.7 to 3.8 cm2, and the pharynx CSAs from 0.7 to 5.8 cm2 (Table 2.1). 
Data on the upper airway CSAs are available in studies using other measurement techniques. These 
include MRI, CT, and fibreoptic bronchoscopy/nasofibroscopy.  A number of these studies are 
included in Table 2.2 presenting data of adult healthy subjects while in supine and/or seated 
positions during wakefulness. 
Table 2.2: The size of different parts of the upper airway lumen in adult healthy subjects expressed 
as mean CSA in cm2. Results from studies using MRI, CT and fibreoptic 
bronchoscopy/nasofibroscopy (F/N) techniques are included. 
 
1st author, 
year 
published 
Subjects 
(male), 
technique 
CSA (cm2, mean) 
Ehtezazi et 
al., 2004 
 
10 (6) 
MRI 
supine 
Oropharynx  
pMDI = 1.5 cm2 
spacer = 2.1 cm2 
DPI = 2.8 cm2 
Ciscar et al., 
2001 
8 (2) 
MRI, supine 
Velopharynx  
1.2 cm2, range 1.0 – 1.2 cm2 
Schwab et al., 
1993b 
15 (10) 
CT 
supine 
Nasopharynx: 2.2 cm2 (maximal expiration); 2.0 cm2 (maximal 
inspiration) 
Velopharynx (high): 1.5 cm2 (maximal expiration); 1.4 cm2 (maximal 
inspiration) 
Velopharynx (low): 2.0 cm2 (maximal expiration); 1.9 cm2 (maximal 
inspiration) 
Hypopharynx: 2.6 cm2 (maximal expiration); 2.5 cm2 (maximal 
inspiration) 
Brancatisano 
et al., 1983 
12 (10) 
F/N 
seated 
GL 
Group = 1.3 cm2 (max, inspiration) 
Group = 0.7 cm2 (min, expiration) 
Scheinherr et 
al., 2015 
20 (10) 
F/N 
seated 
GL, slow breathing 
Men = 2.2 cm2 (max, inspiration; range 1.9-3.5) 
Men = 1.8 cm2 (max, expiration) 
Women = 1.9 cm2 (max, inspiration; range 1.7-2.7) 
Women = 1.7 cm2 (max, expiration) 
 
The CSAs of the upper airways were as with acoustic pharyngometer derived data somewhat larger 
in men than in women. The nasopharynx CSAs ranged from ~2.0 to 2.2 cm2, the velopharynx 
CSAs ranged from 1.0 to 2.0 cm2, the oropharynx CSAs from 1.5 to 2.8 cm2, the hypopharynx 
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ranged from ~2.5 to 2.6 cm2 and the GL CSAs ranged from 1.7 to 3.5 cm2 (Table 2.2). Overall, the 
inter-subject variability both with acoustic pharyngometry, MRI and fibreoptic techniques seems 
to be relatively large even in these small populations. 
2.3 Lung volumes and capacities 
Inspiratory and expiratory airflow and lung volumes are of importance as these can be used to 
differentiate and characterize pulmonary disorders (obstructive or restrictive) and to evaluate 
responses to treatment (Jonson et al., 1998). Measurements with an acoustic pharyngometer have 
also been shown to be lung volume dependent (Kamal, 2002). The lung volumes and capacities 
are presented in Figure 2.6. 
 
 
Figure 2.6: Lung volumes and capacities. Available at and accessed October 2015: 
https://www.boundless.com/biology/textbooks/boundless-biology-textbook/the-respiratory-
system-39/gas-exchange-across-respiratory-surfaces-220/lung-volumes-and-capacities-834-
12079/.  
 
The TV consists of a dead space volume and an alveolar volume. The IRV and ERV represent the 
maximal volume of air that can be voluntarily inspired or expired. The FRC represents the volume 
of air in the lungs at the end of a tidal breath. The VC represents the maximal volume of air that 
can be inhaled and exhaled, whereas the TLC represents the total volume (~6-7 L) of the lung 
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(Jonson et al., 1998). The lung volumes are usually presented as either absolute volumes or as 
percentages of predicted values based on ethnicity, gender, age, and height, and at the same height 
the male values tend to be ~25% higher than the female values (Berne et al., 1988; Jonson et al., 
1998).  
2.4 The aerosol and deposition mechanisms 
2.4.1 The aerosol 
An aerosol has been defined as a dispersion or suspension of solid particles or liquid droplets in a 
gaseous medium (Newman et al., 2009). The size of the aerosol particle (or droplet) that could be 
deposited in the human lungs range between 0.5 and 10 µm (Newman et al., 2009). The general 
relationship between particle size and deposition in the upper airway and the lung of healthy 
subjects is shown in Figure 2.7 (Boe et al., 2001).  
 
Figure 2.7: Relationship between aerosol aerodynamic diameter and deposition in the lung based 
on in vitro models: ○ total body, □ total lung, ◊ oropharyngeal, ● central airways, and ■ peripheral 
airways (Boe et al., 2001). 
 
A particle of for example 1 µm, will more likely deposit in the peripheral airways than in the upper 
airway, whereas a particle of for example 10 µm will more likely deposit in the oropharynx. 
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2.4.2 Deposition mechanisms   
Findeisen published in 1935 the first attempt regarding deposition patterns of inhaled particles, 
and identified 4 deposition mechanisms: impaction, sedimentation, Brownian movement, and the 
“rim-effect” (Findeisen, 1935; Zanen, 2003). Presently 3 main mechanisms for the deposition of 
an aerosol in the human upper airway and lungs tend to be acknowledged; inertial impaction, 
gravitational sedimentation, and Brownian diffusion (Figure 2.8; Newman et al., 2009; Carvalho 
et al., 2011).  
 
Figure 2.8: Schematic presentation of the deposition of particles in the upper airway and the lungs 
through inertial impaction, sedimentation and diffusion (Carvalho et al., 2011). 
 
Deposition by inertial impaction occurs in the upper airways - during both inhalation and 
exhalation - at bifurcations between the central airways within the lungs. When the airway or the 
airstream change direction the larger particles or droplets have too much inertia to change direction 
and will therefore impact on the airway wall (Figure 2.8, top section). 
Deposition by gravitational sedimentation occurs in the small conducting airways during slow 
inhalation or during breath holding when aerosol particles or droplets sediment under gravity onto 
an airway surface (Figure 2.8, middle section). Finally, deposition by Brownian movement or 
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diffusion is the most likely deposition mechanism mainly in the alveoli for particles or droplets <1 
µm in diameter, as these particles or droplets have insufficient inertia for impaction and too low 
settling velocity for gravitational sedimentation (Figure 2.8, bottom section). In the Brownian 
diffusion mechanism the particle or droplet is deflected by molecular bombardment, and therefore 
moved towards the airway surface (Newman et al., 2009). 
The “rim-effect” was defined by Findeisen as a situation when a particle by pure chance in close 
vicinity of the airway surface touches it and is deposited (Zanen, 2003). 
2.5 Aerosol delivery to and through the upper airways 
The mouth, the pharynx and the larynx are potential sites of aerosol deposition in the upper airways 
during oral inhalation. The right angle bend of the lumen at the back of the mouth, the variable 
position of the tongue during inhalation, the variable size and shape of the lumen in the pharynx 
and larynx, and the breathing pattern can – in addition to aerosol characteristics - promote upper 
airway deposition and restrict lung deposition (Kumazawa et al., 1997; Newman et al, 2009; 
Nikander et al., 2010c; Scheuch et al., 2010; Diaz et al., 2012; van Velzen et al., 2015). Aerosol 
delivery can be directed to the upper airways (Kumazawa et al., 1997), and obviously through the 
upper airways to the lungs (Newman et al., 2009). 
2.5.1 Aerosol delivery to the upper airways 
Delivery of aerosol to the upper airways may be indicated for treatment of inflammation in the 
upper airways (pharyngitis, laryngitis) and rhinitis, for anesthesia, and for delivery of aerosol for 
systemic effects (Nilsestuen et al., 1994; Kumazawa et al., 1997). A high upper airway (pharynx 
and larynx) deposition was the target in the scintigraphy study by Kumazawa et al (1997). The 
study was designed to compare the upper airway and lung deposition of a nebulised saline solution 
into which 40 mBq of 99mTc-DTPA had been mixed. Six healthy subjects inhaled the aerosol from 
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an ultrasonic nebuliser using 3 different breathing patterns and vocalisation as follows: deep and 
slow inhalation during 12 breaths/min, fast inhalation during 36 breaths/min, and fast inhalation 
during 36 breaths/min with intermittent vocalisation. No information on droplet size was given. 
The results showed that lung deposition decreased and deposition in larynx increased statistically 
significantly when the subjects changed from deep and slow inhalation to fast inhalation with 
vocalisation (Figure 2.9). The authors did not report any data on inspiratory flows, but the results 
indicate that a deep and slow inhalation breathing pattern maximised lung deposition, whereas a 
fast inhalation breathing pattern decreased lung deposition and increased larynx deposition with 
no changes in the pharynx deposition. 
 
Figure 2.9: A comparison of the aerosol deposition in the lungs, the pharynx and the larynx of 6 
healthy subjects following deep and slow inhalation (dark grey), fast inhalation (light grey) and 
fast inhalation with intermittent vocalisation (black) (Kumazawa et al., 1997). 
 
The greatest change from the deep and slow depositions was found with a fast inhalation with 
vocalisation in which lung deposition decreased to ~56% and the larynx deposition increased to 
~36% (Figure 2.9; Figure 2.10; Kumazawa et al., 1997).  
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Figure 2.10: A comparison of 2 scintigraph images showing the deposition of 99mTc-DTPA 
labelled aerosol in 1 subject after deep and slow inhalation (left) and fast inhalation with 
intermittent vocalisation (right) (Kumazawa et al., 1997). 
 
The comparison of the deposition in 1 subject (Figure 2.10) between a deep and slow inhalation 
versus a fast inhalation with vocalisation suggested according to the authors that the closing of the 
vocal cords by intermittent vocalisation led to deposition of the 99mTc-DTPA labeled aerosol on 
both sides of the vocal cords. The authors further suggested that part of the deposition of the 
aerosol on the vocal cords could emanate from the aerosol which was exhaled (Kumazawa et al., 
1997). 
2.5.2 Aerosol delivery through the upper airways to the lungs 
As the upper airway is not a fixed, rigid tube but rather a structure in which the CSA and shape of 
the lumen can change (Brancatisano et al., 1983; Schwab et al., 1993a; Schwab et al., 1993b; 
Schwab et al., 1996; Schwab, 1998; Scheinherr et al., 2015), breathing pattern, inspiratory flow, 
airflow resistance and inhaler mouthpiece design could affect upper airway dimensions and hence 
lung deposition (Newman et al., 2009).  
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2.5.3 Impact of inhaler design and inspiratory manoeuvre on the upper 
airways  
The impact of inhalation from different inhalation devices on the upper airway has been the focus 
of a number of clinical studies in which the upper airways have been measured by MRI during 
forced inspiration or tidal breathing with the subjects in a supine position (Ehtezazi et al., 2004; 
Ehtezazi et al., 2005; Pritchard et al., 2004; McRobbie et al., 2005). In the first study by Ehtezazi 
et al (2004) the authors investigated through MRI the impact of a pMDI, a pMDI with spacer, and 
a high-resistance DPI on the size of the oral cavity, oropharynx, larynx and trachea of 10 healthy 
adult subjects. The subjects inhaled through the pMDI, the pMDI with spacer, and the DPI as 
recommended by the manufacturer and were scanned in a supine position. The CSAs of the oral 
cavity, the oropharynx and the larynx were shown to have considerable variability during 
inhalation, which according to the authors was primarily due to the variability of the tongue 
position during the measurements, and secondarily due to differences in device airflow resistance 
and subject effort (Figure 2.11). Information regarding the diameter of the pMDI, DPI and spacer 
mouthpieces was not included but would have been of interest as at least the size of the oral cavity 
should have been affected by the opening of the mouth (Ehtezazi et al., 2004). 
 
Figure 2.11: Mean CSAs of the upper airways of 10 healthy subjects inhaling through a pMDI, a 
spacer and a high-resistance DPI. The bars present SEM (Ehtezazi et al., 2004). 
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In the second study by Ehtezazi et al (2005) the authors investigated through MRI the impact of 
different inhaler airflow resistances on the upper airways of 7 healthy adult subjects in a supine 
position. The subjects inhaled deeply and forcefully through the test inhaler which had a 22 mm 
mouthpiece diameter and 6 different resistances. An increase in the CSAs of the oral cavity, 
oropharynx and larynx was observed following a decrease in inhaler resistance, whereas the CSAs 
of the upper trachea did not change. The mean volume of the upper airway increased with 
decreasing resistance from 72 cm3 to 101 cm3 (Ehtezazi et al., 2005). 
In the study by Pritchard et al (2004) the authors investigated through an inhalation-gated MRI the 
impact of 4 dummy inhalers with varying mouthpiece diameters (14 mm and 25 mm; small and 
large) and resistances (bores 3.1 mm and 11.3 mm; low and high) on the upper airways of 20 
healthy adult subjects (Figure 2.12).  
 
Figure 2.12: Mean regional volumes for 4 dummy inhalers with different resistances. A_bucc = 
buccal region from back of teeth to soft palate; B_np = naso-pharynx region including nasal 
airways (not part above roof of mouth) to tip of EG; C_lp = laryngeal-pharynx region, tip of EG 
to just above vocal cords; D_lc = laryngeal cavity just above vocal cords to trachea level with 5th 
intervertebral disc. Error bars represent ± 1 SD (Pritchard et al., 2004). 
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The subjects inhaled through the inhalers during tidal breathing without any instructions regarding 
tongue position, and were scanned in a supine position. Only the total airway and buccal volumes 
showed a consistent dependence on the dummy inhaler characteristics (Figure 2.12). Mean airway 
minimum and maximum CSAs and radii were not influenced by the dummy inhalers (Pritchard et 
al., 2004). In the study by McRobbie et al (2005) the authors investigated through an inhalation-
gated MRI the impact of two dummy inhalers (mouthpiece diameter 14 mm) with different 
resistances on the upper airways of five healthy adult subjects. The subjects inhaled through the 
dummy inhalers with a forced inspiratory manoeuvre and were scanned in a supine position. The 
authors did not report the CSA values but compared upper airway volumes (Figure 2.13) to data 
from a previous study, in which the subjects inhaled through the 2 dummy devices with tidal 
breathing (Pritchard et al., 2004).   
 
Figure 2.13: Mean regional volumes for combinations of devices and breathing strategies. A_bucc 
= buccal region from back of teeth to soft palate; B_np = naso-pharynx region including nasal 
airways to the tip of EG; C_lp = laryngeal-pharynx region, tip of EG to just above vocal cords; 
D_lc = laryngeal cavity just above vocal cords to trachea level with 5th intervertebral disc. FM = 
forced maneuver and TB = tidal breathing. Error bars represent ± 1 SD (McRobbie et al., 2005). 
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The mean upper airway volume was shown to be larger (60 cm3) when the subjects inhaled with a 
forced manoeuvre through the low-resistance dummy inhaler in comparison with tidal inhalation 
(38 cm3) through the same device (Figure 2.13). There were no significant changes in airway 
volume between the two breathing modes when using the high-resistance dummy inhaler 
(McRobbie et al., 2005). 
2.5.4 Impact of mouthpiece design and inspiratory manoeuvre on lung 
deposition 
In the study by Boyd et al (2004) the impact of mouthpiece cross-sectional shape, volume, and 
taper on oropharyngeal and lung deposition of inhaled insulin was tested using a prototype AERx 
inhaler (Aradigm Corporation, Hayward, CA, USA). The 3 clinically tested mouthpieces were 
designed either as a cylindrical mouthpiece or as an elliptical mouthpiece, both with constant CSAs 
of 7.9 cm2 and 7.5 cm2, or as a tapered elliptical mouthpiece with an exit CSA equal (3.7 cm2) to 
one half the entrance CSA (7.5 cm2). Fifteen healthy subjects participated in the gamma 
scintigraphy study in which each inhalation of the radiolabelled aerosol was followed by a 5-s 
breath-hold. The MMAD ranged from 2.2 to 2.3 µm. There were no statistically significant 
differences in oropharyngeal or lung depositions between males and females, and the cross-
sectional shapes of the mouthpieces had no significant effect on the oropharyngeal or lung 
depositions. The lack of effect of the cross-sectional shapes of the mouthpieces might have been 
related to the use of particles too small to be affected by the differences in mouthpiece designs.  
Svartengren et al (1996) investigated whether the mouthpiece length, ~4 cm versus ~6.4 cm, would 
have an impact on oropharyngeal and lung depositions in 9 subjects diagnosed with obstructive 
airway diseases. The shorter mouthpiece was a standard mouthpiece, whereas the longer 
mouthpiece was designed to bypass part of the oral cavity and thereby reduce oropharyngeal 
deposition and was cut off at the level of the hard palate for each subject. The subjects inhaled at 
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0.5 L/s an aerosol consisting of monodisperse radiolabelled Teflon particles with a mean 
aerodynamic diameter of 3.5 µm. There were, however, no statistically significant differences in 
oropharyngeal or lung depositions between the mouthpieces.  
2.5.5 Impact of mouthpiece design on the upper airway CSA 
Van Holsbeke et al (2014b) have recently presented the results of a study in which the impact of 
mouthpiece design on the upper airway CSA was investigated. An ultrafast spoiled gradient echo 
sequence MRI was used in 12 healthy adult male subjects who were supine during the scans. The 
influence of mouthpiece height (12-27 mm), width (19-32.1 mm), protrusion (4-40 mm into the 
mouth), orifice size (3-7 mm) and resistance to airflow were investigated. The upper airways were 
divided into the oral cavity (zone 1), the oropharynx (zone 2), and the hypopharynx (zone 3). The 
results showed that mouthpiece protrusion and height had the most positive effect on CSA, 
whereas the impact of width and orifice size was minimal. The changes in CSA were mainly found 
in the oral cavity, whereas the changes in the oropharynx were small and inverse. The mouthpiece 
design parameters did not affect the hypopharynx (Figure 2.14 and Figure 2.15). The authors 
concluded that the influence of the mouthpiece protrusion on the CSAs of the oral cavity and the 
oropharynx was probably a consequence of the interaction between the mouthpiece and the tongue 
(Van Holsbeke et al., 2014b). 
 
Figure 2.14: Interaction between mouthpiece protrusion and tongue position. In the left graph the 
mouthpiece protrusion is small, and large in the right graph (Van Holsbeke et al., 2014b; from 
poster at the European Respiratory Society congress 2014). 
 64 
  
 
 
Figure 2.15: Influence of mouthpiece protrusion on the CSAs of the oral cavity, the oropharynx 
and the hypopharynx. The 3 sections represent the oral cavity (left, zone 1), the oropharynx 
(middle, zone 2), and the hypopharynx (right, zone 3) (Van Holsbeke et al., 2014b; from poster at 
the European Respiratory Society congress 2014). 
 
2.6 Nebulisers 
2.6.1 Atomisers and jet nebulisers 
The evolution of the modern jet nebuliser, which was developed for aerosolisation of liquids, can 
be traced through available published sources to the mid-nineteenth century and the evolution of 
the atomisers. The early jet nebulisers were in essence atomisers and the terms “nebuliser” and 
“atomiser” seem to have been used synonymously during the nineteenth century. In the Oxford 
English Dictionary the term “nebulizer” was included in 1872, and both terms have the same 
definition and are attributed to late nineteenth century. The early atomisers – for example perfume 
atomisers - lacked a baffle system which would have created an aerosol with small droplets and 
therefore a respirable aerosol. May (1973) defined a nebuliser as a “baffled spray cloud-producing 
device”. 
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2.6.2 Early jet nebulisers  
Several physicians published descriptions of early jet nebulisers designed with baffles and pumps 
to create compressed air (Waldenburg, 1864; Moeller, 1882; Tissier, 1903). In these descriptions 
the jet of liquid was directed against a baffle to create a respirable aerosol. Early information on 
droplet size was provided by Abramson (1946) who described the DeVilbiss No. 40 jet nebuliser 
(The DeVilbiss Company, PA, USA) as a nebuliser that baffled out the large droplets leaving a 
droplet spectrum of 0.3-2 µm. Abramson did not describe the technique for measuring the droplet 
size but defined “aerosol”, “atomisation” and “nebulisation” and argued that “nebulization should 
be restricted to the special type of atomization in which the large particles are removed by the 
introduction of suitable baffle into the construction of the atomizer”. Harsh (1948) compared 15 
different jet nebulisers in terms of output per squeeze with the rubber bulb, the capacity of the 
bulb, droplet size and nebulisation time. The amount of solution delivered by one bulb 
compression was highly variable (range 0.4-13.0 mg) as was nebulisation time for the delivery of 
1 mL (range 31-450 sec). An ocular micrometre in a microscope was used to determine the droplet 
size, and the median size ranged from 8 to 29 µm, whereas the largest droplets ranged from 40 to 
308 µm.  
2.6.3 Ultrasonic nebulisers 
The introduction of ultrasonic nebulisers in the 1960ies created a new class of nebulisers with a 
higher output rate in comparison with jet nebulisers (Abramson, 1968). An early model of the 
DeVilbiss Ultrasonic Nebulizer nebulised 4-10 mL of solution per minute and created an aerosol 
with a median diameter of 7.7-9.6 µm (Goddard et al., 1968). Apart from a high output rate, the 
advantages of the ultrasonic nebulisers included independence of a compressed air flow through 
the nebuliser chamber, and the control of droplet size through adjustment of the ultrasonic 
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frequency (Goddard et al., 1968). A major drawback with modern ultrasonic nebulisers is the poor 
performance when nebulising for example suspensions with micronised particles (Nikander et al., 
1999b) and viscous solutions (Newman et al., 2009). 
2.6.4 Vibrating mesh nebulisers 
The introduction of vibrating mesh nebulisers built on the experience with the ultrasonic 
nebulisers, and piezoelectric crystals are used to create the vibrations of the meshes. In vibrating 
mesh nebulisers the mesh contains hundreds or thousands of nozzles depending on technology and 
manufacturer (Newman et al., 2009). A number of vibrating mesh nebulisers have been introduced; 
the AeroNeb (Aerogen, CA, USA), the eFlow nebulisers (PARI, Germany), the I-neb Adaptive 
Aerosol Delivery (AAD) System (Philips Respironics, UK), and the MicroAir (Omron, Japan) 
nebuliser. In the eFlow nebuliser a stainless steel mesh is actuated by a battery powered annular 
piezoelectric element to vibrate at a frequency of ~100 kHz (Knoch et al., 2005). In the AeroNeb 
nebuliser a domed aperture plate is moved up and down by a battery powered ceramic piezoelectric 
element (Dhand, 2002). In the I-neb AAD System and the MicroAir nebulisers an ultrasonic horn 
transducer in the nebuliser cup is vibrated forcing liquid through a static mesh (Dhand, 2002). The 
MicroAir mesh is made of metal alloy with ~6000 holes with a diameter of 3 µm, and the aerosol 
droplets have a mean droplet diameter slightly larger than the diameter of the hole (Newman et al., 
2009). 
2.6.5 The Adaptive Aerosol Delivery (AAD) System 
The Adaptive Aerosol Delivery (AAD) technology was developed to minimise wastage of drug 
during the patient’s exhalation during jet nebulisation (Nikander, 1997; Denyer et al., 2004). The 
first nebuliser based on the AAD technology (HaloLite AAD System; Denyer, 1997) was based 
on jet nebuliser/compressor technology and was a breath activated, dosimetric jet nebuliser which 
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was co-developed by Medic-Aid Ltd. UK and Astra, Lund, Sweden, and made commercially 
available in 1997 (Denyer et al., 2010b). In the system a flow sensor monitored the subject’s 
breathing pattern, and after an analysis by the AAD software, aerosol was pulsed from the 
beginning of the inspiration during 50% of the inspiration minimising waste of aerosol during 
expiration. The analysis of the breathing pattern continued during the whole nebulisation and 
adapted the pulse of aerosol continuously to the subject’s breathing pattern. The background to the 
development of the HaloLite AAD System was partly in vitro and clinical studies performed by 
Astra during the development of nebulised budesonide. 
The advantage of a breath-synchronised, dosimetric jet nebuliser with lack of wastage of drug 
during exhalation had in the early 1990ies been highlighted in an in vitro study of the differences 
in nebulisation of budesonide between breath-activated, breath-enhanced and conventional jet 
nebulisers (Nikander, 1994; O’Callaghan, 1997). Filter studies with nebulised budesonide in which 
children with asthma (age range 0.5-15.7 years) were inhaling through filters attached to the 
nebuliser inhalation port, showed that the inhaled mass (amount of drug on filter) could be 
increased with a breath-activated jet nebuliser and the waste of aerosol during exhalation reduced 
(Nikander, 1994; Nikander et al., 1999a; Nikander et al., 2000a). In a follow-up filter study in 
asthmatic children (2.5-5.8 years), adolescents and adults (13-52 years), continuous jet 
nebulisation, breath-activated jet nebulisation during the whole inspiration and breath activated 
pulsed jet nebulisation for up to 1 sec from start of inspiration were compared (Nikander et al., 
2000c). The authors concluded that the results supported breath-activated jet nebulisation during 
the whole inspiration but not pulsed jet nebulisation with conventional jet nebulisers, and that 
pulsed nebulisation in children required further studies (Nikander et al., 2000c). 
The use of the HaloLite AAD System was investigated in subjects with CF (Kastelik et al., 2002; 
Byrne et al., 2003), with hereditary α1–proteinase inhibitor deficiency (Brand et al., 2003), and 
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with pulmonary hypertension (Olschewski et al., 2003). The AAD technology was further 
developed with the introduction of the 2nd generation AAD system, the Prodose AAD System 
(Denyer et al., 2004) – also based on jet nebuliser/compressor technology - in which the maximal 
length of the aerosol pulse time was set to 8 sec. The aerosol pulse was also made dependent on 
the tidal volume; aerosol was pulsed into the first 50% of the subjects tidal volume if the volume 
was <1 L, if it was larger the pulse time was longer. Due to the introduction of the AAD Disc 
technology, a plastic disc with a microchip and an antenna with information regarding aerosol 
dosage, dosing frequency, number of doses to be delivered, drug lot number and expiry date could 
be introduced (Denyer et al., 2004). The new technology made the use of the ProDose AAD 
System in a telehealth setting possible (Nikander et al., 2010a).  
2.6.6 The I-neb Adaptive Aerosol Delivery (AAD) System 
The I-neb AAD System (I-neb nebuliser; Figure 2.16) was the 3rd generation AAD system which 
was developed with Omron Healthcare (Kyoto, Japan) based on a vibrating mesh technology 
(Denyer et al., 2004).  
 
Figure 2.16: The I-neb nebuliser shown with the AAD disc. Available at and accessed October, 
2015: http://www.healthcare.philips.com/main/homehealth/respiratory_drug_delivery/index.wpd 
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The main parts of the I-neb nebuliser are the body, the medication chamber assembly including 
the metering chamber, the mesh and the mouthpiece (Figure 2.17).  
 
Figure 2.17: The figure shows the different parts of the I-neb nebuliser (Nikander et al., 2008). 
 
2.6.6.1 The breathing modes, TBM and TIM 
Two different breathing modes, the Tidal Breathing Mode (TBM) and the Target Inhalation Mode 
(TIM) are used with the I-neb nebuliser. In TBM the subject breathes tidally through the TBM 
mouthpiece, and through the function of the AAD algorithm a pulse of aerosol is delivered during 
50% of the first part of each inspiration (Figure 2.18).  
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Figure 2.18: A schematic presentation of the two breathing modes used with the I-neb nebuliser, 
the TBM and the TIM. In the TBM graph the aerosol is pulsed in 50-80% of the inspiration (grey 
area). In the TIM graphs (2nd, 3rd, last graphs) the gradual extension of the inspiration from a 3-sec 
inhalation (2-sec aerosol pulse) to an 8-sec inhalation (7-sec aerosol pulse) is shown. Reproduced 
from (Denyer et al, 2010a). 
 
The pulsed aerosol delivery is based on a continuous calculation of the average of the past three 
tidal inspirations, and from these the length of the following inspiration is predicted. The pulse 
time is continuously monitored and adjusted depending on variability in the subject’s inspirations. 
If the inspiration is extended past 2 sec, the pulse time is extended beyond the 50% of the predicted 
inspiration time and up to ~1sec before the start of the predicted expiration (Denyer et al., 2010a; 
Denyer et al., 2010b; Denyer et al., 2010c). 
In TIM a slow and deep inspiration is performed through the TIM mouthpiece guided by feedback 
from the device, and achieved via a magnet in the TIM mouthpiece which activates the TIM 
algorithm. The peak inspiratory flow through the TIM mouthpiece is restricted to ~20 L/min by 
an elastomeric valve in the mouthpiece with no resistance on expiration (Figure 2.19).  
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Figure 2.19: A schematic presentation of the main components of the I-neb nebuliser; the 
mouthpiece, the medication chamber assembly, and the body. The valve system in the mouthpiece 
is shown for the two different breathing modes, the TBM (left), and the TIM (right) (Denyer et al., 
2010a; Nikander et al., 2010c). 
 
2.6.6.2 The mouthpiece 
The aerosol generated by the horn and the mesh passes the mesh at a low velocity, and the subject’s 
inspiration carries the aerosol through the mouthpiece (Figure 2.20). The inspiratory airflow 
through the inhalation and exhalation valve in the mouthpiece mixes with the aerosol during 
inhalation (Denyer et al., 2010b).  
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Figure 2.20: The mouthpiece of the I-neb nebuliser shown with the medication chamber (light 
grey), the mesh in the middle of the medication chamber, and aerosol flowing through the 
mouthpiece (Denyer et al., 2010b). 
 
2.6.6.3 The vibrating mesh technology 
The mesh in the I-neb nebuliser is made of platinum with ~7000 holes with an average diameter 
of 2 µm. The solution or suspension poured into the medication chamber fills the gap between the 
ultrasonic horn and the mesh by gravity, and is pumped through the mesh at a frequency of 178 
kHz. At the end of nebulisation when the liquid in the medication chamber has been aerosolised, 
an electronic control circuit detects the change in power required by the horn and signals the end 
of nebulisation. The aerosol output rate can be adjusted depending on the requirements of different 
drug formulations as the piezoelectric element connected to the horn has a variable power range 
(Denyer et al., 2010b). 
2.6.6.4 The medication chambers 
The I-neb nebuliser medication chambers were designed for metering or non-metering purposes 
(Figure 2.21). The metering chamber was designed with a central section for a metered dose of 
liquid drug formulations in volumes of 0.25-0.75 mL. If a commercially available drug vial with 
a volume of 2-5 mL was used to fill the metering chamber, the remaining liquid flowed into an 
outer chamber and this part of the liquid was not aerosolised.  
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Figure 2.21: The medication chambers designed for the I-neb nebuliser; the metering chamber 
(left) and the non-metering chamber (right) (Denyer et al., 2010b). 
 
The metered dose was defined ex-mouthpiece which meant that the metered dose was calculated 
to compensate for drug losses in the mouthpiece. The non-metering chamber was designed for 
liquid volumes ranging from 0.25 mL to 1.7 mL and was filled by using a pipette (Denyer et al., 
2010b). 
2.6.6.5 Upper airway and lung deposition with the I-neb nebuliser 
The upper airway and lung deposition with the I-neb nebuliser has been investigated in several 
studies both in healthy subjects (Nikander et al., 2010c), and in subjects diagnosed with IPF (Diaz 
et al., 2012), and in subjects diagnosed with CF (van Velzen et al., 2015). In the study by van 
Velzen et al (2015) the bioavailability of nebulised tobramycin was used as a surrogate marker for 
lung deposition in adult subjects diagnosed with CF. Eighteen subjects (10 male) aged 19-57 years 
were included in a randomised, open-label, crossover study in which the I-neb nebuliser was used 
with a 1 mL medication chamber. The subjects nebulised 1 mL of a ~10% tobramycin solution in 
both TBM and TIM breathing modes. The results showed that lung deposition when inhaling 
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tobramycin in the TIM breathing mode was 53% higher compared to inhalation in the TBM 
breathing mode. Due to the study design, data on upper airway deposition was not reported.  
In the study by Diaz et al (2012) the safety, and lung and upper airway deposition of nebulised 
INF-γ was investigated in subjects diagnosed with IPF. Ten subjects (majority male) with a mean 
age of 68 years were included in a non-randomised, interventional pilot study in which the I-neb 
nebuliser was used in the TIM breathing mode. INF-γ was nebulised in a dose of 100 µg 3 times 
a week for 80 weeks. Lung and stomach deposition was investigated using radiolabelled INF-γ 
solution. The subjects drank a glass of water immediately after nebulisation of the radiolabelled 
INF-γ solution in order to wash the aerosol deposited in the oropharynx into the stomach. A scan 
of both the lungs and the stomach defined lung and upper airway (stomach activity) deposition. 
The mean lung deposition was 65.4 ± 4.8% (± SEM) of the nebuliser charge and ranged from 21.6 
to 95.1%, whereas the mean upper airway deposition was 12.6 ± 3.0% and ranged from -2.8 to 
35.3%. The mean ratio between central and peripheral lung zones (sC/P) was 1.20 ± 0.06 and 
ranged from 1.00 to 2.21; a ratio of 1.0 indicated deposition in the small airways and alveoli and 
a ratio >1.0 more central airway deposition. 
In the study by Nikander et al (2010c) the lung and upper airway deposition of nebulised 99mTc-
DTPA in saline was investigated in healthy adult subjects. Twelve subjects (3 male) with a mean 
age of 33.8 years (range 20-65 years) were included in a randomised, open-label, crossover study 
in which the I-neb nebuliser with a power level 10 AAD Disc was used both in TBM and TIM. 
An exhalation filter was fitted to the inhalation/exhalation port of the mouthpiece to capture 
exhaled 99mTc-DTPA. The TIM breathing mode had a maximum length of 9 sec with an aerosol 
pulse of to 7 sec, and with no aerosol delivered during the last 2 sec. This is in contrast with the 
present TIM breathing mode with a maximum length of 8 sec with no aerosol delivered during the 
last 1 sec. All subjects were in a seated position during nebulisation and nose clips were used 
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during the nebulisation process. Inspiratory and expiratory flows through the mouthpiece, aerosol 
pulse times during nebulisation, time spent in inspiration, number of breaths and minute volume 
were monitored electronically during the study (Table 2.3).  
Table 2.3: Summary of a number of parameters recorded during the nebulisation with the I-neb 
nebuliser: inspiratory and expiratory flows through mouthpiece, aerosol pulse times during 
nebulisation, length of inspiration, number of breaths and inspiratory minute volume (Nikander et 
al., 2010c). The data are shown as means ± SD. 
 
Mean TBM SD TIM ± SD 
Inspiratory flow (L/min) 23.92 8.23 12.95 4.29 
Expiratory flow (L/min) 27.51 10.89 18.39 7.57 
Aerosol pulse time (sec) 2.13 0.89 5.83 1.06 
Length of inspiration (sec) 3.53 1.32 8.75 0.92 
Number of breaths 44.80 23.19 11.60 3.20 
Inspiratory minute volume (L) 7.19 2.44 7.77 2.36 
 
The lung deposition of 99mTc-DTPA (with central and peripheral lung deposition shown 
separately), the upper airway deposition, and the exhaled fraction caught on the filter attached to 
the mouthpiece are shown in Figure 2.22. The data is presented in percent of emitted dose ex-
mouthpiece. A lung deposition image is shown in Figure 2.23. The lung deposition in TIM (mean 
73.29%, SD 16.3) was statistically significantly (p=0.0020) higher than the lung deposition in 
TBM (62.82%, 19.6). The upper airway deposition in TBM (36.18%; 19.7) was statistically 
significantly (p=0.0039) higher than the upper airway lung deposition in TIM (26.49%; 16.3). The 
central lung deposition was 17.95% (3.89) in TIM and 16.50% (5.2) in TBM, whereas the 
peripheral lung deposition was 34.83% (8.38) in TIM and 28.73% (9.62) in TBM. The mean sC/P 
was in TBM 1.66 (0.33) and in TIM 1.57 (0.32) with no statistically significant difference. The 
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amount of aerosol on the exhalation filter was in TBM (0.99%; 0.43) statistically significantly 
(p<0.0001) higher than in TIM (0.20%; 0.13). The mean deposition in the mouthpiece in 
percentage of loaded dose was 5.1% (1.8) in TBM and 5.0% (1.7) in TIM. 
 
 
Figure 2.22: The lung, central lung, peripheral lung, and upper airways deposition of 99mTc-DTPA 
plus the exhaled amount of 99mTc-DTPA in healthy subjects with TBM data in black and TIM in 
gray (Nikander et al., 2010c).  
 
 
 
 
Figure 2.23: Posterior lung deposition images of 99mTc-DTPA delivered with the I-neb nebuliser 
in TBM (left) and TIM (right) for subject 4 (Nikander et al., 2010c). 
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The MMD of the saline aerosol emitted from the I-neb nebuliser was for the 14 devices allocated 
for the study 4.6 µm with a FPF of 56.8% which was substantially lower than the lung deposition 
in either breathing mode. 
2.7 Acoustic pharyngometry 
2.7.1 Early acoustic reflection (AR) method, development and studies 
The Sondhi et al (1971) paper has been described as the original description of acoustic pulse-
response analysis (Buenting et al., 1994; Kamal, 2004c). The first clinical study of the AR method 
has been attributed to Fredberg et al (1980) who tested the hypothesis that upper airway and 
tracheal geometry could be determined through AR at the mouth (Kamal, 2004c). The acoustic 
equipment consisted of a mouthpiece, a sliding 2-position valve, a 5 m long wavetube of stainless 
steel, a microphone, and a loudspeaker (Figure 2.24). The mouthpiece was designed to limit 
variability due to tongue movement, and jaw position, and filled the oral interstices between the 
posterior margin of the hard palate and the lips. 
 
Figure 2.24: Diagram of the test equipment consisting of a mouthpiece, a 2-position valve, a 5 m 
long wave tube of stainless steel, a microphone, and a loudspeaker (Fredberg et al., 1980). 
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The 6 healthy adult subjects breathed either room air or a humidified mixture of helium (80%) and 
oxygen (20%). The authors concluded that the study suggested that the geometry of the upper 
airways between mouth and carina could be determined accurately with the equipment (Fredberg 
et al., 1980). The equipment was later used in several clinical studies due to lack of commercially 
available equipment (Marshall et al., 1991). 
The early AR studies were focused on measuring the upper airways, the trachea and part of the 
lungs (Hoffstein et al., 1991). An example of an airway echogram of the upper airway, the trachea 
and the lungs is shown in Figure 2.25 (Hoffstein et al., 1991).  
 
Figure 2.25: An echogram acquired during tidal breathing. Some major anatomical landmarks can 
be identified. The first ~6 cm correspond to the end of the wave tube and the mouthpiece, the large 
peak is the pharynx, the 1st minimum following the pharynx is the GL and the plateau region distal 
to the GL is the trachea followed by the central airway (Hoffstein et al., 1991). 
 
The authors highlighted the reproducibility of the echogram from the wavetube to the trachea as 
evidenced by the small standard deviations, but also noted that the reproducibility decreased for 
the distal structures as the assumptions of the method were satisfied only for the central airways 
(Hoffstein et al., 1991). 
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In 1991 Marshall et al (1991) presented a paper in which they described the theory and limitations 
of AR, and suggested some modifications to the equipment used by Fredberg et al (1980; Figure 
2.26). The equipment was “closed” as the subject could not breathe during the measurement in 
contrast to the older Fredberg et al (1980) equipment (Marshall et al, 1991) 
 
Figure 2.26: A diagram of the closed acoustic reflectometer equipment (Marshall et al., 1991).  
 
In 1993 Marshall et al (1993) presented a new AR equipment which allowed the subject to breathe 
during the measurement (Figure 2.27). This was achieved by a hole in the wavetube wall 
immediately proximal to the mouthpiece and the hole was closed just before a measurement was 
made. A flexible wavetube made of PVC with a 16 mm internal diameter with a loudspeaker-
microphone distance of 1130 mm and a microphone-mouthpiece distance of 130 mm was included 
in the equipment (Figure 2.27). Marshall et al (1993) focused on the upper airways from the mouth 
to the hypopharynx and started using room air for the AR measurements instead of the 
helium/oxygen mixture used in previous studies with the Fredberg et al (1980) equipment 
(Marshall et al., 1993). 
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Figure 2.27: A diagram of the new AR equipment. PT = pressure transducer, CV = calibration 
(slide) valve, RV = respiratory (shutter) valve (Marshall et al., 1993).  
 
In 1994 Louis et al suggested a two-microphone method in order to be able to use a shorter 
wavetube. They published a year later the results of in vitro and clinical tests in 3 healthy subjects 
in which they compared a one-microphone method versus the two-microphone method, and a 
helium/oxygen mixture versus room air (Figure 2.28; Louis et al., 1994).  
 
Figure 2.28: A diagram of the Louis et al (1994) wave tube developed for measurement of upper 
airway area by a two-microphone AR method. Pi stands for an incident pressure wave which 
impinges on airway opening and gives rise to a reflected wave, Pr. The pressure sum of the incident 
and the reflected waves was recorded in 2 loci of the wavetube to infer area (A) versus axial 
position (x) along the airway. L = length of wave tube (Louis et al., 1994). 
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The new equipment that Louis et al (1994) tested was considerably smaller than the equipment 
used by Marshall et al (1993), with a 30 cm long wavetube with a 1.89 cm internal diameter (Figure 
2.28). The results of the tests indicated that the two-microphone method with a helium/oxygen 
mixture was equivalent with the one-microphone method over a distance up to 60 cm. The AR 
method was further developed into the commercially available Eccovision acoustic pharyngometer 
used in this thesis. The focus of the pharyngogram was limited to the upper airways between the 
wavetube and the GL. 
2.7.2 Principles of acoustic reflectometry 
The principles of the acoustic method has been explained by a number of authors (Fredberg et al., 
1980; Brooks et al., 1984; Hoffstein et al., 1991; Marshall et al., 1991; Marshall et al., 1993, Louis 
et al., 1994, Kamal, 2004c). The basic principle of the AR method has been described as follows 
by Hoffstein (Hoffstein et al., 1991): 
- As a sound pulse travels along a tube and comes across a change in area from A1 to A2, 
part of the pulse is reflected and travels back along the tube, and part is transmitted. 
- With known wavespeed (c) and travel time (t), the length of the tube (d) can be calculated 
to be d = ct. 
- With one-dimensional wave propagation, the measurement of wave travel time is 
equivalent to the measurement of distance. 
- The amplitude of the reflected pulse (Pr) is determined by the amplitude of the incident 
pulse (Po), and the physical property of the tube. Considering a tube with a single discrete 
area change from A1 to A2, and assuming constant and uniform gas composition, the 
amplitude of the reflected pulse is given by: Pr = Po[(A1 - A2) / (A1 + A2)]. 
The CSA of A2 can be calculated by measuring the amplitude of the incident and reflected pulses, 
since A1 is presumed known. Therefore, the determination of the length and area of the straight 
tube is reduced to measuring the travel time of the pressure pulses from the area change of the 
tube, and the amplitudes of the incident and reflected waves. In case of a duct consisting of many 
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segments - each with different area – the incident sound wave (pressure wave) will be reflected in 
part every time for each new segment. Determination of the lengths and areas of the individual 
segments is based on measurement of arrival times and amplitudes of the reflections. This gives 
the area of the duct versus distance from inlet that is the area-distance function or the airway 
echogram (Hoffstein et al., 1991). 
Kamal expanded on the principles of the AR method as used in the Eccovision equipment (Kamal, 
2004c) as follows: 
- An acoustic impulse traveling through a wavetube into an upper airway will undergo partial 
reflection and partial transmission at each change in the CSA creating a reflection sequence 
which will return through the wavetube without further reflection. The passage of the 
impulse is recorded through a microphone in the wavetube close to the connection between 
wavetube and the upper airway, the input impulse response. An area-distance relationship  
of the upper airway geometry can be created by comparing the incident and the reflected 
acoustic impulse. 
- The input impulse response is a series of reflections created by changes in the impedance 
within the upper airway. The reflection can be either single due to a single change of a tube 
CSA or multiple as in a human upper airway. The input impulse response and the input 
impedance are closely related. 
- A straight tube with a single change in CSA can be used as an example to highlight how 
acoustic reflection is used to obtain an area distance function (Figure 2.29). 
- The pulse is recorded as it passes the microphone and when the pulse  reaches the area of 
discontinuity some of it is reflected back from right to left (r0) and some continues through 
the discontinuity (1-r0). The amplitude of the reflected part is calculated as follows: r0 = 
(A0 – A1) / (A0 + A1) which can be rearranged as: A1 = A0 × (1 – r0) / (1 + r0). Assuming 
the pulse travels at a constant speed (C, meters per second) in the wavetube, the distance 
from the microphone to area change can be computed (Kamal, 2004c). 
 
 83 
  
 
 
Figure 2.29: The amplitudes of reflected and transmitted impulses (waves) for unit pulse arriving 
from left (top) and right (bottom) of a single area change (Kamal, 2004c). 
 
Kamal expanded on the principles for a tube with variable CSAs as follows:  
- A tube with variable CSAs can represent the upper airway as highlighted in a schematic 
space-time diagram (Figure 2.30). In this diagram the first reflection has amplitude r0, and 
with r0 and A0 we can get A1. Thus the amplitude of the pulse transmitted through the first 
area change is 1 –r0. In the second area change the reflected portion becomes (1 – r0) × 
r1. The pulse travels back and reaches the first area change and the amplitude which 
reaches the microphone is (1 – r0) × r1 × (1 + r0). As r0 is known r1 can be computed 
given the amplitude of the pulse reaching the microphone at time 2 × 2L / C where L is the 
length, and with r1 and A1 known, A2 can be computed. This is more complex with 
increasing number of segments as there are two components of the pulse arriving at the 
microphone at time 2 × 3L / C. The first is the part of the original impulse which is 
transmitted through the first two area changes, is reflected from the third area change and 
is then transmitted again through the first two area changes and reaches the microphone. 
This component has amplitude r2 × (1 – r12) × (1 – r02). The second component is due to 
the part of the impulse which was transmitted through area change 1 (A1), then reflected 
back and forth from A2 to A1 again and then through A1 to the microphone. As this 
component is determined by the known r0 and r1 , this can be subtracted from the impulse 
and solve for r2.  
- In summary, the impulse response of an upper airway with multiple area changes consists 
of a series of impulses arriving at times 2 × n × L / C. The impulse arriving at tn = n × 2L 
 84 
  
 
/ C consists of two components of which one is due to the original impulse transmitted 
through area changes A1 through n-1, reflected back at area change n and then transmitted 
back through area change n-1 to A1 to the microphone. The amplitude of this component 
is rn-1 × (1 – rn -22) × (1 – rn – 2 2) ×…× (1 – r02). The other component is caused by 
reverberations between area changes A1 through n-1 and this component is determined by 
r0 through r n-2. The major assumption is that once a reflected impulse passes the 
microphone it does not return which can be assured by having a wavetube which is at least 
as long as the farthest area change measured (Kamal, 2004c). Thus the wavetube should 
be at least as long as the upper airway measured. 
 
Figure 2.30: A schematic drawing of components of reflected waves as a function of multiple 
discontinuities with the microphone highlighted as “Mic” (Kamal, 2004c). 
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2.7.3 Early AR method - accuracy  
The early clinical studies that investigated the accuracy of the AR method used the equipment 
tested by Fredberg et al (1980) and are listed in Table 2.4 (Hoffstein et al., 1991). All but 2 of the 
studies - including both clinical studies, studies in dogs and in vitro studies - were focused on the 
trachea and showed close correspondence between the areas measured with the AR method, and 
the radiographic techniques with ratios ranging from 0.88 to 1.15.   
Table 2.4: Early comparative clinical studies between the AR technique, and the X-ray and the 
CT techniques. The comparison is presented as a ratio between area determined by AR and the 
other methods (Adapted from Hoffstein et al., 1991). 
 
Study Region 
examined 
Comparison 
technique 
Ratio 
Brooks et al., 1984  Trachea PA, lateral X-rays 1.06 
D’Urzo et al., 1987 Trachea CT scans 0.96 
D’Urzo et al., 1988 GL CT scans 1.06 
 
In the study by D’Urzo et al (1988; Table 2.4), the authors compared the results of the AR 
measurements of the upper airways of 11 subjects with “glottal pathology” with CT scans of the 
GL. Both measurements were performed during different days with the subjects in a supine 
position, during tidal breathing and at FRC. The mean (± SD) CSA values for the GL were 1.8 ± 
0.8 cm2 (AR) and 1.7 ± 0.9 cm2 (CT), and there was a statistically significant correlation between 
the two measurements. The authors discussed the suggestion by Brooks et al (1984) – based on in 
vitro glass tube model analysis - that in normal subjects the lower limit of the GL area that might 
be resolved by the AR would be in the range 0.9-1.0 cm2. As a number of subjects in the D’Urzo 
et al study had smaller GL areas confirmed by the CT scans, the results indicated that at least in 
subjects with glottal pathology the AR method could be used to measure quite small CSAs down 
to 0.4 cm2. It should, however, be noted that the smallest GL areas measured by CT scan (0.3, 0.6 
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and 0.8 cm2; 3 subjects) were somewhat larger when measured with the AR method (0.4, 0.7 and 
1.2 cm2; D’Urzo et al., 1988). 
In their 1993 paper Marshall et al (1993) presented a comparison between AR and MRI CSAs of 
the upper airways of 10 subjects (Table 2.5). The comparison for 1 subject is presented in Figure 
2.31 and the authors pointed out the apparent “smoothing” effect of the AR method. The 
hypopharynx maximum was the only comparison which was statistically significantly different (p 
= 0.04) between the 2 methods. The AR measurement underestimated the hypopharynx maximum 
by 35% in comparison with the MRI measurement. However, the minimum values of the OPJ and 
the GL were similar.  
Table 2.5: CSAs (cm2) of the OPJ, the hypopharynx (HP) maximum and the GL, and the pharynx 
volume (cm3) measured by MRI and by AR. Data from 10 subjects presented as mean ± SD 
(Marshall et al., 1993). 
 
 OPJ, cm2 HP, cm2 GL, cm2 Pharynx, cm3 
MRI 0.9 ± 0.5 2.6 ± 0.9 1.1 ± 6.0 14.9 ± 6.0 
AR 0.3 1.6 ± 0.6 1.3 ± 0.3 13.2 ± 2.7 
MRI - AR -0.04 ± 0.42 0.92 ± 1.18 -0.22 ± 0.36 1.6 ± 5.8 
p-values 0.77 0.04 0.09 0.40 
 
One reason for the differences could be found in the measurement techniques (Table 2.5). The 
MRI measurement took several minutes to perform with data averaged over several breaths and 
might have included swallowing, whereas the AR measurement was essentially instantaneous 
(Marshall et al., 1993). 
 87 
  
 
 
 
Figure 2.31: A comparison of AR and MRI estimates of an airway area in a supine, gently 
breathing subject. The estimates were aligned at the vocal cords and the positions of the landmarks: 
the oropharynx (OP), the hypopharynx (HP) and the vocal cords (VC). These were determined 
from a midline sagittal image (Marshall et al., 1993). 
 
2.7.4 Early AR method - reproducibility  
The reproducibility of the AR method in humans was evaluated by Brooks et al (1984) in 10 
healthy adult male subjects using the Fredberg et al (1980) equipment with a shorter (2 m) wave 
tube. The subjects were seated and the measurements performed during tidal breathing near FRC. 
The AR measurements were repeated during 3 days to assess reproducibility which was calculated 
as a CV expressed as a percentage (100 × SD / mean) for the average area of the tracheal segment 
6-10 cm beyond the GL. The within-run tracheal variability (90 measurements; ± SD) for all 
subjects was 10 ± 4%, and the day-to-day variability (270 measurements) was 9 ± 4%.  
In 1989 Brooks et al (1989) published a second study on the reproducibility of the AR in 
measurements of the upper airway area, using the same kind of technique as in their study 
published in 1984 (Figure 2.32). The main difference in the technique was related to the wave tube 
inner diameter of 1.95 cm2, instead of 1.57 cm2 as in the first study (1984).  
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Figure 2.32: An echogram acquired during tidal breathing from a single subject with the airway 
CSA measured by AR plotted versus distance from the mouth. The landmarks (oropharynx, 
hypopharynx, GL and carina) were identified by X-ray. Peak pharyngeal area (P), and mean 
pharyngeal area (A; end of mouthpiece to GL) are highlighted (Brooks et al., 1989). 
 
Ninety AR measurements were performed in 10 healthy adult subjects, and the mean echograms 
were analysed in terms of peak pharyngeal area (P), mean pharyngeal area (A) (end of mouthpiece 
to GL), and pharyngeal volume (V) (A × distance mouthpiece to GL; Figure 2.30).  The within-
run variability (CV = SD/mean) for all subjects was for P, A and V: 0.11, 0.08 and 0.08, and the 
day-to-day variability for P, A and V: 0.08, 0.08 and 0.12. 
Marshall et al (1993) tested a new AR equipment in 10 subjects to measure reproducibility and 
focused on the upper airway area from mouth to hypopharynx. The subjects were breathing room 
air during the measurements. An example of the typical within-run reproducibility for 1 subject is 
show in Figure 2.33. The CV of the measurements was ~10% and close to the CV reported by 
Brooks et al (1984).  
The within-run CV was 10% (range 2-25%) for the 10 subjects. The day-to-day CV in 5 subjects 
over 21 days (± SD) was 13 ± 3% at the oropharynx minimum and 11 ± 3% at the hypopharynx 
maximum and GL mimimum, close to the 9 ± 4% reported by Brooks et al (1984). 
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Figure 2.33: Example of the within-run reproducibility of the AR technique developed by 
Marshall et al (1993). The mean (solid line) and ±1 SD limits (dotted line) of 10 consecutive 
measurements are shown. The approximate position of the incisors (I), the oropharynx (OP), the 
hypopharynx (HP) and the vocal cords (VC) are highlighted (Marshall et al., 1993). 
 
2.7.5 Sources of artefacts of the AR method  
A number of authors have highlighted the risk of artefacts when performing AR measurements of 
the upper airways (Molfino et al., 1990; Marshall et al., 1993; Kamal, 2004c). 
2.7.5.1 Position of subject and wavetube during measurement 
Posture control of the subject during measurements with an acoustic pharyngometer is important 
as the pharyngeal volume may be affected by the position of the subject’s head and neck 
(Rubinstein et al., 1987; Eckmann et al., 1996; Walsh et al., 2008; Kamal, 2004c). In order to avoid 
movement of the head during the measurement, the subject should be asked to fix the gaze at a 
spot at the opposite wall on the same level. Monitoring of the subject’s posture is important during 
the measurements, and the position and height of the wavetube has to be adjusted in relation to the 
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subject so that the wavetube can be kept in a fixed position during the measurement (Kamal, 
2004c). 
2.7.5.2 Physiological variations of the pharynx CSA during breathing 
As breathing related motion of soft tissue in the pharynx and related bony structures has been 
shown to create dimensional changes in the pharynx (check 2.2.8), the subject’s breathing during 
the acoustic pharyngometer measurement should be observed (Kamal, 2004c). During tidal 
breathing the FRC is the volume of air in the lungs at the end of the expiration. In order to ensure 
reproducible acoustic pharyngometer measurements of the upper airway area at its most narrow 
point, acoustic pharyngometer measurements should be made at FRC (Kamal, 2004c; Viviano, 
2004). 
2.7.5.3 The impact of an open velum  
In one of the early publications regarding the AR measurements by Fredberg et al (1980), the 
authors commented upon the necessity to ensure that the “nasopharyngeal aperture (velum)” was 
closed during data acquisition so that the airway could be “modeled as a one-dimensional duct of 
varying area”. Brooks et al (1984) did also include a comment regarding the open velum (soft 
palate not closed) in their paper. Molfino et al (1990) presented perhaps the first published example 
of an echogram measured with an open (A) and a closed (B) velum in their letter to the Editor of 
the American Review of Respiratory Diseases (Figure 2.34).  
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Figure 2.34: The figure shows an echogram (“Average Area Distance Function”; area in cm2 
plotted versus distance in cm) measured at FRC in a subject wearing a nose clip (A), and 10 s after 
removal of the nose clip (B) (Molfino et al., 1990).  
 
Hoffstein et al (1991) discussed the open velum in terms of “branching”. If the velum was open 
there were 2 parallel pathways for the sound pulse, mouth to subglottic airways and mouth to nasal 
airways. The AR algorithm would interpret the mouth to nasal airways area as an increase in the 
subglottic airway area, and the echogram would be meaningless. Hoffstein et al (1991) stated that 
the artefact was “easily recognized in practice and measures may be taken to prevent the opening 
of the velum (e.g. removing the noseclips or instructing the subject to breathe through the mouth)”. 
Marshall et al (1993) included 2 figures of interest relating to the open velum artefact, Figures 2.35 
and 2.36, in their 1993 paper. In Figure 2.35 the upper airway anatomy is shown with the soft 
palate (velum) in 2 positions, when breathing through the mouth (the velum closes off the 
nasopharynx from the pharyngeal area) and when breathing through the nose (the velum is open 
between the nasopharynx and the pharyngeal area). 
 92 
  
 
 
Figure 2.35: The figure highlights the soft palate (velum) position when breathing through the 
mouth (dotted curve, the passage between nasopharynx and the pharyngeal area closed) and when 
breathing through the nose (broken curve, the passage between nasopharynx and the pharyngeal 
area open (Marshall et al., 1993). 
 
Marshall et al (1993) included an echogram showing the effect of the open velum in comparison 
with a closed velum, Figure 2.36. The measurement with an open velum (nasal) created a curve 
with a larger CSA in comparison with the curve acquired with a closed velum (oral). 
 
Figure 2.36: The figure shows the effect of the soft palate (velum) position (open or closed) on 
the echogram. The open velum (nasal) created an echogram with a larger CSA in comparison with 
the curve acquired with a closed velum (oral). The main differences in the 2 echograms occur from 
the OPJ at ~10 cm (x-axis) onwards to the right. The broken curve shows the effect of a mixed 
oral/nasal (closed velum/open velum) breathing (Marshall et al., 1993). 
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In order to avoid an open velum during the acoustic pharyngometer measurement, the subject 
could be asked to silently think of making an “oooh” sound. This should be helpful in keeping the 
tongue relaxed on the floor of the mouth (Kamal, 2004c). 
2.7.6 The Eccovision Acoustic Reflection Pharyngometer (ARP) 
The first FDA approved ARP – used in the studies presented in this thesis – was the Eccovision 
ARP (Hood Laboratories, Pembroke, MA, USA; presently www.sleepgroupsolutions.com). The 
Eccovision ARP is composed of a mouthpiece, wavetube, speaker, microphone, filter strips, 
acoustic device, C.P.U., printer, monitor, PC, board, software and source code 
(www.sleepgroupsolutions.com). A recording with the Eccovision ARP creates a pharyngogram 
and the different upper airway anatomic structures on the pharyngogram is shown in Figure 2.37.  
 
Figure 2.37: The figure shows a pharyngogram obtained from an Eccovision ARP measurement 
(y-axis shows CSA in cm2, x-axis shows distance from mouth in cm). Along the pharyngogram 
different anatomic structures can be identified, and the CSA of the upper airways can be measured 
at several anatomical levels. The oral cavity is recorded as a peak from 0 to ~7.5 cm, the OPJ is 
located at the dip of the curve at ~9 cm followed by the oropharynx from ~9 to ~12 cm, the EG is 
recorded as the second dip at ~13 cm followed by the hypopharynx from ~13 to ~20 cm and the 
GL between ~20 to ~21 cm (Viviano, 2004). 
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The Eccovision ARP has been used in a number of clinical studies in healthy subjects (Kamal, 
2001; Kamal, 2002; Kamal, 2004b; Monahan et al., 2005; Shiota et al., 2007), and in adults (Jung 
et al., 2004; Kamal, 2004a; Gelardi et al., 2007; DeYoung et al., 2013) and children diagnosed 
with OSA for measurements of upper airway CSAs and volumes (Monahan et al., 2005; Kumar et 
al., 2015). 
A number of clinical studies with the Eccovision ARP have reported mean CSA values for the 
upper airways for healthy subjects of both genders. In one of the largest studies with the Eccovision 
ARP Kamal (2001) measured the upper airways of 350 healthy subjects, and showed a mean 
pharyngeal CSA of ~3.2 cm2 (minimum 2.7 cm2, maximum 3.8 cm2) in males and of ~2.8 cm2 
(minimum 2.1 cm2, maximum 3.4 cm2) in females (Kamal, 2001). In the same study the mean GL 
CSA were in males 1.06 cm2 (minimum 0.9 cm2, maximum 1.2 cm2), and in females 0.94 cm2 
(minimum 0.75 cm2, maximum 1.09 cm2) (Kamal, 2001).  
The repeatability of pharyngeal CSA measurements was investigated by Kamal (2004b) in 20 
healthy adult subjects (16 men) using the Eccovision ARP and following a developed SOP. The 
SOP highlighted 5 general pharyngometry test related points, as follows: 
- Position of subject. The subject should be seated in a firm chair in order to keep the head 
in a neutral position and the wavetube in proper position. 
- Subject considerations. The test is performed during normal quiet breathing. The subject 
is told to think silently of “oooh” in order to place the tongue in a relaxed position on the 
floor of the mouth and keepthe velum closed. 
- Mouthpiece. The mouthpiece is made of rubber and is designed to be placed with the teeth 
against the flange. The subject is told to bite down on the protruding tabs and to place the 
lips over the flange to form an acoustic seal. 
- Position of the wavetube. The wavetube should be kept horizontally parallel to the floor. 
- Operator. Training and familiarity with the equipment is important. Accuracy of the test is 
improved by performing 4 tests on the same session in order to be able to calculate the CV. 
The results of 3 separate measurements - consisting of several recorded pharyngograms - of the 
mean pharyngeal CSAs in the 20 subjects showed a good repeatability (Kamal, 2004b). The first 
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2 measurements were performed the same day and showed mean pharyngeal CSAs of 3.187 cm2 
(SD 0.249) and 3.239 cm2 (SD 0.0790). The 3rd test was performed 7-10 days later and showed a 
pharyngeal mean CSA of 3.245 cm2 (SD 0.0811). There was no statistically significant difference 
(p = 0.440) among the measurements of the pharyngeal mean CSAs made during the 3 sessions. 
Kamal (2004b) concluded that provided an SOP is adopted and maintained, repeatability of 
pharyngometry measurements could be achieved. 
Kamal (2004c) discussed the need to  standardize the use of the acoustic pharyngometry equipment 
and reproducibility. The argument was that this could be achieved by performing 3-4 
pharyngometry recordings and a CV of 5-10% of these seems to have been accepted by most 
authors in the field (Kamal, 2004c). An understanding of the “true” reproducibility” of the 
pharyngometry recordings can be found in the in vitro study presented in Chapter 6. The four 
pharyngometer recordings per measurement were in the in vitro study design with a cast of a 
human airway not affected by any subject related movement. 
Searches during October 2015 at www.pubmed.gov for “pharyngometry”, “acoustic 
pharyngometry”, for “acoustic pharyngometry and sleep apnoea” and for “acoustic pharyngometry 
and sleep apnea” provided numerous hits whereas searches for “acoustic pharyngometry and upper 
airway aerosol deposition”, “acoustic pharyngometry and lung deposition of aerosol”, “acoustic 
pharyngometry and upper airway deposition of aerosol” and “acoustic pharyngometry and aerosol 
inhalation” provided no hits. Thus, the use of the ARP methodology seems to have been mainly 
published in relation to studies of sleep apnoea, but not in studies of upper airway and lung 
deposition of inhaled aerosols. As the existing studies do not cover acoustic pharyngometry and 
lung deposition and/or breathing modes, a power calculation could not be made regarding the use 
of acoustic pharyngometry and lung deposition and/or breathing modes. 
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2.7.7 Analysis of the pharyngogram  
As highlighted in Figure 2.37, different anatomic structures can be identified in the pharyngogram, 
and the CSA of the upper airway can be measured at several anatomical levels (and volumes 
between these) including the oral cavity, the OPJ, the oropharynx, the EG, the hypopharynx, and 
the GL. A number of authors have developed the analysis further for diagnostic purposes, and 
examples from five published articles have been included (Jung et al., 2004, Monahan et al., 2005, 
Gelardi et al., 2007; Patel et al., 2008; Friedman et al., 2014). In the study by Jung et al (2004), 
the authors defined 5 upper airway landmarks in the pharyngograms; the OPJ, the maximum 
pharyngeal area (Apmax), the GL, the mean pharyngeal area from OPJ to GL (Apmean), and the 
pharyngeal volume between the OPJ and the GL (Vp) (Figure 2.38). 
 
Figure 2.38: A representative pharyngogram by Jung et al. Five parameters are shown through 
arrows and a thick line: the OPJ, the Apmax (maximum pharyngeal area), the GL, the Apmean 
(mean pharyngeal area from OPJ to GL), and the Vp (pharyngeal volume between OPJ and GL) 
(Jung et al., 2004). 
 
Monahan et al (2005) defined several features of the pharyngogram as additional descriptors of 
the oropharyngeal anatomy with the maximum CSA as the reference point (Figure 2.39). 
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Figure 2.39: Sample pharyngogram by Monahan et al (2005). The proximal and distal minima 
referred to the values before and after the maximum CSA. The proximal and distal slopes defined 
the rates of change in CSAs around the maximum CSA. The fractional increase and decrease 
represented the relative amounts that the CSA changed between a respective minimum and the 
maximum CSA. The maximum negative slope and the fractional distance at which it occurred 
facilitated the detection of changes in calibre (Monahan et al., 2005). 
 
In the study by Gelardi et al (2007) the authors defined several dimensions from each 
pharyngogram (Figure 2.40); wave I amplitude (changes in the volume of the tongue), extension 
and amplitude of the oropharyngeal segment (OP) and the area of the hypopharynx. 
 
Figure 2.40: Main pharyngometric parameters (Gelardi et al., 2007). 
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Patel et al (2008) defined 8 dimensions from each pharyngogram (Figure 2.41); 5 CSAs (OPJ, EG, 
overall minimum CSA, maximum CSA, mean CSA), and 3 axial dimensions (oropharyngeal 
segment length, relative position of maximum CSA over segment length and segment volume).  
 
Figure 2.41: Schematic pharyngogram by Patel et al. The oral cavity is shown as (#). The mean 
CSA was obtained by averaging the OPJ (¶) and the EG (§), the volume was calculated from the 
mean CSA and the oropharyngeal length (##). The relative maximum location was defined as the 
ratio of maximum location (ƒ) to oropharyngeal length. Maximum CSA (+) (Patel et al., 2008). 
 
Friedman et al (2014) used the pharyngogram to identify the anatomical locations (OPJ, EG, GL) 
of the maximal collapse (Figure 2.42), which were classified into a retropalatal, a retroglossal or a 
retroepiglottic obstruction. 
 
Figure 2.42: A normal pharyngogram by Friedman et al highlighting the OPJ, the EG and the GL. 
The authors used these landmarks to measure the CSAs of the retropalatal (RP), the retroglossal 
(RG), and the retroepiglottic (RE) anatomical regions (Friedman et al., 2014). 
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Examples of the 3 anatomical regions in the pharyngograms based on the Friedman et al paper 
(2014) have been included, as follows: 
 
 
Figure 2.43: The pharyngogram shows the minimal CSA ~8-10 cm from the mouth indicating a 
retropalatal obstruction (Friedman et al., 2014). 
 
 
Figure 2.44: The pharyngogram shows the minimal CSA ~12-14 cm from the mouth indicating a 
retroglossal obstruction (Friedman et al., 2014). 
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Figure 2.45: The pharyngogram shows the minimal CSA ~19-20 cm from the mouth indicating a 
retroepiglottic obstruction (Friedman et al., 2014). 
 
2.8 Measurements when seated or supine 
The impact of the seated position in comparison with the supine position on the size of the upper 
airways has been measured in healthy subjects using AR (Fouke et al., 1987; Jan et al., 1994), 
ARP (Eccovision; Jung et al., 2004), and CT/CBCT scans (Van Holsbeke et al., 2014a). All 4 
studies showed that the CSAs of the upper airway were smaller in the supine than in the seated 
position. 
Fouke et al (1987) showed that the CSA was smaller in the supine than in the upright position in 
9 out of 10 subjects, and that the overall pharyngeal CSA was 23% smaller in the supine position. 
They also showed that the mechanism of change was independent of the change in FRC. Jan et al 
(1994) showed that the CSAs of the OPJ were larger in the seated versus the supine position (1.65 
cm2 versus 1.31 cm2), which was in agreement with the results achieved by Jung et al (2004) for 
the CSAs of the OPJ (1.61 cm2 versus 1.25 cm2). Jung et al (2004) also reported mean CSA results 
for the GL which were 1.78 cm2 (seated) versus 1.35 cm2 (supine). Van Holsbeke et al (2014a) 
showed that for the upper airway the average CSA was ~10% and the minimal CSA 26.90% larger 
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in the seated position in comparison with the supine position. The largest difference of ~50% in 
favour of the seated position was shown for the region between the hard palate and the bottom of 
the uvula.  
In the study by Walsh et al (2008) the authors compared the pharyngeal shape and size in the 
supine versus the lateral recumbent posture in subjects with and without OSA using anatomical 
optical coherent tomography. The airway CSAs, and anteroposterior and lateral diameters of the 
velopharynx and the oropharynx were measured. The ratio of anteroposterior to lateral diameter 
in the velopharynx was significantly less for the supine than for the lateral recumbent posture in 
both groups. CSA was smaller in subjects with OSA than in healthy subjects and was unaffected 
by posture. 
2.9 Mandibular advancement 
The right angle bend of the lumen at the back of the mouth, the variable position of the tongue 
during inhalation, the variable size and shape of the lumen in the pharynx and larynx, and the 
breathing pattern (tidal versus slow and deep) could – in addition to aerosol characteristics - 
promote upper airway deposition and restrict lung deposition (Kumazawa et al., 1997; Borgström 
et al., 2006; Newman et al., 2009; Nikander et al., 2010c; Scheuch et al., 2010; Diaz et al, 2012; 
van Velzen et al., 2015). The part of the pharynx located behind the tongue, and mainly between 
the OPJ and the EG, seems to present the narrowest part of the upper airways (Fajdiga, 2005). 
Mandibular advancement has in the past been practiced as a means to open up the upper airway 
behind the tongue during inhalation (Tissier, 1903). Tissier discussed the opposition of the EG to 
the penetration of atomised liquids into the larynx. He also described an interesting “general 
method” of practicing inhalation of atomised liquid, gas, or vapour, as follows: 
“In the more general method, patients are first instructed to project the tongue as far as possible. 
It is then grasped with a cloth held in the fingers, preferably between the thumb and forefinger of 
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the patient’s right hand, and pulled downward as far as possible. Lazarus recommends that the 
organ be rolled, as it were, around the lower lip. In this way is prevented the arching of the base 
of the tongue that often causes a narrowing of the ostium of the pharynx, while the lingual traction 
causes the epiglottis to be lifted up and well forward. The patient throws his head slightly forward, 
at the same time tilting it a trifle backward and upward, bringing his lower jaw as far as possible. 
These manoeuvres have for their object the greatest possible widening out of the angle between 
the axes of the buccal and laryngeal cavities. In this position the medication may be made to reach 
the vestibule of the larynx, even in the most difficult cases.” 
 
Mandibular advancement was already used during the late 1800s in cases of mandibular retrusion, 
and is still used as a means to prevent collapse up the upper airway during sleep in subjects with 
OSA through the use of oral appliances (Bailey, 2005; Fleetham et al., 2010).  
2.9.1 Oral appliances for the treatment of OSA 
In subjects with enough teeth in order to retain an oral appliance, the appliance is a simple and 
non-invasive device for treatment of snoring and mild to moderate OSA (Wee, 2012). There are 
presently a number of different oral appliances available for the treatment of OSA, which are used 
to increase the size - and prevent a collapse - of the upper airway by either advancing the mandible 
or the tongue (Ferguson et al., 2006; Fleetham et al., 2010; Wee, 2012).  
There is a wide variety of oral appliances in terms of design, material, location of coupling 
mechanism, and amount of mandibular advancement and incisal opening (Ferguson et al., 1997b; 
Hoekema et al., 2004; Viviano, 2004; Bailey, 2005; Chan et al., 2007; Hoffstein, 2007; Fleetham 
et al., 2010; Dort et al., 2012; Wee, 2012). The terminology regarding the oral appliances is 
somewhat variable and some of the labels in English include: oral appliances, functional 
appliances, mandibular advancement devices, mandibular advancement splints, mandibular 
repositioning devices, anterior mandibular positioners, oral airway dilators and airway orthotic 
devices (Viviano, 2002a; Bailey, 2005; Ferguson et al., 2006; Horchover, 2007; Fleetham et al., 
2010; Wee, 2012, Friedman et al., 2014). Two of the main proposed mechanisms of action during 
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sleep for these devices are increasing the size of the upper airway (Ryan et al., 1999), and 
decreasing the collapsibility of the upper airway (Ng et al., 2003; Hoekema et al., 2004; Viviano, 
2004; Bailey, 2005; Hoffstein, 2007; Fleetham et al., 2010; Wee, 2012). In order to get an 
understanding of the degree of mandibular advancement and vertical incisal opening achieved with 
oral appliances, a number of studies in subjects with OSA have been listed in Table 2.6. 
Table 2.6: The table presents a number of studies in which data on mandibular advancement and 
incisal opening achieved with oral appliances in subjects with OSA or snorers are reported (mm; 
means ± SD). 
 
First author, year 
published 
Subjects (male)  Maximal mandibular 
protrusion* 
Vertical opening  
Barnes et al., 2004 114 (NA) 10.3 (0.3) NA** 
Barthlen et al., 2000 8 (7)  3-5 NA** 
Bloch et al., 2000 24 (NA)  10.0 (0.4) = 75%*  5-10, 4-6 
Chan et al., 2010a 35 (28)  5.8 (2.2) = 75%* NA** 
Chan et al., 2010b 69 (47)  6.5 (2.3) = 76.1% (12.8)* NA** 
Chan et al., 2011 35 (29)  4.8 (1.6) = 70.9% (20.5)* NA** 
Dort et al., 2012 41 (29) 6 and 8  NA** 
Ferguson et al., 1996 27 (24)  7 NA** 
Fleury et al., 2004 44 (36), 3 groups 12.0 (3.0), 11.0 (4.0), 12.0 (4.0) NA** 
Fransson et al., 2003 77 (63)  10.7 (2.3) 6.9 (2.1) 
Gale et al., 2000 32 (27)  5.7 (2.5) NA** 
Johnston et al., 2002 20 (16)  5.7 = 75%* 4 
Kyung et al., 2005 14 (12)  7.1 (1.9) 7.7 (2.5) 
Lazard et al., 2009 84 (64)  7.0 (1.5) NA** 
Lettieri et al., 2011 805 (698), 2 groups NA 3-5 
Marklund et al., 2004 630 (508)  4-6 At least 5 
Mehta et al., 2001 24 (19)  7.5 (1.8) = 75%*  NA** 
Sari et al., 2011 24 (NA)  9.4 (1.3) 5 
Tsuiki et al., 2004 20 (20), 2 groups 10.5 (1.5), 10.5 (1.4) NA** 
Vroegop et al., 2012 40 (32)  7.2 (1.8) 6.8-20 
Walker-Engström et 
al., 2002 
95 (95)  9.7 2.0 
Walker-Engström et 
al., 2003 
86 (86), 2 groups 
 
9.8 (0.6) 
9.6 (0.6) 
2.0 
*If maximum advancement not reported the mean protrusion at a specific percentage has been 
included;  
** NA, if no data on vertical bite opening reported. 
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The mandibular protrusion ranged from 3 to 12 mm, and the incisal opening ranged from 2 to 20 
mm in the studies included in Table 2.6. In the Walker-Engström studies (2002; 2003) the mouth 
opening capacity was reported as 51.2 mm (2002), and 49.9 mm and 52.0 mm, respectively (2003). 
In order to achieve a degree of mandibular advancement which is tolerable or free of discomfort, 
a titration process is used as shown in Figure 2.46 (Wee, 2012). The subject is initially given an 
oral appliance set at 50-75% of the subject’s maximal mandibular advancement, which is later 
changed with incremental steps of 0.5 to 1.0 mm every week based on the comfort or the 
discomfort with the appliance and the advancement. Assuming the therapeutically effective 
position for the treatment of OSA is at A, the use of the oral appliance should be tolerable as this 
is between the initial advancement and the maximum discomfort free advancement (Figure 2.44).  
 
Figure 2.46: Diagram of mandibular advancement (protrusion) (Wee, 2012). 
 
If the therapeutically effective position for the treatment of OSA is at B or C, the subject could not 
tolerate the maximal mandibular advancement, and the treatment would be either suboptimal (B) 
or ineffective (C) (Ferguson et al., 2006; Wee, 2012). 
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2.9.2 Examples of oral appliances  
A number of different oral appliances available for the treatment of OSA are used to increase the 
size - and prevent a collapse - of the upper airway by either advancing the mandible or the tongue 
as shown in Figure 2.47 (Hoekema et al., 2004; Hoffstein, 2007; Fleetham et al., 2010; 
Vanderveken et al., 2010; Ahrens et al., 2011; Randerath et al., 2011; Sutherland et al., 2014). 
 
 
 
 
Figure 2.47: Eight different brands of oral appliances used for the treatment of OSA are shown 
(Fleetham et al., 2010). From top left to bottom right: Aveo-TSD1 (Innovative Health 
Technologies, Christchurch, New Zealand); SomnoDent1 MAS (SomnoMed, Denton, TX, USA); 
PM positioner1 (Great Lakes Orthodontics Ltd, Tonawanda, NY, USA); Monoblock appliance 
(courtesy of M. Marklund, Umeå University, Sweden); HerbstTM (Great Lakes Orthodontics Ltd); 
MDSA1 (Medical Dental Sleep Appliance; R.J. and V.K. Bird Pty Ltd, Melbourne, VIC, 
Australia); KlearwayTM (Great Lakes Orthodontics Ltd), lateral view; KlearwayTM, hinge view.  
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2.9.3 Impact of mandibular advancement on the pharyngeal dimensions 
The efficacy of oral appliances has been tested in a number of clinical studies in subjects with 
OSA using the AHI as the main outcome variable (Barthlen et al., 2000, Johnston et al., 2002; 
Walker-Engström et al., 2002; Walker-Engström et al., 2003; Petri et al., 2008, Aarab et al., 2010; 
Lazard et al., 2009; Lettieri et al., 2011; Sari et al., 2011; Marklund et al., 2012; Friedman et al., 
2014).  
Airway-imaging studies have been performed in both healthy subjects and in subjects with OSA 
using oral appliances. The imaging techniques used included cephalometry, CT, MRI, and 
videoendoscopy (Fleetham et al., 2010). Mandibular and tongue advancement have been shown 
to increase the size of the upper airway, and to alter the shape of the upper airways particularly in 
the velopharynx in both healthy subjects and in subjects with OSA (Ferguson et al., 1997a; Johal 
et al., 1999).  
The use of oral appliances have in other studies been shown to increase the anteroposterior 
diameter of the oropharynx and hypopharynx (Ng et al., 2003), to increase the total volume of the 
upper airway, and the CSAs of the retropalatal and retroglossal regions (Sam et al., 2006; Kyung 
et al., 2005), to increase the lateral dimensions of the velopharynx (Tsuiki et al., 2004; Zhao et al., 
2008; Chan et al., 2010a; Chan et al., 2010b; Marklund et al., 2012), and to move the entire tongue 
forward (Brown et al., 2013). Mandibular advancement has also been shown to decrease 
respiratory resistance in subjects with OSA (Lorino et al., 2000).  
There are, however, studies showing that in some subjects the use of an oral appliance might not 
create an enlargement of the upper airway (Gale et al., 2000; Mostafiz et al., 2011; Sutherland et 
al., 2011). 
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2.9.4 Impact of incisal opening on the pharyngeal dimensions 
Whereas the impact of mandibular advancement on the upper airways has been the focus of a large 
number of studies, only a few have focused on the potential impact of the vertical incisal opening 
on the size of the upper airways mainly in subjects with OSA (Meurice et al., 1996; Pitsis et al., 
2002; Ahrens et al., 2011; Nikolopoulou et al., 2011; Vroegop et al., 2012). In the study by Meurice 
et al (1996) the authors investigated the influence of a 15 mm bite opening on the collapsibility of 
the upper airways in 6 sleeping healthy subjects. Pressure-flow measurements of the subjects’ 
upper airways showed that the bite opening increased the upper airway collapsibility. The study 
by Nikolopoulou et al (2011) in 18 subjects with OSA investigated the effect of an incisal opening 
of 6 mm using an oral appliance without mandibular advancement on the AHI. The results 
indicated that an increased incisal opening without mandibular advancement might be associated 
with aggravation of OSA in some subjects.  
Pitsis et al (2002) investigated the impact of 2 incisal openings (4 mm and 14 mm) in 2 oral 
appliances in a randomised, cross-over study in 23 subjects with OSA using a reduction in AHI 
after 2 weeks of usage as a measure of response. Both incisal openings reduced AHI in a similar 
fashion, although 78% of the subjects preferred the smaller incisal opening. The authors concluded 
that the results suggested that the amount of incisal opening did not have a significant impact on 
treatment efficacy of the oral appliances.  
Vroegop et al (2012) investigated the impact of the incisal opening on the pharyngeal collapsibility 
in 40 subjects with OSA using video-endoscopy during sleep endoscopy. During the sleep 
endoscopy the incisal opening was increased from a baseline mean of 6.8 (SD 1.0) mm, and a 
mean maximal comfortable advancement of 7.2 (1.8) mm, to an incisal opening of 20 mm by 
manual downwards movement of the subjects’ mandibles (Figure 2.48).  
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The effects of the incisal opening on the CSA of the upper airway at the level of the tongue base 
was scored as either adverse (narrowing), positive (widening) or indifferent (no change in 
pharyngeal dimensions). Thirty-two subjects had an adverse effect of the incisal opening (top row 
of pictures in Figure 2.48), 1 had a positive effect (middle row of pictures in Figure 2.48), and 7 
subjects had an indifferent effect (bottom row of pictures in Figure 2.48). 
 
 
 
 
 
Figure 2.48: Effects of vertical incisal opening of the mouth on pharyngeal dimensions in subjects 
assessed video-endoscopically during sleep endoscopy. The left panel shows the baseline, the 
middle panel the impact of the maximal comfortable protrusion and the right panel the impact of 
the vertical opening. The top row of photos shows adverse effects of vertical incisal opening on 
pharyngeal dimensions, the middle row the positive effects and the bottom row the indifferent 
effects of vertical opening on pharyngeal dimensions (Vroegop et al., 2012). 
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2.9.5 Combination of incisal opening and mandibular advancement  
In the studies reviewed in 2.9.2 the subjects were either diagnosed with OSA (Meurice et al., 1996; 
Pitsis et al., 2002; Vroegop et al., 2012) or were sleeping when the impact of the increase in incisal 
opening was registered (Nikolopoulou et al., 2011; Vroegop et al., 2012). In contrast the study by 
Gao et al (2004) examined in 14 non-apnoeic men adaptive changes in the CSAs of the upper 
airways following mandibular advancement and incisal opening. A custom made oral appliance 
was used to keep the mandible at 0%, 50%, 75% and 100% of maximal mandibular advancement 
and at 50%, 75% and 100% of maximum incisal opening at 75% mandibular advancement. The 
incisal openings were 4 mm (V0), 9.8 ± 4.1 mm (V50), 14.7 ± 4.1 mm (V75) and 19.6 ± 4.1 mm 
(V100). An MRI was used to examine differences in the CSAs of the upper airways in the 7 possible 
mandibular advancement and incisal opening positions with the study subjects in a supine position. 
The percent changes in the minimum and mean CSA of the whole upper airway, the velopharynx, 
the oropharynx and the hypopharynx were reported. The changes of the minimum CSAs of the 
whole upper airway (p = 0.0004), the velopharynx (p = 0.0006) and the oropharynx (p = 0.0258) 
were statistically significant during mandibular advancement. In contrast, the changes of the mean 
CSAs of the upper airway (p = 0.0434) and the velopharynx (p = 0.0027) were the only statistically 
significant changes during mandibular advancement. The relative changes in the minimum CSA 
for the whole upper airway, the velopharynx, the oropharynx and the hypopharynx are shown in 
Figure 2.49. 
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Figure 2.49: The relative changes in the minimum CSA (min%) for the whole upper airway, the 
velopharynx, the oropharynx, and hypopharynx following mandibular advancement at 50%, 75% 
and 100% (F50, F75 and F100) without increase in incisal opening (V0) (Gao et al., 2004). 
 
However, when the incisal openings were included in the measurements there were no statistically 
significant differences in either the minimum or the mean CSAs for any of the mandibular 
advancements due to the large inter-individual variability (Figure 2.50).  
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Figure 2.50: The actual minimum CSA of the velopharynx, the oropharynx and the hypopharynx 
per subject for the different mandibular positions. The “A-P dimensions” refer to the mandibular 
advancements (F0-100), and the “Vertical dimensions” to the incisal openings (V0-100). The mean 
values are shown by open circles and thick lines (Gao et al., 2004). 
 
The minimum CSAs for the velopharynx, the oropharynx and the hypopharynx are shown in 
Figure 2.50. Some of the individual changes were actually negative when compared with baseline 
(F0; V0) further highlighting the large variability of the individual results especially in the 
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hypopharynx. As the impact of the incisal opening was limited in comparison with the mandibular 
advancement it would have been of interest to investigate the vertical incisal opening also at F0 
and F50 mandibular protrusions instead of only at F75. 
2.9.6 The distensibility of the upper airway  
The human upper airway lacks a fixed rigid structural support and the position of structures like 
the soft palate, the tongue and the wall of the oropharynx determine the shape and size of the upper 
airway. The anterior wall of the oropharynx is primarily composed of the soft palate, the tongue 
and the lingual tonsils, and the posterior wall is bounded by the superior, middle and inferior 
constrictor muscles. The lateral pharyngeal walls are made up of muscles, lymphoid tissue and 
pharyngeal mucosa. Due to the structure of the upper airway, the collapsibility of it and the impact 
of dilator muscles, it does not have a fixed CSA (Ayappa et al., 2003).  
The distensibility of the upper airways has been investigated in response to nasal CPAP, and the 
collapsibility of it in response to nasal CNAP (Shepard et al., 1990, Schwab et al., 1996). Shepard 
et al included 13 healthy subject and 17 subjects with moderately severe OSA in a study of the 
distensibility and the collapsibility of the upper airways. The airway pressures ranged from -5 cm 
H2O to 0 cm H2O and +5 cm H2O and the upper airway size was measured through CT with the 
subjects awake and in a supine position. In the healthy subjects the CNAP had little impact and 
only decreased the CSAs in the most caudal segments of the hypopharynx (Figure 2.51). The 
impact of CNAP was similar in the subjects with OSA (Figure 2.52). The CPAP increased the 
CSAs of the upper airways at most levels (Figure 2.51; Figure 2.52) (Shepard et al., 1990). 
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Figure 2.51: CSAs of upper airway regions from velopharynx to hypopharynx measured through 
CT under conditions of -5, 0 and +10 cm H2O of CAP ventilation in healthy subjects. Data are 
presented as means ± SE, * = p<0.05, and ** = p>0.01) (Shepard et al., 1990). 
 
 
Figure 2.52: CSAs of upper airway regions from velopharynx to hypopharynx measured through 
CT under conditions of -5, 0 and +10 cm H2O of CAP ventilation in subjects with OSA. Data are 
presented as means ± SE, * = p<0.05, and ** = p>0.01) (Shepard et al., 1990). 
 
Schwab et al (1996) used MRI to investigate the effects of increasing levels of nasal CPAP (0, 5, 
10, and 15 cm H2O) on the upper airway size in 10 healthy adult subjects awake and in supine 
position (Figure 2.53). 
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Figure 2.53: Three-dimensional surface renderings of the upper airway in one subject. The effects 
of different levels of CPAP pressure (0-15 cm H2O) on the volume of the upper airways is shown 
with focus on the retropalatal and the retroglossal regions. The lateral widening is obvious 
(Schwab et al., 1996). 
 
The results of the progressive increases in CPAP showed an increase in both volume and area 
within the retropalatal and retroglossal regions of the pharynx. The volume was almost doubled in 
both regions, whereas the changes in the CSAs were even more pronounced, especially in the 
retropalatal region (Table 2.7). 
Table 2.7: Mean airway CSAs (cm2 ± SD) in the retropalatal (RP) and retroglossal (RG) regions 
at three anatomic locations (midregion, minimal, and maximal) with increasing levels of nasal 
CPAP (0, 5, 10, and 15 cm H2O). (Adapted from Schwab et al., 1996). 
 
Anatomic site 0 cm H2O 5 cm H2O 10 cm H2O 15 cm H2O 
RP midregion 1.0 ± 0.5 1.3 ± 0.7 2.0 ± 0.8 2.8 ± 1.1 
RP minimal 0.8 ± 0.5 1.0 ± 0.6 1.5 ± 0.8 2.1 ± 1.1 
RP maximal 2.5 ± 0.6 2.6 ± 0.6 3.1 ± 0.8 3.6 ± 0.9 
RG midregion 1.9 ± 0.7 1.8 ± 0.6 2.3 ± 0.7 2.8 ± 0.6 
RG minimal 1.4 ± 0.7 1.4 ± 0.5 1.9 ± 0.5 2.2 ± 0.6 
RG maximal 2.1 ± 0.7 2.1 ± 0.7 2.7 ± 0.9 3.1 ± 0.8 
 
The lateral dimensional changes were greater than the anteroposterior changes, and the structural 
changes in the lateral upper airway soft tissue were significantly greater than the anteroposterior 
changes. Overall, the changes in the CSAs were similar to those found in the study by Shepard et 
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al (1990). The distance between the lateral parapharyngeal fat pads increased and the lateral 
pharyngeal wall thickness decreased. The authors concluded that the study provided further 
evidence that the lateral pharyngeal walls play an important role in the mediation of the size of the 
upper airway (Schwab et al., 1996). The distensibility of the upper airways in the studies by 
Shepard et al (1990), and Schwab et al (1996) proved to be considerable. The CSAs ranged from 
~1 cm2 to ~7 cm2 and were close to some of the values on CSAs in studies in which oral appliances 
(Gao et al., 2004), and the ARP technique had been used (Busetto et al., 2009; Table 2.1). 
2.10 The stepped mouthpieces 
During the analysis of the study presented in Chapter 3, the question regarding the variability in 
the size of the subjects’ upper airways and the impact of the subjects’ anatomy of the upper airways 
on lung deposition was discussed. The possibility to enlarge the upper airway through mandibular 
advancement led to the development of a new stepped mouthpiece as a tool to achieve mandibular 
advancement when using an inhaler. The inhaler could be a pMDI (with spacer or VHC), a DPI or 
a nebuliser. The stepped mouthpiece without tongue depressor is shown in Figure 1.1 (patent US 
2011/0240015 A1; published 6 October, 2011; PCT filed 23 November, 2009). 
The abstract of the new stepped mouthpiece in the patent US 2011/0240015 A1 stated: 
“The invention of the present application relates to an apparatus to aid in administering inhaled 
pharmaceutical aerosol to a patient. The apparatus is used in conjunction with an aerosol delivery 
device. The apparatus comprises steps on the top and bottom of the apparatus, which when used 
aid the patient causes mandibular advancement, and opening of the mouth, causing opening of 
patient’s airway, resulting in improved aerosol lung deposition. The invention also relates to a 
method of using such apparatus in a combination with an aerosol delivery device or a system, and 
to the mouthpiece of said apparatus.” 
 
The stepped mouthpiece without a tongue depressor was tested in the proof-of-concept study 
presented in Chapter 4. It was designed in several sizes with front ends with 10 mm, 15 mm and 
20 mm orifices (vertical diameters). These front orifices were also designed with a single 
 116 
  
 
protrusion on the upper side for the upper incisors and 1 of 4 protrusions on the lower side at 
different distances (-3 mm, ±0 mm, +3 mm and +6 mm) in relation to the protrusion on the upper 
side for horizontal movement of the mandible. The horizontal offsets were -3 mm (lower jaw 
moved back from an incisal edge-to-edge position), ±0 (incisal edge-to-edge position), + 3 mm 
and +6 mm (mandible moved forward from an incisal edge-to-edge position). The stepped 
mouthpiece was 40 mm long.  
The stepped mouthpiece with a tongue depressor was developed based on the experience from the 
proof-of-concept study in Chapter 4 and is shown in Figure 1.2 (patent US 2012/0240922 A1; 
published 27 September, 2012; PCT filed 9 November, 2010). 
The abstract of the new stepped mouthpiece in the patent US 2012/0240922 A1 stated: 
“An apparatus and method to aid in administering inhaled pharmaceutical aerosol to a patient is 
configured to maintain a tongue in proper position and offset the patient’s upper and lower jaws 
during aerosol delivery. An adjustable member is provided adjacent a mouthpiece and at least 
partially surrounds and moves with respect to the body of the apparatus. The adjustable member 
has a step structure to impart a selected amount of mandibular advancement to a patient during 
aerosol delivery. A tongue depressor which may be integrally formed with the adjustable member 
configured to prevent a tongue from occluding a flow of aerosol is also provided.” 
 
The stepped mouthpiece with a tongue depressor was tested in the study presented in Chapter 5. 
The tongue depressor and the related part of the mouthpiece to be held in the mouth were 33 mm 
long, and the external horizontal and vertical diameters 34 mm and 18 mm, respectively. The 18 
mm vertical external diameter was chosen partly based on the results of the previous proof-of-
concept study in which the largest mouthpiece had an external vertical mouthpiece diameter of 20 
mm, and partly as this is a common vertical size of jet nebuliser mouthpieces.  
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Chapter 3 Assessment of the upper airways in healthy 
subjects when using acoustic pharyngometry 
3.1 Introduction 
3.1.1 Deposition of aerosol in the upper airway 
Deposition of aerosol in the upper airways is the major anatomical determinant for deposition of 
aerosol in the lungs (Svartengren et al., 1996), and the relative variability in lung deposition seems 
to be high for low lung deposition and low for high lung deposition (Borgström et al., 2006).  
Deposition of aerosol in the upper airway can be the purpose of inhaled drug therapy as highlighted 
in the study by Kumazawa et al (1997), in which the authors aimed for a high upper airway 
deposition (pharynx and the larynx) in a scintigraphic study in 6 healthy subjects. An ultrasonic 
nebuliser was used for the aerosolisation of a saline solution labelled with 99mTc-DTPA. The 
subjects inhaled the aerosol during either deep and slow breathing with 12 breaths/minute, fast 
breathing with 36 breaths/minute, or fast breathing with 36 breaths/minute with intermittent 
vocalisation. The lung deposition decreased, and deposition in larynx increased, when the subjects 
changed from deep and slow breathing to fast breathing with vocalisation. 
Slow and deep inhalation of aerosol has in a number of studies been shown to increase deposition 
of aerosol in the lungs (Svartengren et al., 1996; Brand et al., 2000; Nikander et al., 2010c; van 
Velzen et al., 2015). In the study by Nikander et al (2010c) performed in the summer of 2006, the 
lung and upper airway deposition of 99mTc-DTPA in a saline solution was investigated in 12 
healthy adult subjects in a randomised, open-label, crossover study with the I-neb nebuliser in 
TBM and TIM breathing modes. All subjects were in a seated position during nebulisation, used 
nose clips during nebulisation, and inspiratory and expiratory flows through the mouthpiece were 
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monitored electronically during the study. The mean lung deposition of 99mTc-DTPA, expressed 
in percent of emitted dose ex-mouthpiece, was in TIM 73.29% (SD 16.3) and in TBM 62.82% 
(19.6), and the difference was statistically significant (Figure 3.1). The mean upper airway 
deposition in TIM was 26.49% (16.3) and in TBM 36.18% (19.7), and the difference was 
statistically significant (Figure 3.1).   
 
Figure 3.1: The lung, the central lung, the peripheral lung, and the upper airway deposition of 
99mTc-DTPA plus the exhaled amount of 99mTc-DTPA is presented in percentage of the emitted 
dose ex-mouthpiece of the I-neb nebuliser. TBM in black and TIM in grey bars, respectively 
(Nikander et al., 2010c). 
 
The variability in the upper airway deposition is difficult to explain considering the slow and deep 
breathing pattern and the relatively small droplet size of 4.6 µm. It would therefore be of interest 
to investigate the subjects’ upper airway CSAs and volumes using acoustic pharyngometry and to 
measure the oral cavity and the size of the tongue using other techniques. 
3.1.2 Acoustic pharyngometry 
As described in Chapter 2, section 2.7 of this thesis. 
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The Eccovision Acoustic Pharyngometer (Hood Laboratories, Pembroke, MA, USA; presently 
www.sleepgroupsolutions.com) has been used in a large number of clinical studies of the upper 
airways (section 2.7.6-2.7.7). The pharyngogram obtained from the measurements with the 
acoustic pharyngometer were analysed in terms of the oral cavity, the OPJ, the oropharynx, the 
EG, the hypopharynx and the GL (Chapter 2, section 2.7.6 and Figure 2.35). 
3.1.3 The oral cavity 
As acoustic pharyngometry only measures the CSAs and volumes of the upper airways, other tools 
are required for more detailed measurements of for example displaced mandibles, highly arched 
palates, and disproportionately large amounts of oral soft tissue (i.e., an oversized tongue and/or 
soft palate). These tools cover the assessment of the pharyngeal space (Tsai et al., 2003), the 
Mallampati scoring technique for assessment of the tongue size (Berkow, 2004), the measurement 
of the cricomental space (Tsai et al., 2003), and tongue scalloping (Weiss et al., 2005).  
A number of other variables such as palatal height, maxillary inter-molar distance, mandibular 
inter-molar distance, incisor overjet, and tongue length might affect deposition of aerosol in the 
oral cavity and in the upper airway. These variables could be measured with a prototype Oral Mez 
device (Philips Respironics, PA, USA). 
3.1.3.1 Assessment of the pharyngeal space 
Tsai et al (2003) described a grading system of the pharyngeal space which was based on a four-
point ordinal scale (Tsai et al., 2003; Figure 3.2). The grading system created 4 pharyngeal grades 
from left to right in Figure 3.3 as follows:  
- Class I - the palatopharyngeal arch intersects at the edge of the tongue. 
- Class II - the palatopharyngeal arch intersects at 25% or more of the tongue diameter. 
- Class III - the palatopharyngeal arch intersects at 50% or more of the tongue diameter. 
- Class IV - the palatopharyngeal arch intersects at 75% or more of the tongue diameter. 
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Figure 3.2: The pharyngeal grading system by Tsai et al (2003). The grading system created 4 
pharyngeal grades, Class I-IV, from left to right. 
 
3.1.3.2 Mallampati scoring technique for assessment of tongue size 
Mallampati initially described his classification of airway assessment in 1985 (Mallampati, 1985) 
and hypothesized that a large tongue would cause difficulty in exposing the larynx leading to 
difficult laryngoscopy. Since a large tongue also obscures the view of the uvula and tonsillar 
pillars, 3 classes were created which were shown to be correlated with the degree of difficulties 
experienced at laryngoscopy. With the subject sitting up and with maximal protrusion of the 
tongue, visibility of the faucial pillars, soft palate and uvula were noted. The classification was as 
follows: 
- Class I - described full visualization of all three structures.  
- Class II - allowed visualization of only the faucial pillars and soft palate. 
- Class III - only the soft palate was visible. 
Samsoon et al (1987) modified the original classification to add a 4th class in which not even the 
soft palate was visible (Figure 3.3). 
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Figure 3.3: The modified Mallampati scoring system (Lam et al., 2005). 
 
3.1.3.3 Measurement of the cricomental space 
The cricomental space can be determined using a thin ruler to connect the cricoid cartilage to the 
inner mentum with the head in a neutral position. The cricomental line should be bisected, and the 
perpendicular distance to the skin of the neck should be measured (Figure 3.4). The use of a thin 
ruler (1 mm or less) has been considered essential because thicker devices might influence 
measurement (Tsai et al., 2003; Persaud, 2010). 
 
Figure 3.4: Assessment of the cricomental space, which is defined as the distance between the 
neck and the bisection of a line from the chin to the cricoid membrane, when the head is in a neutral 
position (Persaud, 2010). 
 
 122 
  
 
3.1.3.4 Tongue scalloping 
Tongue scalloping can be measured using the grades (0-3) published by Weiss et al (2005) as 
follows (Figure 3.5):  
- 0 - complete absence of scalloping. 
- 1 - scalloping evident but not pronounced.  
- 2 - scalloping pronounced but resolved with tongue protrusion. 
- 3 - scalloping pronounced and unresolved with tongue protrusion. 
 
Figure 3.5: The lateral glossal margin in a normal subject is shown in (A), and the same area in a 
subject with grade III tongue scalloping evident during tongue protrusion in (B) (Weiss et al., 
2005). 
 
3.1.3.5 The Oral Mez 
The Oral Mez device (Figures 3.6 and 3.7) was a prototype device developed by Philips 
Respironics (PA, USA) for measurements of the palatal height, maxillary inter-molar distance, 
mandibular inter-molar distance, incisor overjet, and tongue length in the oral cavity. There are no 
published validation data on the Oral Mez device and it has not been commercialised. It has been 
described in the abstract of the US patent US 7632238 B1 (published 2009), as follows: 
“A device for taking measurements associated with an oral cavity of an individual. The device 
comprises a body and measuring indicia formed on the body which can be used to measure at least 
one parameter of the individual's mouth. An upper surface and a lower surface of the body are 
formed from an markable material capable of being marked by application of force from the 
individual's teeth. The body may also comprise a pallet measuring member constructed and 
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arranged to extend operably from the body. The pallet measuring member has indicia formed 
thereon to enable measurement of the height of the individual's hard pallet. The body may also be 
provided with indicia to measure the length of the individual's tongue.” 
 
 
Figure 3.6: Top view of the Oral Mez device (Philips Respironics, PA, USA). 
 
 
 
Figure 3.7: Bottom view of the Oral Mez device (Philips Respironics, PA, USA). 
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Before the measurement the Oral Mez was placed in hot water for some minutes, then cooled in 
running cold tap water and then placed in the subject´s mouth. The procedure with hot water was 
necessary in order to make the plastic soft enough for the teeth to leave marks on it. 
3.1.4 Study hypothesis 
The anatomy of the upper airway (CSAs, and volumes) determines subsequent deposition of 
aerosol in the upper airway and therefore the deposition of aerosol in the lung. 
3.2 Study objectives 
3.2.1 Primary Objective 
The primary objective of the study was to measure the upper airways of 12 healthy subjects - 
enrolled in the previous lung deposition study (Nikander et al., 2010c) - by means of AR using an 
acoustic pharyngometer (Eccovision ARP). The measurements were performed with the subjects 
seated in the same upright position as when they were inhaling through the I-neb nebuliser in the 
previous lung deposition study. The subjects were also instructed to inhale with the same 
inspiratory flows as in the previous study. 
3.2.2 Secondary Objectives 
The secondary objectives included several assessments and measurements of the oral cavity which 
were performed with the healthy subjects seated in the same upright position as when inhaling 
through the I-neb nebuliser in the previous lung deposition study. The assessments and 
measurements were based on the techniques described in the previous section (3.1.3.1. – 3.1.3.5.). 
3.3 Methods 
The study was performed as an open investigation including one study group. The healthy subjects 
included had all participated in a lung deposition study using the I-neb nebuliser (Nikander et al., 
2010c). The subjects attended the clinic (Cardiff Scintigraphics Ltd., Cardiff, UK) once for 
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eligibility confirmation, consent, measurements of the upper airways by acoustic pharyngometry, 
and assessments and measurements of the oral cavity. 
3.3.1 Study design and study variables 
- Physical examination including measurement of vital signs (supine blood pressure and pulse 
rate). 
- Height (cm) and weight (kg) for calculation of BMI [weight in kg/(height in m2)]. 
- Collar size (cm). 
- Lung function. In order to be able to compare each subject’s lung function to that of the 
previous lung deposition study, lung function was measured following the recommendations 
of the ATS Standardization of Spirometry 1994 Update to establish reproducibility of FEV1. 
(ATS, 1994).  
- Measurement of the upper airways by acoustic pharyngometry without and with nose clip as 
nose clips were used in the previous lung deposition study to prevent inhalation and exhalation 
via the nose. The primary acoustic pharyngometer measurements each consisting of 4 
pharyngogram recordings are outlined in A, B and C (B and C were applied in the randomised 
order used in the previous lung deposition study; Nikander et al., 2010c), and the secondary 
acoustic pharyngometer measurements are outlined in D and E (applied in that order). 
 (A) Measurement with 4 baseline recordings with the subject exhaling air through the 
pharyngometer (without and with nose clip).  
 B and C were then applied in the randomised order used in the previous lung deposition 
study: 
 (B) Measurement with 4 recordings with the subject inhaling air through the 
pharyngometer wavetube with the I-neb nebuliser TBM mouthpiece attached to the back 
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end of the wavetube. The subject was trained to inhale with an inspiratory flow similar 
to the one recorded in the original lung deposition study in TBM (without and with nose 
clip). 
 (C) Measurement with 4 recordings with the subject inhaling air through the 
pharyngometer wavetube with the I-neb nebuliser TIM mouthpiece attached to the back 
end of the wavetube. The subject was trained to inhale with an inspiratory flow similar 
to the one recorded in the original lung deposition study in TIM (without and with nose 
clip).  
 D and E were then applied in the order outlined below: 
 (D) Measurements (4 recordings at each flow) with the subject inhaling air through the 
pharyngometer wavetube with inspiratory flows of 10, 20, 30, 40 and 60 L/min (without 
and with nose clip). 
 (E) Measurements (4 recordings at each flow) with the subject inhaling air through the 
pharyngometer wavetube with the I-neb nebuliser TBM mouthpiece attached to the 
wavetube with inspiratory flows of 10, 20, 30, 40 and 60 L/min (without and with nose 
clip). 
 Assessment of the tongue size using a modified Mallampati score. 
 Measurement of the cricomental space. 
 Measurement of tongue scalloping. 
 Measurement of palatal height, maxillary intermolar distance, mandibular intermolar 
distance, incisor overjet, and tongue length using the Oral Mez. 
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The study procedures have been outlined in a diagram (Table 3.1). 
 
Table 3.1: Diagram over study measurements and assessments. 
 
 
3.3.2 Study equipment and timing of pharyngometer measurements 
3.3.2.1 Acoustic pharyngometer 
The acoustic pharyngometer measurements followed the instructions regarding measurements 
with the device as outlined in the Eccovision Acoustic Pharyngometry Operator Manual. The 
acoustic pharyngometer measurements were performed with the subjects seated on a straight-
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backed chair. The aim was to keep the wavetube horizontally parallel to the floor and prevent head, 
neck and shoulder movement by instructing the subjects to keep their gaze fixed at a point on the 
wall. A comfortable position was important in order to avoid any increase in muscle tonus through 
heavy occlusion on the mouthpieces (Viviano, 2002a). The recordings during exhalation followed 
the instructions to a subject in the Eccovision Acoustic Pharyngometry Operator Manual (Hood 
Laboratories, Pembroke, MA, USA; presently www.sleepgroupsolutions.com): 
- You will sit in a chair and hold a wand with a mouthpiece on it.   
- You will place the mouthpiece in your mouth and do various breathing on the mouthpiece 
as instructed by the technologist. 
- Breathing through the mouth normally for 10 to 12 seconds.  
- Breathing through the nose for 10 to 12 seconds.  
- Closing your glottis and exhaling.  
- Closing your glottis and inhaling.  
- A technologist will instruct you on how to perform the test and coach and encourage you 
to do your best.  
3.3.2.2 Acoustic pharyngometer wavetube modifications 
Due to the design of the study it was important that the acoustic pharyngometer measurements of 
the upper airways of the subjects were recorded with the subjects inhaling through the I-neb 
nebuliser mouthpieces in both TBM and TIM breathing modes. In order to mimic the TBM and 
TIM breathing modes during the acoustic pharyngometer measurements, the I-neb nebuliser 
mouthpieces were attached to the back end of the pharyngometer wavetube (Figure 3.8). The 
subjects’ inhalation and exhalation flow rates during both TBM and TIM breathing had in the 
previous lung deposition study been recorded through an I-neb Function Monitor (Philips 
Respironics, Chichester, UK) (Nikander et al., 2010c). As the I-neb Function Monitor was not 
available for the present study, a pneumotachograph was connected between the I-neb nebuliser 
mouthpiece and the wavetube in series with a Mimic Breathing Monitor (Philips Respironics, 
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Chichester, UK) (Nikander et al., 2000a; Nikander et al., 2000b) which was connected to a laptop. 
During breathing through the wavetube the subjects could follow their breathing patterns on a PC 
laptop screen and were guided to use their mean peak inspiratory flow rates from the previous 
study. In order to guide the subjects to the right peak inspiratory flow rates a transparent plastic 
sheet was placed on the PC laptop screen with horizontal lines highlighting flows of either 20 
L/min or 30 L/min. 
The back end of the I-neb nebuliser mouthpiece, which in normal use is connected to the body of 
the nebuliser, was covered by a plastic wrapping so that the subject’s inspiratory flow was directed 
through the inhalation and exhalation valve of the mouthpiece (Figure 3.8). 
 
 
Figure 3.8: The back end of the pharyngometer wavetube is shown with a pneumotachograph and 
an I-neb nebuliser mouthpiece attached. The back end of the mouthpiece was covered by a plastic 
wrapping so that the subject’s inspiratory flow was directed through the inhalation and exhalation 
valve of the mouthpiece. 
 
3.3.2.3 Timing of acoustic pharyngometer measurements 
Timing of the pharyngometry measurement – when to start and when to stop during the subject’s 
breathing – could be challenging when timing is restricted to an observation of the subject. The 
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use of the Mimic Breathing Monitor pneumotachograph connected to the wavetube offered both a 
method to follow the subject’s breathing breath-by-breath, and a tool for when to start and when 
to stop the acoustic pharyngometer measurement. As the acoustic pharyngometer measurements 
were performed both during exhalation and inhalation, the timing of the measurements was of 
importance as motion of soft tissue in the upper airway and related bony structures has been shown 
to create dimensional changes in the upper airways (Figure 2.5; Schwab, 1998).   
Interestingly the dimensional changes were predominantly found in the lateral dimension and 
Schwab concluded that this suggested “that the lateral walls may have an important role in 
modulating airway caliber”, and that “those studies indicate that significant changes in upper 
airway caliber occur during the respiratory cycle” (Schwab, 1998). The upper airway has been 
shown to be significantly smaller in apnoeic subjects than in healthy subjects (Schwab et al., 
1993a), but similar dimensional changes in the upper airways were shown to occur in healthy 
subjects (Schwab et al., 1993b).  
Although the dimensional changes in the upper airway area reported by Schwab (1998) occurring 
during breathing were recorded with the subjects in a supine position the results might be relevant 
for the current study. The possible impact of the supine position in comparison with the seated 
position on the size of the upper airways has been measured in healthy subjects using AR (Fouke 
et al., 1987; Jan et al., 1994), ARP (Eccovision; Jung et al, 2004) and CT/CBCT techniques (Van 
Holsbeke et al., 2014a) as discussed in section 2.8. The CSAs were shown to be 23% (Fouke et 
al., 1987), ~21% (OPJ; Jan et al., 1994), ~22% (OPJ) and ~24% (GL; Jung et al, 2004) smaller in 
the supine position. Van Holsbeke et al (2014a) showed that the region between the hard palate 
and the bottom of the uvula was ~50% larger in the seated position. 
As the subject’s breathing pattern through the wavetube could be followed on a PC laptop screen, 
the technician could plan the recording of the pharyngogram based on each individual breathing 
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pattern. As shown in Figure 3.9, the measurement during exhalation (measurement A; 3.3.1) was 
started at mid-inhalation and stopped at end of exhalation with the pharyngograms recorded from 
mid to end of exhalation.  
The pharyngometer measurements during inhalation without the addition of an I-neb nebuliser 
mouthpiece (measurement D; 3.3.1.) were started at mid-exhalation and stopped at end of 
inhalation with the pharyngograms recorded during mid to end of inhalation. The same start and 
stop points were followed when performing the measurements with the I-neb TBM mouthpiece 
attached to the wavetube (measurements B and E; 3.3.1.). When the I-neb TIM mouthpiece 
(measurement C; 3.3.1.) was attached to the wavetube the pharyngometer measurement followed 
different start and stop points with start early during the slow and deep inhalation, and with stop 
at the end of the inhalation and with the pharyngograms recorded during mid to end of inhalation. 
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Figure 3.9: An example of TBM and TIM breathing patterns with red arrows showing when the 
acoustic pharyngometer measurements should be started and stopped in the different 
measurements during exhalation (measurement A; 3.3.1.), and inhalation (measurements B, C, D, 
and E; 3.3.1.). 
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3.3.3 Study Subjects 
3.3.3.1 Inclusion Criteria 
- Subjects had to provide written informed consent to participate in the study. 
- Healthy male or female subjects who had participated in the previous lung deposition study 
(Nikander et al., 2010c). 
- Subjects with no clinically significant findings in vital signs. 
- Subjects must be available to complete the study. 
- Subjects must satisfy a medical examiner about their fitness to participate in the study. 
3.3.3.2 Exclusion Criteria 
- Subjects not compliant with the instructions for use of the acoustic pharyngometer 
wavetube. 
- Subjects who had participated in a clinical study in the previous month. 
3.3.3.3 Withdrawal Criteria 
- If the Investigator considered that the subject’s health was compromised by remaining in 
the study or the subject was not sufficiently cooperative. 
- On request from the subject for any reason. 
3.4 Adverse events 
AEs were recorded on the CRFs and defined as any untoward medical occurrence in a subject or 
clinical investigation subject undergoing an investigational procedure, and which did not 
necessarily have a causal relationship with the device under investigation. An AE could therefore 
be any unfavourable and unintended sign (for example including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a device whether or not considered 
related to the device under investigation. 
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3.5 Ethical considerations 
The study was performed in the summer of 2008 according to the principles of the Declaration of 
Helsinki (South Africa, 1996) and the ABPI Guidelines for Medical Experiments in Non-Patient 
Human Volunteers - 1988, amended May 1990 and the ICH Harmonised Tripartite Guideline for 
Good Clinical Practice (GCP).   
Ethics Committee approval was obtained from the South East Wales Research Ethics Committee 
prior to the start of the study and prior to any communication with potential study subjects. No 
study related procedures were carried out before ethics committee approval had been granted 
(APPENDIX A.1).  
Both verbal and written information was given to the subjects.  Sufficient time was allowed for 
the subject to consider participation in the study and providing consent for inclusion, if they 
decided to enter the study. Written consent was obtained prior to commencement of any study 
procedures. 
3.6 Statistical analysis  
3.6.1 Data analysis 
A formal plan for the statistical analysis was not pre-specified. Due to the exploratory nature of 
the study the main statistical analysis (ANOVA; Pearson correlation) was focused on the analysis 
of the pharyngograms and possible correlations between the outcomes of the acoustic 
pharyngometer measurements and the lung and the upper airway deposition of 99mTc-DTPA in the 
previous lung deposition study (Nikander et al., 2010c). The study data has been analysed by SAS 
9.2 for Windows (W32_VSPRO platform), running on a Lenovo L412 under Windows 7 
Professional. The significance level was established at 0.05. 
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3.6.2 Deviations from study protocol 
The study protocol stated that acoustic pharyngometer measurements D and E were to be made at 
inspiratory flows of 10, 20, 30, 40 and 60 L/min, but the Mimic Breathing Monitor equipment 
supplied for the study fitted with a 22 mm pneumotachograph rather than the alternative 30 mm 
pneumotachograph could not record flows in excess of 35 L/min.  
In addition, it was found that a tidal breathing pattern at 10 L/min resulted in an inhalation duration 
that was too short for the acoustic pharyngometer to record a stable reading. For these reasons the 
acoustic pharyngometer measurements D and E were limited to 20 and 30 L/min. 
3.6.3 Acoustic pharyngometer data 
For each subject each of the 7 measurements where investigated both without and with a nose clip 
resulting in 2 × 7 = 14 measurements, and for each measurement 4 acoustic pharyngograms were 
recorded. Thus a total of 126 (9 subjects × 14) measurements were made comprising 504 (126 × 
4) acoustic pharyngograms. One measurement was performed during exhalation without a nose 
clip and 1 measurement was performed during exhalation with a nose clip (check 3.3.2.1), and the 
rest during inhalation (check 3.3.2.3). Thus 108 (9 subjects × 12) measurements were made during 
inhalation. 
The measurements were coded A, B, C, D20, D30, E20 and E30 for the descriptive presentations 
of the data and for the statistical analyses. The addition of “NC” was included when the 
measurement was performed with a nose clip (ANC, BNC, CNC, D20NC, D30NC, E20NC and 
E30NC), Table 3.2.  
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Table 3.2: Description of the coding system for the measurements. For each subject 7 acoustic 
pharyngometer measurements were first performed without a nose clip, and then 7 measurements 
were performed with a nose clip (to prevent inhalation/exhalation via the nose). 
 
Code Description 
 
 
A 
Baseline acoustic pharyngometer measurement during exhalation with the subject 
breathing through the pharyngometer wavetube without additional attachments to the 
end of the wavetube (without and with nose clip). 
 
B 
Acoustic pharyngometer measurements during inhalation with the subject breathing 
through the pharyngometer wavetube with the I-neb nebuliser TBM mouthpiece 
attached to the end of the wavetube (without and with nose clip).  
 
C 
Acoustic pharyngometer measurements during inhalation with the subject breathing 
through the pharyngometer wavetube with the I-neb nebuliser TIM mouthpiece 
attached to the end of the wavetube (without and with nose clip). 
 
D20, 
D30 
Acoustic pharyngometer measurements (4 at each flow) during inhalation with the 
subject breathing through the pharyngometer wavetube during tidal breathing with 
inspiratory flows of 20 and 30 L/min without attachments to the wavetube (without and 
with nose clip). 
 
E20, 
E30 
Acoustic pharyngometer measurements (4 at each flow) during inhalation with the 
subject breathing through the pharyngometer wavetube with the I-neb nebuliser TBM 
mouthpiece attached to the end of the wavetube during tidal breathing with inspiratory 
flows of 20 and 30 L/min (without and with nose clip). 
 
The raw acoustic pharyngometer data from each measurement was imported into Microsoft Excel 
as space delimited data and then converted to SAS data sets for the statistical analysis. All 
pharyngometer measurements were first performed “without nose clip” and then “with nose clip”. 
3.6.4 Goodness of Fit (GOF) analysis of pharyngograms 
An initial review of all pharyngograms recorded during inhalation indicated that some of these 
deviated from the rest of the pharyngograms as illustrated in Figure 3.10 (subject 3) in which 
pharyngograms 1-3 follow a similar pattern, whereas the 4th pharyngogram (“Test No. 4”) shows 
a deviating pattern. For the purpose of the analysis it was important to remove all such deviating 
pharyngograms as retaining these would decrease the chances to detect effects and correlations. 
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Figure 3.10: Subject 3, measurement D20NC (measurement D, at 20 L/min, with nose clip). 
 
As noted above in section 3.6.3 there were 108 graphs like the one shown in Figure 3.10 each 
presenting the results of an acoustic pharyngometer measurement during inhalation and 
comprising 4 pharyngograms. It was therefore not practical to review and manually remove 
pharyngograms which did not fit with the general trend. An automatic procedure was required as 
this would create an objective tool for exclusion of pharyngograms. To identify deviating curves 
a measure of the “goodness of fit” (GOF) was required. For the process each of the 4 
pharyngograms was compared to the median pharyngogram and those deviating too much were 
removed. The GOF was calculated as the square root of the average squared vertical distance 
between the median curve and the curve under study. The region over which the GOF-calculation 
was performed was limited to the region covering the pharyngogram from the start of the 
pharyngogram to the GL. Three maxima at approximately x = 2.5, 10 and 17 cm and three minima 
at approximately x = 7, 13 and 19 cm can be detected (Figure 3.10). The 3 minima should 
correspond with landmarks (L) equal to the OPJ (L1), the EG (L2) and the GL (L3) as highlighted 
in Figure 3.12. The positions of the maxima and minima were slightly different for different 
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pharyngograms and very different for deviating pharyngograms. Taking this into account the 1st 
maxima (oral cavity) and the 3rd minima (GL) were determined for each subject and for each of 
the 8 pharyngograms collected under measurements A and ANC (exhalation).  Based on the 16 
obtained estimates, the median 1st maxima and 3rd landmark (last minima, GL) were calculated for 
each subject. Using these cut-offs, the GOF value was calculated for B, C, D20, D30, E20 and 
E30, and BNC, CNC, D20NC, D30NC, E20NC and E30NC) (Figure 3.11). 
 
Figure 3.11: GOF analysis for the pharyngograms of each of the 9 subjects (colour codes). The 
measurements without (left; B, C, D20, D30, E20 and E30), and with nose clip (right; BNC, CNC, 
D20NC, D30NC, E20NC and E30NC) are highlighted on the x-axis. 
 
As shown in Figure 3.11 most high GOF values occurred with subjects 3, 4 and 10. The GOF value 
was typically below 0.5 but a number of cases with higher values existed and the associated 
pharyngograms were removed from further analysis. The choice of a GOF value of 0.5 as cut-off 
between accepted or not was subjectively made based on the results in Figure 3.11.  
3.6.5 Analysis of pharyngograms 
The typical pharyngogram showed 3 landmarks (minima) along the pharyngogram and these 
corresponded to the OPJ, the EG and the GL. The CSA at each landmark was of interest as the 
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contribution to deposition of aerosol in the upper airways and the lungs could be related to the 
CSAs of the different landmarks. The volume of the upper airway from the end of the wavetube 
mouthpiece (teeth) to the 1st landmark, and between the 2 consecutive landmarks was also of 
interest as the contribution to deposition of aerosol in the upper airways and the lungs could also 
be related to the volume of the upper airway between the different landmarks (Figure 3.12). The 
volume of the portion of the airway between 2 landmarks (for example a, and b), where a, and b 
were distances from the mouthpiece was defined as the AUC between these points. A natural 
choice for a, and b, and thus for AUCs, was to use the points defined by the 3 landmarks as 
illustrated in Figure 3.12.  
 
Figure 3.12: Illustration of AUCs defined by the wavetube mouthpiece (0) and 3 landmarks (L1, 
L2 and L3). The pharyngogram represents a CSA of the upper airway from the oral cavity (0 to 
L1) caudal to the GL (L3). The AUC represents volume over a given length of airway, and 
landmarks along the pharyngogram relate to specific anatomical landmarks (OPJ, EG, GL). The 
AUCs (AUC1, AUC2, AUC3) have been highlighted as have the CSAs for each landmark (CSA1, 
CSA2 and CSA3). 
 
The definition of the landmarks required experience with acoustic pharyngometry and the 3 
landmarks were for measurements A and ANC (baseline measurement during exhalation) for each 
subject therefore defined by an expert in the field (Dr John Viviano, Mississauga, Ontario, Canada) 
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(Viviano, 2002a, Viviano, 2002b, Viviano, 2004). The distances between the landmarks for each 
subject are presented in Table 3.3. 
Table 3.3: Position of the individual landmarks (minima) on the x-axis of the pharyngogram (in 
cm from 0, check Figure 3.12). 
 
Subject 
number 
L1 
(cm from 0) 
L2 
(cm from 0) 
L3 
(cm from 0) 
3 7.16 13.59 20.02 
4 7.81 14.88 21.96 
5 9.09 18.31 23.45 
6 8.67 15.74 20.24 
8 7.81 15.74 20.45 
9 7.81 14.88 22.60 
10 8.45 14.45 20.88 
11 7.16 15.31 20.02 
12 7.81 15.10 19.60 
Mean 8.0 15.3 21.0 
SD 0.7 1.3 1.3 
 
3.6.6 Analysis of CSAs 
For each subject and measurement the mean CSA per landmark was determined and the results 
summarised descriptively. An ANOVA was performed per CSA (CSA1-3) for factors “Nose clip”, 
“Inhalation mode” (TBM or TIM) and “Flow rate” (20 or 30 L/min). 
3.6.7 Analysis of the areas under the curve (AUCs) 
For each subject and measurement the mean AUC between consecutive landmarks was determined 
and the results summarised descriptively. An ANOVA was performed per AUC1-3 for factors 
“Nose clip”, “Inhalation mode” (TBM or TIM)” and “Flow rate” (20 or 30 L/min).  
3.6.8 Correlation analysis 
Based on the results from the past lung deposition study and the present acoustic pharyngometer 
study, the correlation (Pearson correlation coefficient) between the 6 acoustic pharyngometer 
endpoints (CSA1-3, AUC1-3) and the lung, the upper airway and other depositions (12 endpoints) 
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was determined. The correlation analysis was performed with data from measurements BNC and 
CNC in the present study since nose clips were used in the past lung deposition study (Nikander 
et al., 2010c). 
3.6.9 Analysis of secondary variables 
The secondary variables have been listed per subject. The possible effect on the lung, the upper 
airway and other depositions was explored using correlation analysis for continuous variables and 
by ANOVA for discrete variables. 
3.7 Results 
3.7.1 Subject demographics 
Nine of the original 12 subjects agreed to participate in the present study. No AEs were reported. 
In Table 3.4 the demographic data including age, height, weight, BMI and collar diameter are 
presented.  
Table 3.4: Demographic data for the 9 study subjects (mean ± SD). 
 
 All Male Female 
Number of subjects 9 2 7 
Age (years, mean ± SD) 38.2 
(15.8) 
31.0 
(9.9) 
40.3 
(17.2)  
Height (m, mean ± SD) 1.69  
(0.05) 
1.73 
(0.04) 
1.68 
(0.05) 
Weight (kilograms, mean ± SD) 77.5 
(13.1) 
84.8 
(24.0) 
75.4 
(10.5) 
BMI (kilograms/(height in m2, 
mean ± SD) 
27.1 
(4.0) 
28.2 
(6.6) 
26.7 
(3.7) 
Collar diameter (cm, mean ± 
SD) 
35.3 
(3.7) 
40.3 
(2.5) 
33.9 
(2.7) 
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For comparative purposes information on lung function has been included both from the previous 
lung deposition study (Nikander et al., 2010c) and from the present study (Table 3.5 and Table 
3.6). There were no major differences in the two sets of lung function data for the 9 subjects. 
Table 3.5: Lung function data for the 9 subjects from the previous lung deposition study (Nikander 
et al., 2010c). 
 
Subject 
Number  
FEV1  (L)  FEV1 
Predicted 
(%)  
FVC (L)  FVC 
Predicted (%)  
3 2.92 105 3.87 120 
4 4.42 110 5.6 115 
5 3.82 112 4.8 122 
6 2.79 116 3.59 126 
8 3.37 97 3.96 99 
9 4.04 99 4.77 99 
10 3.59 104 4.37 111 
11 2.29 92 3.3 113 
12 3.36 101 3.78 99 
Mean 3.4 104 4.23 112 
SD 0.66 7.68 0.72 10.47 
 
Table 3.6: Lung function data for the same 9 subjects from the present study. 
 
Subject 
Number  
FEV1  (L)  FEV1 
Predicted 
(%)  
FVC (L)  FVC 
Predicted (%)  
3 2.78 102 3.88 122 
4 4.58 115 5.59 116 
5 3.43 103 4.71 122 
6 2.76 117 3.36 120 
8 3.49 100 4.26 107 
9 4.09 98 4.91 101 
10 3.53 103 4.24 108 
11 2.14 87 3.16 108 
12 3.26 98 3.82 100 
Mean 3.34 102 4.21 112 
SD 0.73 9.04 0.77 8.66 
 
The individual deposition of 99mTc-DTPA in the lung, the oropharynx, the stomach and the mouth 
(emitted doses ex-mouthpiece) has been included in Table 3.7 (I-neb nebuliser; TBM) and Table 
3.8 (I-neb nebuliser; TIM).  
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Table 3.7: Individual deposition data for each subject when using the I-neb nebuliser in TBM 
(Nikander et al., 2010c). 
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3 50.54 6.30 13.37 5.87 10.71 12.17 24.08 8.06 39.74 49.41 1.62 
4 61.24 8.09 13.46 9.36 11.79 17.44 25.25 4.34 32.18 37.82 1.30 
5 58.64 6.74 17.39 6.88 12.55 13.62 29.94 4.08 33.49 39.88 2.31 
6 89.89 9.90 23.69 14.50 17.51 24.40 41.20 2.96 3.72 8.34 1.66 
8 92.26 11.69 27.80 10.20 18.39 21.89 46.19 4.01 2.05 6.71 0.65 
9 54.95 9.48 12.31 7.93 8.71 17.42 21.02 4.30 38.89 44.49 1.29 
10 38.81 3.96 11.27 4.43 9.28 8.40 20.55 6.93 44.26 60.18 8.98 
11 53.50 7.18 12.52 10.57 9.87 17.76 22.39 5.06 40.12 45.79 0.61 
12 80.64 11.62 17.73 10.82 17.17 22.44 34.90 5.00 12.60 18.10 0.50 
Mean 64.50 8.33 16.62 8.95 12.89 17.28 29.50 4.97 27.45 34.52 2.10 
SD 18.67 2.57 5.72 3.04 3.80 5.21 9.32 1.58 16.63 18.96 2.65 
 
Table 3.8: Individual deposition data for each subject when using the I-neb nebuliser in TIM 
(Nikander et al., 2010c). 
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3 70.07 7.82 18.88 8.15 15.04 15.97 33.92 3.09 25.95 29.82 0.78 
4 89.91 11.88 18.28 11.36 19.27 23.24 37.55 2.52 7.07 9.98 0.39 
5 70.01 7.46 20.62 7.48 15.37 14.94 35.99 2.82 26.40 29.86 0.64 
6 94.48 9.64 25.75 12.49 19.15 22.13 44.90 1.47 2.84 4.97 0.66 
8 91.93 11.21 26.55 11.84 19.75 23.05 46.30 4.03 3.75 7.81 0.04 
9 70.67 9.04 21.13 8.21 13.95 17.25 35.07 2.80 25.83 29.17 0.53 
10 57.19 6.34 15.20 5.79 13.91 12.13 29.11 2.99 38.74 42.54 0.80 
11 66.20 9.44 14.55 10.93 12.75 20.37 27.29 6.81 26.18 33.55 0.56 
12 81.84 11.34 19.37 9.19 20.68 20.53 40.05 4.74 12.84 17.99 0.42 
Mean 76.92 9.35 20.04 9.49 16.65 18.85 36.69 3.47 18.84 22.85 0.54 
SD 13.06 1.90 4.11 2.27 3.02 3.94 6.41 1.55 12.57 13.11 0.23 
 
The results for “Total Lung”, “Total oropharyngeal” and “Stomach” depositions with the I-neb 
nebuliser used in TBM was in percent of the ex-mouthpiece dose 64.50%, 34.52% and 27.45%, 
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whereas the corresponding depositions with the I-neb nebuliser used in TIM were 76.92%, 22.85% 
and 18.84%, respectively. The inter-subject variability was large and especially large in the “Total 
oropharyngeal” and “Stomach” depositions. 
3.7.2 Individual pharyngograms 
The individual mean pharyngograms are presented in APPENDIX A.2. As an example, the results 
for subject 3 are shown in Figure 3.13. The plot covers 7 measurements each including 4 
pharyngograms (check 3.6.3) with legend “Measurement”: A, B, C, D20, D30, E20, E30 for the 
pharyngometer measurements without a nose clip, and 7 mean measurements with legend 
“Measurement”: ANC, BNC, CNC, D20NC, D30NC, E20NC, E30NC for the pharyngometer 
measurements with a nose clip. In the plots the y-axis presents the CSA (in cm2) of the upper 
airway, and the x-axis presents the length of the upper airway from end of the pharyngometer 
wavetube (0) to the GL (in cm).  
 
Figure 3.13: Subject 3, mean curve by measurement (measurements A to E30 without nose clip, 
and ANC to E30NC with nose clip). Each measurement consisted of 4 pharyngograms. 
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The position of the GL is obviously different for different subjects and therefore not fixed at a 
certain point, for example 20 cm (subject 3), as shown in Table 3.3. 
3.7.3 CSAs at landmarks 
For each subject and measurement the mean CSA (cm2) at each of the 3 landmarks was determined 
(check and compare 3.6.5 and Figure 3.12). In Table 3.9 summary statistics for CSA1, CSA2 and 
CSA3 are presented for each of the 14 measurements (without and with nose clip). 
Table 3.9: Summary statistics (mean ± SD) for CSA1-3 (cm2) for each of the 14 study 
measurements (without and with nose clip). 
 
Measurement Without nose clip 
(CSAs in cm2) 
With nose clip 
(CSAs in cm2) 
CSA1 CSA2 CSA3 CSA1 CSA2 CSA3 
A 3.2 ± 2.0 3.5 ± 1.3 5.0 ± 1.4 3.3 ± 1.6 4.0 ± 1.1 4.3 ± 1.3 
B 3.8 ± 1.6 3.0 ± 0.7 4.9 ± 1.2 3.7 ± 1.4 3.9 ± 1.5 5.4 ± 1.8 
C 4.4 ± 2.8 2.9 ± 0.7 4.5 ± 1.2 3.9 ± 1.3 3.8 ± 1.6 5.0 ± 1.4 
D 20 4.0 ± 2.0 3.0 ± 0.7 4.7 ± 1.3 3.9 ± 1.5 4.1 ± 1.5 5.1 ± 0.9 
D 30 4.5 ± 1.5 3.3 ± 1.1 5.0 ± 1.6 3.9 ± 1.5 4.0 ± 1.5 4.6 ± 0.7 
E 20 3.8 ± 1.6 2.9 ± 0.7 4.5 ± 1.2 3.5 ± 1.5 3.9 ± 1.7 4.7 ± 0.5 
E 30 4.1 ± 1.7 3.0 ± 0.8 4.6 ± 1.2 3.9 ± 1.2 3.9 ± 1.5 5.3 ± 1.8 
 
The effect of nose clip was most obvious for CSA2 (EG, Figure 3.12) for which the use of nose 
clip increased the CSA for all measurements in comparison with the measurements without a nose 
clip. The effect of nose clip was smaller for CSA3 (GL), and did not include A and D30 for which 
the effect was the opposite. For CSA1 (OPJ) the results without nose clip were somewhat larger 
than those with nose clip (but for A), but the differences were small. 
3.7.4 Statistical analysis of CSAs 
The possible effects by “Inhalation mode” and “Nose clip” on CSAs have been investigated using 
measurements B and C (without nose clip) and BNC and CNC (with nose clip) as outlined in 3.6.3. 
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Measurements B and BNC were performed during tidal breathing through the pharyngometer 
wavetube with the I-neb nebuliser TBM mouthpiece attached to the end of the wavetube. 
Measurements C and CNC were performed during slow and deep breathing through the 
pharyngometer wavetube with the I-neb nebuliser TIM mouthpiece attached to the end of the 
wavetube. The data has been assessed using a main effects ANOVA including subject as a factor.  
Inhalation mode (TBM or TIM) had no statistically significant effect on the CSAs, whereas 
measurement without or with nose clip had a statistically significant effect for CSA2 (p = 0.0108). 
The use of a nose clip increased CSA2 by 26%. Although measurements without or with nose clip 
did not have a statistically significant effect for CSA3, the effect was an increase by 11%. 
In order to investigate the effect of the two specific inspiratory flow rates (20 L/min or 30 L/min) 
and use of nose clip or not on the CSAs, data from measurements D and DNC or E and ENC - as 
outlined in 3.6.3 - could be used in 2 separate analyses. Measurements D and DNC (without and 
with nose clip) were performed during tidal breathing through the pharyngometer wavetube, with 
inspiratory flows of 20 and 30 L/min without the I-neb nebuliser mouthpiece attached to the back 
end of the wavetube. Measurements E and ENC (without and with nose clip) were performed with 
inspiratory flows of 20 and 30 L/min through the pharyngometer wavetube with the I-neb nebuliser 
TBM mouthpiece attached to the back end of the wavetube. As above subject was included as a 
factor in the statistical model.  
There was no statistically significant effect of flow rate in measurements D and DNC, and E and 
ENC as expected as inhalation mode was shown to be non-significant in the previous analysis. The 
use of nose clip had, however, a statistically significant effect on CSA2 in both measurements D 
and DNC (p = 0.0034) and E and ENC (p = 0.0005). The effect was 25% (D versus DNC) and 
28% (E versus ENC) higher for CSA2 when nose clip was used. This was in agreement with the 
previous analysis. 
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3.7.5 AUCs between landmarks 
As highlighted in Figure 3.12, the acoustic pharyngogram represents a CSA of the upper airway 
from the end of the wavetube caudal to the GL. The AUC represents volume (in cm3) over a given 
length of airway between landmarks along the pharyngogram.  
For each subject and measurement, the mean AUCs between the end of the wavetube and the first 
landmark, and the consecutive 2 landmarks was determined. In Table 3.10 summary statistics for 
AUC1-3 are shown for each of the 14 measurements (without and with nose clip). 
Table 3.10: Summary statistics (mean ± SD) for AUC1-3 (cm3) for each of the 14 study 
measurements (without and with nose clip). 
 
Measurement Without nose clip 
(AUCs in cm3) 
With nose clip 
(AUCs in cm3) 
AUC1 AUC2 AUC3 AUC1 AUC2 AUC3 
A 55 ± 13 31 ± 7 28 ± 10 52 ± 9 33 ± 10 29 ± 8 
B 56 ± 12 23 ± 3 21 ± 8 54 ± 10 30 ± 6 29 ± 11 
C 59 ± 15 24 ± 5 21 ± 8 55 ± 13 29 ± 7 28 ± 11 
D 20 57 ± 12 24 ± 5 22 ± 8 53 ± 10 31 ± 6 30 ± 11 
D 30 56 ± 12 27 ± 4 24 ± 10 54 ± 12 30 ± 7 27 ± 10 
E 20 56 ± 12 23 ± 5 21 ± 7 52 ± 10 30 ± 7 28 ± 11 
E 30 57 ± 13 25 ± 5 20 ± 7 54 ± 11 31 ± 7 28 ± 11 
 
The effect of nose clip was obvious for AUC2 (OPJ to EG) and AUC3 (EG to GLs) for which the 
use of nose clip increased the upper airway volume. For AUC1 the effect was the opposite although 
considerably smaller.  
3.7.6 Statistical analysis of AUCs 
The possible effects by “Inhalation mode” and “Nose clip” on AUCs have been investigated using 
measurements B and C (without nose clip) and BNC and CNC (with nose clip). The data has been 
assessed using a main effects ANOVA including subject as one factor. As for the CSAs, inhalation 
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mode (TBM or TIM) had no statistically significant effect on any of the 3 AUCs, whereas use of 
nose clip or not had a statistically significant effect for AUC2 (P = 0.0006) and AUC3 (p = 0.0002) 
and increased the airway volume with 23% (AUC2) and 31% (AUC3). For AUC1 the effect was 
the opposite and considerably smaller (6.8%). 
In order to investigate the effect of flow rates on AUCs, data from measurements D and DNC or 
E and ENC could be used. The possible effect of use of a nose clip (measurements DNC and ENC) 
could be explored in the same analysis. Data has been assessed using a main effects ANOVA 
including subject as a factor.  
There was no statistically significant effect of flow rate in measurements D, DNC, E and ENC as 
expected as inhalation mode was shown to be non-significant in the previous analysis. The use of 
nose clip had, however, a statistically significant effect on AUCs in both measurements (D and 
DNC; E and ENC). The effects were 18% (AUC2; D versus DNC; p = 0.0014), 23% (AUC3; D 
versus DNC; p = 0.0012), 22% (AUC2; E versus ENC; p = 0.0002) and 30% (AUC2; E versus 
ENC; p <0.0001) higher when nose clip was used. The effects were opposite and smaller for AUC1 
(4.7%). These results were in agreement with the previous analysis of the CSAs. Overall, 5 of the 
9 subjects had clear effects of the use of nose clips.  
3.7.7 Correlations between CSAs and deposition endpoints 
As nose clips were used in the past lung deposition study (Nikander et al., 2010), the correlation 
analysis between CSAs and deposition endpoints has been performed for measurements with a 
nose clip (BNC and CNC). The acoustic pharyngometer data for CSA1-3 from measurements BNC 
and CNC were correlated to each of the 12 deposition endpoints from the lung deposition study: 
mouthwash, oropharyngeal, stomach, total oropharyngeal, right lung – central, left lung – central, 
total central lung, right lung – peripheral, left lung – peripheral, total peripheral lung, total lung 
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and right lung C/P ratio. The obtained Pearson correlation coefficients between CSAs and 
deposition endpoints are presented in Table 3.11. The corresponding p-values for correlations 
between CSA1-3 (with nose clip) and deposition endpoints are presented in Table 3.12. In this 
analysis results from TBM (BNC) and TIM (CNC) measurements were pooled.  
Table 3.11: Pearson correlation coefficients for correlations between CSA1-3 (with nose clip) and 
deposition endpoints. 
 
Deposition endpoints # CSA1 CSA2 CSA3 
Mouth wash 1 0.25 0.06 0.76 
Oropharyngeal 2 -0.36 -0.02 0.22 
Stomach 3 -0.19 -0.21 0.40 
Total oropharyngeal 4 -0.18 -0.18 0.47 
Right lung - central 5 -0.14 0.14 -0.65 
Left lung - central 6 0.21 0.25 -0.50 
Total central lung 7 0.05 0.21 -0.61 
Right lung - peripheral 8 0.25 0.06 -0.37 
Left lung - peripheral 9 0.11 0.22 -0.27 
Total peripheral lung 10 0.20 0.13 -0.34 
Total lung 11 0.17 0.17 -0.48 
Right lung C/P ratio 12 -0.42 0.06 -0.39 
 
Table 3.12: The p-values for correlations between CSA1-3 (with nose clip) and deposition 
endpoints. 
 
Deposition endpoints No CSA1 CSA2 CSA3 
Mouth wash 1 0.31 0.82 0.0003 
Oropharyngeal 2 0.14 0.92 0.39 
Stomach 3 0.44 0.40 0.10 
Total oropharyngeal 4 0.48 0.47 0.0495 
Right lung - central 5 0.59 0.58 0.0037 
Left lung - central 6 0.40 0.31 0.0342 
Total central lung 7 0.83 0.39 0.0073 
Right lung - peripheral 8 0.31 0.81 0.13 
Left lung - peripheral 9 0.67 0.38 0.27 
Total peripheral lung 10 0.43 0.59 0.16 
Total lung 11 0.49 0.49 0.0454 
Right lung C/P ratio 12 0.09 0.82 0.11 
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None of the correlation coefficients showed a strong correlation between CSA1-2 and deposition 
endpoints, whereas for CSA3 several relatively strong correlations (mouth wash, lung deposition 
parameters) were found (Table 3.11). There were several statistically significant correlations 
between CSA3 and mouth wash, total oropharyngeal and lung deposition endpoints (Table 3.12). 
3.7.8 Correlations between AUCs and deposition endpoints 
The acoustic pharyngometer data for AUC1-3 from measurements BNC and CNC were correlated 
to each of the 12 deposition endpoints from the lung deposition study. The obtained Pearson 
correlation coefficients between AUCs and depositions endpoints are presented in Table 3.13. The 
corresponding p-values for correlations between AUC1-3 (with nose clip) and deposition 
endpoints are presented in Table 3.14. As in the analysis for the CSAs and deposition endpoints 
the results from TBM (BNC) and TIM (CNC) measurements were pooled.  
Table 3.13: Pearson correlation coefficients for correlations between AUC1-3 (with nose clip) and 
deposition endpoints. 
 
Deposition endpoints # AUC1 AUC2 AUC3 
Mouth wash 1 0.27 -0.18 0.33 
Oropharyngeal 2 -0.25 -0.20 0.18 
Stomach 3 0.40 -0.27 0.60 
Total oropharyngeal 4 0.36 -0.28 0.59 
Right lung – central 5 -0.53 0.30 -0.43 
Left lung – central 6 -0.45 0.36 -0.61 
Total central lung 7 -0.52 0.36 -0.56 
Right lung - peripheral 8 -0.15 0.31 -0.52 
Left lung - peripheral 9 -0.38 0.15 -0.54 
Total peripheral lung 10 -0.26 0.25 -0.55 
Total lung 11 -0.36 0.28 -0.58 
Right lung C/P ratio 12 -0.36 0.06 0.11 
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Table 3.14: The p-values for correlations between AUC1-3 (with nose clip) and deposition 
endpoints. 
 
Deposition endpoints # AUC1 AUC2 AUC3 
Mouth wash 1 0.29 0.47 0.18 
Oropharyngeal 2 0.32 0.43 0.48 
Stomach 3 0.10 0.27 0.0086 
Total oropharyngeal 4 0.14 0.25 0.0103 
Right lung - central 5 0.0251 0.22 0.07 
Left lung - central 6 0.06 0.15 0.0077 
Total central lung 7 0.0270 0.15 0.0151 
Right lung - peripheral 8 0.55 0.21 0.0277 
Left lung - peripheral 9 0.12 0.56 0.0199 
Total peripheral lung 10 0.30 0.31 0.0172 
Total lung 11 0.14 0.27 0.0113 
Right lung C/P ratio 12 0.14 0.82 0.67 
 
None of the correlation coefficients showed a strong correlation between AUC1-2 and depositions 
endpoints, whereas for AUC3 several relatively strong correlations (stomach, total oropharyngeal 
and lung depositions related parameters) were found.  
The p-values in Table 3.14 show statistically significant correlations between AUC3 and stomach, 
total oropharyngeal and lung depositions related endpoints. The results matched the stronger 
correlation coefficients for AUC3 shown in Table 3.13.  
The correlations between AUCs and deposition endpoints - one for each AUC – are presented 
graphically in Figures 3.14 to 3.16, as follows: 
- Figure 3.14, correlation between AUC1 and right lung - central deposition. 
- Figure 3.15, correlation between AUC2 and total central lung deposition. 
- Figure 3.16, correlation between AUC3 and stomach deposition. 
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Figure 3.14: Correlation between AUC1 and right lung - central deposition. TBM (blue) and TIM 
(red) data were pooled. 
 
The plot in Figure 3.14 shows that the right lung central deposition was negatively correlated with 
AUC1 and that TIM and TBM data followed the same trend.  
 
Figure 3.15: Correlation between AUC2 and total central lung deposition. TBM (blue) and TIM 
(red) data were pooled. 
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The plot in Figure 3.15 shows a weak correlation between the total central lung deposition and 
AUC2, and that the trend appears somewhat stronger for TBM data. The plot in Figure 3.16 shows 
that the stomach deposition was positively correlated with AUC3.  
 
Figure 3.16: Correlation between AUC3 and stomach deposition. TBM (blue) and TIM (red) data 
were pooled. 
 
3.7.9 Analysis of secondary variables 
The parameters included in the secondary objectives were as follows:  
- Assessment of the pharyngeal space using the pharyngeal grading system. 
- Assessment of the tongue size using a modified Mallampati score.  
- Measurement of the cricomental space.  
- Measurement of tongue scalloping.  
- Measurements with the Oral Mez device.  
The results of the analysis of the secondary variables are presented in Table 3.15. 
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Table 3.15: Results of secondary parameters for each subject. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keys: 
1 Individual patient results for the assessment of pharyngeal space using the pharyngeal grading 
system: 
 I = Palatopharyngeal arch intersects at the edge of the tongue 
 II = Palatopharyngeal arch intersects at 25% or more of the tongue diameter 
 III = Palatopharyngeal arch intersects at 50% or more of the tongue diameter 
2 Individual results for the assessment of tongue size using a modified Mallampati score 
3 Individual results for the measurement of cricomental space 
4 Individual results for the measurement of tongue scalloping:  
A = Complete absence of scalloping 
  B = Scalloping evident but not pronounced 
C = Scalloping pronounced and unresolved with tongue protrusion 
  D = Scalloping pronounced but resolved with tongue protrusion 
5 Individual subject results for parameters measured using the Oral Mez: 
                            R = Right 
                            L = Left 
* Partial dentures 
 
Subject 3 4 5 6 8 9 10 11 12 
Pharyngeal Space 
(class)1 
I II III I I I III I I 
Mallampati score 
(class)2 
II IV IV II I I I II II 
Cricomental space 
(value)3 
2 0 11 2 7 15 0 8 5 
Tongue scalloping 
(class)4 
A C B A A A D B A 
O
ra
l 
M
ez
 
Palatal 
height5 
14 14 15 14 16 25 9 12 8 
Maxillary 
intermolar 
distance5 
R: 4 
L: 2 
R: 5 
L:4.5 
R: 3 
L: 4 
R: 7.5 
L: 2.5 
R: 2 
L: 4 
R: 5 
L: 6 
R: 3 
L: 4 
R: 3 
L: 2 
R: 2 
L: 4 
Mandibular 
intermolar 
distance5 
R: 3.5 
L: 2 
R: 5 
L: 5 
R: 2 
L: 4 
R: 6 
L: 3 
R: 2 
L: 6 
R: 6 
L: 5 
R: 3 
L: 4 
R: 3 
L: 4 
R: 3 
L: 6 
Incisor 
overjet5 
8 7.5 8 12.5 7 9 8 11 8 
Tongue 
length5 
30 38 28 29 42 28 40 38 42 
Comments5    *      
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The pharyngeal space and tongue scalloping measurements followed the same trend with low (6 
out of 9, I versus A or B), and high values for the same subjects, whereas this was less obvious for 
the Mallampati scores, and the cricomental space measurements. For the Oral Mez measurements 
the palatal height and the incisor overjet measurements (8 and 7 out of 9) followed the same trend 
with low values for the same subjects. 
3.7.10 Correlation between secondary variables and deposition 
The 8 numeric secondary parameters were correlated to each of the 12 deposition endpoints, and 
the results are shown in Table 3.16. 
Table 3.16: Pearson correlation coefficients for correlations between numeric secondary 
parameters and deposition endpoints. 
 
Deposition endpoint 
Crico-
mental 
Space 
Palatal 
Height 
Maxillary 
Intermolar 
Distance 
Mandibular 
Intermolar 
Distance 
Incisor 
Overjet 
Tongue 
Length 
R L R L 
Mouth wash -0.26 -0.22 -0.03 0.04 -0.07 -0.19 -0.07 0.05 
Oropharyngeal -0.06 -0.29 -0.45 -0.27 -0.36 -0.07 -0.16 0.29 
Stomach 0.12 0.03 -0.17 0.04 -0.11 -0.34 -0.13 -0.19 
Total Oroharyngeal 0.07 -0.03 -0.20 0.02 -0.14 -0.33 -0.14 -0.13 
Right lung - central 0.13 0.13 0.01 0.19 0.16 0.60 -0.01 0.29 
Left lung - central -0.06 0.02 0.38 -0.24 0.32 0.19 0.52 0.10 
Total central lung 0.03 0.07 0.22 -0.04 0.26 0.40 0.30 0.20 
Right lung - peripheral 0.08 0.17 0.13 -0.00 -0.02 0.22 0.07 -0.02 
Left lung - peripheral -0.21 -0.21 0.01 -0.03 -0.05 0.34 -0.04 0.27 
Total peripheral lung -0.05 0.01 0.08 -0.01 -0.03 0.28 0.02 0.11 
Total lung -0.07 0.03 0.20 -0.02 0.14 0.33 0.13 0.13 
Right lung C/P ratio 0.16 0.09 -0.05 0.22 0.26 0.39 0.00 0.24 
 
None of the Pearson correlation coefficients were strong and only two were larger than 0.50; 
mandibular intermolar distance L versus right lung – central (0.60), and incisor overjet versus left 
lung – central (0.52). These were statistically significant, p = 0.0090 and p = 0.0267. For the 3 
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character secondary endpoints the effect of these was explored using ANOVA; the associated 
effects (p-values) are presented in Table 3.17.  
Table 3.17: p-values for correlations between Mallampati scores, pharyngeal spaces, tongue 
scalloping and deposition endpoints. 
 
Deposition endpoint 
Mallampati score Pharyngeal  
space 
Tongue 
scalloping 
Mouth Wash 0.5584 0.0995 0.0448 
Oropharyngeal 0.5377 0.7948 0.7822 
Stomach 0.8150 0.1652 0.0892 
Total oroharyngeal 0.8312 0.1548 0.0729 
Right lung - central 0.8821 0.0128 0.0159 
Left lung - central 0.2760 0.0170 0.0947 
Total central lung 0.5197 0.0062 0.0253 
Right lung - peripheral 0.8992 0.4343 0.1588 
Left lung - peripheral 0.8259 0.5302 0.2920 
Total peripheral lung 0.9686 0.5021 0.1963 
Total lung 0.8329 0.1482 0.0705 
Right lung C/P ratio 0.7911 0.0458 0.3227 
 
No statistically significant results for the Mallampati score were found, whereas for pharyngeal 
space and tongue scalloping some significant results for the central lung endpoints were found.  
There was also a significant effect by tongue scalloping on the mouth wash. 
3.8 Discussion 
The primary objective of the present study was to use an AR technique for measurements of the 
upper airways of healthy subjects that had previously been enrolled in a lung deposition study in 
which the I-neb nebuliser had been used in both TBM and TIM breathing modes (Nikander et al., 
2010c). The purpose of the characterisation of the subjects’ upper airways was to perform 
correlation analyses between the upper airway characteristics, and the deposition of nebulised 
99mTc-DTPA in the upper airways and lungs from the previous lung deposition study.  
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 Acoustic pharyngometry was chosen in favour of other techniques as the subjects could be seated 
during the measurements in the same position as in the previous lung deposition study. The fact 
that acoustic pharyngometry is a non-invasive, inexpensive, simple and fast technique allowing 
numerous measurements, were additional reasons for the choice. Nine out of the 12 subjects that 
participated in the previous lung deposition study agreed to participate in the present study. The 
measurements were standardised such that the subjects would be able to mimic the inspiratory 
flows of their breathing patterns in the previous lung deposition study. The pharyngograms were 
analysed in terms of CSAs for the OPJ (CSA1), the EG (CSA2) and the GL (CSA3), and in terms 
of AUCs for the oral cavity (AUC1), the oropharynx (AUC2) and the hypopharynx (AUC3). The 
correlation of CSAs and AUCs with the oropharyngeal and lung deposition results of the 9 subjects 
from the previous lung deposition study was investigated using an exploratory analysis. No AEs 
were recorded. 
In the present study the timing of the pharyngometer measurement to the subject’s breathing cycle 
was important as the pharyngometer measurements were planned to be performed both during 
exhalation and inhalation. The use of a pneumotachograph connected to the back end of the 
pharyngometer wavetube made it possible to follow the subjects breathing cycle, and based on the 
cycle shown on a laptop monitor, decide when to start and when to stop the measurement. The 
upper airway is a dynamic structure and changes in the CSAs of this structure has been shown to 
occur during breathing with the maximal increase occurring during exhalation (Schwab et al., 
1993a; Schwab et al., 1993b; Schwab, 1998). The pharyngometer measurement during exhalation 
was therefore started at mid-inhalation and stopped at end of exhalation with the pharyngogram 
from mid to end of exhalation recorded. The measurements during inhalation - with and without 
the addition of an I-neb nebuliser TBM mouthpiece - were started at mid-exhalation and stopped 
at end of inhalation with the pharyngogram from mid to end of inhalation recorded. When the I-
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neb nebuliser TIM mouthpiece was used, the measurements were started at the start of inhalation, 
and stopped at end of the same inhalation with the pharyngogram from the mid to end of inhalation 
recorded. The standardisation of the pharyngometer measurement was novel and should have 
minimised variability of the acoustic pharyngometer measurements.  
The aim was to record during inhalation 4 pharyngograms per each measurement and these should 
be as similar as possible. An initial review of all recorded acoustic pharyngograms indicated that 
some of the 4 pharyngograms per measurement deviated from the rest. To identify deviating 
pharyngograms, a measure of the “goodness of fit” (GOF) was developed by which each of the 4 
pharyngograms was compared to the median pharyngogram and pharyngograms deviating too 
much were excluded from further statistical analysis. GOF was defined as the square root of the 
average squared vertical distance between the median pharyngogram and the pharyngogram under 
study. The GOF-calculation was performed from the first maxima to CSA3 and defined for each 
subject individually. The choice of a cut-off of 0.5 between accepted or not was subjectively made 
based on the plot as there were no published references to base the decision upon. There was 
considerable inter-subject variability between the pharyngograms. The addition of a nose clip 
caused a change in the pharyngograms with larger CSAs and AUCs for 5 of the 9 subjects. 
The mean CSAs in the present study ranged from 3.2 cm2 to 5.0 cm2. Data on CSAs from 
pharyngograms in adult healthy subjects from measurements with the Eccovision ARP have been 
published by a number of authors (Kamal, 2001; Kamal, 2002; Jung et al., 2004; Kamal, 2004a; 
Kamal, 2004b; Monahan et al., 2005; Shiota et al., 2007; Allen et al., 2014; Oliver et al., 2014). In 
some of these studies the criteria for the acoustic pharyngometer measurements differ from those 
used in the present study (no information on position during measurements in Allen et al (2014) 
and Oliver et al (2014); supine position during measurements in Shiota et al (2007); different 
definition of CSAs in Monahan et al (2005). However, in the studies by Jung et al (2004), Kamal 
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(2001), Kamal (2002), Kamal (2004a), and Kamal (2004b), the CSAs can be compared with those 
measured in the present study (Table 2.1; section 2.2.9). In the studies by Kamal only mean CSAs 
for the whole pharyngograms are presented and these range from 2.4 cm2 to 3.2 cm2, whereas in 
the study by Jung the mean CSAs for the OPJ and GL are reported (1.6 cm2 and 1.8 cm2). As 
Kamal did not define when in the breathing cycle the pharyngograms were measured it seems 
reasonable to assume that the mean CSAs are similar to those measured in the present study. The 
CSAs reported by Jung are somewhat smaller than CSA2 and CSA3 measured in the present study 
which most probably is due to different populations. 
The analysis of the pharyngograms for CSAs and AUCs showed that the TBM and TIM breathing 
modes (“inhalation mode”), and the different inspiratory flows had no statistically significant 
effect on any of the 3 CSAs or any of the 3 AUCs. This is novel information and interesting as 
lung deposition following slow and deep breathing has been shown to increase with this breathing 
pattern. The effect seems therefore to be related to droplet behaviour during inhalation and  
diminished impaction of the inhaled droplets. 
The correlation analysis - when using “nose clip” data - between the CSAs and oropharyngeal and 
lung depositions, showed statistically significant correlations between CSA3 and total 
oropharyngeal and total lung deposition including some of the subdivisions. The correlation 
coefficients ranged from 0.47 (total oropharyngeal deposition) to -0.61 (total central lung). The 
same analysis between the AUCs and oropharyngeal and lung depositions, showed statistically 
significant correlations between AUC3 and total oropharyngeal and total lung deposition including 
the subdivisions with stronger correlation coefficients (-0.59 and 0.58). The results indicated that 
the volume of the lower parts of the upper airways between the EG and GL had the strongest 
correlation with the oropharyngeal and lung deposition data from the previous study. The reason 
for the lack of correlation between AUC1 and the oropharyngeal and lung depositions might be 
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due to the different study setups. In the lung deposition study the subjects had the chance to move 
their tongues – although they were instructed not to do that - as the I-neb nebuliser mouthpiece has 
a relatively short piece held between the teeth. In the present study the acoustic pharyngometer 
mouthpiece had a tongue depressor preventing major tongue movements.  The small number of 
subjects in the study was most probably the main reason for the lack of more significant 
correlations between the acoustic pharyngometer derived upper airway dimensions, and 
oropharyngeal and lung depositions of 99mTc-DTPA in the 9 subjects.  
The impact of inhalation through different inhalation devices on the upper airway has been the 
focus of a number of clinical studies in which the upper airways have been measured during 
inhalation or tidal breathing with MRI equipment with the subjects in a supine position (Ehtezazi 
et al., 2004; Pritchard et al., 2004; Ehtezazi et al., 2005; McRobbie et al., 2005). In some of these 
studies different CSA measures of the upper airway were shown to be prone to significant 
variations dependent on whether a DPI or a pMDI (with or without spacer or VHC) was used 
(Ehtezazi et al., 2004; Ehtezazi et al., 2005). Expansion of the oropharynx and the laryngo-pharynx 
was shown following forced breathing manoeuvres compared with tidal breathing when testing 
high resistance dummy inhalation devices (McRobbie et al., 2005). The CSAs of the oral cavity, 
the oropharynx and the larynx was shown to have considerable variability mainly due to the 
variability of the tongue position (Ehtezazi et al., 2004). The CSAs of these studies were only 
reported by Ehtezazi et al (2004) and only for the oropharynx instead of the OPJ as in the present 
study, and the CSAs were smaller than those found in the present study (Table 3.18).  
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Table 3.18: The CSAs and volumes of the upper airways in adult healthy subjects in published 
studies compared with CSAs and AUCs in the present study. In the published studies MRI with 
the subjects in supine position was used. 
 
1st author, year 
published 
Subjects 
(male) 
CSA (cm2) Volume (cm3) 
Ehtezazi et al., 
2004 
 
10 (6)  Oropharynx CSA: 
pMDI = 1.5 cm2 
spacer = 2.1 cm2 
DPI = 2.8 cm2 
Mean total upper airway 
volume: 
pMDI = 56 cm3 
spacer = 59 cm3 
DPI = 70 cm3 
Ehtezazi et al., 
2005 
 
7 (5)  Not reported Mean total upper airway 
volume: 
orifice 1 = 72 cm3 
orifice 6 = 101 cm3 
McRobbie et al., 
2005 
5 (3)  
 
Not reported Mean total upper airway 
volume, tidal breathing  
= 38 cm3 
Pritchard et al., 
2004 
 
20 (10)  Not reported Mean total upper airway 
volume, tidal breathing: 
males = 47 cm3 
females = 43 cm3 
Present study 
 
9 (2)  
 
CSA1 = 3.2 cm2 
CSA2 = 3.5 cm2 
CSA3 = 5.0 cm2 
AUC1 = 56 cm3 
AUC2 = 23 cm3 
AUC3 = 21 cm3 
Mean total AUC = 100 cm3 
 
The volumes of the upper airways were reported in these studies but are again somewhat difficult 
to compare with the present results due to different definitions of the volumes measured. As shown 
in Table 3.18 the volumes of the upper airways ranged from 38 cm3 (McRobbie et al., 2005) to 
101 cm3 (Ehtezazi et al., 2005). The reasons for the differences in CSA and upper airway volume 
could probably be found in the somewhat different definitions of the upper airways, in the 
individual differences between subjects, and in the difference in position (seated position versus 
supine position) when measuring the CSAs and the volumes of the upper airways. The impact of 
the supine position in comparison with the seated position on the size of the upper airways has 
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been measured in healthy subjects using AR (Fouke et al., 1987), acoustic pharyngometry (Jan et 
al., 1994; Jung et al, 2004) and CT)/CBCT scans  (Van Holsbeke et al., 2014a) (section 2.8). The 
CSAs were shown to be 23% (Fouke et al., 1987), 21% (OPJ; Jan et al., 1994), 19% (OPJ) and 
24% (GL; Jung et al., 2004), and ~50% (hard palate and the bottom of the uvula; Van Holsbeke et 
al., 2014a) smaller in the supine position. 
Nose clips have been used in lung deposition studies in order to ensure oral breathing. Köhler et 
al (2004) investigated in 10 subjects with CF whether the use of nose clips would improve the 
relative lung deposition of nebulised sodium cromoglycate. The urinary excretion of sodium 
cromoglycate was used as a marker of lung deposition and the results did not show a statistically 
significant difference between inhalation without and with nose clips (Köhler et al., 2004). There 
are, however, other results that indicate that the use of a nose clip might increase the amount of 
drug inhaled when using nose clips (Meier et al., 2001). In the study by Meier et al inspiratory and  
expiratory filters were added to the nebuliser in order to catch the amount of nebulised salbutamol 
that could have been inhaled by the 13 subjects that participated in the study. The authors 
concluded that: “Wearing a noseclip leads to an increase of 113% (SEM 23.5) in drug delivery 
and improves the inspiratory versus expiratory ratio (ratio 2.07 versus 0.75).” Thus the use of nose 
clips during lung deposition studies could have an impact on the deposition of the inhaled aerosol 
as the nose clip would eliminate air entrainment through the nose. The use of a nose clip during 
inhalation might therefore increase inhalation effectiveness. 
To ensure oral breathing during acoustic pharyngometer measurements, nose clips are widely used 
although there is limited information on the possible impact of these on the pharyngogram. As 
nose clips were used in the previous lung deposition study these were also included in the present 
study in which the acoustic pharyngometer measurements were performed both without and with 
nose clips. The correlation analyses were also performed with the nose clip data as an impact of 
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the nose clips could not be ruled out. The statistical analysis of the pharyngograms for the different 
CSAs showed, however, that the use of nose clips had a statistically significant effect on CSA2 
increasing it by 26%. The same analysis for the AUCs showed that the use of nose clips had a 
statistically significant effect on both AUC2 and AUC3 increasing these by 23% (AUC2) and 31% 
(AUC3), respectively. There are few references on the possible impact of the use of nose clips on 
the pharyngograms. In the letter to the editor by Molfino et al (1990) the authors discussed possible 
artefacts during acoustic pharyngometer measurements and mentioned that: “Opening of the 
velum frequently occurs when the subject is wearing noseclips during measurements; removal of 
the noseclips may result in the closure of the velum.” Molfino et al (1990) also showed an example 
of two pharyngograms performed with the subject either wearing a nose clip or not, and stated: 
“Probably the most important and frequent artifact that results in overestimation of glottis and 
tracheal areas is opening of the nasopharyngeal velum.” The artefact discussed by Molfino et al 
has also been reported by Marshall et al (1993) who used a later prototype version of the acoustic 
pharyngometer although not the Eccovision ARP, and mentioned by authors using the Eccovision 
ARP (Monahan et al., 2005; Patel et al., 2008).  
So why would an open velum create an artefact during acoustic pharyngometry measurements? 
According to Molfino et al (1990) an open nasopharyngeal velum during acoustic pharyngometry 
leads to an over-estimation of the lower upper airway (distal pharynx, GL and trachea) as the 
acoustic pulses will propagate from the mouth to the nasopharynx and the paranasal sinuses where 
they are reflected in order to propagate along the rest of the upper airway. The pharyngogram 
presented by Marshall et al (1993) indicated that the artefact might occur at ~10-14 cm from the 
end of the wavetube which should correspond with CSA2. This might be a reasonable explanation 
to the increases found in CSA2, AUC2 and AUC3 in this study. It does not, however, explain why 
this did not occur in all subjects in the present study or why the increases were very modest in 
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comparison with the increases shown by Molfino et al.  It also indicates that based on the present 
results nose clips should be avoided when performing acoustic pharyngometer measurements 
during inhalation. 
The secondary objectives of the study included several assessments and measurements of the oral 
cavity including a grading of the pharyngeal space with focus on the palatopharyngeal arch of the 
tongue, a modified Mallampati classification with focus on the visibility of the faucial pillars, the 
soft palate and the uvula, an assessment of the cricomental space using a ruler to connect the 
cricoid cartilage to the inner mentum, a measurement of the tongue scalloping, and a measurement 
of the oral cavity with the Oral Mez. The pharyngeal space and tongue scalloping measurements 
followed the same trend with high values for the same subjects, whereas this was less obvious for 
the Mallampati scores and the cricomental space measurements. For the Oral Mez measurements 
the palatal height and the incisor overjet measurements followed the same trend with low values 
for the same subjects. The correlation analysis between these oral cavity focused endpoints and 
lung depositions showed statistically significant correlations between mandibular intermolar 
distance L versus right lung – central, incisor overjet versus left lung – central, and pharyngeal 
space and tongue scalloping versus central lung endpoints. 
3.9 Conclusions 
The study hypothesis: “the anatomy of the upper airway determines subsequent deposition of 
aerosol in the upper airway and therefore the deposition of aerosol in the lung” was based on the 
results of the previous lung deposition study (Nikander et al., 2010c), and published results 
supporting the hypothesis (Svartengren et al., 1996; Borgström et al., 2006). In the review by 
Borgström et al (2006), the authors found 71 studies with relevant information on lung deposition 
and its variability. The authors concluded that: “Using a published throat deposition model, the 
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observed correlation of lung deposition variability to mean lung deposition could be explained as 
being determined largely by the extent of and variability in throat deposition”. Borgström et al 
hypothesised that: “throat deposition is the major determinant for lung deposition of an inhaled 
aerosol, and its absolute variability will largely be determined by the absolute variability in throat 
deposition”. Their conclusion and hypothesis support the present study hypothesis. 
The correlation analyses between the acoustic pharyngometry measurements and the 
oropharyngeal and lung depositions showed statistically significant correlations. The correlations 
between AUC3, and total oropharyngeal and total lung deposition showed the strongest correlation 
coefficients. These correlations indicated that the volume of the lower parts of the upper airways 
between the EG and the GL had the strongest correlation with the oropharyngeal and lung 
deposition data from the previous study. Thus the study confirmed the study hypothesis that: “the 
anatomy of the upper airway determines subsequent deposition of aerosol in the upper airway and 
therefore the deposition of aerosol in the lung”. 
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Chapter 4 Mandibular advancement achieved through a 
stepped mouthpiece design and the size of the upper airways 
– a proof-of-concept study 
4.1 Introduction  
4.1.1 Study background 
The background to this proof-of-concept study can be found in the analysis of the acoustic 
pharyngometer data presented in Chapter 3 “Assessment of the upper airways in healthy subjects 
using acoustic pharyngometry”. The analysis of the pharyngograms showed large differences in 
upper airway size and the differences were related to both the CSAs and the AUCs of the upper 
airways. This raised questions related to the expansion and contraction of the upper airways and 
whether it would be possible to increase the size of the CSAs and AUCs of the upper airways. The 
movement of the mandible or the tongue through the use of different oral appliances in order to 
increase the CSAs and AUCs of the upper airways in subjects diagnosed with OSA has been well 
documented (Chapter 2, Table 2.6). The question was whether the upper airways could be 
expanded with a mouthpiece that advanced the mandible during inhalation. The new mouthpiece 
was labelled a “stepped mouthpiece”. The assumption was that as mandibular advancement could 
expand the size of the upper airways in subjects with OSA both during wakefulness and sleep, the 
same might be achieved during wakefulness in subjects not diagnosed with OSA. The stepped 
mouthpiece would be a device that could be adapted to different inhaler designs including 
nebulisers, pMDIs (with or without spacers and VHCs) and DPIs. A patent application was 
subsequently submitted in 2009 for a stepped mouthpiece and was published in October 2011 (US 
2001/0240015 A1; Chapter 2, section 2.10 of this thesis).  
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4.1.2 Oral appliances for the treatment of OSA 
As described in Chapter 2, sections 2.9.1 to 2.9.5 of this thesis. 
Oral appliances for the treatment of OSA differ in terms of design, material, location of coupling 
mechanism and amount of possible horizontal (advancement) and vertical jaw movement 
(Hoekema et al., 2004; Viviano, 2004; Bailey, 2005; Ferguson et al., 2006; Hoffstein, 2007; 
Fleetham et al., 2010; Wee, 2012; Sutherland et al., 2014). An increase of the size of the upper 
airway (Ryan et al., 1999) and a decrease of the collapsibility of the upper airway during sleep are 
the two main proposed actions of oral appliances in subjects with OSA (Ng et al., 2003; Hoekema 
et al., 2004; Viviano, 2004; Bailey, 2005; Hoffstein, 2007; Fleetham et al., 2010; Wee, 2012; 
Sutherland et al., 2014). 
A number of airway-imaging studies have been performed in both healthy subjects and in subjects 
with OSA using oral appliances including cephalometry, CT, MRI and videoendoscopy (Fleetham 
et al., 2010). Mandibular advancement and tongue protrusion have been shown to increase the size 
of the upper airway and alter the shape of the upper airways – particularly in the velopharynx in 
healthy subjects and in subjects with OSA (Ferguson et al., 1997a; Johal et al., 1999). The use of 
oral appliances have in other studies been shown to increase the anteroposterior diameter of the 
upper airway (oropharynx and hypopharynx; Ng et al., 2003), to increase the total volume of the 
upper airway and CSAs of the retropalatal and retroglossal regions (Sam et al., 2006; Kyung et al., 
2005) and to increase the lateral dimensions of the velopharynx (Zhao et al., 2008; Chan et al., 
2010a). These results indicate that mandibular advancement achieved with a new stepped 
mouthpiece might expand the upper airway during inhalation. 
4.1.3 Acoustic pharyngometry 
As described in Chapter 2, section 2.7 of this thesis. 
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The Eccovision ARP (Hood Laboratories, Pembroke, MA, USA; presently 
www.sleepgroupsolutions.com) was used in the study and the pharyngograms obtained from the 
acoustic pharyngometer measurements were analysed in terms of CSAs and AUCs of the oral 
cavity, the OPJ, the oropharynx, the EG, the hypopharynx and the GL. 
4.1.4 A new stepped mouthpiece – the patent 
As described in Chapter 2, section 2.10 of this thesis. 
The possibility to enlarge the upper airway through mandibular advancement led to the 
development of a new stepped mouthpiece as a tool to achieve mandibular advancement when 
using an inhaler such as a nebuliser, a pMDI or a DPI. The stepped mouthpiece (without tongue 
depressor) is shown in Chapter 1, Figure 1.1 (patent US 2011/0240015 A1; published 6 October, 
2011; PCT filed 23 November, 2009). The new stepped mouthpiece is described in the abstract of 
the patent US 2011/0240015 A1 as follows: 
“The invention of the present application relates to an apparatus to aid in administering inhaled 
pharmaceutical aerosol to a patient. The apparatus is used in conjunction with an aerosol delivery 
device. The apparatus comprises steps on the top and bottom of the apparatus, which when used 
aid the patient causes mandibular advancement, and opening of the mouth, causing opening of 
patient’s airway, resulting in improved aerosol lung deposition. The invention also relates to a 
method of using such apparatus in a combination with an aerosol delivery device or a system, and 
to the mouthpiece of said apparatus.” 
 
A proof-of-concept study of a stepped mouthpiece design was discussed in order to gain 
information regarding the potential effects of mandibular advancement achieved with the stepped 
mouthpiece on the upper airway CSAs and AUCs during inhalation.  
4.1.5 Study hypothesis 
Horizontal mandibular advancement and incisal opening following use of a stepped mouthpiece 
can increase the CSAs and AUCs of the upper airways - including the oral cavity, the OPJ, the 
oropharynx, the EG, the hypopharynx and the GL - in healthy subjects.  
 169 
  
 
4.2 Methods 
4.2.1 Study design and study variables 
The study was designed as a proof-of-concept study including 4 healthy subjects. The analysis of 
the upper airways included the oral cavity, the OPJ, the oropharynx, the EG, the hypopharynx and 
the GL. The following acoustic pharyngometry recordings were made: 
- Two baseline acoustic pharyngometer recordings during exhalation using the standard 
mouthpiece attached to the wavetube. The recordings were made at FRC during tidal 
breathing without nose clips.  
- Two baseline acoustic pharyngometer recordings during inhalation using the standard 
mouthpiece attached to the wavetube. The recordings were made at mid-inhalation during 
tidal breathing without nose clips.  
- Two acoustic pharyngometer recordings during exhalation per each of the 12 stepped 
mouthpiece options. The recordings were made at FRC during tidal breathing without nose 
clips.  
- Two acoustic pharyngometer recordings during inhalation per each of the 12 stepped 
mouthpiece options. The recordings were made at mid-inhalation during tidal breathing 
without nose clips. 
In the study the Eccovision  ARP was used. The measurements with the acoustic pharyngometer 
were performed and analysed by a dentist, Dr John Viviano at his office in Mississauga, Ontario, 
Canada and the raw data was saved onto the hard disk of the Eccovision ARP in his office. The 
pharyngograms were further analysed in terms of mean CSAs and AUCs through the acoustic 
pharyngometer software.  
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4.2.2 The new stepped mouthpieces 
A set of 12 stepped mouthpieces were designed with a round back orifice to be connected to the 
pharyngometer wavetube and an oval front orifice to be kept between the incisors (Figure 4.1).  
 
Figure 4.1: The stepped mouthpieces used in the study. The oval orifices to be kept between the 
incisors were designed with 10 mm, 15 mm and 20 mm vertical distances (right 3 columns). The 
protrusion on the lower side (left column) was made to achieve 4 horizontal advancements of the 
mandible of either -3 mm, ±0 mm, +3 mm or +6 mm in relation to the protrusion on the upper side. 
 
The oval orifices of the mouthpiece to be kept between the incisors were designed with 10 mm, 
15 mm and 20 mm orifices (vertical diameters). These orifices were also designed with a single 
protrusion on the upper side and 4 protrusions on the lower side at different distances (-3 mm, ±0 
mm, +3 mm and +6 mm) in relation to the protrusion on the upper side for horizontal movement 
of the mandible. The horizontal offsets were -3 mm (lower jaw moved back from an incisal edge-
to-edge position), ±0 (incisal edge-to-edge position), + 3 mm and +6 mm (mandible moved 
forward from an incisal edge-to-edge position). The stepped mouthpiece was 40 mm long and the 
CSAs of the orifices with 10 mm, 15 mm and 20 mm vertical diameters were 161 mm2, 232 mm2 
and 278 mm2, respectively. The stepped mouthpieces were manufactured on a 3D prototyping 
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machine (Stratasys Dimension BST 768; Eden Prairie, MN, USA) from an acrylonitrile butadiene 
styrene copolymer. 
In Figure 4.2 a stepped mouthpiece is shown with the medium (15 mm) sized orifice kept between 
the incisors.  The round back orifice was designed to fit the acoustic pharyngometer wavetube. In 
the figure the area of the upper airways that might be expanded covers the upper airways from the 
oral cavity to the GL.  
 
Figure 4.2: The medium (15 mm orifice) sized stepped mouthpiece shown between the incisors. 
The upper incisors are set against the protrusion on the upper side of the stepped mouthpiece, 
whereas the lower incisors are extended over a similar protrusion on the lower side of the stepped 
mouthpiece. The area of the upper airways that might show a change in dimensions is highlighted 
in dark violet. 
 
The stepped mouthpiece (to the left in Figure 4.3) was connected with the acoustic pharyngometer 
wavetube through a green elastomeric-lipped ISO connector (Intersurgical Ltd, Wokingham, UK). 
 
Figure 4.3: The stepped mouthpiece (to the left) attached to the pharyngometer wavetube through 
a green connector as used in the study.   
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4.2.3 Study subjects 
Four healthy male subjects (A, B, C and D), age range 45-65, were included. The acoustic 
pharyngometer measurements were performed with the subjects seated on a straight-backed chair. 
The aim was to keep the wavetube horizontally parallel to the floor and prevent head, neck and 
shoulder movement by instructing the subjects to keep their gaze fixed at a point on the wall. A 
comfortable position was important in order to avoid any increase in muscle tonus through heavy 
occlusion on the mouthpieces (Viviano, 2002a). The measurements followed the instructions to a 
subject in the Eccovision Acoustic Pharyngometry Operator Manual (Hood Laboratories, 
Pembroke, MA, USA; presently www.sleepgroupsolutions.com) and as outlined in Chapter 3, 
section 3.3.2.1. 
4.3 Statistical analysis 
4.3.1 Data analysis 
The analysis of the data was descriptive due to the proof-of-concept study design with only 4 
subjects included. The primary analysis of the pharyngograms was focused on the mean CSAs and 
AUCs of the upper airways measured with the stepped mouthpieces during exhalation and 
inhalation.  
The addition of the stepped mouthpiece to the end of the pharyngometer wavetube created a 
displacement of the pharyngograms of ~4 cm to the right (x-axis) on the screen in comparison with 
pharyngograms performed without a stepped mouthpiece. The actual displacement was defined by 
the dentist Dr John Viviano ( Mississauga, Ontario, Canada) who performed all the pharyngometry 
measurements in his office. 
The raw acoustic pharyngometer data of each measurement was imported into Microsoft Excel as 
space delimited data and then converted to SAS data sets for the descriptive analyses and graphic 
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presentations. The measurements were coded separately for baseline measurements performed 
during exhalation and inhalation without the stepped mouthpieces, for stepped mouthpiece 
measurements performed during exhalation (2 recordings per stepped mouthpiece) and inhalation 
(2 recordings per stepped mouthpiece) based on the stepped mouthpiece orifice size (10 mm, 15 
mm or 20 mm orifice, vertical distance) and based on the 4 protrusions on the lower side of the 
mouthpiece (-3 mm, ±0 mm, +3 mm and +6 mm). 
A secondary analysis was focused on CSA1-3 and AUC1-3. This was based on the identification 
of three landmarks along the pharyngograms from the exhalation measurements with the standard 
mouthpiece. This was performed for each subject and these corresponded to the OPJ, the EG and 
the GL. The displacement of the pharyngograms due to the addition of the steppe mouthpiece to 
the wavetube is shown for each subject in Table 4.1 together with data on the positions of the OPJ, 
the EG and the GL, and the length of the upper airway analysed. 
Table 4.1: Position of landmarks (OPJ, EG, GL) on the pharyngograms per subject after correction 
for the displacement caused by the stepped mouthpiece on the pharyngogram (x-axis) including 
the length of the upper airway analysed. The position is given in cm from the y-axis. 
 
Subject Stepped 
mouthpiece         
ended at (cm) 
OPJ  
(cm) 
EG 
(cm) 
GL  
(cm) 
Airway length  
analysed (cm) 
A 4.16 9.31 12.31 20.45 18.00 
B 4.59 9.31 12.31 20.45 18.43 
C 4.59 8.88 12.74 21.74 18.87 
D 4.16 7.59 12.74 20.88 18.43 
4.4 Results 
4.4.1 Baseline - individual pharyngograms 
The mean CSAs and AUCs of the individual baseline acoustic pharyngograms are presented per 
subject in Table 4.2. The measurements were performed without stepped mouthpieces during 
exhalation (2 pharyngograms) and inhalation (2 pharyngograms). 
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Table 4.2: Baseline acoustic pharyngometer mean CSAs (cm2) and mean AUCs (cm3) recorded 
with the standard pharyngometer mouthpiece during exhalation (E) and inhalation (I). The 
segment (cm) of the upper airways included in the analysis is highlighted for each subject. 
 
Subject A Mean CSA, segment 2.5 cm to 20.5 cm 
Baseline E E Mean I I Mean 
 3.82 3.75 3.79 3.79 3.79 3.79 
       
Subject B Mean CSA, segment 2.0 cm to 20.5 cm 
Baseline E E Mean I I Mean 
 3.08 3.15 3.12 3.25 3.38 3.32 
       
Subject C Mean CSA, segment 2.9 cm to 21.7 cm 
Baseline E E Mean I I Mean 
 3.44 3.27 3.36 3.39 3.29 3.34 
       
Subject D Mean CSA, segment 2.5 cm to 20.9 cm 
Baseline E E Mean I I Mean 
 3.15 3.26 3.21 3.30 3.33 3.32 
 
Subject A Mean AUC, segment 2.5 cm to 20.5 cm 
Baseline E E Mean I I Mean 
  68.67 67.44 68.06 68.22 68.15 68.19 
       
Subject B Mean AUC, segment 2.0 cm to 20.5 cm 
Baseline E E Mean I I Mean 
  56.94 58.29 57.62 60.20 62.47 61.34 
       
Subject C Mean AUC, segment 2.9 cm to 21.7 cm 
Baseline E E Mean I I Mean 
  64.75 61.50 63.13 63.78 61.76 62.77 
       
Subject D Mean AUC, segment 2.5 cm to 20.9 cm 
Baseline E E Mean I I Mean 
  58.01 59.94 58.98 60.64 61.27 60.96 
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4.4.2 Stepped mouthpiece - individual measurements 
The individual pharyngograms from the different measurements are included in APPENDIX B.1. 
As examples the measurements (2 pharyngograms per measurement) for subject A recorded during 
exhalation (Figure 4.4) and inhalation (Figure 4.5) are shown. The graphs in each figure cover 12 
measurements with the stepped mouthpieces (2 pharyngograms per measurement) with separate 
legends, as follows: 
- small (S; 10 mm orifice; -3 mm, 0 mm, 3 mm, 6 mm protrusions),  
- medium (M; 15 mm orifice; -3 mm, 0 mm, 3 mm, 6 mm protrusions). 
- large (L; 20 mm orifice; -3 mm, 0 mm, 3 mm, 6 mm protrusions).  
In the figures the y-axis presents the CSA (cm2) of the upper airway and the x-axis presents the 
length of the upper airway from the end of the pharyngometer wavetube (0; check Table 4.1 for 
clarification) somewhat past the GL (cm). 
 
Figure 4.4: The measurements (2 pharyngograms per measurement) performed with the stepped 
mouthpieces connected to the acoustic pharyngometer wavetube during exhalation have been 
plotted for subject A for each of the 12 stepped mouthpiece configurations. 
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Figure 4.5: The measurements (2 pharyngograms per measurement) performed with the stepped 
mouthpieces connected to the acoustic pharyngometer wavetube during inhalation have been 
plotted for subject A for each of the 12 stepped mouthpiece configurations. 
 
4.4.3 Individual mean CSAs 
The individual mean upper airway CSAs are presented in Tables 4.3 to 4.6 per subject for the 
segment on the x-axis ranging from the end of the stepped mouthpiece to the GL. The CSAs are 
presented per stepped mouthpiece size (small, medium, large) and per protrusion (-3 mm, ±0 mm, 
+3 mm, +6 mm). Two acoustic pharyngometer recordings were performed during exhalation (E) 
and 2 during inhalation (I) for each stepped mouthpiece configuration. 
Table 4.3: Subject A, CSAs (cm2) for segment 4.16 cm to 22.16 cm on the x-axis with 2 acoustic 
pharyngometer recordings performed during exhalation (E) and 2 during inhalation (I). 
 
Subject A Small mouthpiece Medium mouthpiece Large mouthpiece 
 E E I I E E I I E E I I 
-3 mm 3.55 3.46 3.52 3.45 3.97 4.08 4.09 4.01 4.36 4.41 4.47 4.54 
±0 mm 3.83 3.76 3.69 3.69 4.35 4.21 4.30 4.31 4.34 4.41 4.50 4.55 
+3 mm 4.00 3.71 3.73 3.69 4.32 4.31 4.34 4.31 4.70 4.75 4.83 4.86 
+6 mm 4.39 4.08 4.15 4.09 4.63 4.69 4.71 4.70 5.03 4.96 5.05 5.11 
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Table 4.4: Subject B, CSAs (cm2) for segment 4.59 cm to 23.02 cm on the x-axis with 2 acoustic 
pharyngometer recordings performed during exhalation (E) and 2 during inhalation (I). 
 
Subject B Small mouthpiece Medium mouthpiece Large mouthpiece 
 E E I I E E I I E E I I 
-3 mm 2.69 2.51 2.66 2.65 3.34 3.19 3.37 3.36 3.81 3.82 3.88 3.67 
±0 mm 2.77 2.78 2.72 2.62 3.15 3.06 3.16 3.35 3.71 3.48 3.65 3.82 
+3 mm 3.20 2.97 3.13 3.11 3.44 3.50 3.59 3.53 3.82 3.68 3.72 3.73 
+6 mm 3.25 3.16 3.15 3.13 3.61 3.44 3.56 3.52 3.60 3.65 3.85 4.01 
 
Table 4.5: Subject C, CSAs (cm2) for segment 4.59 cm to 23.46 cm on the x-axis with 2 acoustic 
pharyngometer recordings performed during exhalation (E) and 2 during inhalation (I). 
 
Subject C Small mouthpiece Medium mouthpiece Large mouthpiece 
 E E I I E E I I E E I I 
-3 mm 4.91 5.02 4.89 4.85 4.53 4.56 4.59 4.66 4.74 4.96 4.82 4.71 
±0 mm 4.85 4.80 4.78 4.75 4.82 4.83 4.92 4.96 4.65 4.79 4.89 4.99 
+3 mm 4.95 4.88 4.92 4.91 5.22 5.30 5.45 5.55 4.94 4.94 5.05 5.17 
+6 mm 5.23 5.24 5.20 5.25 5.37 5.38 5.61 5.53 5.81 5.86 5.92 5.98 
 
Table 4.6: Subject D, CSAs (cm2) for segment 4.16 cm to 22.59 cm on the x-axis with 2 acoustic 
pharyngometer recordings performed during exhalation (E) and 2 during inhalation (I). 
 
Subject D Small mouthpiece Medium mouthpiece Large mouthpiece 
 E E I I E E I I E E I I 
-3 mm 3.36 3.29 3.51 3.33 3.76 3.97 4.06 4.03 4.38 4.69 4.41 4.36 
±0 mm 3.62 3.67 3.89 3.60 4.32 4.35 4.41 4.14 4.71 4.82 4.70 4.64 
+3 mm 4.08 3.91 4.11 3.89 3.88 4.35 4.45 3.96 4.83 4.82 4.88 5.01 
+6 mm 4.31 4.61 4.33 4.54 4.94 4.75 4.67 4.63 4.95 4.63 4.91 4.71 
 
Some observations regarding the effects of the stepped mouthpieces on the mean CSAs can be 
made from the results in Tables 4.3 to 4.6: 
- For Subject A the change in mean CSA during inhalation following mandibular 
advancement was from baseline to maximal advancement (+6 mm) with the “Small 
mouthpiece” ~9%, with the “Medium mouthpiece” ~24% and with the “Large mouthpiece” 
~34%. The change in mean CSA during inhalation following the introduction of the 
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mouthpieces (impact of vertical size) was from baseline to the “Small mouthpiece” (-3 
mm) ~-8%, to the “Medium mouthpiece” ~7% and to the “Large mouthpiece” ~19%. 
- For Subject B the change in mean CSA during inhalation following mandibular 
advancement was from baseline to maximal advancement (+6 mm) with the “Small 
mouthpiece” ~-5%, with the “Medium mouthpiece” ~7% and with the “Large mouthpiece” 
~18%. The change in mean CSA during inhalation following the introduction of the 
mouthpieces (impact of vertical size) was from baseline to the “Small mouthpiece” (-3 
mm) ~-20%, to the “Medium mouthpiece” ~1% and to the “Large mouthpiece” ~14%. 
- For Subject C the change in mean CSA during inhalation following mandibular 
advancement was from baseline to maximal advancement (+6 mm) with the “Small 
mouthpiece” ~56%, with the “Medium mouthpiece” ~67% and with the “Large 
mouthpiece” ~78%. The change in mean CSA during inhalation following the introduction 
of the mouthpieces (impact of vertical size) was from baseline to the “Small mouthpiece” 
(-3 mm) ~46%, to the “Medium mouthpiece” ~38% and to the “Large mouthpiece” ~43%. 
- For Subject D the change in mean CSA during inhalation following mandibular 
advancement was from baseline to maximal advancement (+6 mm) with the “Small 
mouthpiece” ~34%, with the “Medium mouthpiece” ~41% and with the “Large 
mouthpiece” ~45%. The change in mean CSA during inhalation following the introduction 
of the mouthpieces (impact of vertical size) was from baseline to the “Small mouthpiece” 
(-3 mm) ~3%, to the “Medium mouthpiece” ~22% and to the “Large mouthpiece” ~33%. 
- The trends were relatively similar for changes during exhalation and inhalation. 
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4.4.4 Individual mean AUCs 
The individual mean upper airway AUCs are presented per subject for the segment on the x-axis 
ranging from the end of the stepped mouthpiece to the GL in Tables 4.7 to 4.10. The mean AUCs 
are presented per stepped mouthpiece size (small, medium, large) and per protrusion (-3 mm, ±0 
mm, +3 mm, +6 mm). Two acoustic pharyngometer recordings were performed during exhalation 
(E) and 2 during inhalation (I). 
Table 4.7: Subject A, AUCs (cm3) for segment 4.16 cm to 22.16 cm on the x-axis with two 
acoustic pharyngometry recordings performed during exhalation (E) and 2 during inhalation (I). 
 
Subject A Small mouthpiece 
 E E I I 
-3 mm 63.81 62.23 63.28 62.05 
±0 mm 68.97 67.71 66.38 66.36 
+3 mm 71.96 74.21 74.66 73.82 
+6 mm 78.94 81.54 82.93 81.90 
 
Subject A Medium mouthpiece 
 E E I I 
-3 mm 71.41 73.45 73.67 72.22 
±0 mm 78.31 75.71 77.35 77.59 
+3 mm 77.69 77.59 78.21 77.65 
+6 mm 83.30 84.41 84.71 84.59 
 
Subject A Large mouthpiece 
 E E I I 
-3 mm 78.48 79.44 80.45 81.63 
±0 mm 78.21 79.43 81.03 81.93 
+3 mm 84.66 85.46 86.89 87.55 
+6 mm 89.53 88.27 89.80 90.99 
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Table 4.8: Subject B, AUCs (cm3) for segment 4.59 cm to 23.02 cm on the x-axis with two 
acoustic pharyngometry recordings performed during exhalation (E) and 2 during inhalation (I). 
 
Subject B Small mouthpiece 
 E E I I 
-3 mm 46.76 43.66 46.34 46.11 
±0 mm 51.06 51.09 49.97 48.30 
+3 mm 58.96 54.68 57.60 57.15 
+6 mm 59.72 58.14 58.03 57.53 
 
Subject B Medium mouthpiece 
 E E I I 
-3 mm 61.50 58.69 62.08 61.80 
±0 mm 58.03 56.32 58.06 61.65 
+3 mm 63.38 64.34 66.13 64.93 
+6 mm 66.40 63.38 65.59 64.69 
 
Subject B Large mouthpiece 
 E E I I 
-3 mm 70.12 70.30 71.46 67.53 
±0 mm 68.33 64.11 67.16 70.22 
+3 mm 70.20 67.79 68.40 68.64 
+6 mm 66.26 67.24 70.85 73.87 
 
Table 4.9: Subject C, AUCs (cm3) for segment 4.59 cm to 23.46 cm on the x-axis with two 
acoustic pharyngometry recordings performed during exhalation (E) and 2 during inhalation (I). 
 
Subject C Small mouthpiece 
 E E I I 
-3 mm 92.73 94.79 92.39 91.71 
±0 mm 91.58 90.80 90.43 90.30 
+3 mm 93.52 92.30 93.04 92.85 
+6 mm 98.77 99.13 98.28 99.26 
 
Subject C Medium mouthpiece 
 E E I I 
-3 mm 85.71 86.13 86.83 87.98 
±0 mm 91.13 91.32 93.07 93.82 
+3 mm 98.59 100.17 102.94 104.86 
+6 mm 101.43 101.70 105.96 104.55 
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Subject C Large mouthpiece 
 E E I I 
-3 mm 89.56 93.76 91.19 89.04 
±0 mm 87.97 90.55 92.39 94.23 
+3 mm 93.41 93.45 95.44 97.73 
+6 mm 109.80 110.69 111.87 113.00 
 
Table 4.10: Subject D, AUCs (cm3) for segment 4.16 cm to 22.59 cm on the x-axis with two 
acoustic pharyngometry recordings performed during exhalation (E) and 2 during inhalation (I). 
 
Subject D Small mouthpiece 
 E E I I 
-3 mm 61.81 60.48 64.54 61.32 
±0 mm 66.54 67.55 71.57 66.18 
+3 mm 75.12 71.93 75.54 71.56 
+6 mm 79.24 84.85 79.66 83.61 
 
Subject D Medium mouthpiece 
 E E I I 
-3 mm 69.15 73.02 74.64 74.23 
±0 mm 79.46 80.03 81.17 76.18 
+3 mm 71.35 80.06 81.97 72.88 
+6 mm 90.97 87.40 85.95 85.22 
 
Subject D Large mouthpiece 
 E E I I 
-3 mm 80.55 86.27 81.09 80.29 
±0 mm 86.75 88.72 86.39 85.34 
+3 mm 88.82 88.78 89.79 92.20 
+6 mm 91.15 85.20 90.31 86.62 
 
Again, some observations regarding the effects of the stepped mouthpiece on the mean AUCs can 
be made from the results in Tables 4.7 to 4.10: 
- For Subject A the change in mean AUC during inhalation following mandibular 
advancement was from baseline to maximal advancement (+6 mm) with the “Small 
mouthpiece” ~21%, with the “Medium mouthpiece” ~24% and with the “Large 
mouthpiece” ~33%. The change in mean AUC during inhalation following the introduction 
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of the mouthpieces (impact of vertical size) was from baseline to the “Small mouthpiece” 
(-3 mm) ~-8%, to the “Medium mouthpiece” ~7% and to the “Large mouthpiece” ~19%. 
- For Subject B the change in mean AUC during inhalation following mandibular 
advancement was from baseline to maximal advancement (+6 mm) with the “Small 
mouthpiece” ~-6%, with the “Medium mouthpiece” ~6% and with the “Large mouthpiece” 
~18%. The change in mean AUC during inhalation following the introduction of the 
mouthpieces (impact of vertical size) was from baseline to the “Small mouthpiece” (-3 
mm) ~-25%, to the “Medium mouthpiece” ~1% and to the “Large mouthpiece” ~13%. 
- For Subject C the change in mean AUC during inhalation following mandibular 
advancement was from baseline to maximal advancement (+6 mm) with the “Small 
mouthpiece” ~57%, with the “Medium mouthpiece” ~68% and with the “Large 
mouthpiece” ~79%. The change in mean AUC during inhalation following the introduction 
of the mouthpieces (impact of vertical size) was from baseline to the “Small mouthpiece” 
(-3 mm) ~47%, to the “Medium mouthpiece” ~39% and to the “Large mouthpiece” ~44%. 
- For Subject D the change in mean AUC during inhalation following mandibular 
advancement was from baseline to maximal advancement (+6 mm) with the “Small 
mouthpiece” ~34%, with the “Medium mouthpiece” ~40% and with the “Large 
mouthpiece” ~45%. The change in mean AUC during inhalation following the introduction 
of the mouthpieces (impact of vertical size) was from baseline to the “Small mouthpiece” 
(-3 mm) ~3%, to the “Medium mouthpiece” ~22% and to the “Large mouthpiece” ~32%. 
- The trends were relatively similar for changes measured during exhalation and inhalation. 
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4.4.5 Individual mean CSA1-3 and AUC1-3 
The individual mean CSA1-3 measured at the OPJ, the EG and the GL are presented per subject, 
stepped mouthpiece size and protrusion in Table 4.11.  
Table 4.11: Mean CSAs (cm2) presented per subject, stepped mouthpiece size (small, medium, 
large) and per protrusion (-3 mm, ±0 mm, +3 mm, +6 mm). Two acoustic pharyngometer 
recordings were performed during exhalation and 2 during inhalation. 
 
End-
point 
Subject Mouth-
piece size 
Exhalation Inhalation 
-3 mm 0 mm 3 mm 6 mm -3 mm 0 mm 3 mm 6 mm 
CSA1 A Small 3.60 4.64 4.04 6.30 4.02 4.02 4.66 5.82 
CSA1 A Medium 4.60 4.41 4.26 5.16 4.97 4.58 4.57 5.49 
CSA1 A Large 5.01 4.73 4.92 6.08 5.40 5.14 5.61 6.54 
CSA1 B Small 3.77 4.15 4.87 4.91 3.55 3.80 4.36 4.64 
CSA1 B Medium 4.66 3.78 5.58 5.63 4.54 4.18 6.08 5.71 
CSA1 B Large 5.26 5.13 6.73 6.43 5.80 5.31 6.79 7.32 
CSA1 C Small 7.05 7.48 7.91 7.11 7.17 7.73 8.17 7.51 
CSA1 C Medium 7.37 8.05 7.08 7.46 7.92 8.67 8.19 8.55 
CSA1 C Large 9.15 8.65 9.06 8.19 9.16 9.37 9.53 8.69 
CSA1 D Small 6.97 5.26 6.86 6.85 5.46 5.43 6.92 7.16 
CSA1 D Medium 7.64 7.20 8.32 8.30 7.86 7.36 7.71 8.86 
CSA1 D Large 9.09 8.96 9.87 10.12 9.08 9.59 10.02 9.87 
CSA2 A Small 3.17 2.65 3.11 3.16 2.62 2.55 2.66 3.56 
CSA2 A Medium 2.98 3.67 3.61 4.01 2.82 3.40 3.56 3.55 
CSA2 A Large 3.69 3.68 4.16 4.36 3.46 3.59 4.12 4.03 
CSA2 B Small 2.23 2.60 2.64 2.70 2.01 2.11 2.16 2.18 
CSA2 B Medium 2.79 2.86 2.81 2.66 2.59 2.54 2.25 2.19 
CSA2 B Large 2.95 2.73 2.67 2.61 2.44 2.38 2.22 2.10 
CSA2 C Small 3.99 5.96 6.29 7.02 4.35 6.14 6.70 7.22 
CSA2 C Medium 5.64 6.34 4.52 5.42 6.15 6.83 5.09 5.63 
CSA2 C Large 5.66 6.27 6.80 5.39 5.52 6.80 7.42 5.70 
CSA2 D Small 2.78 3.39 3.44 3.39 3.83 3.70 3.57 3.79 
CSA2 D Medium 3.66 3.50 4.39 4.95 3.74 4.74 4.65 4.42 
CSA2 D Large 4.11 3.47 5.10 4.11 4.08 4.84 4.99 5.11 
CSA3 A Small 2.74 2.76 2.86 3.32 2.60 3.07 3.57 3.74 
CSA3 A Medium 3.21 3.25 3.32 3.38 3.40 3.55 3.40 3.80 
CSA3 A Large 3.43 3.57 3.56 3.54 3.69 3.80 3.72 3.87 
CSA3 B Small 2.59 3.07 3.33 2.74 2.79 3.24 3.59 3.19 
CSA3 B Medium 3.21 2.80 3.41 3.59 3.67 3.54 3.66 3.88 
CSA3 B Large 3.58 3.34 3.65 3.48 3.76 3.78 3.75 3.46 
CSA3 C Small 2.96 2.47 2.35 2.17 3.34 2.71 2.44 2.34 
CSA3 C Medium 2.24 2.13 3.36 3.28 2.23 2.30 3.85 3.67 
CSA3 C Large 2.62 2.22 2.23 3.23 2.56 2.35 2.32 3.71 
CSA3 D Small 1.77 2.25 2.25 3.17 2.11 2.30 2.53 3.25 
CSA3 D Medium 2.11 2.85 2.37 2.67 2.32 2.44 2.48 2.46 
CSA3 D Large 2.65 3.32 2.25 2.72 2.36 2.54 2.46 2.38 
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The individual mean AUC1-3 measured between the end of the wavetube and the OPJ, and 
between the following landmarks are presented per subject, stepped mouthpiece size and 
protrusion in Table 4.12. 
Table 4.12: Mean AUCs (cm3) presented per subject, stepped mouthpiece size (small, medium, 
large) and per protrusion (-3 mm, ±0 mm, +3 mm, +6 mm). Two acoustic pharyngometer 
recordings performed during exhalation and 2 during inhalation. 
 
End-
point 
Subject Mouthpiece 
size 
Exhalation Inhalation 
-3 mm 0 mm 3 mm 6 mm -3 mm 0 mm 3 mm 6 mm 
AUC1 A Small 16.7 21.6 19.8 26.1 19.3 19.7 22.4 24.4 
AUC1 A Medium 24.3 21.7 23.2 26.3 25.7 22.7 23.7 26.8 
AUC1 A Large 26.5 27.0 27.3 31.7 28.0 28.3 28.5 32.0 
AUC1 B Small 13.5 15.4 17.6 21.3 15.0 14.7 18.0 21.0 
AUC1 B Medium 22.3 21.8 23.8 24.1 23.0 22.0 24.2 23.2 
AUC1 B Large 28.2 28.8 28.6 28.4 27.7 28.8 27.6 31.6 
AUC1 C Small 19.1 19.8 21.3 20.1 18.8 19.7 21.0 20.3 
AUC1 C Medium 22.8 24.3 22.6 23.0 22.9 24.7 24.2 24.6 
AUC1 C Large 29.2 28.4 28.8 28.0 28.6 29.4 28.8 27.9 
AUC1 D Small 13.3 11.6 13.2 13.0 11.7 11.4 13.0 13.1 
AUC1 D Medium 16.2 15.8 17.1 16.7 16.0 15.8 16.0 17.0 
AUC1 D Large 19.9 19.8 21.0 21.2 19.7 20.4 20.7 20.8 
AUC2 A Small 12.7 12.9 12.7 15.5 11.7 11.4 12.3 15.7 
AUC2 A Medium 13.6 15.0 14.1 15.5 13.5 14.2 14.5 14.7 
AUC2 A Large 15.7 15.1 16.2 17.3 15.8 15.3 17.2 17.2 
AUC2 B Small 11.0 12.2 13.4 12.9 10.2 10.6 11.7 11.3 
AUC2 B Medium 14.3 12.2 14.6 14.2 13.2 12.5 14.8 13.5 
AUC2 B Large 15.5 14.2 16.2 15.4 16.0 14.0 15.6 15.5 
AUC2 C Small 27.6 31.7 32.0 31.2 28.0 32.1 33.0 31.8 
AUC2 C Medium 30.5 32.9 26.2 27.8 33.3 34.1 29.1 29.8 
AUC2 C Large 33.8 34.1 35.6 28.2 32.6 35.4 37.7 30.1 
AUC2 D Small 30.7 24.1 29.7 29.5 29.5 27.5 30.9 33.0 
AUC2 D Medium 32.2 33.6 36.7 38.0 36.7 35.4 34.9 38.6 
AUC2 D Large 39.2 39.0 42.1 40.6 40.2 42.1 44.0 43.3 
AUC3 A Small 33.4 34.1 38.9 38.0 31.5 34.7 36.7 40.7 
AUC3 A Medium 34.5 40.8 40.6 42.9 33.4 40.6 40.1 43.2 
AUC3 A Large 37.2 36.6 42.1 41.6 37.3 37.6 42.3 42.4 
AUC3 B Small 18.2 19.5 21.9 21.4 17.6 19.2 22.3 20.7 
AUC3 B Medium 19.8 19.0 21.9 22.8 21.0 20.6 22.8 24.6 
AUC3 B Large 22.0 19.3 21.1 19.9 21.5 21.2 21.8 21.9 
AUC3 C Small 71.4 76.2 77.6 76.0 71.4 76.2 78.1 76.4 
AUC3 C Medium 79.0 82.6 74.6 76.4 81.5 84.0 78.6 79.5 
AUC3 C Large 89.2 88.9 90.6 82.4 87.3 90.7 92.4 83.9 
AUC3 D Small 19.7 32.5 33.1 40.6 23.5 31.5 31.8 36.9 
AUC3 D Medium 25.4 32.3 25.1 37.4 24.4 30.4 29.5 33.1 
AUC3 D Large 27.4 30.9 30.2 29.8 24.0 27.1 30.6 28.6 
 
 185 
  
 
There were some differences in the three CSAs (CSA1, CSA2, CSA3) between acoustic 
pharyngometer measurements made during exhalation versus inhalation. For measurements made 
during inhalation, the largest CSA1-3 per subject was in only 4 out of 12 cases found for the 
combination “Large” orifice and the “+6 mm” protrusion. Focusing on the acoustic pharyngometer 
measurements made during inhalation, the largest AUC1-3 per subject was in only 5 out of 12 
cases found for the combination “Large” orifice and the “+6 mm” protrusion. The largest AUC1-
3 matched in most cases the largest CSA1-3. 
4.4.6 Graphical presentation of the changes in mean CSAs 
The changes in mean CSAs (measured from end of stepped mouthpiece to GL; cm2) during 
exhalation (Figure 4.6) and inhalation (Figure 4.7) following the use of the stepped mouthpieces 
have been plotted for the 4 subjects (A, B, C and D). 
 
Figure 4.6: The changes in mean CSA during exhalation are shown for the 4 subjects (A, B, C 
and D). The baseline CSA data per subject are shown as a dot in blue colour. The impact of the 
vertical movement of the lower jaw is shown through the three colour codes for the 10 mm (Small), 
the 15 mm (Medium) and the 20 mm (Large) diameter mouthpiece orifices. The impact of the 
horizontal movement of -3, ±0, +3 and +6 mm of the lower jaw is shown as a function of the X-
axis scale. 
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The plotted mean CSA data in Figure 4.6 (exhalation) highlights the impact of the vertical 
movement in subjects A, B and D, the impact of the mandibular advancement in subject C and the 
effect of the combination of the vertical movement and the mandibular advancement in subjects 
A and D following use of the stepped mouthpieces. The medium and large mouthpieces had partly 
a negative effect in subjects B and D. 
 
Figure 4.7: The changes in mean CSA during inhalation are shown for the 4 subjects A, B, C and 
D. The baseline CSA data per subject are shown as a dot in blue colour. The impact of the vertical 
movement of the lower jaw is shown through the three colour codes for the 10 mm (Small), the 15 
mm (Medium) and the 20 mm (Large) diameter mouthpiece orifices. The impact of the horizontal 
movement of -3, ±0, +3 and +6 mm of the lower jaw is shown as a function of the X-axis scale. 
 
The plotted mean CSA data in Figure 4.7 (inhalation) follows the trend in Figure 4.6 (exhalation) 
and highlights the impact of the vertical movement in subjects A, B and D, the impact of the 
mandibular advancement in subject C and the effect of the combination of the vertical movement 
and the mandibular advancement in subjects A and D following use of the stepped mouthpieces. 
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The large mouthpiece with the +6 mm protrusion had in contrast to the measurements during 
exhalation a positive effect in subject B and a somewhat more negative effect in subject D. 
4.4.7 Graphical presentation of the changes in mean AUCs 
The changes in mean AUCs measured (from end of stepped mouthpiece to GL, cm3) during 
exhalation (Figure 4.8) and inhalation (Figure 4.9) following the use of the stepped mouthpieces 
has been plotted for the 4 subjects (A, B, C and D). 
 
Figure 4.8: The changes in mean AUCs (mL) during exhalation are shown for the 4 subjects A, 
B, C and D. The baseline AUC data per subject are shown as a dot in blue colour. The impact of 
the vertical movement of the lower jaw is shown through the three colour codes for the 10 mm 
(Small), the 15 mm (Medium) and the 20 mm (Large) diameter mouthpiece orifices. The impact 
of the horizontal movement of -3, ±0, +3 and +6 mm of the lower jaw is shown as a function of 
the X-axis scale. 
 
The plotted mean AUC data in Figure 4.8 (exhalation) follows the trend in Figure 4.6 (CSA, 
exhalation) and highlights the impact of the vertical movement especially in subjects B and D, the 
impact of the mandibular advancement in subject C and the effect of the combination of the vertical 
movement and the mandibular advancement in subjects A, B and D following use of the stepped 
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mouthpieces. The large mouthpiece with the +6 mm protrusion had a somewhat negative effect in 
subjects B and D. 
 
Figure 4.9: The changes in mean AUCs (mL) during inhalation are shown for the four subjects A, 
B, C and D. The baseline AUC data per subject are shown as a dot in blue colour. The impact of 
the vertical movement of the lower jaw is shown through the three colour codes for the 10 mm 
(Small), the 15 mm (Medium) and the 20 mm (Large) diameter mouthpiece orifices. The impact 
of the horizontal movement of -3, ±0, +3 and +6 mm of the lower jaw is shown as a function of 
the X-axis scale. 
 
The plotted mean AUC data in Figure 4.9 (inhalation) follows the trend in Figures 4.6 to 4.8 and 
highlights the impact of the vertical movement in subjects A, B and D, the impact of the 
mandibular advancement in subject C and the effect of the combination of the vertical movement 
and the mandibular advancement in subjects A and D following use of the stepped mouthpieces. 
The large mouthpiece with the +6 mm protrusion had as in Figure 4.7 (CSA, inhalation) a negative 
effect in subject D. 
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4.4.8 Graphical presentation of the changes in mean CSA1-3 
The changes in mean CSA1-3 during exhalation (Figure 4.10) and inhalation (Figure 4.11) 
following the use of the stepped mouthpieces are shown for the four subjects (A, B, C and D). The 
CSA1, CSA2 and CSA3 present the OPJ, the EG and the GL. The data has been plotted on the X-
axis for S0 (small mouthpiece with 0 mm protrusion), L0 (large mouthpiece with 0 mm protrusion), 
L3 (large mouthpiece with 3 mm protrusion), and L6 (large mouthpiece with 6 mm protrusion). 
This presents the impact of the movement of the incisors (S0 to L0) and the mandibular 
advancement (L0 to L3 and L6). 
 
Figure 4.10: The changes in mean CSA1-3 during exhalation when testing the stepped 
mouthpieces are presented. The data has been plotted on the X-axis for S0 (small mouthpiece with 
0 mm protrusion), L0 (large mouthpiece with 0 mm protrusion), L3 (large mouthpiece with 3 mm 
protrusion), and L6 (large mouthpiece with 6 mm protrusion). 
 
The plotted specific landmarks (mean CSA1-3) in Figure 4.10 (exhalation) at the OPJ, the EG and 
the GL highlight the individual differences in response to the use of the stepped mouthpieces. The 
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change in CSA1 due to the change from small (S0) to large (L0) stepped mouthpiece for subject 
D differs from the changes seen in the other subjects. The use of the large mouthpiece with the +6 
mm protrusion had in subject C a negative effect at CSA1 and CSA2 whereas the effect at CSA3 
was the opposite. 
 
 
Figure 4.11: The changes in CSA1-3 during inhalation when testing the stepped mouthpieces are 
presented. The data has been plotted on the X-axis for S0 (small mouthpiece with 0 mm 
protrusion), L0 (large mouthpiece with 0 mm protrusion), L3 (large mouthpiece with 3 mm 
protrusion), and L6 (large mouthpiece with 6 mm protrusion). 
 
The plotted mean CSA1-3 in Figure 4.11 (inhalation) highlight as in Figure 4.10 (exhalation) the 
individual differences in response to the use of the stepped mouthpieces. The change in CSA1 due 
to the change from small (S0) to large (L0) stepped mouthpiece for subject D differs from the 
changes seen in the other subjects. The use of the large mouthpiece with the +6 mm protrusion had 
in subject C a negative effect at CSA1 and CSA2 whereas the effect at CSA3 was the opposite. 
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4.4.9 Graphical presentation of the changes in mean AUC1-3 
The changes in AUC1-3 during exhalation (Figure 4.12) and inhalation (Figure 4.13) following 
the use of the stepped mouthpieces are shown for the four subjects (A, B, C and D). AUC1 covers 
the volume for the oral cavity, AUC2 the volume from the OPJ to the EG and AUC3 the volume 
from the Eg to the GL.  
 
Figure 4.12: The changes in AUC1-3 during exhalation when testing the stepped mouthpieces. 
The data has been plotted on the X-axis for S0 (small mouthpiece with 0 mm protrusion), L0 = 
(large mouthpiece with 0 mm protrusion), L3 (large mouthpiece with 3 mm protrusion), and L6 
(large mouthpiece with 6 mm protrusion). 
 
The plotted mean AUC1-3 in Figure 4.12 (exhalation) highlight the individual differences in 
response to the use of the stepped mouthpieces. The changes were relatively similar for all 4 
subjects with the exception of the magnitude of AUC3 in subject C.  
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The plotted mean AUC1-3 in Figure 4.13 (inhalation) are quite similar to the AUC1-3 in Figure 
4.12 (exhalation), and again the changes were relatively similar for all 4 subjects with the exception 
of the magnitude of AUC3 in subject C. 
 
Figure 4.13: The changes in AUC1-3 during inhalation when testing the stepped mouthpieces. 
The data has been plotted on the X-axis for S0 (small mouthpiece with 0 mm protrusion), L0 = 
(large mouthpiece with 0 mm protrusion), L3 (large mouthpiece with 3 mm protrusion), and L6 
(large mouthpiece with 6 mm protrusion). 
 
4.4.10 Observations made during the performance of the measurements 
The stepped mouthpieces were designed with front end orifices with four protrusions on the lower 
side at different distances (-3 mm, ±0 mm, +3 mm and +6 mm) in relation to the protrusion on the 
upper side for horizontal movement of the mandible. Some of the subjects found it difficult to use 
the stepped mouthpiece with the +6 mm protrusion. In these cases it was a struggle to advance the 
mandible that far without bending the head backwards which would have deviated from the 
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standard position for the acoustic pharyngometer measurements. Hypersalivation did also occur 
as the subjects could not swallow during the acoustic pharyngometer measurements. 
The standard acoustic pharyngometer mouthpiece has been designed with a short tongue 
depressor. The lack of a tongue depressor on the stepped mouthpieces tested could be observed 
initially when going from baseline measurements to the measurements with the stepped 
mouthpieces but could be dealt with through instructions from the dentist. 
4.5 Discussion 
The primary objective of this proof-of-concept study was to measure with an acoustic 
pharyngometer changes in the upper airways of 4 healthy subjects while these were using a set of 
stepped mouthpieces. The mouthpieces were designed to facilitate mandibular advancements and 
incisal opening in order to increase the mean CSA and the volume (AUCs) of the upper airways. 
The acoustic pharyngometer software was used for the analysis of the pharyngograms in terms of 
mean CSAs and mean AUCs. The stepped mouthpieces were attached to the pharyngometer 
wavetube for the measurements. Due to the addition of the 40 mm long stepped mouthpieces to 
the wavetube the pharyngograms were extended ~4 cm on the x-axis. In order to avoid inclusion 
of the area of the pharyngogram covered by the stepped mouthpieces in the analyses of the 
pharyngograms, these were set to cover only the area from the incisors to the GL. 
During inhalation through the stepped mouthpieces the mean CSAs were in 3 of 4 subjects affected 
by both the horizontal advancement of the mandible and the incisal opening. The changes in the 
CSAs showed a large variability between the 4 subjects and were far from linear.  The change in 
the CSA following mandibular advancement ranged for subject A from ~9% to ~34%, for subject 
B from ~-5% to ~18%, for subject C from ~56% to ~78% and for subject D from ~34% to ~45%. 
The impact of the incisal opening on these changes was in subjects A, B and D considerable 
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especially when testing the large mouthpiece whereas this effect was almost the opposite when 
testing the small mouthpiece. The 10 mm incisal opening created by the small mouthpiece (-3 mm) 
had a surprisingly negative effect in subjects A and B. The changes in the mean AUCs during 
inhalation followed the changes in the mean CSAs. 
There were a few negative changes in the mean CSAs and AUCs in response to the mandibular 
advancements and the incisal opening. The negative changes were surprising but in accordance 
with the results published by Gao et al (2004) who in 14 healthy subjects investigated through 
MRI changes in the CSAs of the upper airways following mandibular advancement and incisal 
opening. A custom made oral appliance was used to keep the mandible at 0%, 50%, 75% and 
100% of maximal mandibular advancement, and at 50%, 75% and 100% of maximum incisal 
opening at 75% mandibular advancement. The incisal openings were 4 mm, 9.8 ± 4.1 mm, 14.7 ± 
4.1 mm and 19.6 ± 4.1 mm and therefore similar in size to the vertical orifices of the stepped 
mouthpieces. Some of the individual changes were negative when compared with baseline further 
highlighting the large variability of the individual results especially in the hypopharynx. One of 
the reasons for the large variability might have been the lack of tongue depressor.  
The changes in the CSAs highlighted the large variability in response to the vertical movements 
of the mouth and the mandibular advancements. The impact of the incisal opening during 
inhalation was obvious in CSA1 and less pronounced in CSA2 and CSA3. An increase in CSA1 
might be more important than changes in CSA2-3 as the OPJ is a critical location from an 
impaction perspective as particles during inhalation change direction from horizontal to almost 
vertical. The impact of the mandibular advancement was rather variable with very positive results 
in CSA1 for subjects A and B and in CSA2 for subjects A and C. The changes in AUC1-3 followed 
partly those seen in the CSA1-3 but for the AUC3 result for subject C following mandibular 
advancement from +3 to +6 mm when the AUC3 was reduced. The question is whether this large 
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AUC3 represents an artefact due to leakage at the velum as discussed by Molfino et al (1990) and 
Marshall et al (1993). A check of the pharyngograms of subject C (APPENDIX B.1) shows that 
the increase in the pharyngogram from the measurement with the large stepped mouthpiece with 
the +6 mm protrusion is located within the hypopharynx. Thus the change could be a result of an 
artefact due to leakage at velum as discussed by Molfino et al and Marshall et al. Overall the results 
highlight large variability of the CSAs and the AUCs, and the need for a stepped mouthpiece with 
a smaller distance between each step, at least after +3 mm. 
Following use of the stepped mouthpieces the changes in mean CSAs and AUCs during inhalation 
were similar to those measured during exhalation. This was surprising since results of several 
studies have shown that the upper airway is a dynamic structure and that changes in upper airway 
CSAs occur during breathing with maximal increase occurring during exhalation (Schwab et al., 
1993a; Schwab et al., 1993b; Schwab, 1998). The reason for the lack of difference between the 
measurements performed during exhalation and inhalation is difficult to explain but might be a 
consequence of the seated position - in contrast with the supine position in the Schwab studies 
(Schwab et al., 1993a; Schwab et al., 1993b; Schwab, 1998) - and the use of the stepped 
mouthpieces. 
As the stepped mouthpiece represents a new mouthpiece design in terms of mandibular 
advancement properties the results cannot directly be compared with any previously published 
results. The impact of the vertical diameters of the stepped mouthpieces (10-20 mm) on the upper 
airways can, however, be compared to the results of the study by Pritchard et al (2004) who 
investigated the impact of 4 dummy inhalation devices - essentially prototype mouthpieces with 
different diameters and resistances – on the size of the upper airways measured through an 
inhalation-gated MRI technique developed to allow data acquisition at a fixed point in the subject`s 
breathing cycle. The 20 healthy subjects were scanned in a supine position. Data from 2 of the 
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mouthpieces (Device A, mouthpiece diameter 25 mm; Device C, mouthpiece diameter 14 mm) 
were of interest as these mouthpieces had diameters resembling those used in the present study 
and had low resistances. The results indicated that the size of the buccal volume and total upper 
airway volume were statistically significantly larger with the large diameter (mean 33.2 cm3) 
versus the small diameter mouthpiece (mean 22.4 cm3). There were, however, no statistically 
significant effects on the CSAs. The authors concluded that the measured CSAs (naso-pharynx-
soft palate, EG, vocal cords) seemed to be independent of mouthpiece design. The lack of 
statistically significant differences in the area from the OPJ to the vocal cords might have been 
due to the smaller size of the upper airways while in the supine position during scanning.  
The Pritchard et al (2004) results can be compared with those of Van Holsbeke et al (2014b) who 
recently presented the results of a study in which the impact of mouthpiece design on the upper 
airway CSA was investigated. An ultrafast spoiled gradient echo sequence MRI was used in 12 
healthy subjects who were supine during the scans. The influence of mouthpiece height (12-27 
mm), width (19-32.1 mm), protrusion (4-40 mm into the mouth), orifice size (3-7 mm) and 
resistance to airflow were investigated. Mouthpiece protrusion and height had the most positive 
effect on CSA whereas the impact of width and orifice size was minimal. The changes in CSA 
were mainly found in the oral cavity whereas the changes in the oropharynx were small and inverse 
and did not affect the hypopharynx. The authors concluded that the influence of the mouthpiece 
protrusion on the CSAs of the oral cavity and the oropharynx was probably a consequence of the 
interaction between the mouthpiece and the tongue (Van Holsbeke et al., 2014b). Thus both 
Pritchard et al (2004) and Van Holsbeke et al (2014b) showed considerable increases in the oral 
cavity following use of the mouthpieces but less so in the rest of the upper airways. 
As a stepped mouthpiece might eventually be used with an inhaler, the impact of different 
mouthpiece designs on aerosol passage through the mouthpiece would be of interest. Boyd et al 
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(2004) investigated the impact of mouthpiece cross-sectional shape, volume and taper on 
oropharyngeal and lung deposition of inhaled insulin using a prototype AERx inhaler (Aradigm 
Corporation, Hayward, CA, USA). The 3 tested mouthpieces were designed either as a cylindrical 
mouthpiece or as an elliptical mouthpiece, both with constant CSAs of 7.9 cm2 and 7.5 cm2, or as 
a tapered elliptical mouthpiece with an exit CSA equal (3.7 cm2) to one half the entrance CSA (7.5 
cm2). The CSAs of these mouthpieces were quite large compared with the CSAs of the stepped 
mouthpieces (1.6 cm2, 2.3 cm2 and 2.8 cm2) used in the present study. Fifteen healthy subjects 
participated in the gamma scintigraphy study in which each inhalation of the radiolabelled aerosol 
was followed by a 5-second breath-hold. The MMADs ranged from 2.2 to 2.3 µm. There were no 
statistically significant differences in oropharyngeal or lung depositions between males and 
females and the cross-sectional shapes of the mouthpieces had no significant effect on the 
oropharyngeal or lung depositions. The lack of effect of the cross-sectional shapes of the 
mouthpieces might have been related to the use of particles too small to be affected by the 
differences in mouthpiece designs.  
Svartengren et al (1996) investigated whether the mouthpiece length, ~4 cm versus ~6.4 cm, would 
have an impact on oropharyngeal and lung depositions in 9 patients with obstructive airway 
diseases. The shorter mouthpiece was a standard mouthpiece whereas the longer mouthpiece was 
designed to bypass part of the oral cavity and thereby reduce oropharyngeal deposition and was 
cut off at the level of the hard palate for each subject. The subjects inhaled at 0.5 L/s an aerosol 
consisting of monodisperse radiolabelled Teflon particles with a mean aerodynamic diameter of 
3.5 µm. There were, however, no statistically significant differences in oropharyngeal or lung 
depositions between the mouthpieces.  
As a patent application may require some demonstration of functionality of a new invention like 
the stepped mouthpiece, a small proof-of-concept study is a reasonable means of providing the 
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early proof. As the stepped mouthpiece design was novel, some guidance for possible future 
clinical studies on the design of a more durable stepped mouthpiece was also required in terms of 
design, size and number of mandibular advancement steps. The results showed that increases in 
upper airway CSA and AUC could be achieved with mandibular advancement during both 
exhalation and inhalation through a tube design. The results also highlighted that the vertical 
diameter of a new stepped mouthpiece would be an important factor to consider. The difficulty 
some of the subjects had with the +6 mm protrusion highlighted the need for a stepped mouthpiece 
with a smaller distance between each advancement. The possible need for a tongue depressor was 
highlighted when moving from baseline measurements to the measurements with the stepped 
mouthpieces. 
4.6 Conclusions 
In the present study the hypothesis that horizontal mandibular advancement and incisal opening 
following use of a stepped mouthpiece would increase the mean CSAs and the volumes of the 
upper airways in 4 healthy subjects was tested. The results – although quite variable – indicated 
that the size of the upper airways could be increased following use of the stepped mouthpiece 
during both exhalation and inhalation. Considering the results and the design of the stepped 
mouthpieces a follow-up clinical study with a redesigned stepped mouthpiece would be warranted. 
The new stepped mouthpiece should be designed with a tongue depressor, ideally with 1 mm 
mandibular advancement steps and a vertical diameter of the mouthpiece close to the large 
mouthpiece used in the present study. 
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Chapter 5 Assessment of the impact of a stepped mouthpiece 
on the size of the upper airways of healthy subjects and 
subjects with OSA measured by acoustic pharyngometry 
5.1 Introduction 
5.1.1 Study background 
A set of stepped mouthpieces were tested in a proof-of-concept study presented in Chapter 4. The 
stepped mouthpieces were designed with a round back orifice to be connected to the wavetube of 
the acoustic pharyngometer and an oval front orifice to be kept between the teeth. The front end 
of the stepped mouthpieces kept between the teeth was designed with 10 mm, 15 mm or 20 mm 
orifices (vertical diameters). These front end orifices were designed with a single protrusion on 
the upper side for the upper incisors, and 4 protrusions on the opposite side of the mouthpiece at 
distances of -3 mm, ±0 mm, +3 mm and +6 mm in relation to the protrusion on the upper side. The 
purpose of these was to facilitate a horizontal movement of the mandible as shown in Chapter 4, 
Figure 4.2. 
The CSAs (mm2) of the three different orifices with 10 mm, 15 mm and 20 mm vertical diameters 
were 161 mm2, 232 mm2 and 278 mm2, and the length 40 mm. The stepped mouthpieces were not 
designed with a tongue depressor. The results reported in Chapter 4 indicated that a tongue 
depressor might be required, and that the vertical dimension of the stepped mouthpieces, the 
horizontal mandibular advancement and a combination of these increased the size of the upper 
airways defined as the area between the incisors and the GL. 
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5.1.2 A redesigned stepped mouthpiece 
A new stepped mouthpiece with tongue depressor was designed for the purpose of a parallel group 
clinical study. The abstract of the patent of the stepped mouthpiece with tongue depressor (patent 
US 2012/0240922 A1; published 27 September, 2012; PCT filed 9 November, 2010) described 
the new invention, as follows: 
“An apparatus and method to aid in administering inhaled pharmaceutical aerosol to a patient is 
configured to maintain a tongue in proper position and offset the patient’s upper and lower jaws 
during aerosol delivery. An adjustable member is provided adjacent a mouthpiece and at least 
partially surrounds and moves with respect to the body of the apparatus. The adjustable member 
has a step structure to impart a selected amount of mandibular advancement to a patient during 
aerosol delivery. A tongue depressor which may be integrally formed with the adjustable member 
configured to prevent a tongue from occluding a flow of aerosol is also provided.” 
 
The new stepped mouthpiece was 81 mm long fully extended including tongue depressor and the 
external horizontal and vertical diameters were 34 mm and 24 mm, respectively (Figure 5.1). The 
tongue depressor and the related part of the mouthpiece to be held in the mouth were 33 mm long 
and the external horizontal and vertical diameters 34 mm and 18 mm, respectively. The 18 mm 
vertical external diameter was chosen partly based on the results of the previous proof-of-concept 
study in which the largest mouthpiece had an external vertical mouthpiece diameter of 20 mm and 
partly as this is a common vertical size of jet nebuliser mouthpieces. The length of the stepped 
mouthpiece from the round end (right in Figure 5.1) to the position for the upper incisors was 52 
mm. 
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Figure 5.1: Picture of the stepped mouthpiece with the circular back end to be connected to the 
acoustic pharyngometer wavetube to the right and the tongue depressor with the mouthpiece slider 
to the left. 
 
The round 22 mm end of the stepped mouthpiece was designed to be connected to the 22 mm end 
of the wavetube through a green elastomeric-lipped ISO connector (Intersurgical Ltd, Wokingham, 
UK) (Figure 5.2). 
 
Figure 5.2: The stepped mouthpiece attached to the pharyngometer wavetube through a green 
elastomeric-lipped ISO connector (Intersurgical Ltd, Wokingham, UK) as used in the study. 
 
The stepped mouthpiece was designed with a wall thickness of 1.1 mm, and with 6 steps of 1 mm 
pitch each providing a total horizontal movement of 6 mm. The new stepped mouthpiece was made 
of transparent Polycarbonate Makrolon 2858 resin (Bayer Material Science, Pittsburgh, PA, USA). 
The design of the stepped mouthpiece is shown in more detail in Figure 5.3 (body of stepped 
mouthpiece) and Figure 5.4 (slider with tongue depressor). 
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Figure 5.3: The body of the stepped mouthpiece shown with the circular back end to be connected 
to the acoustic pharyngometry wavetube (top) used in the study. 
 
 
Figure 5.4: The stepped mouthpiece slider with tongue depressor shown from the cavity side. The 
pitches designed for 1 mm incremental movement are shown on both sides of the slider. 
 
The CSAs (mm2) of the three stepped mouthpieces used in the proof-of-concept study were 161 
mm2, 232 mm2 and 278 mm2. As the new stepped mouthpiece was designed to partly match the 
largest of the stepped mouthpieces, the CSAs of the new stepped mouthpiece were 266 mm2 
(front), 247 mm2 (middle) and 298 mm2 (rear) as shown in Figure 5.5.  
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Figure 5.5: The stepped mouthpiece used in the study with CSAs of 266 mm2 (front), 247 mm2 
(middle) and 298 mm2 (rear). 
 
The transparent stepped mouthpiece used in the study is shown in 2 photographs in Figure 5.6.  
 
 
 
 
 
Figure 5.6: Two photographs of the new stepped mouthpiece are shown. In the left hand picture 
the stepped mouthpiece is shown with the slider in the 1st position with no horizontal movement. 
In the right hand picture the stepped mouthpiece is shown with the slider in the 6th position with 6 
mm horizontal movement. 
 
5.1.3 Acoustic pharyngometry 
As described in Chapter 2, section 2.7 of this thesis. 
The Eccovision ARP has been used in a large number of clinical studies of the upper airways 
(section 2.7.6-2.7.7). The pharyngogram obtained from a measurement with the acoustic 
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pharyngometer can be analysed in terms of the CSAs and AUCs of the oral cavity, the OPJ, the 
oropharynx, the EG, the hypopharynx and the GL. 
5.1.4 Measurement of the range of motion of the mandible 
A George Gauge (Great Lake Orthodontic Products, Tonawanda, NY, USA) is a tool for 
measurement of the protrusive and retrusive capacities of the mandible (Figure 5.7). The George 
Gauge was used in the present study for the measurement of the most protrusive (mm) and most 
retrusive positions (mm) of the mandible, each measured from an edge-to-edge position of the 
upper and lower incisors. The incisal edge-to-edge position was selected as basis for the 
measurements due to the limited adjustability of the mouthpiece. In addition to the above 
measurements, the anteroposterior range of motion (mm) of the mandible was measured. 
 
Figure 5.7: The George Gauge is shown in a subject’s mouth (left), and with the bite fork 
connected to the body with the mm rule and the bite fork alone (right). 
 
The George Gauge consists of a body and a bite fork and is available in either 2- or 5-mm incisal 
thickness and the 2-mm bite fork was used in the present study (Figure 5.7) (Wee, 2012). 
5.1.5 The Epworth Sleepiness Scale 
The Epworth Sleepiness Scale test is a subjective questionnaire for evaluation of the extent of 
daytime sleepiness in everyday situations (Johns, 1991; Johns, 1992). Through this questionnaire 
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a subject is asked to rate the likelihood of falling asleep in certain situations he/she would 
encounter in the course of a day. On the form the subject can choose the option that best reflects 
his/her recent experience. There are 8 questions, and answers are rated from 0 to 3 and the scale is 
0-24. An answer of 0 means that the subject would never fall asleep in that situation, whereas 
answering 3 means it was very likely that the subject would fall asleep. The following scale was 
used: 0 = no chance of dozing; 1 = slight chance of dozing; 2 = moderate chance of dozing; 3 = 
high chance of dozing. A “Situation” table was used to clarify the examples (Table 5.1). 
 
Table 5.1: The “Situation” table used in the Epworth questionnaire. 
 
 Situation Chance of 
dosing 
Sitting and reading  
Watching TV  
Sitting inactive in a public place (e.g. a theatre or a 
meeting) 
 
As a passenger in a car for an hour without a break  
Lying down to rest in the afternoon when circumstances 
permit 
 
Sitting and talking to someone  
Sitting quietly after a lunch without alcohol  
In a car, while stopped for a few minutes in traffic  
 
The Epworth Sleepiness Scale test was used during study inclusion to test subjects claiming no 
history of OSA.  
5.1.6 Study hypothesis 
Mandibular advancement together with incisal opening during tidal breathing achieved through a 
stepped mouthpiece design affects the size of the upper airways in subjects without and with OSA. 
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5.2 Study objectives 
5.2.1 Primary objective 
The primary objective of the study was to measure through acoustic pharyngometry the impact of 
different horizontal mandibular advancement positions - achieved with a stepped mouthpiece with 
a tongue depressor - on the size of the upper airways in subjects without and with OSA. Subjects 
with OSA were selected as a control group as mandibular advancement has been practised in in 
this group during several decades. Therefore a large number of publications on CSAs, AUCs and 
protrusive and retrusive data following mandibular advancement is available from studies in 
subjects with OSA. The definition of “upper airways” included the area from the incisors to the 
GL. The measurements were performed while the subjects were seated in a chair and inhaled room 
air during tidal breathing through the stepped mouthpiece. The acoustic pharyngometry 
measurement was performed at mid inhalation.  
5.2.2 Secondary objectives 
The secondary objectives included: 
- Assessment of the most protrusive and most retrusive positions of the mandible - each 
measured from an incisal edge-to-edge position - and the anteroposterior range of motion of 
the mandible.  
- Four baseline acoustic pharyngometry measurements during exhalation during tidal breathing 
with the standard wavetube mouthpiece which included a tongue depressor (without the 
stepped mouthpiece); 2 at FRC, 1 during nasal breathing and 1 with a Mueller or a Valsalva 
manoeuvre (Brown et al., 1986; www.sleepgroupsolutions.com).  
- Four baseline acoustic pharyngometry measurements during inhalation during tidal breathing 
with the standard wavetube mouthpiece which included a tongue depressor (without the 
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stepped mouthpiece). The acoustic pharyngometry measurement was performed at mid 
inhalation. 
- Measurement of the upper airways through acoustic pharyngometry during inhalation during 
slow and deep breathing while the subject used a stepped mouthpiece. The acoustic 
pharyngometry measurement was performed at mid inhalation.  
- Assessment of the most comfortable mandibular protrusion position for the subject when using 
the stepped mouthpiece during tidal breathing. The scoring of the “comfortable position” was 
performed through a Likert-style questionnaire (Likert, 1932).   
- Assessment of the most comfortable mandibular advancement position for the subject when 
using the stepped mouthpiece during slow and deep breathing. The scoring of the “comfortable 
position” was performed through a Likert-style questionnaire (Likert, 1932). 
- When the most “comfortable position” with the stepped mouthpiece during both tidal, and slow 
and deep breathing had been established as outlined above, the subject was asked to hold that 
position for 3 minutes. After 3 minutes, the subject’s level of comfort was re-evaluated through 
a Likert-style questionnaire (Likert, 1932). 
5.3 Methods 
5.3.1 Study design  
The study was performed as an open investigation including 60 subjects. The subjects were 
enrolled from subjects visiting the dental practice of Dr John Viviano (Mississauga, ON, Canada). 
When enrolled, the subjects visited the dental practise once for study inclusion and measurements 
of their upper airways through acoustic pharyngometry which was performed by Dr Viviano. The 
60 subjects were stratified such that 30 were healthy subjects and 30 had been diagnosed with 
OSA with equal numbers of male and female subjects. The acoustic pharyngometer measurements 
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were performed with the subjects seated on a straight-backed chair. The aim was to keep the 
wavetube horizontally parallel to the floor and prevent head, neck and shoulder movement by 
instructing the subjects to keep their gaze fixed at a point on the wall. A comfortable position was 
important in order to avoid any increase in muscle tonus through heavy occlusion on the 
mouthpieces (Viviano, 2002a). The measurements followed the instructions to a subject in the 
Eccovision Acoustic Pharyngometry Operator Manual Hood Laboratories, Pembroke, MA, USA; 
presently (www.sleepgroupsolutions.com): 
- You will sit in a chair and hold a wand with a mouthpiece on it.   
- You will place the mouthpiece in your mouth and do various breathing on the mouthpiece 
as instructed by the technologist. 
- Breathing through the mouth normally for 10 to 12 seconds.  
- Breathing through the nose for 10 to 12 seconds.  
- Closing your glottis and exhaling.  
- Closing your glottis and inhaling.  
- A technologist will instruct you on how to perform the test and coach and encourage you 
to do your best.  
5.3.2 Clinical assessments 
Demographics included: age (years), height (cm), weight (kg), Body Mass Index (BMI; [weight 
in kg/(height in m2)], gender, diagnosis of OSA (yes/no), neck circumference (cm), most 
protrusive (mm) and most retrusive positions (mm) of the mandible, and the range of motion of 
the mandible (mm). 
Measurement of the upper airways by acoustic pharyngometry (as described in Chapter 2, section 
2.7 of this thesis), as follows: 
- Four baseline pharyngograms with the acoustic pharyngometer with the subject exhaling 
through the wavetube (without stepped mouthpiece and nose clip) were recorded. Two of 
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the pharyngograms were recorded at FRC, 1 during nasal breathing and 1 with a Mueller or 
a Valsalva manoeuvre (Brown et al., 1986). The Investigator highlighted and recorded the 
positions of the OPJ, the EG and the GL when saving the data onto the acoustic 
pharyngometer. 
- Four baseline recordings made during mid-inhalation with the subject inhaling through the 
wavetube (without stepped mouthpiece and nose clip).  
- During tidal breathing 4 pharyngograms were recorded at mid-inhalation per each 
mandibular protrusion achieved with the stepped mouthpiece. Five of the 6 possible 
protrusions of the stepped mouthpiece were used (1, 2, 3, 4, and 5 mm). The pharyngograms 
were recorded during tidal breathing (without nose clip) with the stepped mouthpiece 
connected to the wavetube. Due to the addition of the stepped mouthpiece to the wavetube a 
shift of the pharyngogram to the right occurred in comparison with the baseline 
pharyngograms. The Investigator highlighted and recorded the positions of the OPJ, EG and 
GL when saving the data onto the acoustic pharyngometer. 
- During slow and deep breathing 4 pharyngograms were recorded at mid-inhalation per each 
mandibular protrusion achieved with the stepped mouthpiece. Five of the 6 possible 
advancements of the stepped mouthpiece were used (1, 2, 3, 4, and 5 mm). The 
pharyngograms were recorded during slow and deep breathing (without nose clip) with the 
stepped mouthpiece connected to the wavetube. Due to the addition of the stepped 
mouthpiece to the wavetube a shift of the pharyngogram to the right occurred in comparison 
with the baseline pharyngograms. The Investigator highlighted and recorded the positions of 
the OPJ, EG and GL when saving the data onto the acoustic pharyngometer. 
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5.3.3 Study subjects 
5.3.3.1 Inclusion criteria 
- Subjects provided written informed consent to participate in the study. 
- Adult male or female subjects over 18 years of age who had not been or had been diagnosed 
with OSA.  
- Subjects claiming no history of OSA were tested through the Epworth Sleepiness Scale 
test and obtained a result less than 10 (scale 0-24).  
- Subjects satisfied the study investigator about their fitness to participate in the study and 
their availability to complete the study. 
5.3.3.2 Exclusion criteria 
- Subjects not compliant with the instructions for use of the stepped mouthpiece and the 
study procedures. 
- Subjects who had participated in a clinical trial in the previous month. 
5.3.3.3 Withdrawal criteria 
- If the Investigator considered that the subject’s health would be compromised by remaining 
in the study or the subject was not sufficiently cooperative. 
- On request from the subject for any reason. 
Verbal and written (information form) description of the study was given to the subjects who were 
given sufficient time to decide whether they would like to enter the study.  Written consent would 
be obtained prior to commencement of any study procedures. If a subject withdrew from the study 
at any time either at his/her request or at the Investigator’s discretion, the reason(s) for withdrawal 
was recorded on the relevant page of the CRF.  Data from such subjects would be used in the 
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analyses of the study if appropriate data was available.  Furthermore, it was vital to obtain follow 
up data on any subject withdrawn because of an adverse event. 
5.3.4 Study variables 
5.3.4.1 Primary study variables 
The primary study variable was the size of the upper airways from the incisors to the GL defined 
in terms of CSA1-3 (for OPJ, EP and GL; in cm2) and volume (area under the curve, AUC; AUC1-
3 for the area between incisors and OPJ, between OPJ and EG, between EG and GL; in cm3). The 
CSAs and the AUCs were derived through computer processing.  
5.3.4.2 Secondary study variables 
The secondary study variables included the demographics, the collar size and the most protusive 
and retrusive positions of the mandible - each measured from an incisal edge-to-edge position - 
and the anteroposterior range of motion of the mandible.   
5.4 Adverse events  
An AE was defined as any untoward medical occurrence in a subject undergoing an investigational 
procedure and which did not necessarily have a causal relationship with the device under 
investigation. An AE could therefore be any unfavourable and unintended sign, symptom, or 
disease temporally associated with the use of a device, whether or not considered related to the 
device under investigation. AEs were recorded on the CRFs. 
5.5 Ethical considerations 
The study was performed according to the principles of the Declaration of Helsinki (South Africa, 
1996) and the ABPI Guidelines for Medical Experiments in Non-Patient Human Volunteers - 
1988, amended May 1990 and the ICH Harmonised Tripartite Guideline for Good Clinical Practice 
(GCP). The study was registered at www.clinicaltrials.gov - a service of the U.S. National 
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Institutes of Health - with the identifier: NCT01069068. Ethics Committee approval was obtained 
(APPENDIX C-1) prior to the start of the study and prior to any communication with potential 
study subjects and no study related procedures were carried out before ethics committee approval 
had been granted. 
5.6 Statistical analysis 
Due to the exploratory nature of this study, the sample size employed in the study was not based 
on any previous results. The main statistical analysis was planned to be focused on the impact of 
the stepped mouthpiece on the upper airways and the possible differences in this aspect between 
the two study groups. The study data was analysed by SAS 9.2 for Windows (W32_VSPRO 
platform), running on a Lenovo L412 under Windows 7 Professional. The significance level was 
established at 0.05. 
5.6.1 Acoustic pharyngometry data 
The acoustic pharyngometry measurements were coded BFL (baseline, exhalation, in all BFL1-
4), BMI0 (baseline, inhalation), SMI0-5 (tidal breathing) and SSI0-5 (slow and deep breathing), 
Table 5.2. 
For each subject 4 pharyngograms were recorded for baseline measurements during exhalation 
and 4 for baseline measurements during inhalation. For measurements during either tidal 
breathing or slow and deep breathing, 4 pharyngograms were recorded for each subject per 
stepped mouthpiece position, in total 24 pharyngograms per breathing pattern. The 6 stepped 
mouthpiece positions tested included no advancement (0), and advancements of 1, 2, 3, 4, and 5 
mm. Thus the last possible stepped mouthpiece advancement of 6 mm was not tested. The decision 
not to test the 6 mm advancement was based on the experience from the proof-of-concept study in 
which the subjects found the +6 mm protrusion to be difficult to achieve. The raw acoustic 
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pharyngometry data from each measurement was imported into Microsoft Excel as space delimited 
data for statistical analysis. 
Table 5.2: Codes for the acoustic pharyngometry data. 
Codes Explanations 
BFL1-4 BFL, in which B = Baseline, F = FRC and L = Landmarks. Each BFL file contained 4 
acoustic pharyngometry readings as follows:  
 1 – FRC  
 2 -  FRC  
 3 - Nasal breathing 
 4 - Coaching for glottal closure 
In the figures the following short forms were used: BFL = two measurements from FRC, 
BFL3 = one measurement during nasal breathing, and BFL4 = one measurement during 
glottal closure. 
BMI0 BMI0, in which B = Baseline, M = Mid tidal inhalation and I = Inhalation. The BMI file 
contained 4 acoustic pharyngometry readings. 
SMI0 SMI0, in which S = Stepped mouthpiece, M = Measurement at mid tidal inhalation, I = 
Inhalation and 0 = 0 mm, no advancement with stepped mouthpiece. 
SMI1 SMI1, as above with 1 mm advancement with stepped mouthpiece. 
SMI2 SMI2, as above with 2 mm advancement with stepped mouthpiece. 
SMI3 SMI3, as above with 3 mm advancement with stepped mouthpiece. 
SMI4 SMI4, as above with 4 mm advancement with stepped mouthpiece. 
SMI5 SMI5, as above with 5 mm advancement with stepped mouthpiece. 
SSI0 SSI0, in which S = Stepped mouthpiece, S = Measurement during slow and deep 
inhalation, I = Inhalation and 0 = 0 mm, no advancement with stepped mouthpiece. 
SSI1 SSI1, as above with 1 mm advancement with stepped mouthpiece.  
SSI2 SSI2, as above with 2 mm advancement with stepped mouthpiece. 
SSI3 SSI3, as above with 3 mm advancement with stepped mouthpiece. 
SSI4 SSI4, as above with 4 mm advancement with stepped mouthpiece. 
SSI5 SSI5, as above with 5 mm advancement with stepped mouthpiece. 
 
5.6.2 Pharyngograms – analysis of CSA 
Three CSAs were identified, CSA1-3 as described in Chapter 3, section 3.6.5 in this thesis. For 
each subject and pharyngograms the CSA for each landmark (OPJ, EG and GL) was determined 
and the results summarised descriptively.  
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5.6.3 Pharyngograms – analysis of AUC 
Three AUCs were identified, AUC1-3 as described in Chapter 3, section 3.6.5 in this thesis. For 
each subject and pharyngograms, the AUC between the incisors/wavetube mouthpiece and CSA1, 
and between CSA1 and CSA2, and between CSA2 and CSA3 was determined and the results 
summarised descriptively.  
5.6.4 Statistical analyses of CSAs and AUCs 
For each of the endpoints (CSAs, AUCs) the possible effect of the introduction of the stepped 
mouthpiece - and therefore the possible impact of the vertical diameter of 18 mm – and the possible 
effect of the mandibular advancement was investigated using a main fixed effect ANOVA 
analysis, using subject and displacement in mm as factors. Separate analyses were performed for 
the 2 study groups and the 2 breathing patterns. The same analysis was performed both with and 
without some extreme data (data outside ± 3 SD). 
5.6.5 GOF analysis of the pharyngograms 
As described in Chapter 3, section 3.6.4 in this thesis. 
As noted in previous evaluations of pharyngograms in Chapter 3, outlier pharyngograms were 
occasionally recorded and were removed from the analysis. A similar approach was followed in 
the present study. For each subject and group of acoustic pharyngometry data (BMI0, SMI0-5, 
SSI0-5) the individual pharyngograms were compared to the median curve by calculating a GOF 
measure. GOF was defined as the square root of the average squared vertical distance between the 
median curve and the curve under study. Individual pharyngograms with too large GOF values 
were excluded from subsequent evaluations. However, a slightly different approach for the GOF 
evaluation compared to the one presented in Chapter 3 was adopted due to differences in study 
design: 
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- BFL pharyngograms were excluded from the GOF calculation. 
- For the BMI0, SMI0-5 and SSI0-5 (13 measurements each consisting of 4 pharyngograms) 
measurements and each subject, the first maxima and last minima that coincided for at least 
2 of the 4 pharyngograms was recorded (total of 13 measurements × 60 subjects = 780 
measurements × 4 pharyngograms = 3120 pharyngograms). 
- GOF was calculated between these two points. 
- Using the calculated cut-offs, GOF was calculated for each of the 3,120 pharyngograms 
(Figure 5.8).  
 
 
Figure 5.8: GOF analysis of the pharyngograms from the 13 measurements highlighted on the x-
axis. The legend refers to the 4 pharyngograms recorded during each of the measurements for each 
of the 60 study subjects. 
 
The GOF value was mainly below 0.5 but for a few higher values which were removed from 
further analysis. Five pharyngograms had GOF>1 (0.2%) and 1.7% had GOF>0.5. The choice of 
a GOF value of 0.5 as a cut-off between accepted or not was subjectively made based on Figure 
5.8. 
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5.7 Results 
5.7.1 Demographics 
Sixty subjects were included and all met the inclusion and none the exclusion criteria. No AEs 
were reported. The majority of the subjects were Caucasian (57), with two Black but not Hispanic 
subjects and one Asian subject. The demographic data including age, height, weight, BMI, and 
neck circumference are presented in Tables 5.3 to 5.7, separately for the 30 healthy subjects (non-
OSA group) and the 30 subjects diagnosed with OSA (OSA group).  
Table 5.3: Eight demographic parameters compared statistically between groups.  
 
Parameter 
Mean Difference 
p-value 
Non-OSA OSA Absolute 
Relative 
(%) 
Age (years) 40.2 50.6 -10.4 -22.9 0.0003 
Height (cm) 171.3 170.1 1.24 0.7 0.57 
Weight (kg) 76.8 86.1 -9.4 -11.5 0.0388 
BMI 26.0 29.8 -3.8 -13.6 0.0048 
Neck circumference (cm) 38.2 40.8 -2.7 -6.8 0.0100 
Most protrusive (cm) 5.93 7.40 -1.47 -22.1 0.0306 
Most retrusive (cm) 6.40 5.47 0.93 15.7 0.0763 
Range (cm) 12.3 12.9 -0.5 -4.0 0.24 
 
The two groups differed statistically significantly for age, weight, BMI, collar size and most 
protrusive mandibular position. 
Table 5.4: Subject demographics – subject age (years) at time of study. 
 
OSA Sex Mean Median Min Max ± SD 
 
N 
F 43.8 41.0 26 62 11.0 
M 36.6 34.0 23 59 8.9 
All 40.2 36.5 23 62 10.5 
 
 
Y 
F 52.8 51.0 38 76 10.3 
M 48.3 50.0 31 66 9.9 
All 50.6 50.0 31 76 10.2 
All 45.4 43.5 23 76 11.5 
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The group with OSA was statistically significantly (~10 years) older than the non-OSA group, 
females were ~5 years older than males (Table 5.4). Males were ~10 cm taller than females, but 
there were no apparent differences between groups (Table 5.5). 
Table 5.5: Subject demographics – height (cm). 
 
OSA Sex Mean Median Min Max ± SD 
 
N 
F 164.9 164.0 158 173 4.8 
M 177.7 177.5 170 190 5.0 
All 171.3 172.3 158 190 8.1 
 
Y 
F 165.9 165.0 152 177 7.9 
M 174.2 174.0 160 188 7.3 
All 170.1 171.5 152 188 8.6 
All 170.1 171.5 152 188 8.6 
 
The group with OSA was statistically significantly heavier than the non-OSA group mainly 
because the females in the OSA group had higher mean weight than the females in the non-OSA 
group (Table 5.6). 
Table 5.6: Subject demographics – weight (kg). 
 
OSA Sex Mean Median Min Max ± SD 
 
N 
F 67.8 63.0 55 97 12.0 
M 85.8 80.0 71 113 12.9 
All 76.8 75.0 55 113 15.3 
 
Y 
F 85.4 77.6 54 150 24.7 
M 86.8 90.8 68 104 11.0 
All 86.1 83.8 54 150 18.8 
All 81.5 78.5 54 150 17.6 
 
The group with OSA had a statistically significantly higher average BMI than the non-OSA group 
mainly due to the fact that the females in the OSA group had a higher mean BMI than the females 
in the non-OSA group (Table 5.7). The differences between the females of the OSA group in 
comparison with the non-OSA group were similar to the differences in weight. 
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Table 5.7: Subject demographics - BMI. 
 
OSA Sex Mean Median Min Max ± SD 
 
N 
F 24.9 23.4 21 35 4.0 
M 27.1 26.0 24 33 3.0 
All 26.0 24.7 21 35 3.7 
 
Y 
F 30.8 29.3 20 48 7.3 
M 28.7 28.0 23 38 4.5 
All 29.8 28.5 20 48 6.0 
All 27.9 27.3 20 48 5.3 
 
The group with OSA had a statistically significantly larger average neck circumference than the 
non-OSA group mainly due to the fact that the females in the OSA group had a larger neck 
circumference than the females in the non-OSA group (Table 5.8). The differences between the 
females of the OSA group in comparison with the non-OSA group were similar to the differences 
in weight and BMI. 
Table 5.8: Subject demographics – neck circumference (cm). 
 
OSA Sex Mean Median Min Max ± SD 
 
N 
F 34.7 34.0 32 39 2.2 
M 41.6 41.0 39 46 2.3 
All 38.2 39.0 32 46 4.1 
 
Y 
F 39.4 38.0 36 51 4.2 
M 42.3 42.5 38 46 2.4 
All 40.8 40.0 36 51 3.7 
All 39.5 39.8 32 51 4.1 
 
The demographic data included information about the subjects’ ability to move the mandible. Data 
on the most protrusive and most retrusive positions of the mandible measured from an edge-to 
edge position of the incisors and the range of motion of the mandible are presented in Tables 5.9 
to 5.11, separately for the non-OSA and the OSA groups. 
 
 219 
  
 
Table 5.9: Subject demographics – most protrusive mandible position (mm). 
 
OSA Sex Mean Median Min Max ± SD 
 
N 
F 6.0 6 2 9 1.6 
M 5.9 6 2 9 1.8 
All 5.9 6 2 9 1.7 
 
Y 
F 6.1 7 0 10 3.1 
M 8.7 8 4 14 2.9 
All 7.4 8 0 14 3.2 
All 6.7 6 0 14 2.6 
 
The most protrusive mandible position was largest for males in the OSA group and mainly due to 
the difference between males in the two groups there was a statistically significantt difference of 
~1.5 mm between the non-OSA and OSA groups (Table 5.9).  
The most retrusive mandible position was smallest for males in the OSA group and mainly due to 
the difference between males in the two groups there was a nonsignificant difference of 1.1 mm 
between the non-OSA and OSA groups (Table 5.10).  
Table 5.10: Subject demographics – most retrusive mandible position (mm). 
 
OSA Sex Mean Median Min Max ± SD 
 
N 
F 6.2 6 5 8 1.1 
M 6.6 7 4 9 1.4 
All 6.4 7 4 9 1.2 
 
Y 
F 6.5 6 2 12 2.6 
M 4.4 4 2 9 2.1 
All 5.5 5 2 12 2.5 
All 5.9 6 2 12 2.0 
 
The range of motion of the mandible is presented separately for the non-OSA and the OSA groups 
in Table 5.11. 
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Table 5.11: Subject demographics – range of motion of the mandible (mm). 
 
OSA Sex Mean Median Min Max ± SD 
 
N 
F 12.2 12 9 17 1.8 
M 12.5 13 9 15 1.7 
All 12.3 12 9 17 1.7 
 
Y 
F 12.6 12 10 16 1.6 
M 13.1 13 10 16 2.0 
All 12.9 13 10 16 1.8 
All 12.6 12 9 17 1.8 
 
5.7.2 Landmarks, CSA1-3 
For each subject the position of the OPJ, EG and GL was determined by the Investigator during 
the recording of the four baseline pharyngograms (BFL, exhalation). The individual landmarks are 
included in APPENDIX C.2, whereas summary statistics for the OP, EG and GL for all 60 subjects 
are presented as distance (cm) from the incisors in Table 5.12. 
Table 5.12: Summary statistics for landmark (OPJ, EG and GL) positions for the 60 subjects in 
relation to the incisors (cm from incisors; mean, minimum and maximum, median, ± SD). 
 
Landmark Mean Median Min Max ± SD 
OPJ 8.48 8.88 6.30 9.31 0.95 
EG 12.22 12.53 9.31 13.59 1.08 
GL 20.72 20.45 18.74 23.45 1.34 
 
In Table 5.13 the mean position for each of the three landmarks is presented by gender and 
separately for the non-OSA and OSA groups. There was no apparent effect on the landmark 
positions by gender or OSA (Table 5.13) which was confirmed by ANOVA (Table 5.14). 
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Table 5.13: Mean landmark (OPJ, EG, GL) position (cm from incisors) by gender and OSA. 
 
Gender 
OPJ EG GL 
OSA=No OSA=Yes OSA=No OSA=Yes OSA=No OSA=Yes 
Female 8.3 8.3 11.9 12.3 20.8 21.2 
Male 8.6 8.7 12.4 12.3 20.7 20.2 
 
Table 5.14: ANOVA for effects (p-values) by gender and OSA. 
 
Factor OPJ EG GL 
Gender 0.20 0.37 0.10 
OSA 0.73 0.54 0.80 
 
For each landmark, the Pearson correlation coefficient was calculated to quantify the association 
between landmark position and each of the parameters age, height, weight, BMI and neck 
circumference (Table 5.15). All correlations were close to zero indicating weak associations.  
Table 5.15: Correlation between landmarks and patient characteristics. 
 
Landmark Age Height Weight BMI Neck 
circumference 
OPJ 0.07 0.11 -0.08 -0.20 0.10 
EPI 0.11 0.09 -0.02 -0.11 0.13 
GL -0.13 -0.04 0.04 0.11 0.08 
 
5.7.3 Individual pharyngograms 
The individual mean pharyngometry data and individual mean pharyngograms are included in 
APPENDIX C-3. As an example the measurements of subject 1 are shown in Figure 5.9 showing 
the measurements (each mean of 4 pharyngograms but for BFL, BFL3, and BFL4; check Table 
5.2, section 5.6.1) with legends. The y-axis presents the CSA (in cm2) of the upper airway and the 
x-axis presents the length of the upper airway (in cm) from the end of the wavetube mouthpiece 
(BFL, BMI measurements) or the end of the stepped mouthpiece to the GL.  
 222 
  
 
 
Figure 5.9: Pharyngograms (mean of 4 recordings) by measurement are shown for Subject 1 from 
the non-OSA group (w/o = without). The codes for the different measurements (BFL, BMI, SMI 
and SSI) are presented in Table 5.2, section 5.6.1. The baseline measurements differed from the 
stepped mouthpiece measurements due to the addition of the stepped mouthpiece to the acoustic 
pharyngometer wavetube which created a shift of the pharyngograms to the right on the x-axis. 
 
The baseline pharyngograms differed from the pharyngograms recorded with the stepped 
mouthpiece as the addition of the stepped mouthpiece to the acoustic pharyngometer wavetube 
created a shift of the pharyngograms to the right. BFL and BMI pharyngograms agreed closely, 
whereas Mueller or Valsalva (Brown et al., 1986) and nasal exhalation pharyngograms deviated 
as expected. 
5.7.4 Summary statistics for CSA1-3 for the non-OSA and OSA groups 
Summary statistics for the CSAs are presented in subsections 5.7.4.1 to 5.7.4.3 and Tables 5.16-
5.18 for the non-OSA and OSA groups. 
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5.7.4.1 Summary statistics for CSA1 
Table 5.16: Summary statistics for the CSA1 (cm2) by OSA. The results are presented as mean, 
median, minimum, maximum, ± SD for baseline measurements (BFL1-2 during exhalation, BMI0 
during inhalation), measurements during tidal breathing with the stepped mouthpiece (SMI0-5) 
and measurements during slow and deep breathing with the stepped mouthpiece (SSI0-5). 
 
O
S
A
 
Measurement N Mean Median Min Max ± SD 
 
N 
 
BFL1-2 
 
30 
 
2.13 
 
1.98 
 
0.89 
 
4.25 
 
0.71 
BMI0 30 2.18 2.14 0.98 3.92 0.71 
SMI0 30 3.73 3.33 1.86 6.91 1.38 
SMI1 30 3.79 3.04 2.03 7.42 1.49 
SMI2 30 3.82 3.58 1.80 7.27 1.46 
SMI3 30 3.75 3.28 2.03 6.98 1.47 
SMI4 30 4.07 3.86 2.18 7.31 1.54 
SMI5 29 3.89 3.26 1.85 6.63 1.45 
SSI0 30 3.84 3.72 1.50 7.41 1.56 
SSI1 30 3.77 3.55 1.58 6.75 1.44 
SSI2 30 3.90 3.93 1.84 6.59 1.27 
SSI3 30 3.78 3.42 1.49 7.24 1.49 
SSI4 30 4.07 4.07 2.13 6.54 1.38 
SSI5 29 3.98 3.83 1.97 5.93 1.23 
 
Y 
 
BFL1-2 
 
30 
 
1.58 
 
1.56 
 
0.84 
 
2.68 
 
0.39 
BMI0 30 1.60 1.51 0.85 3.03 0.48 
SMI0 30 2.92 2.78 1.18 8.79 1.41 
SMI1 30 2.97 2.71 1.21 10.91 1.68 
SMI2 30 2.99 2.89 1.07 9.31 1.40 
SMI3 29 3.25 2.83 1.13 10.90 1.80 
SMI4 29 3.21 3.03 1.20 8.67 1.40 
SMI5 29 3.10 2.70 1.14 9.06 1.51 
SSI0 30 2.86 2.54 1.18 10.06 1.56 
SSI1 30 3.21 2.78 1.34 9.94 1.68 
SSI2 30 3.24 2.68 1.26 9.40 1.66 
SSI3 29 3.22 3.04 1.07 8.55 1.41 
SSI4 29 3.14 3.21 1.12 7.60 1.17 
SSI5 29 3.27 2.88 1.05 8.32 1.48 
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5.7.4.2 Summary statistics for CSA2 
Table 5.17: Summary statistics for CSA2 (cm2) by OSA. The results are presented as mean, 
median, minimum, maximum, ± SD for baseline measurements (BFL1-2 during exhalation, BMI0 
during inhalation), measurements during tidal breathing with the stepped mouthpiece (SMI0-5) 
and measurements during slow and deep breathing with the stepped mouthpiece (SSI0-5). 
 
O
S
A
 
Measurement N Mean Median 
 
Min Max ± SD 
 
N 
 
BFL1-2 
 
30 
 
2.64 
 
2.41 
 
1.05 
 
6.57 
 
1.09 
BMI0 30 2.58 2.32 1.10 5.83 1.06 
SMI0 30 3.32 3.42 1.17 5.94 1.30 
SMI1 30 3.59 3.66 1.17 6.99 1.51 
SMI2 30 3.58 3.38 1.23 7.78 1.65 
SMI3 30 3.84 3.63 1.30 7.45 1.71 
SMI4 30 3.96 3.98 1.38 7.78 1.75 
SMI5 29 4.23 4.03 1.15 8.20 2.07 
SSI0 30 3.38 3.17 1.02 6.42 1.47 
SSI1 30 3.28 3.03 1.15 6.33 1.35 
SSI2 30 3.57 3.32 1.14 7.74 1.58 
SSI3 30 3.77 3.37 1.10 7.70 1.65 
SSI4 30 3.67 3.54 1.40 7.50 1.58 
SSI5 29 3.72 3.79 1.46 8.08 1.72 
 
Y 
 
BFL1-2 
 
30 
 
2.59 
 
2.58 
 
1.23 
 
4.21 
 
0.76 
BMI0 30 2.59 2.52 1.38 4.77 0.74 
SMI0 30 2.72 2.47 1.29 5.73 1.07 
SMI1 30 2.96 2.65 1.46 6.74 1.26 
SMI2 30 2.91 2.70 1.44 5.60 1.08 
SMI3 29 2.93 2.77 1.47 5.99 1.10 
SMI4 29 2.99 2.78 1.33 5.94 1.16 
SMI5 29 3.05 3.00 1.57 6.23 1.20 
SSI0 30 2.84 2.71 1.41 5.61 1.14 
SSI1 30 2.74 2.53 1.25 6.06 1.17 
SSI2 30 2.92 2.63 1.60 6.07 1.22 
SSI3 29 2.97 2.54 1.44 7.00 1.44 
SSI4 29 2.98 2.42 1.43 7.19 1.47 
SSI5 29 3.02 2.72 1.40 6.91 1.44 
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5.7.4.3 Summary statistics for CSA3 
Table 5.18: Summary statistics for CSA3 (cm2) by OSA. The results are presented as mean, 
median, minimum, maximum, ± SD for baseline measurements (BFL1-2 during exhalation, BMI0 
during inhalation), measurements during tidal breathing with the stepped mouthpiece (SMI0-5) 
and measurements during slow and deep breathing with the stepped mouthpiece (SSI0-5). 
 
O
S
A
 
Measurement N Mean Median 
 
Min Max ± SD 
 
N 
 
BFL1-2 
 
30 
 
2.88 
 
2.87 
 
1.20 
 
4.84 
 
0.87 
 BMI0 30 2.98 3.04 2.03 4.50 0.67 
 SMI0 30 4.42 3.85 1.03 10.37 2.26 
 SMI1 30 4.10 3.89 1.34 7.76 1.68 
 SMI2 30 3.95 3.52 1.42 9.86 1.94 
 SMI3 30 4.21 3.72 1.34 10.57 2.01 
 SMI4 30 3.95 3.74 1.33 10.49 1.74 
 SMI5 29 3.95 3.92 1.36 7.65 1.65 
 SSI0 29 4.71 3.46 0.66 15.09 3.91 
 SSI1 29 3.89 3.35 1.03 9.77 2.25 
 SSI2 30 3.81 3.13 0.54 11.96 2.47 
 SSI3 30 4.02 3.29 1.59 11.52 2.33 
 SSI4 30 3.92 3.27 1.16 10.89 2.17 
 SSI5 29 3.66 3.47 0.87 8.62 1.74 
 
Y 
 
BFL1-2 
 
30 
 
2.79 
 
2.69 
 
1.55 
 
5.24 
 
0.80 
 BMI0 30 2.95 3.05 1.62 4.96 0.74 
 SMI0 29 3.87 3.25 1.35 11.55 2.23 
 SMI1 29 3.79 3.11 1.19 9.88 2.22 
 SMI2 30 3.69 3.13 0.61 9.95 2.23 
 SMI3 29 3.74 3.16 1.59 8.57 1.87 
 SMI4 29 3.75 3.41 1.52 10.18 1.98 
 SMI5 29 3.83 3.41 1.47 12.78 2.19 
 SSI0 29 3.81 3.16 0.61 12.20 2.44 
 SSI1 29 3.81 2.83 1.05 11.73 2.60 
 SSI2 29 3.91 2.89 0.18 11.44 2.86 
 SSI3 28 3.92 2.81 1.33 10.39 2.67 
 SSI4 28 3.72 2.89 1.37 14.39 2.77 
 SSI5 28 3.63 3.11 1.30 10.38 2.07 
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5.7.5 Graphical presentation of the changes in CSAs 
During tidal breathing (SMI0-5) the impact of the vertical diameter of the stepped mouthpiece on 
the CSAs was larger than the effect of the mandibular advancement for CSA1 and CSA3 for both 
groups (Figure 5.10). However, for CSA2 in the non-OSA group the change in the size of CSA2 
was larger following mandibular advancement (SMI5-SMI0 = 0.91 cm2) than following the 
introduction of the stepped mouthpiece (SMI0 - BMI0 = 0.74 cm2). The change in size of CSA2 
in the OSA group was also larger following mandibular advancement (0.33 cm2) than following 
the introduction of the stepped mouthpiece (0.13 cm2) although the magnitude was smaller. 
 
Figure 5.10: The CSAs are presented as mean values (± SD) for tidal breathing per group (non-
OSA, OSA) following introduction of the stepped mouthpiece (B = baseline BMI0) and following 
the mandibular advancements (0-5 mm, SMI0 to SMI5).  
 
During slow and deep breathing (SSI0-5) the impact of the vertical diameter of the stepped 
mouthpiece on the CSAs was larger in relation to the effect of the mandibular advancements for 
all of the CSAs (Figure 5.11). In the non-OSA group the change in the size of CSA2 was smaller 
 227 
  
 
following full mandibular advancement (SSI5 - SSI0 = 0.34 cm2) and larger (difference between 
SSI0 - BMI0 = 0.80 cm2; Figure 5.11) following the introduction of the stepped mouthpiece 
(vertical change). The change in size of CSA2 in the OSA group followed the same pattern with 
smaller change following mandibular advancement (0.18 cm2) and larger (0.25 cm2) following the 
introduction of the stepped mouthpiece (vertical change). 
 
Figure 5.11: The CSAs are presented as mean values (± SD) for slow and deep breathing per 
group (non-OSA, OSA) following introduction of the stepped mouthpiece (B = baseline BMI0) 
and following the mandibular advancements (0-5 mm, SSI0 to SSI5).  
 
5.7.6 Summary statistics for AUC1-3 for the non-OSA and OSA groups 
Summary statistics for the AUCs are presented in subsections 5.7.6.1 to 5.7.6.3 and Tables 5.19-
5.21 for the non-OSA and OSA groups. 
  
 228 
  
 
5.7.6.1 Summary statistics for AUC1 
Table 5.19: Summary statistics for AUC1 (cm3) by OSA. The results are presented as mean, 
median, minimum, maximum, ± SD for baseline measurements (BFL1-2 during exhalation, BMI0 
during inhalation), measurements during tidal breathing with the stepped mouthpiece (SMI0-5) 
and measurements during slow and deep breathing with the stepped mouthpiece (SSI0-5). 
 
O
S
A
 
Measurement N Mean Median 
 
Min Max ± SD 
 
N 
 
BFL1-2 
 
30 
 
36.27 
 
36.14 
 
18.75 
 
49.54 
 
7.13 
BMI0 30 35.57 36.24 21.95 49.15 7.14 
SMI0 30 45.84 46.09 29.41 62.23 8.39 
SMI1 30 44.78 44.02 28.57 65.49 8.55 
SMI2 30 44.37 45.44 28.23 60.53 8.66 
SMI3 30 44.11 45.14 29.52 64.69 9.42 
SMI4 30 45.23 45.80 28.02 58.85 8.58 
SMI5 29 44.06 44.29 25.31 59.33 9.63 
SSI0 30 46.13 46.52 23.95 69.26 9.68 
SSI1 30 46.09 45.91 28.70 61.40 8.84 
SSI2 30 44.21 44.51 31.23 61.10 8.29 
SSI3 30 44.49 44.53 28.97 59.87 8.40 
SSI4 30 45.38 46.51 29.87 60.81 8.93 
SSI5 29 44.87 46.21 27.18 60.79 9.19 
 
Y 
 
BFL1-2 
 
30 
 
33.12 
 
34.30 
 
24.41 
 
45.54 
 
5.46 
BMI0 30 33.99 34.37 21.23 46.59 6.46 
SMI0 30 46.14 46.71 29.58 60.66 6.95 
SMI1 30 45.81 45.95 31.59 61.00 6.83 
SMI2 30 45.42 45.76 28.90 61.07 7.55 
SMI3 29 46.32 45.67 32.92 60.62 6.86 
SMI4 29 45.33 46.31 30.18 60.00 7.05 
SMI5 29 45.27 45.86 27.70 63.10 7.99 
SSI0 30 45.34 45.16 30.69 57.72 6.63 
SSI1 30 47.50 46.46 34.46 59.10 5.84 
SSI2 30 47.03 46.65 33.35 61.21 5.88 
SSI3 29 47.26 47.52 30.66 59.75 6.84 
SSI4 29 46.48 46.13 29.13 60.78 7.60 
SSI5 29 46.13 46.24 30.24 64.41 8.24 
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5.7.6.2 Summary statistics for AUC2 
Table 5.20: Summary statistics for AUC2 (cm3) by OSA. The results are presented as mean, 
median, minimum, maximum, ± SD for baseline measurements (BFL1-2 during exhalation, BMI0 
during inhalation), measurements during tidal breathing with the stepped mouthpiece (SMI0-5) 
and measurements during slow and deep breathing with the stepped mouthpiece (SSI0-5).  
 
O
S
A
 
Measurement N Mean Median 
 
Min Max ± SD 
 
N 
 
BFL1-2 
 
30 
 
9.37 
 
8.91 
 
4.60 
 
19.02 
 
3.46 
BMI0 30 9.20 8.67 4.57 18.67 3.28 
SMI0 30 10.92 10.41 4.58 19.91 3.51 
SMI1 30 11.72 11.12 5.08 21.99 3.79 
SMI2 30 11.75 11.84 4.86 19.66 3.81 
       
SMI3 30 12.16 11.49 4.48 22.67 4.27 
SMI4 30 13.12 12.07 4.73 22.84 4.49 
SMI5 29 13.40 13.77 4.61 28.00 4.76 
SSI0 30 10.98 10.72 4.47 19.11 3.62 
SSI1 30 11.06 10.05 4.30 20.91 4.03 
SSI2 30 11.68 12.25 4.60 18.03 3.31 
SSI3 30 11.86 11.30 5.24 20.48 3.50 
SSI4 30 12.37 12.08 4.87 22.92 4.19 
SSI5 29 12.33 11.86 4.63 22.13 4.01 
 
Y 
 
BFL1-2 
 
30 
 
7.96 
 
7.90 
 
4.44 
 
11.03 
 
1.79 
BMI0 30 7.90 7.49 4.40 14.12 2.33 
SMI0 30 8.75 8.20 4.67 15.26 2.61 
SMI1 30 9.07 8.34 4.30 17.63 2.96 
SMI2 30 9.30 9.18 4.31 15.53 2.51 
SMI3 29 9.67 9.18 4.48 17.37 2.80 
SMI4 29 9.64 9.32 4.53 13.91 2.45 
SMI5 29 9.69 9.45 4.23 15.31 2.90 
SSI0 30 8.40 8.11 3.89 17.94 2.88 
SSI1 30 8.94 8.34 4.16 16.47 3.08 
SSI2 30 9.26 8.61 4.68 16.23 3.07 
SSI3 29 9.37 8.51 4.08 15.72 3.38 
SSI4 29 9.41 8.76 4.63 15.34 3.24 
SSI5 29 9.73 9.35 5.07 16.03 3.28 
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5.7.6.3 Summary statistics for AUC3 
Table 5.21: Summary statistics for AUC3 (cm3) by OSA. The results are presented as mean, 
median, minimum, maximum, ± SD for baseline measurements (BFL1-2 during exhalation, BMI0 
during inhalation), measurements during tidal breathing with the stepped mouthpiece (SMI0-5) 
and measurements during slow and deep breathing with the stepped mouthpiece (SSI0-5). 
 
O
S
A
 
Measurement N Mean Median 
 
Min Max ± SD 
 
N 
 
BFL1-2 
 
30 
 
27.49 
 
27.23 
 
14.62 
 
44.81 
 
8.14 
BMI0 30 27.00 27.37 11.99 45.33 8.46 
SMI0 30 29.83 29.41 12.30 48.46 9.35 
SMI1 30 30.78 30.47 14.39 55.31 9.63 
SMI2 30 30.12 29.95 15.52 49.70 9.08 
SMI3 30 30.61 31.90 13.88 51.23 8.98 
SMI4 30 30.19 30.72 13.89 55.78 9.56 
SMI5 29 31.31 32.04 11.05 53.66 10.88 
SSI0 30 28.63 27.13 14.28 55.52 9.70 
SSI1 30 28.20 27.76 15.01 45.90 8.43 
SSI2 30 28.27 28.40 14.32 43.59 8.02 
SSI3 30 29.03 29.25 15.63 53.19 8.88 
SSI4 30 28.28 29.45 15.65 41.94 7.78 
SSI5 29 29.00 29.91 14.84 43.37 7.61 
 
Y 
 
BFL1-2 
 
30 
 
26.62 
 
25.71 
 
14.22 
 
48.94 
 
7.90 
BMI0 30 26.51 24.42 14.23 49.32 7.29 
SMI0 30 27.80 25.07 16.09 49.47 8.74 
SMI1 30 27.92 25.84 15.70 52.55 8.61 
SMI2 30 27.65 25.93 16.50 44.77 7.88 
SMI3 29 27.54 23.78 15.89 46.43 8.49 
SMI4 29 28.00 26.46 16.09 46.69 8.17 
SMI5 29 28.05 25.31 17.05 49.32 8.90 
SSI0 30 27.34 25.37 13.15 50.39 8.36 
SSI1 30 27.43 25.56 15.29 51.50 8.77 
SSI2 30 27.24 26.62 15.30 51.86 8.82 
SSI3 29 28.14 28.06 15.91 53.77 9.91 
SSI4 29 26.84 24.90 16.30 52.89 8.99 
SSI5 29 27.90 25.56 16.65 52.83 9.64 
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5.7.7 Graphical presentation of the changes in AUCs 
During tidal breathing (SMI0-5) the impact of the vertical diameter of the stepped mouthpiece on 
AUC1 was larger than the effect of the mandibular advancements for both groups (Figure 5.12). 
For AUC2 in the non-OSA group the change in the size of AUC2 was larger following mandibular 
advancement (SMI5 - SMI0 = 2.48 cm3) than following the introduction of the stepped mouthpiece 
(SMI0 - BMI0 = 1.72 cm3).  
 
Figure 5.12: The AUCs are presented as mean values (± SD) for tidal breathing per group (non-
OSA, OSA) following introduction of the stepped mouthpiece (B = baseline BMI0) and following 
the mandibular advancements (0-5 mm, SMI0 to SMI5).  
 
The change in size of AUC2 in the OSA group followed the same pattern with larger change 
following mandibular advancement (0.94 cm3) than following the introduction of the stepped 
mouthpiece (0.85 cm3) although the magnitude was smaller. The changes in size of AUC3 were 
small in relation to the volume of the AUC3 and the impact of the vertical diameter of the stepped 
mouthpiece on the AUC3 was larger than the effect of the mandibular advancements (non-OSA 
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group, SSI0 - BMI0 = 2.83 cm3 versus SSI5 - SSI0 = 1.48 cm3; OSA group, SSI0 - BMI0 = 1.63 
cm3 versus SSI5 - SSI0 =   0.37 cm3). 
During slow and deep breathing (SSI0-5) the impact of the vertical diameter of the stepped 
mouthpiece on AUC1 was larger than the effect of the mandibular advancements for both groups 
(Figure 5.13).  This was also the case for the changes in AUC2 in the non-OSA group (SSI0 - 
BMI0 = 1.78 cm3 and versus SSI5 - SSI0 = 1.35 cm3).  
 
Figure 5.13: The AUCs are presented as mean values (± SD) for slow and deep breathing per 
group (non-OSA, OSA) following introduction of the stepped mouthpiece (B = baseline BMI0) 
and following the mandibular advancements (0-5 mm, SSI0 to SSI5).  
 
However, in the OSA group the effects were the opposite (SSI0 - BMI0 = 0.50 cm3 versus SSI5 - 
SSI0 = 1.33 cm3). The changes in size of AUC3 were small in relation to the volume of the AUC3 
and the impact of the vertical diameter of the stepped mouthpiece on the AUC3 was larger than 
the effect of the mandibular advancements (non-OSA group, SSI0 - BMI0 = 1.63 cm3 versus SSI5 
- SSI0 = 0.37 cm3; OSA group, SSI0 - BMI0 = 0.83 cm3 versus SSI5 - SSI0 = 0.56 cm3). 
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5.7.8 Statistics - effects of the vertical diameter of the stepped mouthpiece 
The effects of the introduction of the stepped mouthpiece (incisal opening) on CSA1-3 and AUC1-
3 were investigated by ANOVA for data from BMI0, SMI0 and SSI0 (Tables 5.22-5.23). The data 
from tidal, and slow and deep breathing patterns were pooled for this analysis. 
Table 5.22: The non-OSA group, summary statistics and results of ANOVA based on data from 
SMI0 and SSI0 for changes in CSA1-3 (cm2) and AUC1-3 (cm3) depending on the introduction of 
the stepped mouthpiece (incisal opening). 
 
Endpoint Means with 
mouthpiece 
Means without 
mouthpiece 
p-values 
CSA1 3.78 2.18 <0.0001 
CSA2 3.35 2.58 0.0004 
CSA3 4.62 2.98 0.0033 
AUC1 45.99 35.57 <0.0001 
AUC2 10.95 9.20 0.0001 
AUC3 29.23 27.00 0.0091 
 
Table 5.23: The OSA group, summary statistics and results of ANOVA based on data from SMI0 
and SSI0 for changes in CSA1-3 (cm2) and AUC1-3 (cm3) depending on the introduction of the 
stepped mouthpiece (incisal opening). 
 
Endpoint Means with 
mouthpiece 
Means without 
mouthpiece 
p-values 
CSA1 2.89 1.60 <0.0001 
CSA2 2.78 2.59 0.1602 
CSA3 3.87 2.95 0.0257 
AUC1 45.74 33.99 <0.0001 
AUC2 8.57 7.90 0.0679 
AUC3 27.57 26.51 0.1709 
 
The results for the non-OSA group (Table 5.22) showed that the changes in CSA1-3 and AUC1-3 
following the introduction of the stepped mouthpiece (incisal opening) were all statistically 
significant. This was in contrast with the results for the OSA group (Table 5.23) which only 
showed statistically significant results for CSA1, CSA3 and AUC1.  
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5.7.9 Statistics- effects by OSA, gender, breathing pattern, and mouthpiece 
position 
An ANOVA with fixed factors OSA, gender, breathing pattern and mouthpiece position was 
performed for endpoints CSA1-3 and AUC1-3 for data from SMI0-5 and SSI0-5. The results of 
the analysis (p-values) is presented in Table 5.24. 
Table 5.24: Results of ANOVA (p-values) for endpoints CSA1-3 and AUC1-3 based on data from 
SMI0-5 and SSI0-5 evaluating effects by factors OSA, gender, breathing pattern and mouthpiece 
position. 
 
Endpoint OSA Gender Breathing 
pattern 
Mouthpiece 
position 
CSA1 <0.0001 0.7915 0.5365 0.7378 
CSA2 <0.0001 0.3492 0.3374 0.1461 
CSA3 0.1383 0.0001 0.7748 0.7392 
AUC1 0.0419 <0.0001 0.2264 0.9261 
AUC2 <0.0001 0.8825 0.2235 0.0058 
AUC3 0.0046 0.0968 0.0879 0.9829 
 
The breathing pattern had no statistically significant effects on any of the endpoints whereas OSA 
was statistically significant for all endpoints but CSA3, and gender was statistically significant 
only for CSA3 and AUC1. Mouthpiece position was statistically significant for AUC2. To assess 
if effects were associated with relevant differences the overall means for factors OSA, gender and 
breathing pattern are presented in Table 5.25, and for mouthpiece position in Table 5.26. 
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Table 5.25: Main effects from ANOVA for endpoints CSA1-3 (cm2) and AUC1-3 (cm3) for 
factors OSA status, gender and breathing pattern. 
 
Endpoint OSA Gender Breathing pattern 
No Yes Female Male SMI SSI 
CSA1 3.86 3.11 3.48 3.50 3.46 3.52 
CSA2 3.66 2.92 3.24 3.34 3.34 3.24 
CSA3 4.05 3.79 4.25 3.59 3.94 3.90 
AUC1 44.97 46.17 42.86 48.24 45.22 45.90 
AUC2 11.94 9.26 10.60 10.62 10.77 10.45 
AUC3 29.52 27.65 28.05 29.13 29.15 28.03 
 
A couple of examples from factors OSA and gender might be of interest. The statistically 
significant effect by OSA on CSA2 was 0.74 cm2 or equal to a ~25% difference, whereas the 
statistically significant effect by gender on AUC1 was 5.38 cm3 or equal to a ~13% difference. 
Table 5.26: Main effects from ANOVA for endpoints CSA1-3 (cm2) and AUC1-3 (cm3) for factor 
mouthpiece position. 
 
Endpoint Mouthpiece position 
 0 mm 1 mm 2 mm 3 mm 4 mm 5 mm 
CSA1 3.34 3.43 3.49 3.50 3.63 3.56 
CSA2 3.06 3.14 3.25 3.38 3.41 3.51 
CSA3 4.20 3.90 3.84 3.97 3.84 3.77 
AUC1 45.86 46.05 45.26 45.52 45.60 45.08 
AUC2 9.76 10.20 10.50 10.79 11.16 11.29 
AUC3 28.40 28.58 28.32 28.85 28.34 29.06 
 
The statistically significant effect by mouthpiece position on AUC2 (non-OSA and OSA data 
combined) corresponded to an increase in volume from 9.76 to 11.29 cm3, a difference of 1.53 cm3 
or ~16% of the 0 mm value. In Table 5.27 the mean AUC2 is presented in a cross-tabulation for 
mouthpiece position versus non-OSA and OSA groups. 
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Table 5.27: AUC2 (cm3) for stepped mouthpiece position versus non-OSA and OSA groups. 
 
Mouthpiece position 
(mm) 
Non-OSA 
(cm3) 
OSA 
(cm3) 
0 10.95 8.57 
1 11.39 9.00 
2 11.71 9.28 
3 12.01 9.52 
4 12.75 9.52 
5 12.87 9.71 
Change (%) 17.5% 13.3% 
 
The effect of shifting the stepped mouthpiece position from 0 to 5 mm was relatively comparable 
for the non-OSA and OSA groups, although the degree of change was different between the 
groups. 
5.7.10 Statistics - effect of extreme endpoints 
A number of relatively extreme CSA1-3 and AUC1-3 results were recorded (Tables 5.16-5.18 in 
5.7.4.1 - 5.7.4.3; Tables 5.19-5.21 in 5.7.6.1 - 5.7.6.3) and an analysis of these was performed. For 
each measurement and each of the CSA1-3 and AUC1-3 endpoints the mean and SD was 
calculated based on the 60 subjects. Based on these calculations upper and lower limits for normal 
measurements were defined as mean ± 3 SDs.  
Through the analysis 51 results were identified from 46 measurements, and of these 15 concerned 
CSA1, 6 CSA2, 17 CSA3, 9 AUC2 and 4 AUC3. The atypical results concerned 17 subjects and 
the subject with the highest number of extreme results was subject 46 with 12 outliers, all of which 
were related to CSA1 and of these all but one were related to measurements with the stepped 
mouthpiece. Out of the 17 CSA3 outliers, 4 were related to baseline measurements and 13 to 
measurements in 5 subjects (11, 12, 16, 25 and 34) with the stepped mouthpiece.  
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A main effects ANOVA with fixed factors inhalation mode, mouthpiece position, OSA status and 
gender was performed for each of the 6 endpoints (excluding data for BFL and BMI) using the 
data set without “outliers” (Table 5.28). 
Table 5.28: p-values from ANOVA evaluating effects by OSA and gender, based on data without 
“outliers”. 
 
Endpoint OSA Gender Inhalation 
mode 
Mouthpiece 
position 
CSA1 <0.0001 0.0098 0.3139 0.3308 
CSA2 <0.0001 0.2423 0.3320 0.1103 
CSA3 0.0656 0.0001 0.5024 0.7720 
AUC1 0.0419 <0.0001 0.2264 0.9261 
AUC2 <0.0001 0.7194 0.4571 0.0039 
AUC3 0.0043 0.1459 0.0514 0.9521 
 
A number of statistically significant effects are presented in Table 5.28. Most importantly, the 
same conclusions as found using the full data set can be draw. This shows that the “outliers” did 
not affect the analysis to a significant degree. To assess if the significant effects were associated 
with relevant differences the overall means for each level of the 4 factors are presented. 
 
Table 5.29: Main effects from ANOVA: OSA, gender & inhalation mode – based on data without 
“outliers”. 
 
Endpoint OSA Gender Breathing pattern 
No Yes Female Male SMI SSI 
CSA1 3.87 2.90 3.27 3.50 3.34 3.43 
CSA2 3.64 2.92 3.22 3.34 3.33 3.23 
CSA3 3.91 3.63 4.06 3.47 3.82 3.72 
AUC1 44.98 46.12 42.87 48.23 45.21 45.89 
AUC2 11.82 9.27 10.59 10.50 10.64 10.45 
AUC3 29.45 27.57 28.03 28.99 29.15 27.87 
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Table 5.30: Main effects from ANOVA: mouthpiece position – based on cleaned data without 
“outliers”. 
 
Endpoint Mouthpiece position 
 0 mm 1 mm 2 mm 3 mm 4 mm 5 mm 
CSA1 3.22 3.30 3.38 3.38 3.57 3.46 
CSA2 3.06 3.14 3.17 3.38 3.40 3.51 
CSA3 3.96 3.77 3.77 3.86 3.62 3.62 
AUC1 45.86 46.05 45.26 45.49 45.56 45.08 
AUC2 9.69 10.11 10.50 10.68 11.14 11.15 
AUC3 28.18 28.58 28.32 28.82 28.10 29.06 
 
The main effects presented in Tables 5.29 and 5.30 agree very closely to those presented in Tables 
5.25 and 5.26 based on the full data set.  
5.7.11 Graphical presentation of the endpoints 
In order to visually highlight the range of the endpoints including the “outliers”, these have been 
plotted in increasing order in Figure 5.14 (CSA1-3) and Figure 5.15 (AUC1-3). The endpoints are 
from measurements BMI0, SMI0-5 and SSI0-5 for all 60 subjects. 
 
Figure 5.14: The mean CSA1-3 (mean of 4 pharyngograms) endpoints from measurements BMI0, 
SMI0-5 and SSI0-5 plotted in increasing order for the 60 subjects.  
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Figure 5.15: The mean AUC1-3 (mean of 4 pharyngograms) endpoints from measurements BMI0, 
SMI0-5 and SSI0-5 plotted in increasing order for the 60 subjects.  
 
5.7.12 Measurements (SMI, SSI) in relation to the baseline value (BMI0) 
As some of the SMI0-5 and/or the SSI0-5 measurements had endpoint (CSA1-3, AUC1-3) values 
which were lower than the corresponding baseline measurement (BMI0) endpoint values, it was 
of interest to present the number of such measurements per endpoint per the non-OSA and OSA 
groups (Table 5.31). 
Table 5.31: The number of measurements (SMI0-5, SSI0-5) per endpoint (CSA1-3, AUC1-3) 
smaller than the baseline measurement (BMI0) per OSA group in percent of the total number of 
measurements. 
 
 CSA1 CSA2 CSA3 AUC1 AUC2 AUC3 
Total number of measurements  712 712 712 712 712 712 
Non-OSA, SMI, SSI <BMI0 19 88 123 24 61 104 
% of total 2.7 12.4 17.3 3.4 8.6 14.6 
OSA, SMI, SSI <BMI0 15 140 154 4 120 165 
% of total 2.1 19.7 21.6 0.6 16.9 23.2 
 
 240 
  
 
5.7.13 Statistics - the subjects’ comfort with stepped mouthpiece positions 
The comfort with different mandibular advancement positions achieved with the stepped 
mouthpiece was assessed for each subject during both tidal and slow deep breathing. For each of 
the 6 stepped mouthpiece positions (0-5 mm) the subject scored the degree of comfort as follows:  
- 1 = Very Uncomfortable.  
- 2 = Uncomfortable. 
- 3 = Acceptable.  
- 4 = Comfortable.  
- 5 = Very Comfortable.  
In Table 5.32 the number of subjects recording each of the 5 scores for different breathing patterns 
and mandibular advancements are presented.  
Table 5.32: Comfort scores presented by position (1-6) and breathing pattern. The comfort scores 
(1-5) were scored by the subjects when testing the different mandibular advancements (positions 
1-6, 0-5 mm mandibular advancements) achieved with the stepped mouthpiece during both tidal 
(T) and slow and deep (S) breathing. 
 
S
co
re
 
Positions 1-6 (mandibular advancement 0-5 mm) 
 
1 2 3 4 5 6 
T S T S T S T S T S T S 
1 0 0 0 0 1 1 0 2 3 1 5 8 
2 2 0 4 3 7 4 13 7 12 15 18 20 
3 10 12 10 12 16 16 20 22 21 22 18 14 
4 30 34 35 35 27 34 20 24 19 17 16 16 
5 18 14 11 10 9 5 4 6 4 4 2 1 
 
The most common score was 4 (comfortable) and the degree of comfort decreased with increasing 
mandibular advancement as highlighted in the decrease of scores 4 and 5 from position 1 to 6. The 
mean scores scored during tidal (3.48) and slow and deep (3.45) breathing were not statistically 
significantly different. 
The plot of the scores shown in Figure 5.16 presents the mean score by position and breathing 
pattern. The plot highlights the minimal difference between the scores for the two breathing 
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patterns up to position 5 (4 mm mandibular advancement). However, for position 6 (5 mm 
mandibular advancement) there was a statistically significant (p = 0.0171) difference in the scores 
between the two breathing patterns although the difference was small (0.2 units).   
 
Figure 5.16: Mean comfort scores presented by stepped mouthpiece position for tidal, and slow 
and deep breathing patterns. The scores were scored using the stepped mouthpiece in six different 
positions (position 1 to position 6; 0-5 mm mandibular advancements).  
 
When the most “comfortable position” with the stepped mouthpiece during both tidal (3.40) and 
slow and deep (3.70) breathing had been established, the subject was asked to hold both positions 
for 3 minutes during both tidal, and slow and deep breathing. After 3 minutes per breathing pattern, 
the subject’s level of comfort with the stepped mouthpiece was re-evaluated using the same scoring 
system. The results are shown in Figure 5.17 in which the individual comfort scores after 3 minutes 
in the most comfortable mandibular advancement position for tidal, and slow and deep breathing 
are shown. Some variability can be seen between the two breathing patterns. For example, the 
subjects scoring 4 during tidal breathing scored 1-5 during slow and deep breathing. Neither the 
most comfortable positions nor the scores after 3 minutes of tidal (3.62) and slow and deep (3.40) 
breathing were statistically significantly different. The results have also been presented in a Bland-
Altman plot (Figure 5.18). 
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Figure 5.17: The individual comfort scores after holding the most comfortable stepped 
mouthpiece mandibular advancement position for 3 minutes during both tidal, and slow and deep 
breathing. 
 
 
Figure 5.18: A Bland-Altman plot of the individual comfort scores after holding the most 
comfortable stepped mouthpiece mandibular advancement position for 3 minutes during both tidal, 
and slow and deep breathing. 
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An analysis of the impact of demographic factors on the comfort score showed that only gender 
(p=0.0232) and age (p=0.0277) had statistically significant influences on the most comfortable 
position, whereas for example OSA did not. For each subject the mean endpoint was determined 
from the two breathing patterns as there was no statistically significant effect by breathing pattern. 
The mean most comfortable position was 2.7 for females and 4.5 for males indicating that men 
preferred a somewhat larger mandibular advancement. The analysis of the impact of age indicated 
that for males the most comfortable position increased with increasing age, whereas for females 
the preference was independent of age. 
5.8 Discussion 
The primary objective of the study was to measure through acoustic pharyngometry the impact of 
different horizontal mandibular advancements on the size of the upper airways in subjects without 
(non-OSA group) and with OSA (OSA group). The mandibular advancement was maximised to 5 
mm from an incisal edge-to edge position and was achieved through a stepped mouthpiece attached 
to the wavetube of the acoustic pharyngometer wavetube. The part of the upper airways that was 
investigated included the area from the oral cavity to the GL. The measurements were performed 
while the subjects were seated and inhaled room air during tidal breathing through the stepped 
mouthpiece. The secondary objectives included measurements of the impact of the stepped 
mouthpiece on the upper airways during slow and deep breathing, and assessment of the most 
comfortable mandibular advancement position during both tidal and slow and deep breathing. No 
adverse events were recorded. 
The were some differences in demographic data between the non-OSA and the OSA groups 
including age, weight, BMI, neck circumference and mandibular movement (protrusive, retrusive). 
Subjects with OSA were approximately 10 years older than non-OSA subjects, whereas females 
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with OSA were heavier (~17 kg), had a larger BMI (~6) and a larger neck circumference (~5 cm) 
than the non-OSA females. There were also differences regarding the mandibular movement from 
an incisal edge-to-edge position as the males with OSA had a larger protrusive movement of the 
mandible (2.8 mm) and a smaller retrusive movement of the mandible (2.2 mm) than the non-OSA 
males.  
The stepped mouthpiece design was based on the design of the stepped mouthpieces used in the 
proof-of-concept study presented in Chapter 4. The addition of a slider and a tongue depressor to 
the design created a stepped mouthpiece with which mandibular advancements from 1 to 6 mm 
could be achieved measured from an incisal edge-to-edge position. The incisal edge-to-edge 
position was selected as basis for the stepwise advancements due to the limited adjustability of the 
stepped mouthpiece. As a 6 mm protrusion from an incisal edge-to-edge position proved to be 
difficult to achieve in the proof-of-concept study, the maximal advancement in the present study 
was limited to 5 mm. The difficulty in achieving a larger than 5-6 mm protrusion from an incisal 
edge-to-edge position with the stepped mouthpieces was somewhat related to the vertical diameter 
of 18 mm. The larger the vertical diameter of the stepped mouthpieces and hence the vertical 
opening of the mouth was in the proof-of-concept study (10, 15 and 20 mm), the more difficult it 
was to advance the mandible. The baseline pharyngograms differed from the pharyngograms with 
the stepped mouthpiece as the addition of the stepped mouthpiece to the acoustic pharyngometry 
wavetube created a shift to the right on the x-axis of ~5 cm. In other aspects the pharyngograms 
performed with the stepped mouthpiece attached to the wavetube were similar to the baseline 
pharyngograms performed with the standard mouthpiece apart from differences in CSAs and 
AUCs due to the stepped mouthpiece settings. 
As in the studies presented in Chapters 3 and 4, acoustic pharyngometry was chosen in favour of 
other techniques such as MRI and CT as the subjects could be seated instead of being supine during 
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the measurements. Acoustic pharyngometry is a non-invasive, fast and relatively cheap technique 
which is ideal for numerous measurements (Kamal, 2001; Kamal, 2002; Viviano, 2002a; Viviano, 
2002b; Kamal, 2004a; Kamal, 2004b; Jung et al., 2004; Viviano, 2004; Monahan et al., 2005; 
Shiota et al., 2007; Gelardi et al., 2007; Patel et al., 2008; Busetto et al., 2009; Allen et al., 2014; 
Oliver et al., 2014; Kumar et al., 2015). The pharyngograms were analysed in terms of landmarks 
(CSAs) for the OPJ (CSA1), the EG (CSA2) and the GL (CSA3), and in terms of volume (AUCs) 
for the oral cavity (AUC1), the oropharynx (AUC2) and the hypopharynx (AUC3).  
The mean baseline (BFL0) CSAs measured during expiration without the stepped mouthpiece 
were for the non-OSA group 2.13 cm2 (CSA1), 2.64 cm2 (CSA2) and 2.88 cm2 (CSA3), and for 
the OSA group 1.58 cm2 (CSA1), 2.59 cm2 (CSA2) and 2.79 cm2 (CSA3). The CSAs were 
relatively similar for the groups but for CSA1. A comparison of mean CSAs of the non-OSA group 
with the mean CSAs of the healthy subjects in the study presented in Chapter 3 shows that the 
mean CSA1 and CSA2 of the non-OSA group were somewhat smaller than those found in the 
previous study whereas the mean CSA3 of the non-OSA group was ~50% of the CSA3 in the 
previous study. As highlighted in Chapters 2 and 3, data on CSAs (OPJ, EG and GL) from 
pharyngograms in adult healthy subjects from measurements with the Eccovision ARP during 
expiration have been published by several authors (Table 5.33).  
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Table 5.33: The mean CSAs of the upper airways from studies in adult healthy subjects in which 
the Eccovision ARP has been used. The table includes data from Chapters 3, 4 and 5. The 
measurements were performed during expiration while the subjects were seated - if supine this has 
been highlighted specifically. 
 
1st author, 
year 
published 
Healthy 
subjects 
(male)  
CSA (cm2, mean), presented with one decimal 
Range (minimum – maximum) included if available 
Allen et al., 
2014 
80 (*), 
20/ethnic 
group 
Mouth to larynx 
Caucasian = 2.7 cm2 ; Chinese = 2.9 cm2 ; 
Japanese = 2.6 cm2 ; Korean = 2.9 cm2  
Busetto et al., 
2009 
145 (no 
male) 
Seated: Pharynx = 2.6 cm2 (0.7-5.8);  OPJ = 1.6 cm2 (0.3-4.0); GL = 
2.2 cm2 (0.5-4.4) 
Supine: Pharynx = 2.2 cm2 (0.7-4.4); OPJ = 1.2 cm2 (0.5-2.0); GL = 2.0 
cm2 (0.5-3.9) 
Jung et al., 
2004 
16 (14) Seated: Pharynx = 2.5 cm2; OPJ = 1.6 cm2; GL = 1.8 cm2 
Supine: Pharynx = 1.9 cm2; OPJ = 1.3 cm2; GL = 1.4 cm2 
Kamal, 2001 350 (271)  
 
Pharynx: Men = 2.7 - 3.8 cm2; Women = 2.1 - 3.4 cm2 
GL: Men = 0.9 - 1.2 cm2; Women = 0.8 - 1.1 cm2 
Kamal, 2002 40 (29) Pharynx: Men = 3.2 cm2, Women = 2.8 cm2 
Kamal, 2004b 20 (16) Pharynx: Test 1 = 3.2 cm2, Test 2 = 3.2 cm2, Test 3 = 3.2 cm2 
Monahan et 
al., 2005 
75 (36) 
white 62 
(23) black 
Oropharynx: White = 2.7 cm2, 1.9 - 3.8 cm2; Black = 2.4 cm2, 1.7 - 3.3 
cm2  
OPJ: White = 2.4 cm2; Black = 2.0 cm2  
EG: White = 2.2 cm2; Black = 2.6 cm2 
Chapter 3  9 (2)  CSA1 = 3.2 cm2; CSA2 = 3.5 cm2; CSA3 = 5.0 cm2 
Chapter 4  4 (4) Upper airway: CSA = 3.4 cm2 
Chapter 5 30 (15)  
  
Non-OSA group: CSA1 = 2.1 cm2; CSA2 = 2.6 cm2; CSA3 = 2.9 cm2 
*No data. 
Most of the mean CSAs are in the same range apart from the mean CSA3 value in the Chapter 3 
study. Ranges for CSA3 were, however, included in the Busetto et al (2009) paper and ranged 
from 0.5 to 4.4 cm2 (CSA3). As the Busetto et al (2009) CSA3 study only included female subjects 
it seems reasonable to assume that the CSA3 data in the Chapter 3 study is in the normal range as 
men tend to have larger upper airways (Martin et al., 1997).  
Data on CSAs from pharyngograms in subjects with OSA from measurements with the Eccovision 
ARP have also been published by several authors (Table 5.33). The CSAs of the OSA group in the 
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present study were similar to the CSAs (OPJ, EG, GL) in the papers by Jung et al (2004), Monahan 
et al (2005) and Patel et al (2008) (Table 5.34). 
Table 5.34: The CSAs of the upper airways from studies in which the Eccovision ARP has been 
used to measure the upper airways of subjects with OSA including Chapter 5 data on subjects with 
OSA. The measurements were performed during expiration while the subjects were seated - if 
supine this has been highlighted specifically. 
 
1st author, 
year 
published 
Adult 
healthy 
subjects 
(male)  
CSA (cm2, mean) 
Range (minimum – maximum) included if available 
Jung et al., 
2004 
54 (13) 
 
Seated: Pharynx = 2.4 cm2; OPJ = 1.4 cm2; GL = 1.9 cm2 
Supine: Pharynx = 1.6 cm2; OPJ = 0.8 cm2; GL = 1.4 cm2  
Monahan et 
al., 2005 
32 (32) White 
41 (27) Black 
Oropharynx: White = 2.4 cm2 (1.6-3.5 cm2); Black = 2.1 cm2  (1.5–
2.8 cm2 ) 
OPJ: White = 1.9 cm2; Black = 2.0 cm2  
EG: White = 2.5 cm2; Black = 2.0 cm2 
Patel et al., 
2008 
229 (102) 
White 
339 (140) 
Black 
Oropharynx: White = 2.7 cm2 (1.9-3.2 cm2);  Black = 2.3 cm2 (1.8–
2.8 cm2 ) 
OPJ: White = 2.1 cm2; Black = 1.9 cm2  
EG: White = 2.6 cm2; Black = 2.4 cm2 
Chapter 5 30 (15)  
  
OSA group: CSA1 = 1.6 cm2; CSA2 = 2.6 cm2; CSA3 = 2.8 cm2 
 
The mean baseline (BFL0) AUCs were for the non-OSA group in the present study 36.27 cm3 
(AUC1), 9.37 cm3 (AUC2) and 27.49 cm3 (AUC3) and for the OSA group 33.12 cm3 (AUC1), 
7.96 cm3 (AUC2) and 26.62 cm3 (AUC3). The mean AUC1 and AUC2 of both groups were 
considerably smaller than those found in the study presented in Chapter 3, whereas the AUC3 
values were similar. The mean volumes of the upper airways were 73.2 cm3 (AUC1-3 non-OSA 
group) and 67.7 cm3 (AUC1-3 OSA group) which were considerably smaller than the mean 
volume of 100 cm3 of the previous study (Chapter 3) but similar to the mean volume of the proof-
of-concept study 62.0 cm3. A comparison of the AUC1-3 values from the studies in Chapters 3-5 
with published data on upper airway volumes in healthy subjects shows a relatively large 
variability (Ehtezazi et al., 2004; Pritchard et al., 2004; Ehtezazi et al., 2005; McRobbie et al., 
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2005). In these 4 studies the impact of inhalation from different inhalers on the upper airway 
volume was measured with MRI during inhalation through inhalers or during tidal breathing with 
the subjects in a supine position. As shown in Table 5.35 the volumes of the upper airways reported 
in the studies ranged from 38 cm3 (McRobbie et al., 2005) to 101 cm3 (Ehtezazi et al., 2005). 
Table 5.35: The mean AUCs from the present study (Chapter 5), the studies presented in Chapters 
3 and 4, from published studies. 
 
1st author, 
year published 
Technique, 
position  
Healthy 
subjects 
(male) 
Upper airway volume (cm3, mean) 
Ehtezazi et al., 
2004 
MRI, supine 10 (6)  pMDI = 56 cm3, spacer = 59 cm3, DPI = 
70 cm3 
Ehtezazi et al., 
2005 
MRI, supine 7 (5)  Orifice 1 = 72 cm3, orifice 6 = 101 m3 
McRobbie et 
al., 2005 
MRI, supine 5 (3)  Tidal breathing = 38 cm3 
Pritchard et al., 
2004 
MRI, supine 20 (10)  
 
Tidal breathing: 
males = 47 cm3, females = 43 cm3 
Chapter 3  
 
ARP, seated 9 (2)  
 
AUC1-3 = 100 cm3 
Chapter 4  
 
ARP, seated 4 (4)  
 
AUC = 62.0 cm3 
Chapter 5 
 
ARP, seated 30 (15)  
 
Non-OSA: AUC1-3 = 73.2 cm3 
 
The descriptive analyses of CSAs and AUCs indicated that both the vertical diameter and the 
mandibular advancements of the stepped mouthpiece had an impact on the CSAs and AUCs 
although the impact was somewhat different for different parts of the upper airways. During tidal 
breathing the impact of the mandibular advancements of the stepped mouthpiece on the CSAs 
were in both the non-OSA and the OSA groups larger than the effect of the vertical diameter for 
CSA2 but smaller for CSA1 and CSA3. The same trend was true for the changes in the AUCs in 
which the impact of the mandibular advancements of the stepped mouthpiece was in both groups 
larger than the effect of the vertical diameter for AUC2 but smaller for AUC1 and AUC3. During 
slow and deep breathing the impact of the vertical diameter of the stepped mouthpiece on the CSAs 
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was larger in relation to the effect of the mandibular advancements for all of the CSAs. The same 
trend was true also for the AUCs but for AUC2 in the OSA group in which the effects of the 
mandibular advancements were larger. 
A larger pharyngeal lumen should have a positive effect on inhaled oral drug delivery. Changes in 
the vertical diameter of inhaler mouthpieces together with changes in peak inspiratory flows and 
particle sizes have been shown in vitro to affect the deposition efficiency of inhaled aerosol (Lin 
et al., 2001). The results of the Kumazawa et al clinical pharyngeal, laryngeal and lung deposition 
study (1997) support the results of the Lin et al in vitro study (check Chapter 2, section 2.5.1). An 
open GL lead to a higher lung deposition than a closed GL. An expansion of both the OPJ, the EG 
and the GL should follow the same trend and lead to a higher lung deposition of inhaled droplets 
and particles especially in tandem with a slow and deep inhalation. 
The statistical analysis of the impact of the incisal opening following the introduction of the 
stepped mouthpiece without any mandibular advancement showed that the changes in CSAs and 
AUCs were statistically significant for both CSA1-3 and AUC1-3 for the non-OSA group. For the 
OSA-group only the changes in CSA1, CSA3 and AUC1 were statistically significant. The results 
are in line with published data indicating that the upper airways of subjects diagnosed with OSA 
differ from those of healthy subjects during wakefulness (Schwab et al., 1995; Ciscar et al., 2001). 
The results of the study by Pritchard et al (2004) support the vertical effects of the stepped 
mouthpiece on AUC1 and CSA1 for both groups in the present study. In the Pritchard et al study 
the impact of 4 dummy inhalation devices on the size of the upper airways in 20 healthy subjects 
were measured with the subjects in a supine position through an inhalation-gated MRI technique. 
The results of 2 of the mouthpieces (Device A, diameter 25 mm; Device C, diameter 14 mm) are 
of interest as the diameters were both somewhat smaller and larger than the diameter of the stepped 
mouthpiece and had low resistances. The results showed that the size of the buccal volume was 
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statistically significantly larger with the large diameter (mean 33.2 cm3) in comparison with the 
small diameter mouthpiece (mean 22.4 cm3), and the significant dependence was mainly related 
to the buccal volume. The results were, however, a bit more complex and the authors summarize 
in the abstract as follows:  
“Individual subjects showed varied device dependent changes: 45% having an increase in regional 
airway volumes, particularly in the nasopharynx (+46% volume increase) and laryngo-pharynx 
(+36% volume increase) for the high resistance devices compared with the low-resistance ones. 
However, 30% of subjects showed the opposite behaviour, a reduction in nasopharynx volume (-
17%), laryngo-pharynx volume (-17%), and laryngeal cavity (-11%). 25% showed no significant 
difference in airway volume between high- and low-resistance devices.”  
 
These results are in agreement with the results of the study by Vroegop et al (2012) in which a 
vertical opening of up to 20 mm was tested in subjects with OSA through different oral appliances 
during sleep endoscopy. The results showed that 80% showed an adverse effect of the vertical 
opening, 2.5% had a positive effect and 17.5% an indifferent effect. 
The statistical analysis of the mandibular advancement achieved with the stepped mouthpiece 
showed a statistically significant effect only for AUC2 with a larger change in the non-OSA (18%) 
group in comparison with the OSA group (13%). It is not surprising that the changes in CSA1 and 
AUC1 following mandibular advancements did not show a statistically significant effect as the 
introduction of the stepped mouthpiece had already expanded the oral cavity considerably. 
5.9 Conclusions 
The study hypothesis: “mandibular advancement together with incisal opening during tidal 
breathing achieved through a stepped mouthpiece design affects the size of the upper airways in 
subjects without and with OSA” was based on the results of the proof-of-concept study in Chapter 
4. The results following the introduction of the stepped mouthpiece (incisal opening) showed that 
in the non-OSA group the changes in CSA1-3 and AUC1-3 were all statistically significant in 
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contrast with the results for the OSA group which only showed statistically significant results for 
CSA1, CSA3 and AUC1. The results following mandibular advancement showed that there was a 
statistically significant effect on the oropharynx (AUC2) in both the non-OSA and the OSA 
groups. Thus the study confirmed the study hypothesis, highlighted the impact of the combined 
effect of the incisal opening and the mandibular advancement of the stepped mouthpiece on the 
size of the upper airways, and the large inter-subject variability in respons to the stepped 
mouthpiece. 
The results of the present study highlight a number of questions that might be addressed in future 
research of the stepped mouthpiece. These include research of stepped mouthpieces with variable 
vertical dimensions in addition to a number of mandibular advancement positions, tests of new 
stepped mouthpieces in both healthy subjects and subjects diagnosed with asthma, COPD and the 
“overlap syndrome” - that is patients diagnosed with both COPD and OSA (Weitzenblum et al., 
2008) - and studies of lung deposition when adding the stepped mouthpiece to inhalers.  
 
  
 252 
  
 
Chapter 6 An in vitro evaluation of acoustic pharyngometry 
when using a cast of a human upper airway 
6.1 Introduction 
6.1.1 Acoustic pharyngometry and the open velum effect 
To ensure oral breathing during acoustic pharyngometer measurements, nose clips have been used 
although there is limited information on the possible impact of these on the pharyngogram. 
Rubinstein et al (1987) did not find any significant difference in mean pharyngeal, glottal or 
tracheal areas following use of nose clip or not. In contrast Molfino et al (1990) in a letter to an 
editor made comments regarding a published paper (Brooks, 1990), discussed possible artefacts 
during acoustic pharyngometer measurements, and proposed an open nasopharyngeal velum (soft 
palate) following use of nose clips as the possible reason for an overestimation of the distal 
pharynx, GL, and trachea. The reason for the overestimation would be the propagation of acoustic 
pulses from the mouth through the pharynx, GL, and trachea, and in addition propagation of 
acoustic pulses from the mouth to the nasopharynx and the paranasal sinuses. The acoustic pulses 
from the nasal airways would then propagate along the GL and trachea creating a falsely large 
measurement of GL and tracheal areas. The example included in the letter (Chapter 2, subsection 
2.7.5.3) showed how the use of a nose clip led to an overestimation of the GL and tracheal area 
which was reversed by the removal of the nose clip. They also noted that the velum could be 
partially open even after removal of the nose clip (Molfino et al., 1990).  
Marshall et al (1993) presented the effects of different soft palate (velum) positions on the 
echogram (0-30 cm) which were controlled by the mode of breathing. A mixed oral and nasal 
breathing placed the soft palate in an intermediate position which should create an open velum 
effect (Chapter 2, subsection 2.7.5.3). The CSA of the OPJ did not change whereas the CSAs of 
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the EG and the GL increased and the AUC increased. Based on the graphic presentations of the 
echograms in the Molfino et al (1990) and the Marshall et al (1993) articles the increase of the 
CSAs could be quite variable with increases from ~4 cm2 to ~14 cm2 (Molfino et al., 1990) and 
from ~2 cm2 to ~5 cm2 (Marshall et al., 1993). 
6.1.2 Study background – Chapter 3 study 
This study was designed to investigate the possible artefact found in Chapter 3 which was related 
to the use of nose clips during the acoustic pharyngometer measurements. Based on the Molfino 
et al (1990) and Marshall et al (1993) articles, the open velum might be the cause for the increase 
in the CSAs and AUCs. It would therefore be of interest to shortly review the effects on the CSAs 
and AUCs in the Chapter 3 study. Summary statistics for the CSAs (Table 6.1) and AUCs (Table 
6.2) are presented below.  
Table 6.1: Summary statistics (cm2; mean ± SD) for CSA1, CSA2 and CSA3 for each of the 14 
study measurements (without and with nose clip). 
 
Measurement Without nose clip  
(CSAs in cm2) 
With nose clip  
(CSAs in cm2) 
CSA1 CSA2 CSA3 CSA1 CSA2 CSA3 
A 3.2 ± 2.0 3.5 ± 1.3 5.0 ± 1.4 3.3 ± 1.6 4.0 ± 1.1 4.3 ± 1.3 
B 3.8 ± 1.6 3.0 ± 0.7 4.9 ± 1.2 3.7 ± 1.4 3.9 ± 1.5 5.4 ± 1.8 
C 4.4 ± 2.8 2.9 ± 0.7 4.5 ± 1.2 3.9 ± 1.3 3.8 ± 1.6 5.0 ± 1.4 
D 20 4.0 ± 2.0 3.0 ± 0.7 4.7 ± 1.3 3.9 ± 1.5 4.1 ± 1.5 5.1 ± 0.9 
D 30 4.5 ± 1.5 3.3 ± 1.1 5.0 ± 1.6 3.9 ± 1.5 4.0 ± 1.5 4.6 ± 0.7 
E 20 3.8 ± 1.6 2.9 ± 0.7 4.5 ± 1.2 3.5 ± 1.5 3.9 ± 1.7 4.7 ± 0.5 
E 30 4.1 ± 1.7 3.0 ± 0.8 4.6 ± 1.2 3.9 ± 1.2 3.9 ± 1.5 5.3 ± 1.8 
 
The possible effect by “nose clip” on CSAs was investigated using measurements B and C (without 
nose clip) and BNC and CNC (with nose clip) as outlined in 3.6.3. The data was assessed using a 
main effects ANOVA including subject as one factor. The use of a nose clip was statistically 
significant for CSA2 (p = 0.0108) and increased CSA2 by 26%. Although measurements without 
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or with nose clip did not have a statistically significant effect for CSA3 the effect was an increase 
by 11%. 
Table 6.2: Summary statistics (cm3; mean ± SD) for AUC1-3 for each of the 14 study 
measurements (without and with nose clip). 
 
Measurement Without nose clip  
(AUCs in cm3) 
With nose clip  
(AUCs in cm3) 
AUC1 AUC2 AUC3 AUC1 AUC2 AUC3 
A 55 ± 13 31 ± 7 28 ± 10 52 ± 9 33 ± 10 29 ± 8 
B 56 ± 12 23 ± 3 21 ± 8 54 ± 10 30 ± 6 29 ± 11 
C 59 ± 15 24 ± 5 21 ± 8 55 ± 13 29 ± 7 28 ± 11 
D 20 57 ± 12 24 ± 5 22 ± 8 53 ± 10 31 ± 6 30 ± 11 
D 30 56 ± 12 27 ± 4 24 ± 10 54 ± 12 30 ± 7 27 ± 10 
E 20 56 ± 12 23 ± 5 21 ± 7 52 ± 10 30 ± 7 28 ± 11 
E 30 57 ± 13 25 ± 5 20 ± 7 54 ± 11 31 ± 7 28 ± 11 
 
The possible effect by “Nose clip” on AUCs was investigated using measurements B and C 
(without nose clip) and BNC and CNC (with nose clip). The data was assessed using a main effects 
ANOVA including subject as one factor. The use of a nose clip had a statistically significant effect 
for AUC2  (p = 0.0006) and AUC3 (p = 0.0002) and increased the airway volume with 23% 
(AUC2) and 31% (AUC3). For AUC1 the effect was the opposite and smaller (6.8%). 
6.1.3 The nasopharynx and the open velum 
Why would an open velum create an artefact during acoustic pharyngometer measurements? 
According to Molfino et al (1990) an open nasopharyngeal velum during acoustic pharyngometry 
leads to an over-estimation of the lower upper airway (distal pharynx, GL and trachea) as the 
acoustic pulses will propagate from the mouth to the nasopharynx and the paranasal sinuses where 
they are reflected in order to propagate along the rest of the upper airway. Kamal (2004a) described 
the velum as the port to the nasopharynx and an open velum would pass acoustic impulses from 
the pharyngometer wavetube further up through the nasopharynx into the sinuses creating a form 
of acoustic leak. The consequence would be an overestimation of the assumed oropharyngeal CSA 
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(Kamal, 2004a). As with problems related to tongue position during pharyngometer 
measurements, asking the subject to think or utter “oooh” during the measurement would close the 
velum (Kamal 2004a; Kamal, 2004b). Thus the volume of the nasopharynx and the sinuses is of 
interest as the addition of that volume to the pharyngogram should based on the assumptions by 
Kamal be equal to the artefact (Figure 6.1). 
 
 
Figure 6.1: The figure highlights the soft palate (velum) position when breathing through the 
mouth (dotted curve, the passage between nasopharynx and the pharyngeal area closed) and when 
breathing through the nose (broken curve, the passage between nasopharynx and the pharyngeal 
area open. (Marshall et al., 1993).  
 
Based on the location and size of the nasopharynx and the function as a connection between the 
sinuses and the oropharynx, it seems plausible that an open velum might create an artefact during 
acoustic pharyngometer measurements. The volume of the nasal cavity seems to be quite variable 
as shown in the study by Guilmette et al (1997) in which 21 male and 24 female subjects were 
included for MRI scans of the nasal cavity. The mean left side volume was 9.10 ±2.77 cm3 and the 
mean right side volume 8.69 ±2.11 cm3, with a total volume of 17.79 cm3 with a large range 
(Guilmette et al., 1997; Figure 6.2). 
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Figure 6.2: Nasal airway volumes plotted against the height of the subjects. The volume in the 
figure is for some reason given as “cm2“ although the volumes are given in “cm3“ in the text by 
the authors (Guilmette et al., 1997).  
 
The Guilmette et al (1997) nasal cavity volumes are quite close to the nasal cavity volumes 
measured by Garcia et al (2009) in 4 healthy adult subjects using MRI. They reported volumes of 
18.0, 15.4, 26.5 and 23.8 millilitres (mL). Acoustic rhinometry has also been used to measure the 
volume of the nasal cavity volume and for example de Paula Santos et al (2006) report a mean 
baseline volume of 38.91 cm3 in 21 male and 19 female subjects. This was somewhat larger than 
the results of the Guilmette et al (1997) study. 
6.1.4 In vitro tests of the “open velum” hypothesis 
It would be difficult to reproducibly evaluate the “open velum” hypothesis in human subjects 
without control of the velum during a series of pharyngometer measurements. An in vitro study 
would be preferable as it would allow controlled acoustic pharyngometer measurements to be 
made with a surrogate for a closed or an open velum. A cast of the human upper airways similar 
to the polyester resin cast presented by Cheng et al (1990) could be used in order to mimic both a 
closed and an open velum (Figure 6.3).  
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Figure 6.3: Line drawing of a cast of an adult human upper airway which highlights the different 
compartments from the nasal valve to the trachea (Cheng et al., 1990).  
 
6.1.5 Study hypothesis 
During acoustic pharyngometer measurements an open velum would pass acoustic impulses from 
the wavetube further up through the nasopharynx into the nasal airways creating a form of acoustic 
leak. The consequence would be an overestimation of the volume of the upper airways from the 
pharynx to the GL as displayed on the pharyngogram. 
6.2 Methods 
6.2.1 Overall study design 
The in vitro test setup consisted of an acoustic pharyngometer (Eccovision ARP, Hood 
Laboratories, Pembroke, MA, USA; presently www.sleepgroupsolutions.com), a cast of a human 
upper airway (oral cavity to the GL), a PP tube as a surrogate for the upper airways, and green 
elastomeric-lipped ISO connectors (Intersurgical Ltd, Wokingham, UK) to connect the cast and 
the PP tube to the pharyngometer wavetube. Acoustic pharyngometer measurements were 
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performed without and with surrogate “open velums” in the form of holes of different sizes at the 
back of the cast and the PP tube, and with small or large “nasal cavities” (denoted “T-piece” below) 
attached to the hole. Measurements without any T-piece were also made and these measurements 
had an infinite size of the nasal cavity. In addition baseline measurements were performed with an 
open end of the cast (GL), with a closed end of the cast and with a 2 m hose attached to the end of 
the cast.  
6.2.2 Cast of the human upper airway 
The cast of the human upper airway used in the study was a copy of one of the original Swift casts 
made in resin (Figure 6.4). The original Swift casts of the human upper airways were constructed 
from post mortem anatomical casting and reconstruction of the in vivo airways from MRI 
measurements.  
 
 
Figure 6.4: Photographs of the original Swift cast of the human upper airway from which a copy 
was made for the in vitro study (Swift, 1991; Swift et al., 1994). 
 
The technique used in the creation of the Swift casts has been described in detail by Swift and co-
workers (Swift, 1991; Swift et al., 1994). The cast available for the study was labeled “Cast M3”, 
did not include the nasal airways and was on loan from AstraZeneca, Lund, Sweden (Figure 6.4).  
As the cast was unique and could not be used in an in vitro study, a copy of the original cast was 
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made. The original cast could not be used for 3D scanning so a 3-dimensional internal geometry 
was generated by measuring the internal dimensions of the cast. This was done in sections and the 
CSA per section from section 6 to section 163 is presented in Figure 6.5.  
 
 
Figure 6.5: The CSAs of the cast shown for section 6 to section 163. 
 
The length of the new cast “airway” through the middle of the lumen was ~20 cm. A copy of the 
original cast was made through stereolithography based on the internal geometry; Figure 6.6). The 
external dimensions of the new cast were: maximal height ~14 cm, maximal width of oral cavity 
~7 cm, maximal height of oral cavity ~4.5 cm, length of throat ~12 cm. The volume of the cast 
was ~110 mL when filled with water. The cast was made in two parts so that it could be taken 
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apart and cleaned. For the purposes of the in vitro study with acoustic pharyngometry, the two 
halves were carefully glued together to prevent the acoustic pulses to leak through the splits.  
 
Figure 6.6: The new cast based on the original Swift “M3” cast and shown with the external 
geometry (left) and the internal geometry (right). 
 
The internal geometry of the cast is shown in Figure 6.7 from 4 different angles. Both “ends” of 
the cast were circular, the mouth with an inner diameter of 29 mm and the bottom with an inner 
diameter of 24 mm. 
 
Figure 6.7: The throat of the cast shown from 4 different angles. 
 
6.2.3 A PP tube as surrogate of the human upper airway 
A PP tube (Dearborn Brass, Cleveland, Ohio, USA) with a slip joint washer connecting the long 
piece with the short piece after the 90° bend (Figure 6.8) was purchased to function as a second 
surrogate upper airway. The washer created a leak free seal between the 2 pieces of the tube. The 
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inner diameter of the tube was ~35 mm (area 962.1 mm2 or 9.62 cm2) and the inner length of the 
“airway” through the middle of the lumen as used in the in vitro tests was ~24 cm.  
6.2.4 Creation of an open velum in the surrogates of the upper airways 
In order to mimic an open velum in the cast and the tube the approximate position of the velum 
was identified based on the line drawing in Figure 6.3 at ~9 cm from the mouth (Figure 6.8). A 
round attachment made of PVC with threads was glued to the cast at that position. The attachment 
was taken from a PVC T-piece (D2466; IPEX, Pineville, North Carolina, USA) so that T-pieces 
mimicking nasal cavity volumes could be fitted to the attachment. 
 
 
Figure 6.8: The cast (left) and the tube (right) with a round attachment made of PVC with threads 
glued to the “velum” position. 
 
The same procedure was repeated with the tube with the attachment glued ~9 cm from the “mouth” 
(Figure 6.8). 
A total of 12 different holes were drilled in both the cast and the tube in order to mimic different 
velum sizes. The first hole in the cast was drilled with a dentist drill 3 mm in diameter (area 7.1 
mm2, Figure 6.9) and the hole was subsequently enlarged with the same drill creating 11 
incrementally larger holes (Figure 6.9). The same procedure was followed with the tube. 
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Figure 6.9: The cast shown with the round attachment made of PVC with threads glued (glue light 
brown) to the back of the cast. Holes of different sizes were drilled in the round attachment. The 
initial hole is shown to the left and the final hole to the right. 
 
The largest hole was perfectly circular with a 14 mm diameter equal to the inner diameter of the 
attachment (area 153.9 mm2 or 1.54 cm2) and was prepared with a 7 mm diameter dentist drill 
(Figure 6.9). This was close to the sizes of the velopharynx measured with videoendoscopy in 
healthy subjects and subjects with OSA (Ferguson et al., 1997a). Four pharyngometer 
measurements were performed for each hole size for the cast and the same procedure was followed 
for the tube. 
6.2.5 Addition of ‘nasal cavities’ to the cast 
Two PVC T-pieces (IPEX, Pineville, North Carolina, USA) of different sizes were used in order 
to create nasal cavities that could be fitted on the attachment at the back of the cast and the tube at 
the velum position (Figure 6.10). The large T-piece (D2466) had an ~96 mm long T with an outer 
diameter of ~27 mm and a stem ~20 mm long. The small T-piece (D2464) had an ~85 mm long T 
with an outer diameter of ~18 mm and a stem ~18 mm long. The volumes of the T-pieces measured 
through water displacement were ~20 mL (small T-piece) and ~30 mL (large T-piece). 
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Figure 6.10: Cast (top) and tube (bottom) with large T-pieces connected via green elastomeric-
lipped ISO connectors to the acoustic pharyngometer wavetube. 
 
The “mouths” of the cast and the tube were connected to the acoustic pharyngometer wavetube 
through green elastomeric-lipped ISO connectors (Intersurgical Ltd, Wokingham, UK) as shown 
in Figure 6.10.  
6.2.6 Summary of cast in vitro acoustic pharyngometer measurements 
1. Baseline pharyngometer measurements were performed with the cast before any hole 
mimicking an open velum had been drilled into it. In these pharyngometer measurements 
the bottom end of the cast was initially open, then closed and after that opened again and 
connected to a ~2 m long vinyl hose with 26 mm inner diameter; 
2. In the pharyngometer measurements with a hole mimicking an open velum, the first 
measurement was performed with a 3 mm diameter hole with the bottom end of the cast 
connected to the long vinyl hose. Four pharyngometer measurements were performed with 
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the velum hole open, 4 with the small T-piece connected to the hole and an additional 4 
with the large T-piece connected to the hole, in that order. 
3. A total of 12 different holes were created in order to mimic different velum sizes. The hole 
size was subsequently enlarged from the initial hole creating 11 larger holes, in total 12 
different hole sizes to be tested with the cast connected to the pharyngometer wavetube. 
The same set of pharyngometer measurements were performed as with the 3 mm hole 
creating a total of 12 hole sizes × 12 measurements (hole open, small T-piece, large T-
piece) = 144 pharyngometer measurements. 
6.2.7 Summary of tube in vitro acoustic pharyngometer measurements 
1. Baseline pharyngometer measurements were performed with the tube before any hole had 
been drilled into it and with the bottom end closed; 
2. The first 3 mm diameter hole was drilled at the back of the tube in the same position as in 
the cast. The bottom end of the tube was closed with green putty.  Four pharyngometer 
measurements were performed with the hole open, 4 with the small T-piece connected to 
the hole and an additional 4 with the large T-piece connected to the hole, in that order. 
3. The hole size was subsequently enlarged creating 11 incrementally larger holes, in total 12 
different hole sizes to be tested when connecting the tube to the pharyngometer wavetube. 
The same set of pharyngometer measurements were performed as with the 3 mm hole 
creating a total of 12 hole sizes × 12 measurements (hole open, small T-piece, large T-
piece) = 144 pharyngometer measurements. 
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6.3 Statistical analysis 
6.3.1 Data analysis 
The data has been analysed descriptively. The main analysis of the pharyngograms was focused 
on the impact of the hole sizes on the CSAs and AUCs. The effect by hole size and T-piece on the 
endpoints was investigated using ANOVA including an interaction term. The significance level 
was established at 0.05. 
6.4 Results 
6.4.1 Cast – baseline pharyngograms 
The baseline pharyngometer measurements were performed with the cast in pristine condition 
without a hole to mimic the open velum. Four pharyngograms per measurements were recorded 
with the bottom end of the cast either open, closed or connected to a long vinyl hose (Figure 6.11). 
The variability between the mean baseline pharyngograms was relatively small with two minima 
(CSA1 and CSA2).   
 
Figure 6.11: Cast - baseline mean pharyngograms from measurements with the cast in pristine 
condition. The bottom end was either open, closed or connected to a long vinyl hose. 
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The pharyngograms were relatively reproducible and as examples the mean SD for the cast CSA1 
was 0.01 ranging from 0 to 0.04 (median 0.01) and for CSA2 0.01 ranging from 0.01 to 0.07 
(median 0.02). 
6.4.2 Cast - impact of hole size on pharyngograms 
 
The mean pharyngograms from the measurements with open holes (no T-piece attached) of 
different sizes at the velum position of the cast (vinyl hose attached to the end of the cast) are 
shown in Figure 6.12. 
 
Figure 6.12: Cast - mean pharyngograms from measurements with the cast with holes of different 
sizes and without a T-piece attached. 
 
The size of the hole had an impact on the mean pharyngograms. The hole was drilled ~9 cm from 
the mouth of the cast and there was some separation of the mean pharyngograms in the area 
covering the oral cavity at 4 to 9 cm (x-axis). The CSA of the mean pharyngograms decreased at 
~4.5 cm (x-axis) depending on hole size from ~12 cm2 (baseline) to ~11 cm2 with the largest the 
hole size. Between ~11 cm and ~17 cm (x-axis) a second separation could be seen between the 
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mean pharyngograms. After ~17 cm (x-axis) the separation between the mean pharyngograms 
became more prominent and at 20 cm the mean pharyngograms followed an almost perfect order 
in relation to hole size.   
6.4.3 Cast - impact of hole size and small T-piece on pharyngograms 
The mean pharyngograms from the measurements with the small T-piece attached to the cast and 
with holes of different sizes at the velum position of the cast (vinyl hose attached to the end of the 
cast) are shown in Figure 6.13. 
 
Figure 6.13: Cast - mean pharyngograms from measurements with the cast with holes of different 
sizes and the small T-piece attached. 
 
With the small T-piece attached to the cast, the size of the hole had in comparison with the mean 
pharyngograms measured with an open hole less impact on the mean pharyngograms. The addition 
of the small T-piece eliminated the separation of the mean pharyngograms in the area covering the 
oral cavity at 4 to 9 cm (x-axis). The mean pharyngogram from the measurement with the largest 
hole size was somewhat separated from the other mean pharyngograms at ~8 cm but joined the 
large bundle of mean pharyngograms at ~11 cm. There was some further separation of the mean 
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pharyngograms between ~11 cm and 20 cm but without the order of the mean pharyngograms seen 
in the measurements without a T-piece attached to the hole. 
6.4.4 Cast - impact of hole size and large T-piece on pharyngograms 
The mean pharyngograms from the measurements with the large T-piece attached and with holes 
of different sizes at the velum position of the cast (vinyl hose attached to the end of the cast) are 
shown in Figure 6.14. 
 
Figure 6.14: Cast - mean pharyngograms from measurements with the cast with holes of different 
sizes and a large T-piece attached. 
 
The pharyngograms measured with the large T-piece attached to the cast resembled the 
pharyngograms measured with the small T-piece attached to the cast. The bundle of mean 
pharyngograms from ~11 cm was somewhat more separated in comparison with mean 
pharyngograms from the measurements with the small T-piece but still lacked the order of the 
mean pharyngograms seen in the measurements without a T-piece attached to the hole. 
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6.4.5 Cast – statistical analysis of CSAs and AUCs 
As with the analyses of the pharyngograms reported in Chapters 3-5, the same endpoints (CSAs, 
AUCs) were studied. Based on the average baseline recording for the cast (closed end, no hole, 
black curve in Figure 6.11) the position of the two minima (CSA1, CSA2) following the initial 
peak (oral cavity) were determined with CSA1 positioned at 9.73 cm and CSA2 at 17.02 cm (x-
axis). In addition to the CSAs, the AUCs were calculated for each hole size and T-piece; AUC1 
between the mouth (x = -0.13) and CSA1, AUC2 between CSA1 and CSA2, and AUC3 between 
CSA2 and end of cast (x=20.02). The effect by hole size and T-piece on the endpoints was 
investigated using ANOVA including an interaction term (Table 6.3). 
 
Table 6.3: Cast - results (p-values) from ANOVA exploring effects by hole size and T-piece. 
 
Endpoint Hole T-piece Interaction 
CSA1 <0.0001 0.92 <0.0001 
CSA2 <0.0001 <0.0001 <0.0001 
AUC1 <0.0001 0.60 <0.0001 
AUC2 <0.0001 <0.0001 <0.0001 
AUC3 <0.0001 <0.0001 <0.0001 
 
The statistically significant interactions indicated that the effect by hole size differed depending 
on T-piece used. The numerical effects are presented in the summary statistics (means) for the 
endpoints (CSA1-2, AUC1-3) per hole size and T-piece in Table 6.4. The volume of the cast 
including the green connector when connected to the wavetube was 169.42 cm3 (Table 6.4).
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Table 6.4: Cast – summary statistics for CSA1-2 and AUC1-3 (presented as means) per hole size and T-piece. 
 
 
T-
piece 
H 0 H 1 H 2 H 3 H 4 H 5 H 6 H 7 H 8 H 9 H 10 H 11 H 12 
CSA1 
None 2.91 2.97 2.89 2.88 2.89 2.90 2.86 2.88 2.86 2.82 2.83 2.90 3.30 
Small  2.99 3.00 3.03 3.13 3.20 3.18 3.26 3.23 3.24 3.26 3.32 4.00 
Large  2.94 2.98 3.01 3.06 3.11 3.09 3.13 3.14 3.15 3.13 3.22 3.82 
CSA2 
None 1.37 1.67 2.01 2.40 2.48 2.75 2.79 3.12 3.22 3.21 3.26 3.49 5.55 
Small  1.64 1.92 2.29 2.25 2.39 2.35 2.50 2.42 2.28 2.20 2.36 2.38 
Large  1.66 1.99 2.27 2.38 2.60 2.56 2.84 2.80 2.78 2.67 2.96 3.25 
AUC1 
None 118.64 119.0 115.2 115.4 114.2 114.1 114.4 113.3 113.1 112.8 112.5 112.6 109.2 
Small  119.8 117.1 118.1 117.9 118.4 119.5 118.9 119.2 119.8 120.0 120.9 120.3 
Large  120.0 119.3 117.1 116.6 117.0 117.9 117.3 117.4 118.0 118.2 118.7 120.0 
AUC2 
None 40.49 44.61 46.32 50.02 51.47 53.36 55.30 55.82 58.18 59.87 60.89 61.61 74.80 
Small  45.11 48.24 51.76 53.78 55.46 57.57 57.35 59.72 61.16 61.96 62.62 64.77 
Large  44.89 48.35 50.20 52.17 54.06 55.88 55.97 58.26 60.16 60.95 61.57 68.74 
AUC3 
None 10.29 15.56 18.50 23.25 25.54 29.70 29.92 32.76 39.28 42.11 41.48 38.12 57.59 
Small  15.23 17.57 19.47 19.52 20.72 19.82 20.15 21.38 21.51 20.64 18.05 15.66 
Large  15.15 19.68 19.77 21.30 23.23 22.60 23.73 25.83 27.14 26.26 23.49 26.35 
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The results presented in Table 6.4 indicated that: 
- the effect by hole size was stronger without a T-piece. 
- the effect of hole size was similar for the small and large T-piece.  
- the effects were weakest for CSA1, AUC1, and strongest for CSA2, AUC2 and AUC3. 
6.4.6 Tube - baseline pharyngograms 
The baseline pharyngometer measurements were performed with the tube in pristine condition 
without a hole to mimic the open velum (Figure 6.15). 
 
Figure 6.15: Tube - baseline mean pharyngogram from measurements with the tube in pristine 
condition. The bottom end was closed. 
 
The baseline mean pharyngogram resembled a relatively flat waveform from ~9 cm (x-axis) 
onward. As the inner diameter of the tube was ~35 mm and the CSA of the tube therefore 9.62 
cm2, the tube baseline mean pharyngogram underestimated the true CSA. It was closest (~8 cm2) 
to the true CSA at ~5 cm (x-axis) and then fluctuated about ~7.0 cm2 between ~5 to 24 cm. 
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6.4.7 Tube – impact of hole size on pharyngograms 
The mean pharyngograms from the measurements with open holes (no T-piece attached) of 
different sizes at the velum position of the tube are shown in Figure 6.16. 
 
Figure 6.16: Tube - mean pharyngograms from measurements with holes of different sizes and 
without a T-piece attached. 
 
The size of the hole had an impact on the mean pharyngograms which followed the same pattern 
as the baseline mean pharyngogram up to about ~14 cm (x-axis) after which some separation 
occurred. At ~15 cm the mean pharyngograms started to gradually separate more and more. As 
with the cast, the separation between the mean pharyngograms became more prominent and at ~19 
cm followed an almost perfect order in relation to hole size. The mean pharyngograms 
underestimated the true tube CSA for the small and medium hole sizes and exceeded the true CSA 
only for the largest hole sizes. 
In Figure 6.17 and Figure 6.18 the corresponding mean pharyngograms are shown with the 
addition of the small and large T-pieces to the tube. 
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6.4.8 Tube – impact of hole size and small T-piece on pharyngograms 
 
Figure 6.17: Tube - mean pharyngograms from measurements with the cast with holes of different 
sizes and the small T-piece attached. 
 
6.4.9 Tube – impact of hole and large T-piece on pharyngograms 
 
Figure 6.18: Tube - mean pharyngograms from measurements with the cast with holes of different 
sizes and the large T-piece attached. 
 
As with the cast, the addition of the small T-piece almost eliminated the impact of the hole sizes 
on the mean pharyngograms. Some separation still occurred between the mean pharyngograms but 
this was minimal in comparison with the measurements without the T-piece. The changes in the 
 274 
  
 
mean pharyngograms with the addition of the large T-piece were similar to those seen with the 
small T-piece, although an increase in CSA could be seen at ~19 cm (x-axis) which came close to 
the true tube CSA of 9.62 cm2. 
6.4.10 Tube – statistical analysis of CSAs and AUCs 
Based on the average baseline pharyngogram for the tube (closed end, no hole, black curve in 
Figure 6.15) the position of three minima (CSAs) following the initial peak were determined; 
CSA1 at 9.73 cm, CSA2 at 17.02 cm and CSA3 at 22.6 cm (x-axis). There were more than three  
minima with growing hole size but the minima closest to the cast minima were used. The AUCs 
were calculated for each hole size and T-piece; AUC1 between the mouth (x = -0.13) and CSA1, 
AUC2 between CSA1 and CSA2, and AUC3 between CSA2 and end of tube (x=24.0). The effect 
by hole size and T-piece on the endpoints was investigated using ANOVA including an interaction 
term (Table 6.5).  
Table 6.5: Results (p-values) from ANOVA exploring effects by hole size and T-piece for tube. 
 
Endpoint Hole T-piece Interaction 
CSA1 <0.0001 0.95 <0.0001 
CSA2 <0.0001 0.0104 <0.0001 
CSA3 <0.0001 0.74 <0.0001 
AUC1 <0.0001 0.0566 <0.0001 
AUC2 <0.0001 0.0368 0.0417 
AUC3 <0.0001 0.49 <0.0001 
 
The statistically significant interactions indicated that the effect by hole size differed depending 
on T-piece used. The numerical effects are presented in the summary statistics (means) for the 
endpoints (CSA1-3, AUC1-3) per hole size and T-piece in Table 6.6.  
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Table 6.6: Tube – summary statistics for CSA1-3 and AUC1-3 (presented as means) per hole size and T-piece. 
 
 T-piece H 0 H 1 H 2 H 3 H 4 H 5 H 6 H 7 H 8 H 9 H 10 H 11 H 12 
CSA1 
None 6.59 6.60 6.26 6.09 6.07 5.98 5.96 5.98 5.88 5.98 5.90 5.97 5.77 
Small  6.46 6.35 6.26 6.26 6.28 6.19 6.25 6.14 6.19 6.09 6.24 6.29 
Large  6.53 6.33 6.24 6.21 6.22 6.14 6.23 6.08 6.11 6.02 6.11 6.30 
CSA2 
None 6.40 6.73 7.24 7.28 7.47 7.63 7.79 8.17 8.12 8.22 8.22 8.67 9.22 
Small  6.63 7.24 7.45 7.46 7.70 7.74 7.99 7.94 8.06 8.07 8.32 8.44 
Large  6.58 7.24 7.32 7.40 7.59 7.76 7.82 7.96 8.01 8.00 8.29 8.77 
CSA3 
None 6.55 7.05 7.93 8.52 9.00 8.98 9.50 10.24 9.84 10.00 10.13 10.53 11.92 
Small  6.81 7.18 7.17 7.09 7.03 6.86 6.86 6.99 6.93 6.94 7.05 5.83 
Large  6.80 7.61 7.75 7.61 7.82 7.93 7.82 8.12 8.31 8.00 8.42 7.67 
AUC1 
None 111.9 113.9 112.3 112.5 112.5 111.7 112.1 112.2 111.7 111.3 111.1 111.4 109.4 
Small  113.4 113.5 114.0 114.1 114.1 114.3 114.1 113.6 114.0 112.6 114.0 113.9 
Large  111.9 113.5 114.0 113.4 113.6 114.2 113.5 112.9 113.3 112.1 113.1 113.6 
AUC2 
None 92.54 93.88 95.72 96.63 98.05 98.61 98.70 99.58 99.79 100.1 100.1 100.8 105.0 
Small  93.53 97.58 98.81 100.9 101.4 102.4 102.8 102.7 103.6 102.3 104.6 108.0 
Large  92.46 97.02 98.53 99.22 99.95 100.9 101.1 101.0 101.6 100.4 102.3 105.9 
AUC3 
None 82.51 87.47 94.85 98.23 102.8 103.9 105.8 109.0 108.9 110.0 112.4 112.2 125.5 
Small  86.24 90.61 90.08 91.75 90.72 91.14 90.52 92.12 92.04 90.98 91.54 84.11 
Large  85.96 92.76 94.88 96.58 96.93 98.15 98.31 100.2 100.9 98.88 101.8 98.95 
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The results presented in Table 6.6 indicated that: 
- the effect by hole size was stronger without a T-piece. 
- the effect of hole size was similar for the small and large T-piece.  
- the effects were weakest for CSA1, AUC1, and AUC2, and strongest for CSA2. 
6.5 Graphical comparison of cast and tube data 
6.5.1 Mean CSA1-3 by T-piece (none, small, large) 
In Figure 6.19 the mean CSA1 results are shown by T-piece (none, small and large) for the cast 
and the tube per the different hole sizes. Apart from the size of the CSA1 which was obviously 
different, the trend following the addition of the T-pieces was positive for the cast and negative 
for the tube. 
 
Figure 6.19: Mean CSA1 by T-piece (none, small, large) used with cast and tube per hole size. 
 
In Figure 6.20 the mean CSA2 results and in Figure 6.21 the mean CSA3 results (no data for cast 
as a CSA3 was not identified) are shown by T-piece (none, small and large) for the cast and the 
tube per the different hole sizes. 
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Figure 6.20: Mean CSA2 by T-piece (none, small, large) used with cast and tube per hole size. 
 
 
Figure 6.21: Mean CSA3 by T-piece (none, small, large) used with tube per hole size. 
 
There was an increase in mean CSA2 both without and with T-pieces for both the cast and the tube 
following the increases in hole size. For the tube there was a relatively large increase and no 
separation between the 3 curves, whereas for the cast the curve without a T-piece showed the 
largest increase. The tube CSA3 curve without a T-piece increased with increasing hole size, 
whereas the addition of the T-pieces had no effect on the curves.   
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6.5.2 Mean AUC1-3 by T-piece (none, small, large) 
In Figure 6.22 the mean AUC1 results are shown by T-piece (none, small and large) for the cast 
and the tube per the different hole sizes. 
 
Figure 6.22: Mean AUC1 by T-piece (none, small, large) used with cast and tube per hole size. 
 
The difference in AUC1 (without a T-piece) between the cast and the tube was ~9 cm3 (~8%). The 
introduction of a hole led to a decrease in AUC1 (without a T-piece) for the cast but not for the 
tube, and the cast AUC1 decreased further with increasing hole size. The addition of the T-pieces 
had no major impact on the tube AUC1 values, whereas the cast AUC1 values increased. 
In Figure 6.23 the mean AUC2 results and in Figure 6.24 the mean AUC3 results are shown by T-
piece (none, small and large) for the cast and the tube per the different hole sizes. The cast and 
tube AUC2 values increased with increasing hole size and resembled the results for CSA2. The 
addition of a T-piece had no major effect on the AUC2 for either the cast or the tube. 
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Figure 6.23: Mean AUC2 by T-piece (none, small, large) used with cast and  tube per hole size. 
 
 
Figure 6.24: Mean AUC3 by T-piece (none, small, large) used with cast and tube per hole size. 
 
The introduction of a hole led to an increase in AUC3 (without a T-piece) for both the cast and the 
tube, whereas the addition of the T-pieces had no or a small negative effect. 
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6.6 Discussion 
The primary objective of the present study was to use an acoustic pharyngometer to study the 
effect of an open velum on acoustic pharyngograms. An open velum has been shown to affect the 
pharyngogram, when using prototype acoustic pharyngometers, resulting in overestimations of GL 
and tracheal areas (Molfino et al., 1990; Marshall et al., 1993). An evaluation of the impact of an 
open velum on acoustic pharyngometer measurements in human subjects would be of limited value 
without control of the velum and the amount of leak in terms of the CSA and the volume of the 
nasal cavity.  
An in vitro study design was preferable as controlled acoustic pharyngometer measurements could 
be made with surrogates for a closed or an open velum and a nasal cavity. Two in vitro models 
were used, a cast of a human upper airway and a tube with a bend. The cast was based on a cast of 
the human upper airways without the nasal airways and was similar to the polyester resin cast 
presented by Cheng et al (1990). The shape of the different internal parts of the cast resembled the 
shape of the human upper airway when compared with the shape of a human upper airway 
presented by Strohl et al (2012) based on work by Proctor (1983). The similarity was of importance 
considering the origin of the cast from a post mortem anatomical casting and reconstruction from 
MRI measurements (Swift, 1991; Swift et al., 1994).  
The open velum was mimicked through round holes of 12 different sizes (3 – 14 mm diameters) 
drilled in the posterior pharyngeal wall of the cast and the tube. The smallest hole size had a CSA 
of 0.07 cm2 and largest hole size a CSA of 1.54 cm2, which was close to the sizes of the 
velopharynx measured with videoendoscopy (Ryan et al., 1996; Ferguson et al., 1997a) and CT 
(Schwab et al., 1993b) in healthy subjects. The shape of the velopharynx in both healthy subjects 
and subjects with OSA presented in the study by Ryan et al (1996; Figure 6.25) indicate that the 
round shape selected for the surrogate velum was relevant. 
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Figure 6.25: Schematic presentation of changes in velopharynx during a maximal VC manoeuvre 
against an unoccluded nasal airway in healthy subjects and subjects with OSA. EET = end-tidal 
expiration; EMAX = maximal airway CSA during expiration; IMIN = minimal airway CSA during 
inspiration (Ryan et al., 1996). 
 
The in vitro nasal cavity in the shape of T-pieces was attached to the holes in the posterior 
pharyngeal walls of the cast and the tube. The T-piece volumes (~20 mL and ~30 mL) were based 
on published data of both male and female subjects (Guilmette et al., 1997). Measurements without 
any T-piece were also made in order to have a reference for larger nasal cavities.  
There was a large difference between the shape of the internal parts of the cast and the “smooth” 
mean baseline pharyngogram of the cast. Marshall et al (1993) had observed the same kind of 
difference between an MRI of a subject’s upper airway and a pharyngogram of the same subject 
and pointed out the apparent “smoothing” effect of the AR method. The cast mean baseline 
pharyngogram resembled, however, pharyngograms recorded in healthy subjects and subjects with 
OSA (Chapters 3-5) in terms of the waveform, but presented only 2 minima (CSA1 and CSA2) in 
contrast to the 3 minima (OPJ, EG and GL) found in pharyngograms from subjects in the studies 
presented in Chapters 3-5. This was probably a consequence of the origin of the cast. The mean 
positions of the minima were for example in the study presented in Chapter 5: OPJ (CSA1) at 8.48 
cm, EG (CSA2) at 12.22 cm and GL (CSA3) at 20.72 cm. The position of the CSA1 of the cast 
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was ~9 cm which is close to the results found in Chapter 5, whereas the position of CSA2 was ~17 
cm which is between the CSA2 and CSA3 positions found in Chapter 5. Three AUCs were, 
however, calculated although AUC3 was small due to the position of CSA2. The sizes of the cast 
CSA1 and CSA2 were similar to the mean CSAs found in the studies presented in Chapters 3-5, 
whereas the total volume of the cast (AUC1 + AUC2 + AUC3) was considerably larger. The main 
reason for the large total volume was probably the connection of the cast to the wavetube which 
increased AUC1. In clinical use the end of the wavetube would be within the mouthpiece inserted 
into the mouth of the subject whereas with the cast the end of the wavetube was connected to the 
green connector that was partically within the cast oral orifice. This is most probably the reason 
for the discrepancy between the volume of the cast when filled with water (~110 mL) and the 
volume of the AUC1-3 (~169 cm3).  
The tube mean baseline pharyngogram deviated from the waveform of the human pharyngogram, 
and the minima were therefore identified based on the positions of the minima in the cast mean 
baseline pharyngogram. The sinusoidal waveform of the tube mean baseline pharyngogram did, 
however, resemble the pharyngograms from measurements of endotracheal tubes performed with 
a prototype pharyngometer (Van Surell et al., 1994; Straus et al., 1998), and performed with the 
Eccovision ARP (Raphael et al., 2002). In the study by Straus et al the CSA of the endotracheal 
tube pharyngogram was somewhat smaller than the actual CSA calculated based on the diameter 
of 7.5 mm and showed a waveform pattern. This was in accordance with the results in the present 
study. In the studies by Van Surell et al (1994) and Raphael et al (2002) comparisons could not be 
made. The reasons for the sinusoidal waveform pattern in the tube and the underestimation of the 
true CSA are unclear. 
The pharyngometer measurements with the largest hole size in the cast without T-pieces showed 
the largest increase in the pharyngograms. The pharyngograms were somewhat separated at the 
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peak CSA of the oral cavity with the pharyngogram presenting the largest hole sizes showing the 
smallest CSA. The increase in the pharyngograms after the oral cavity occurred at ~11 cm, reached 
a plateau at ~12 cm, and increased sharply at ~17 cm. The changes in the CSA were initially small 
with an early increase after the oral cavity from ~4 to ~6 cm2 (~10 to ~12 cm) and the late increase 
from ~6 to ~13 cm2 (~17 to ~20 cm). The increase in the pharyngograms at ~20 cm followed the 
order of the size of the holes with the pharyngogram based on the smallest hole size showing the 
least increase and vice versa. The addition of the T-pieces to the posterior pharyngeal wall of the 
cast reduced the increases seen without the addition of the T-pieces. The total increase in upper 
airway volume (difference between “no hole, total AUC1-3” and “total AUC1-3 for the largest 
hole size”) was with the small T-piece ~33 mL and with the large T-piece ~46 mL and thus 
somewhat larger than the volumes of the T-pieces.  
The pharyngometer measurements with the largest hole size in the tube without T-pieces showed 
as with the cast the largest increase in the pharyngograms. The pharyngograms did not show a 
separation at the peak CSA of the oral cavity as with the cast probably due to the simple geometry 
of the tube. As with the cast the increase in the pharyngograms at ~24 cm followed the order of 
the size of the holes with the pharyngogram based on the smallest hole size showing the least 
increase and vice versa. The addition of the T-pieces to the posterior pharyngeal wall of the tube 
did also reduce the increases seen without the addition of the T-pieces. Thus the changes in the 
pharyngograms did largely mimic those of the cast. The total increase in tube upper airway volume 
(difference between “no hole, total AUC1-3” and “total AUC1-3 for the largest hole size”) was 
with the small T-piece ~19 mL and with the large T-piece ~32 mL and thus similar to the volumes 
of the T-pieces. The differences between the volumes of the cast and the tube were surprising. The 
differences between the surrogate upper airway models can be found in the different geometries, 
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the different materials and the different sizes of the surrogates. Could any of these or the 
combination be the reason for the differences? 
The shape of the in vitro cast pharyngogram did not match the pharyngograms published by 
Molfino et al (1990) and Marshall et al (1993). A comparison of the in vitro pharyngograms with 
the artefact pharyngograms published by Molfino et al (1990) and Marshall et al (1993) is difficult 
due to the differences in x-axis scales as both measured the airways from the oral cavity to the 
trachea. Molfino et al used a 0-64 cm scale and Marshall et al a 0-30 cm scale (Chapter 2, section 
2.5.5.4). Molfino et al showed an increase of the peak CSA from ~6 cm2 to ~7.5 cm2 of the oral 
cavity and a second large increase at ~19 cm which then increased up to ~52 cm reaching a CSA 
of ~13 cm2. Thus the magnitude of the increases were similar to those of the in vitro pharyngogram 
but the locations on the x-axis did not match. Marshall et al, on the other hand, showed an increase 
of the peak CSA of the oral cavity from ~6 cm2 to ~12 cm2, whereas the next increase from ~4 
cm2 to ~5 cm2 occurred at ~15 cm and then decreased to ~3 cm2 at ~28 cm. 
6.7 Conclusions 
The study hypothesis: “during acoustic pharyngometer measurements an open velum would pass 
acoustic impulses from the wavetube through the nasopharynx into the nasal airways creating a 
form of acoustic leak, which could create an overestimation of the volume of the upper airways 
from the pharynx to the GL as displayed on the pharyngogram”, was based on the assumption of 
an open velum based artefact as published by Molfino et al (1990) and Marshall et al (1993). 
The pharyngometer measurements with the largest hole size in the cast with the T-pieces attached 
showed a total increase in the upper airway volume (difference between “no hole, total AUC1-3” 
and “total AUC1-3 for the largest hole size”) which was with the small T-piece ~33 mL and with 
the large T-piece ~46 mL and thus somewhat larger than the volumes of the T-pieces. The same 
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analysis with the tube showed a total increase in upper airway volume (difference between “no 
hole, total AUC1-3” and “total AUC1-3 for the largest hole size”) which with the small T-piece 
was ~19 mL and with the large T-piece was ~32 mL and thus similar to the volumes of the T-
pieces. The differences in the impact of the T-piece volumes on the pharyngograms between the 
volumes of the cast and the tube were surprising. The differences between the surrogate upper 
airway models can be found in the different geometries, materials and sizes of the surrogates. 
Could any of these or the combination be the reason for the differences? 
The study did, however, confirm the study hypothesis that: “during acoustic pharyngometer 
measurements an open velum would pass acoustic impulses from the wavetube through the 
nasopharynx into the nasal airways creating a form of acoustic leak, which could create an 
overestimation of the volume of the upper airways from the pharynx to the GL as displayed on the 
pharyngogram”. 
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Chapter 7 General conclusions and future work 
7.1 Summary 
There are several advantages of the delivery of locally acting drugs as aerosols through the upper 
airways for treatment of diseases of the lungs in comparison with for example the oral route 
through the gastrointestinal tract. These include targeting the inhaled drugs directly to the airway 
surfaces, avoiding inactivation through hepatic first pass metabolism, minimising the amount of 
drug required and decreasing time to onset of action in comparison with swallowed drug (Newman 
et al., 2009). The mouth, the pharynx and the larynx are, however, potential sites of aerosol 
deposition during oral inhalation minimising the amount available for deposition in the lungs. 
When using nebulisers for aerosol delivery parameters such as the aerosol characteristics (droplet 
size, FPF, solution versus suspension) and the subject’s breathing pattern (and vocalization) will 
have an impact on the passage of aerosol through the upper airways to the lungs as shown in a 
number of studies (Newman et al., 1988; Zainudin et al., 1988; Newman et al., 1994; Svartengren 
et al., 1994; Svartengren et al., 1996; Kumazawa et al., 1997; Anderson et al., 1999; Häkkinen et 
al., 1999; Erzinger et al., 2007; Nikander et al., 2010c; van Velzen et al., 2015).  
The clinical studies in this Thesis were focused on measurements of the size of the upper airways 
and the correlation of this to upper airway and lung deposition (Chapter 3), and on the possible 
impact of mandibular advancement and incisal opening achieved with novel stepped mouthpieces 
on the size of the upper airways (Chapters 4-5). The in vitro study was designed to investigate the 
impact of a possible artefact – an open velum - on the pharyngogram when using acoustic 
pharyngometry (Eccovision ARP) (Chapter 6).  
In the first study (Chapter 3) 9 of 12 healthy subjects who had participated in a randomised, open-
label, crossover lung deposition study (Nikander et al., 2010c) were included in a follow-up study 
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to measure the size of their upper airways from the oral cavity to the GL. The I-neb nebuliser had 
been used in both TBM and TIM breathing modes to deliver an aerosol with saline mixed with 
99mTc-DTPA. The lung deposition of 99mTc-DTPA (with central and peripheral lung deposition 
shown separately), the upper airway deposition, and the exhaled fraction caught on the filter 
attached to the mouthpiece are shown in Chapter 3 and Figure 3.1. The variability in the upper 
airway deposition is difficult to explain as the aerosol MMD was relatively small (4.6 µm) 
considering the slow and deep breathing pattern (TIM) used as part of the study. It was therefore 
of interest to measure the subjects’ upper airways through acoustic pharyngometry and to correlate 
this information with the upper airway and lung depositions from the previous study.   
The 9 subjects’ lung function data measured during the summer of 2008 were similar to the data 
during the past lung deposition study during the summer of 2006 (Nikander et al., 2010c). The 
summary statistics of the acoustic pharyngometer measurements during inhalation - with subjects 
using nose clips - showed that there was a relatively large inter-subject variability in the CSAs and 
the AUCs. As published information on acoustic pharyngometry data acquired during inhalation 
are lacking, the present data were compared to acoustic pharyngometry data acquired during 
exhalation. The comparison showed that the mean CSA values were similar to those found in 
previous studies with the Eccovision ARP (Kamal, 2001; Kamal, 2002; Monahan et al., 2005; 
Busetto et al., 2009) and the volume of the upper airway similar (Ehtezazi et al., 2004) or somewhat 
larger when compared to upper airway volumes measured with MRI during inhalation in the supine 
position (Pritchard et al., 2004; Ehtezazi et al., 2005; McRobbie et al., 2005). The correlation 
analysis between the CSAs and AUCs and the upper airway and lung deposition data showed that 
the correlations between the CSA3 and the AUC3 and the total oropharyngeal and lung depositions 
were statistically significant. This meant that the volume between the EG and the GL correlated 
with the previous lung deposition results, whereas the oral cavity volume, the OPJ CSA, the 
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volume between the OPJ and the EG, and the EG CSA did not. Thus the anatomy of the lower part 
of the upper airways seemed to have had an impact on oropharyngeal and lung depositions. This 
raised questions related to the expansion and contraction of the upper airways during inhalation 
and whether it would be possible to increase especially the size of the CSAs of the upper airways. 
Oral appliances have been used to facilitate the movement of the mandible and/or the tongue in 
order to increase the size of the CSAs and AUCs of the upper airways in subjects diagnosed with 
OSA (Chapter 2, Table 2.6). The question was whether the upper airways could be expanded with 
a mouthpiece that advanced the mandible during inhalation. This led to the invention of a new 
“stepped mouthpiece”. The assumption was that as mandibular advancement expanded the size of 
the upper airways in subjects with OSA both during wakefulness and sleep, the same might be 
achieved during wakefulness in subjects not diagnosed with OSA. 
The second study (Chapter 4) was a proof-of-concept study of the impact of mandibular 
advancement and incisal opening achieved with the new stepped mouthpiece (without tongue 
depressor) on the size of the upper airways in 4 healthy subjects. A set of 12 stepped mouthpieces 
were designed with a round back orifice to be connected to the pharyngometer wavetube and an 
oval front orifice to be kept between the front teeth as shown in Chapter 4 and Figure 4.2. 
During inhalation through the stepped mouthpieces the mean CSAs were in 3 of 4 subjects affected 
by both the horizontal advancement of the mandible and the incisal opening (10-20 mm). The 
changes in the CSAs showed a large variability between the 4 subjects. The change in the CSA 
following mandibular advancement ranged for subject A from ~9% to ~34%, for subject B from 
~-5% to ~18%, for subject C from ~56% to ~78% and for subject D from ~34% to ~45%. The 
impact of the incisal opening on these changes was in subjects A, B and D considerable especially 
when testing the large mouthpiece whereas this effect was almost the opposite when testing the 
small mouthpiece. The 10 mm incisal opening created by the small mouthpiece (-3 mm) had a 
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surprisingly negative effect in subjects A and B. The changes in the mean AUCs during inhalation 
followed the changes in the mean CSAs. 
The analysis of the results of the proof-of-concept study showed that the response to the 
combination of mandibular advancement and incisal opening was far from linear and quite 
complex. The occurrence of negative results following mandibular advancement and incisal 
opening might have been due to the lack of a tongue depressor. This led to the development of a 
stepped mouthpiece with a tongue depressor which was tested in the next study. 
The study presented in Chapter 5 covers the results of an open investigation including 60 subjects 
- 30 healthy subjects and 30 subjects diagnosed with OSA with equal numbers of male and female 
subjects – using the new stepped mouthpiece with a tongue depressor (Chapter 5 and Figure 5.1). 
The new stepped mouthpiece was 81 mm long fully extended and the 18 mm vertical external 
diameter of the mouthpiece was chosen partly based on the results of the previous proof-of-concept 
study in which the largest mouthpiece had an external vertical mouthpiece diameter of 20 mm and 
partly as this is a common vertical size of jet nebuliser and inhaler mouthpieces. Five of the 6 
possible advancements of the stepped mouthpiece were used (1, 2, 3, 4, and 5 mm). As in the 
proof-of-concept study the back end of the stepped mouthpiece was connected to the acoustic 
pharyngometer wavetube. The primary objective of the study was to measure through acoustic 
pharyngometry the impact of horizontal mandibular advancement on the size of the upper airways 
in subjects without and with OSA while in a seated position.  
The CSA related results during tidal breathing showed that the impact of the introduction (incisal 
opening) of the stepped mouthpiece was for CSA1 and CSA3 larger than the effect of the 
mandibular advancement in both groups of subjects. For CSA2 in the non-OSA group the change 
in size was larger following mandibular advancement than following the introduction of the 
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stepped mouthpiece (incisal opening). The change in size of CSA2 in the OSA group was also 
larger following mandibular advancement although the magnitude was smaller. 
The AUC related results during tidal breathing showed that the impact of the vertical diameter of 
the stepped mouthpiece on AUC1 was larger than the effect of the mandibular advancements for 
both groups. For AUC2 in the non-OSA group the change in the size of AUC2 was larger following 
mandibular advancement than following the incisal opening. The change in size of AUC2 in the 
OSA group followed the same pattern with larger change following mandibular advancement 
although the magnitude was smaller. The changes in size of AUC3 were small in relation to the 
volume of the AUC3 and the impact of the vertical diameter of the stepped mouthpiece on the 
AUC3 was larger than the effect of the mandibular advancements for both groups.  
The statistical analysis of the results for the non-OSA group showed that the changes in CSA1-3 
and AUC1-3 following the introduction of the stepped mouthpiece were all statistically significant. 
This was in contrast with the results for the OSA group which only showed statistically significant 
results for CSA1, CSA3 and AUC1 and not for the important oropharyngeal area (CSA2, AUC2). 
This might reflect the mixed results of incisal openings in subject with OSA published in the past 
(Meurice et al., 1996; Vroegop et al., 2012). The mouthpiece position was, however, statistically 
significant for AUC2 and the significant effect (non-OSA and OSA data combined) corresponded 
to an increase in volume from 9.76 to 11.29 cm3, a difference of 1.53 cm3 or ~16% of the 0 mm 
value. The increases were ~18% in the non-OSA group and ~13% in the OSA group.  
The in vitro study in Chapter 6 was designed to investigate the possible artefact found in Chapter 
3 which was related to the use of nose clips during the acoustic pharyngometer measurements. 
Based on the Molfino et al (1990) and Marshall et al (1993) articles, an open velum might be the 
cause for the increase in the CSAs and AUCs. According to Molfino et al (1990) an open 
nasopharyngeal velum during acoustic pharyngometry leads to an over-estimation of the lower 
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upper airway (distal pharynx, GL and trachea) as the acoustic pulses will propagate from the mouth 
to the nasopharynx and the paranasal sinuses where they are reflected in order to propagate along 
the rest of the upper airway. Kamal (2004a) described the velum as the port to the nasopharynx 
and an open velum would pass acoustic impulses from the pharyngometer wavetube further up 
through the nasopharynx into the sinuses creating a form of acoustic leak. The consequence would 
be an overestimation of the assumed oropharyngeal CSA (Kamal, 2004a). Thus the volume of the 
nasopharynx and the sinuses would be of interest as the addition of that volume to the 
pharyngogram should, based on the assumptions by Kamal (2004a), be equal to the artefact. 
The in vitro test setup consisted of an acoustic pharyngometer, a cast of a human upper airway 
(oral cavity to the GL) and an L-shaped tube. Acoustic pharyngometer measurements were 
performed without and with surrogate “open velums” in the form of holes of different sizes at the 
back of the cast and the tube at the probable location of the velum. Small and large “nasal cavities” 
of ~20 ml (small T-piece) and ~30 mL (large T-piece) volumes were attached to the hole. 
Measurements without any T-piece were also made and these measurements had an infinite size 
of the nasal cavity. 
The pharyngometer measurements with the largest hole size in the cast without T-pieces showed 
the largest increase in the pharyngograms. The pharyngograms were somewhat separated at the 
peak CSA of the oral cavity with the pharyngogram presenting the largest hole sizes showing the 
smallest CSA. The increase in the pharyngograms after the oral cavity occurred at ~11 cm, reached 
a plateau at ~12 cm, and increased sharply at ~17 cm. The changes in the CSA were initially small 
with an early increase after the oral cavity from ~4 to ~6 cm2 (~10 to ~12 cm) and the late increase 
from ~6 to ~13 cm2 (~17 to ~20 cm). The increase in the pharyngograms at ~20 cm followed the 
order of the size of the holes with the pharyngogram based on the smallest hole size showing the 
least increase and vice versa. The addition of the T-pieces to the posterior pharyngeal wall of the 
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cast reduced the increases seen without the addition of the T-pieces. However, the total increase 
in upper airway volume (no hole, total AUC1-3 minus total AUC1-3 for the largest hole size) was 
with the small T-piece ~33 mL and with the large T-piece ~46 mL and thus somewhat larger than 
the volumes of the T-piece. The increase in the pharyngograms based on the largest hole size and 
the volumes of the T-pieces attached indicates that the in vitro model was a reasonable tool for 
evaluation of the open velum effect, but indicates that the open velum effect might be related to 
factors other than the volume of the nasal airways. 
The pharyngometer measurements with the largest hole size in the tube without T-pieces showed 
as with the cast the largest increase in the pharyngograms. The addition of the T-pieces to the 
posterior pharyngeal wall of the tube did also reduce the increases seen without the addition of the 
T-pieces. Thus the changes in the pharyngograms did largely mimic those of the cast. The total 
increase in tube upper airway volume (difference between “no hole, total AUC1-3” and “total 
AUC1-3 for the largest hole size”) was, however, with the small T-piece ~19 mL and with the 
large T-piece ~32 mL and thus similar to the volumes of the T-pieces. The differences between 
the volumes of the cast and the tube were surprising. The differences between the surrogate upper 
airway models can be found in the different geometries, materials and sizes of the surrogates.  
In conclusion, the results of the studies of this Thesis have shown that: 
- oropharyngeal and lung depositions of nebulised saline was related to the anatomy of the 
upper airways. 
- the size of the upper airway can be increased with a stepped mouthpiece and that this effect 
is based on a combination of incisal opening and mandibular advancement. 
- an open velum has an impact on the pharyngogram and that the volume of this effect seems 
to be larger than the size of the nasal cavity. 
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7.2 Future work 
The results of the studies presented in Chapters 4 and 5 indicate that mandibular advancement and 
incisal opening would be a simple method for the enlargement of the area of the pharynx between 
the OPJ and the EG during inhalation. This should enhance the passage of aerosol through the 
lumen of the pharynx to the lungs. A number of questions do, however, remain to be answered 
before the optimal combination of mandibular advancement and incisal opening is identified. 
These questions are related to: 
1. The impact of the incisal opening on the size of the pharynx in subjects with respiratory 
disorders treated with inhaled drugs. 
2. The impact of the mandibular advancement on the size of the pharynx in subjects with 
respiratory disorders treated with inhaled drugs. 
3. The impact of different combinations of incisal openings and mandibular advancements on 
the size of the pharynx in subjects with respiratory disorders treated with inhaled drugs. 
4. The identification of the optimal individual combination of an incisal opening and 
mandibular advancement. 
5. The impact of incisal openings and mandibular advancements on upper airway and lung 
deposition of nebulised saline. 
6. How long could a subject comfortably inhale nebulised drug with a stepped mouthpiece 
with an optimal individual combination of an incisal opening and a mandibular 
advancement. 
7. The impact of high peak inspiratory flows required for inhalation through DPIs on the size 
of pharynx during mandibular advancement with a stepped mouthpiece. 
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The results of the study presented in Chapter 3 indicated that the use of nose clips during recordings 
with an acoustic pharyngometer might lead to an open velum effect which would create an artefact 
in terms of too large CSAs. The results of the study presented in Chapter 5 showed some large 
CSA values that might have been a consequence of the movement of the subject’s head or an open 
velum. Finally, the study presented in Chapter 6 showed how a well-defined open velum could 
affect the pharyngogram, but the results did not match published pharyngograms recorded with an 
open velum (Molfino et al., 1990; Marshall et al., 1993). A number of questions therefore remain 
to be answered regarding the possible open velum effect and the impact of the movement of the 
head during acoustic pharyngometry measurements.   
These questions are related to: 
1. The identification of a possible leakage through the velum during oral breathing versus 
nasal breathing with different combinations of mandibular advancement and incisal 
opening. 
2. The quantification of the leakage through the open velum during oral breathing versus 
nasal breathing with different combinations of mandibular advancement and incisal 
opening. 
3. The impact of a verified open velum on the pharyngogram with different combinations of  
mandibular advancements and incisal openings. 
4. The collection of acoustic pharyngometry reference values of the size of the upper airways 
- including the CSAs of the OPJ, the EG and the GL and the related AUCs – during 
inspiration and expiration in healthy subjects of both genders and in different age groups. 
5. Development of an algorithm for the acoustic pharyngometer equipment for identification 
of deviating pharyngograms following an open velum. This could be based on the GOF 
algorithm used in Chapters 3 and 5. 
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The stepped mouthpieces used in the studies presented in Chapters 4 and 5 could be further 
developed based on the results from the above outlined studies. The size and shape of the stepped 
mouthpiece including the size and shape of the tongue depressor could be further developed in 
order to fit the multitude of different teeth settings. This would include an increase in the 
mandibular advancement settings and most probably a range of vertical dimensions. 
The variable results in acoustic pharyngometry recordings in some subjects following mandibular 
advancement and incisal opening (Chapter 5) indicate that the SOPs presented by Kamal (2004c) 
might require an update. If similar trends are observed during evaluations of oral applainces in 
subjects diagnosed with OSA, additional tools for standardizing the recordings would probably be 
required in the acoustic pharyngometers. These tools could include: 
1.  Measurements of the head position and upper body position.  
2. Measurements of tongue movements. 
3. Measurements of swallowing. 
4. Timing the acoustic pharyngometer recording to either inhalation or exhalation as 
presented in Chapter 3. 
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Appendices 
Appendix A 1 
Presented as a softcopy (Microsoft Word 2013 format) on a DVD attached to the side back cover 
of the thesis. 
Appendix A 2 
Presented as a softcopy (Microsoft Word 2013 format) on a DVD attached to the side back cover 
of the thesis. 
Appendix B 1 
Presented as a softcopy (Microsoft Word 2013 format) on a DVD attached to the side back cover 
of the thesis. 
Appendix C 1 
Presented as a softcopy (Microsoft Word 2013 format) on a DVD attached to the side back cover 
of the thesis. 
Appendix C 2 
Presented as a softcopy (Microsoft Word 2013 format) on a DVD attached to the side back cover 
of the thesis. 
Appendix C 3 
Presented as a softcopy (Microsoft Word 2013 format) on a DVD attached to the side back cover 
of the thesis. 
 
 
 
 297 
  
 
Bibliography 
Aarab, G., Lobbezoo, F., Hamburger, H.L. & Naeije, M. (2010) Effects of an oral appliance with 
different mandibular protrusion positions at a constant vertical dimension on obstructive sleep 
apnea. Clin Oral Invest. 14(3), 339-345. 
 
Abramson, H.A. (1946) Principles and practice of aerosol therapy of the lungs and bronchi. Ann 
Allergy. 4(6). 440-456. 
 
Abramson, H.A. (1968) Clinical applications of the ultrasonic nebulizer. J Astm Resarch. 5(4), 
217-221. 
 
Ahrens, A., McGrath, C. & Hägg, U. (2011) A systematic review of the efficacy of oral appliance 
design in the management of obstructive sleep apnoea. Eur J Orthod. 33(3), 318-324. 
 
Allen, A., Bal, J., Cheesbrough, A., Hamilton, M. & Kempsford, R. (2014) Pharmacokinetics and 
pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East 
Asian subjects. Br J Clin Pharmacol. 77(5), 808-820. 
 
American Thoracic Society. Standardization of Spirometry. 1994 Update. (1995) Am J Respir Crit 
Care Med. 152(3). 1107-1136. 
 
Anderson, M., Svartengren, M. & Camner, P. (1999) Human tracheobronchial deposition and 
effect of a cholinergic aerosol inhaled by extremely slow inhalations. J Aerosol Sci. 30(3), 289-
297. 
 
Ayappa, I. & Rapoport, D.M. (2003) The upper airway in sleep: physiology of the pharynx. Sleep 
Med Rev. 7(1), 9-33.  
 
Bailey, D.R. (2005) Dental therapy for obstructive sleep apnea. Semin Respir Crit Care Med. 
26(1), 89-95.  
 
Barnes, M., McEvoy, R.D., Banks, S., Tarquinio, N., Murray, C.G., Vowles, N. & Pierce, R.J. 
(2004) Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive 
sleep apnea. Am J Respir Crit Care Med. 170(6), 656-664. 
 
Barthlen, G.M., Brown, L.K., Wiland, M.R., Sadeh, J.S., Patwari, J. & Zimmerman, M. (2000) 
Comparison of three oral appliances for treatment of severe obstructive sleep apnea syndrome. 
Sleep Med. 1(4), 299-305. 
 
Berkow, L.C. (2004) Strategies for airway management. Best Pract Res Clin Anaesthesiol. 18(4), 
531-548. 
 
Berne, R.M. & Levy, M.N. (1988) Physiology. Second edition. C.V. Mosby Company, St. Louis. 
MO. 
 298 
  
 
Bland, J.M. & Altman, D.G. (1986) Statistical methods for assessing agreement between two 
methods of clinical measurement. Lancet. 1, 307-310. 
 
Bloch, K.E., Iseli, A., Zhang, J.N., Xie, X., Kaplan, V., Stoeckli, P.W. & Russi, E.W. (2000) A 
randomized, controlled crossover trial of two oral appliances for sleep apnea treatment. Am J 
Respir Crit Care Med. 162(1), 246-251. 
 
Boe, J., Dennis, J.H., O’Driscoll, B.R. and ERS task force members Bauer, T.T., Carone, M., 
Dautzenberg, B., Diot, P., Heslop, K. & Lannefors, L. (2001) European Respiratory Society 
Guidelines on the use of nebulizers. Eur Respir J. 18(1), 228-242.   
 
Boiron, O., Scheinherr, A., Elliot, A.R., Bailly, L., Theilman, R.J. & Darquenne, C. (2015) 
Dynamics of the glottis during breathing. J Aerosol Med Pulm Drug Deliv. 28(3). 
 
Borgström, L., Olsson, B. & Thorsson, L. (2006) Degree of throat deposition can explain the 
variability in lung deposition in inhaled drugs. J Aerosol Med. 19(4), 473-483. 
 
Boyd, B., Noymer, P., Liu, K., Okikawa, J., Hasegawa, D., Warren, S., Taylor, G., Ferguson, E., 
Schuster, J., Farr, S. & Gonda, I. (2004) Effect of gender and device mouthpiece shape on bolus 
insulin aerosol delivery using the AERx pulmonary delivery system. Pharm Res. 21(10), 1776-
1782. 
 
Brancatisano, T., Collett, P.W. & Engel, L.A. (1983) Respiratory movements of the vocal cords. 
J Appl Physiol Respir Environ Exerc Physiol. 54(5), 1269-1276. 
 
Brand, P., Beckmann, H., Maas Enriquez, M., Meyer, T., Müllinger, B., Sommerer, K., Weber, 
N., Weuthen, T. & Scheuch, G. (2003) Peripheral deposition of alpha1-protease inhibitor using 
commercial inhalation devices. Eur Respir J. 22(2), 263-267. 
 
Brand, P., Friemel, I., Meyer, T., Schulz, H., Heyder, J. & Häussinger, K. (2000) Total deposition 
of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci. 89(6), 724-
731. 
 
Brooks, L.J. (1990) Tracheal size and distensibility in patients with cystic fibrosis. Am Rev Respir 
Dis. 141(2), 513-516. 
 
Brooks, L.J., Byard, P.J., Fouke, J.M. & Strohl, K.P. (1989) Reproducibility of measurements of 
upper airway area by acoustic reflection. J Appl Physiol. 66(6), 2901-2905. 
 
Brooks, L.J., Castile, R.G., Glass, G.M., Griscom, N.T., Wohl, M.E. & Fredberg, J.J. (1984) 
Reproducibility and accuracy of airway area by acoustic reflection. J Appl Physiol Respir Environ 
Excerc Physiol. 57(3), 777-787. 
 
Brouns, M., Verbanck, S. & Lacor, C. (2007) Influence of glottis aperture on the tracheal flow. J 
Biomech. 40(1), 165-172. 
 
 299 
  
 
Brown, E.C., Cheng, S., McKenzie, D.K., Butler, J.E., Gandevia, S.C. & Bilston, L.E. (2013) 
Tongue and lateral upper airway movement with mandibular advancement. Sleep. 36(3), 397-404. 
 
Brown, I.G., Webster, P.M., Zamel, N. & Hoffstein, V. (1986) Changes in tracheal cross-sectional 
area during Mueller and Valsava maneuvers in humans. J Appl Physiol. 60(6), 1865-1870. 
 
Buenting, J.E., Dalston, R.M., Smith, T.L. & Drake, A.F. (1994) Artifacts associated with acoustic 
rhinometric assessment of infants and young children: A model study. J Appl Physiol. 77(6), 2558-
2563. 
 
Burnell, P.K., Asking, L., Borgström, L., Nichols, S.C., Olsson, B., Prime, D. & Shrubb, I. (2007) 
Studies of the human oropharyngeal airspaces using magnetic resonance imaging. IV The 
oropharyngeal retention effect for four inhalation delivery systems. J Aerosol Med. 20(3), 269-
281. 
 
Busetto, L., Calo, E., Mazza, M., De Stefano, F., Costa, G., Negrin, V. & Enzi, G. (2009) Upper 
airway size is related to obesity and body fat distribution in women. Eur Arch Otorhinolaryngol. 
266(4), 559-563. 
 
Byrne, N.M., Keavey, P.M., Perry, J.D., Gould, F.K. & Spencer, D.A. (2003) Comparison of lung 
deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic 
fibrosis. Arch Dis Child. 88(8), 715-718. 
 
Carvalho, T.C., Peters, J.I. & Williams, R.O. 3rd. (2011) Influence of particle size on regional lung 
deposition – What evidence is there? Int J Pharm. 406, 1-10. 
 
Chan, A.S., Lee, R.W. & Cistulli, P.A. (2007) Dental appliance treatment for obstructive sleep 
apnea. Chest. 132(2), 693-699.  
 
Chan, A.S., Lee, R.W., Srinivasan, V.K., Darendeliler, M.A. & Cistulli, P.A. (2011) Use of flow-
volume curves to predict oral appliance treatment outcome in obstructive sleep apnea: a 
prospective validation study. Sleep Breath. 15(2), 157-162.  
 
Chan, A.S., Lee, R.W., Srinivasan, V.K., Darendeliler, M.A., Grunstein, R.R. & Cistulli, P.A. 
(2010a) Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea. 
Eur Respir J. 35(4), 836-842. 
 
Chan, A.S., Sutherland, K., Schwab, R.J., Zeng, B., Petocz, P., Lee, R.W., Darendeliler, M.A. & 
Cistulli, P.A. (2010b) The effect of mandibular advancement on upper airway structure in 
obstructive sleep apnoea. Thorax. 65(8), 726-732.  
 
Chang, H.K. & Menon, A.S. (1993) Airflow dynamics in the human airways. In: Aerosol in 
Medicine. Moren, F., Dolovich, M.B., Newhouse, M.T. & Newman, S.P. editors, 2nd revised 
edition. Elsevier, Amsterdam, pp. 85-116.  
 
Cheng, Y.S., Yamada, Y., Yeh, H.C. & Swift, D.L. (1990) Deposition of ultrafine aerosols in a 
human oral cast. Aerosol Sci Technol. 12, 1075-1081. 
 300 
  
 
Ciscar, M.A., Juan, G., Martinez, V., Ramon, M., Lloret, T., Minguez, J., Armengot, M., Marin, 
J. & Basterra, J. (2001) Magnetic resonance imaging of the pharynx in OSA patients and healthy 
subjects. Eur Respir J. 17(1), 79-86.  
 
Denyer, J. (1997) Adaptive aerosol delivery in practice. Eur Respir Rev. 7: 51, 388–389.  
 
Denyer, J., Black, A., Nikander, K., Dyche, T. & Prince, I. (2010a) Domiciliary experience of the 
Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis. J Aerosol Med 
Pulm Drug Deliv. 23 (Suppl 1), S45–S54. 
 
Denyer, J. & Dyche, T. (2010b) The Adaptive Aerosol Delivery (AAD) Technology: Past, present, 
and future. J Aerosol Med Pulm Drug Deliv. 23 (Suppl 1), S1-S10.   
 
Denyer, J., Nikander, K. & Smith, N.J. (2004) Adaptive Aerosol Delivery (AAD) technology. 
Expert Opin Drug Deliv. 1, 165–176.  
 
Denyer, J., Prince, I., Dixon, E., Agent, P., Pryor, J. & Hodson, M. (2010c) Evaluation of the 
Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with 
cystic fibrosis. J Aerosol Med Pulm Drug Deliv. 23 (Suppl 1), S29–S36.  
 
de Paula Santos, R., Habermann, W., Hofmann, T. & Stammberger, H. (2006) Pre and post 
functional endoscopic sinus surgery nasal cavity volume assessment by acoustic rhinometry. Braz 
J Otorhinolaryngol. 72(4), 549-553. 
 
DeYoung, P.N., Bakker, J.P., Sands, S.A., Batool-Anwar, S., Connolly, J.G., Butler, J.P. & 
Malhotra, A. (2013) Acoustic pharyngometry measurement of minimal cross-sectional airway area 
is a significant independent predictor of moderate-to-severe obstructive sleep apnea. J Clin Sleep 
Med. 9(11), 1161-1164. 
 
Dhand, R. (2002) Nebulizers that use a vibrating mesh or plate with multiple apertures to generate 
aerosol. Respir Care. 47(12), 1406-1418. 
 
Diaz, K.T., Skaria, S., Harris, K., Solomita, M., Lau, S., Bauer, K., Smaldone, G.C. & Condos, R. 
(2012) Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis. J Aerosol Med 
Pulm Drug Deliv. 25(2), 79-87.  
 
Dort, L. & Remmers, J. (2012) A combination appliance for obstructive sleep apnea: The 
effectiveness of mandibular advancement and tongue retention. J Clin Sleep Med. 8(3), 265-269. 
 
D’Urzo, A.D., Lawson, V.G., Vassal, K.P., Rebuck, A.S., Slutsky, A.S. & Hoffstein, V. (1987) 
Airway areas by acoustic response measurements and computerized tomography. Am Rev Respir 
Dis. 135(2), 392-395. 
 
D’Urzo, A.D., Rubinstein, I., Lawson, V.G., Vassal, K.P., Rebuck, A.S., Slutsky, A.S. & 
Hoffstein, V. (1988) Comparison of glottic areas measured by acoustic reflections vs. 
computerized tomography. J Appl Physiol. 64(1), 367-370.  
 
 301 
  
 
Eckmann, D.M., Glassenberg, R. & Gavriely, N. (1996) Acoustic reflectometry and endotracheal 
intubation. Anesth Analg. 83(5), 1084-1089. 
 
Ehtezazi, T., Horsfield, M.A., Barry, P.W., Goodenough, P. & O´Callaghan, C. (2005) Effect of 
device inhalational resistance on the three-dimensional configuration of the upper airway. J Pharm 
Sci. 94(7), 1418-1426. 
 
Ehtezazi, T., Horsfield, M.A., Barry, P.W. & O´Callaghan, C. (2004) Dynamic change of the upper 
airway during inhalation via aerosol delivery devices. J Aerosol Med. 17(4), 325-334. 
 
Erzinger, S., Schueepp, K.G., Brooks-Wildhaber, J., Devadason, S.G. & Wildhaber, J.H. (2007) 
Facemasks and aerosol delivery in vivo. J Aerosol Med. 20 (Suppl 1), S78-S83. 
 
Fajdiga, I. (2005) Snoring imaging: could Bernoulli explain it all? Chest. 128(2), 896-901.  
 
Ferguson, K.A., Cartwright, R., Rogers, R. & Schmidt-Nowara, W. (2006) Oral appliances for 
snoring and obstructive sleep apnea: A review. Sleep. 29(2), 244-262.  
 
Ferguson, K.A., Love, L.L. & Ryan, C.F. (1997a) Effect of mandibular and tongue protrusion on 
upper airway size during wakefulness. Am J Respir Crit Care Med. 155(5), 1748-1754. 
 
Ferguson, K.A., Ono, T., Lowe, A.A., al-Majed, S., Love, L.L. & Fleetham, J.A. (1997b) A short-
term controlled trial of an adjustable oral appliance for the treatment of mild to moderate 
obstructive sleep apnoea. Thorax. 52(4), 362-368.  
 
Ferguson, K.A., Ono, T., Lowe, A.A., Keenan, S.P. & Fleetham, J.A. (1996) A randomized 
crossover study of an oral appliance vs nasal-continuous positive airway pressure in the treatment 
of mild-moderate obstructive sleep apnea. Chest. 109(5), 1269-1275.  
 
Findeisen, W. (1935) Uber das Absetzen kleiner in der Luft suspendierten Teilchen in der 
menschlichen Lunge bei der Atmung. Phlügers Arch Ges Physiol. 236, 367-379. 
 
Fleetham, J.A. & Almeida, F.R. (2010) Oral appliances. Eur Respir Mon. 50, 267-285.  
 
Fleury, B., Rakotonanahary, D., Petelle, B., Vincent, G., Pelletier Fleury, N., Meyer, B. & Lebeau, 
B. (2004) Mandibular advancement titration for obstructive sleep apnea: Optimization of the 
procedure by combining clinical and oximetric parameters. Chest. 125(5), 1761-1767.  
 
Fogel, R.B., Malhotra, A. & White, D.P. (2004) Sleep.2: pathophysiology of obstructive sleep 
apnoea/hypopnoea syndrome. Thorax. 59(2), 159-163. 
 
Forrest, J.B. (1993) Lower airway: structure and function. In: Aerosols in Medicine. Moren, F., 
Dolovich, M.B., Newhouse, M.T., & Newman, S.P., editors. 2nd revised edition. Elsevier, 
Amsterdam, pp. 27-60.  
 
Fouke, J.M. & Strohl, K.P. (1987) Effect of position and lung volume on upper airway geometry. 
J Appl Physiol. 63(1), 375-380.  
 302 
  
 
Fransson, A.M., Tegelberg, Å., Svenson, B.A., Wenneberg, B. & Isacsson, G. (2003) Validation 
of measurements of mandibular protrusion in the treatment of obstructive sleep apnoea and snoring 
with a mandibular protruding device. Eur J Orthod. 25, 377-383.  
 
Fredberg, J.J., Wohl, M.E., Glass, G.M. & Dorkin, H.L. (1980) Airway area by acoustic reflections 
measured at the mouth. J Appl Physiol Respir Environ Excerc Physiol. 48(5), 749-758. 
 
Friedman, M., Shnowske, K., Hamilton, C., Samuelson, C.G., Hirsch, M., Pott, T.R. & 
Yalamanchali, S. (2014) Mandibular advancement for obstructive sleep apnea: relating outcomes 
to anatomy. JAMA Otolaryngol Head Neck Surg. 140 (1), 46-51.  
 
Gale, D.J., Sawyer, R.H., Woodcock, A., Stone, P., Thompson, R. & O´Brien, K. (2000) Do oral 
appliances enlarge the airway in patients with obstructive sleep apnoea? A prospective 
computerized tomographic study. Eur J Orthod. 22(2), 159-168. 
 
Gao, X., Otsuka, R., Ono, T., Honda, E., Sasaki, T. & Kuroda, T. (2004) Effect of titrated 
mandibular advancement and jaw opening on the upper airway in nonapneic men: A magnetic 
resonance imaging and cephalometric study. Am J Orthod Dentofacial Orthop. 125(2), 191-199. 
 
Garcia, G.J., Tewksbury, E.W., Wong, B.A. & Kimbell, J.S. (2009) Interindividual variability in 
nasal filtration as a function of nasal cavity geometry. J Aerosol Med Pulm Drug Deliv. 22(2), 
139-155. 
 
Gelardi, M., Del Giudice, A.M., Cariti, F., Cassano, M., Farras, A.C., Fiorella, M.L. & Cassano, 
P. (2007) Acoustic pharyngometry: clinical and instrumental correlations in sleep disorders. Braz 
J Otorhinolaryngol, 73(2), 257-265. 
 
Goddard, R.F., Mercer, T.T., O’Neill, P.X.F., Flores, R.L. & Sanchez, R. (1968) Output 
characteristics and clinical efficacy of ultrasonic nebulizers. J Astm Research. 5(4), 355-368. 
 
Guilmette, R.A., Cheng, Y.S. & Griffith, W.C. (1997) Characterising the variability in adult 
human nasal airway dimensions. Ann Occup Hyg. Vol 41(1) , 491-496.  
 
Harsh, G.F. (1948) A comparative study of commercial nebulizers. Ann Allergy. 6(5). 534-546. 
 
Hoekema, A., Stegenga, B. & De Bont, L.G.M. (2004) Efficacy and co-morbidity of oral 
appliances in the treatment of obstructive sleep apnea-hypopnea: a systematic review. Crit Rev 
Oral Biol Med. 15(3), 137–155.  
 
Hoffstein, V. (2007) Review of oral appliances for treatment of sleep-disordered breathing. Sleep 
Breath. 11, 1-22.  
 
Hoffstein, V. & Fredberg, J.J. (1991) The acoustic reflection technique for non-invasive 
assessment of upper airway area. Eur Respir J. 4(5), 602-611.  
 
Horchover, R.L. (2007) Oral appliances for the treatment of obstructive sleep apnea. Asian 
Biomed. Vol.1., No.1. 
 303 
  
 
Häkkinen, A.M., Uusi-Heikkilä, H., Järvinen, M., Saali, K. & Karhumäki, L. (1999) The effect of 
breathing frequency on deposition of drug aerosol using an inhalation-synchronized dosimeter in 
healthy adults. Clin Physiol. 19(3), 269-274. 
 
Jan, M.A., Marshall, I. & Douglas, N.J. (1994) Effect of posture on upper airway dimensions in 
normal human. Am J Respir Crit Care Med. 149(1), 145-148.  
 
Johal, A. & Battagel, J.M. (1999) An investigation into the changes in airway dimension and the 
efficacy of mandibular advancement appliances in subjects with obstructive sleep apnoea. Br J 
Orthod. 26(3), 205-210. 
 
Johns, M.W. (1991) A new method for measuring daytime sleepiness: The Epworth sleepiness 
scale. Sleep. 14(6), 540-545. 
 
Johns, M.W. (1992) Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 15(4), 
376-381. 
  
Johnston, C.D., Gleadhill, I.C., Cinnamond, M.J., Gabbey, J. & Burden, D.J. (2002) Mandibular 
advancement appliances and obstructive sleep apnoea: a randomized clinical trial. Eur J Orthod. 
24(3), 251-262. 
 
Jonson, B., Westling, H., White, T. & Wollmer, P. (1998) Klinisk fysiologi. Liber AB, Stockholm.  
 
Jung, D.G., Cho, H.Y., Grunstein, R.R. & Yee, B. (2004) Predictive value of Kushida index and 
acoustic pharyngometry for the evaluation of upper airway in subjects with or without obstructive 
sleep apnea. J Korean Med Sci. 19(5), 662-667.  
 
Kamal, I. (2001) Normal standard curve for acoustic pharyngometry. Otolaryngol Head Neck 
Surg. 124(3), 323-330. 
 
Kamal, I. (2002) Lung volume dependence of pharyngeal cross-sectional area by acoustic 
pharyngometry. Otolaryngol Head Neck Surg. 126(2), 164-171.  
 
Kamal, I. (2004a) Acoustic pharyngometry patterns of snoring and obstructive sleep apnea 
patients. Otolaryngol Head Neck Surg. 130(1), 58-66. 
 
Kamal, I. (2004b) Test-retest validity of acoustic pharyngometry measurements. Otolaryngol 
Head Neck Surg. 130(2), 223-228. 
 
Kamal, I. (2004c) Acoustic reflectometry of the nose and pharynx. Universal Publischers, Florida, 
USA. 
 
Kastelik, J.A., Wright, G.A., Aziz, I., Davies, M., Avery, G.R., Paddon, A.J., Howey, S. & Morice, 
A.H. (2002) A widely available method for the assessment of aerosol delivery in cystic fibrosis. 
Pulm Pharmacol Ther. 15(6), 513-519.  
 
 304 
  
 
Knoch, M. & Keller, M. (2005) The customized electronic nebulizer: a new category of liquid 
aerosol drug delivery systems. Expert Opin Drug Deliv. 2(2), 377-390. 
 
Kumar, S., Jayan, B. & Bansal, A.K. (2015) Acoustic pharyngometry: an objective assessment 
tool for determining pharyngeal airway. J Dent Specialities. 3(1), 102-108. 
 
Kumazawa, H., Asako, M., Yamashita, T & Ha-Kawa, S.K. (1997) An increase in laryngeal 
aerosol deposition by ultrasonic nebulizer therapy with intermittent vocalization. Laryngoscope. 
107(5), 671-674. 
 
Kyung, S.H., Park, Y.C. & Pae, E.K. (2005) Obstructive sleep apnea patients with the oral 
appliance experience pharyngeal size and shape changes in three dimensions. Angle Orthod. 75(1), 
15-22.  
 
Köhler, E., Sollich, V., Schuster-Wonka, R., Hühnerbein, J. & Jorch, G. (2004) Does wearing a 
noseclip during inhalation improve lung deposition? J Aerosol Med. 17(2), 116-122. 
 
Lam, B., Ip, M.S., Tench, E. & Ryan, C.F. (2005) Craniofacial profile in Asian and white subjects 
with obstructive sleep apnoea. Thorax. 60(6), 504-510.  
 
Lazard, D.S., Blumen, M., Lévy, P., Chauvin, P., Fragny, D., Buchet, I. & Chabolle, F. (2009) The 
tongue-retaining device: efficacy and side effects in obstructive sleep apnea syndrome. J Clin 
Sleep Med. 5(5), 431-438. 
 
Lettieri, C.J., Paoline, N., Eliasson, A.H., Shah, A.A. & Holley, A.B.  (2011) Comparison of 
adjustable and fixed oral appliances for the treatment of obstructive sleep apnea. J Clin Sleep Med. 
7(5), 439-445. 
 
Likert, R. (1932) A technique for the measurement of attitudes. Arch Psychol. 22, 1-55. 
 
Lin, T-C., Breysse, P.N., Laube, B.L. & Swift, D.L. (2001) Mouthpiece diameter affects deposition 
efficiency in cast models of the human oral airways.  J Aerosol Med. 14(3), 335-341. 
 
Lorino, A.M., Maza, M., d’Ortho, M.P., Coste, A., Harf, A. & Lorino, H. (2000) Effects of 
mandibular advancement on respiratory resistance. Eur Respir J. 16(5), 928-932. 
 
Louis, B., Glass, G.M. & Fredberg, J.J. (1994) Pulmonary airway area by the two-microphone 
acoustic reflection method. J Appl Physiol. 76(5), 2234-2240.  
 
Mallampati, S.R., Gatt, S.P., Gugino, L.D., Desai, S.P., Waraksa, B., Freiberger, D. & Liu, P.L. 
(1985) A clinical sign to predict difficult thacheal intubation: a prospective study. Can Anaesth 
Soc J. 32(4), 429-434. 
 
Marklund, M., Stenlund, H. & Franklin, K.A. (2004) Mandibular advancement devices in 630 men 
and women with obstructive sleep apnea and snoring: tolerability and predictors of treatment 
success. Chest. 125(4), 1270–1278.  
 
 305 
  
 
Marklund, M., Verbraecken, J. & Randerath, W. (2012) Non-CPAP therapies in obstructive sleep 
apnoea: mandibular advancement device therapy. Eur Respir J. 39(5), 1241-1247.  
 
Marshall, I., Maran, N.J., Martin, S., Jan, M.A., Rimmington, J.E. Best, J.J., Drummond, G.B. & 
Douglas, N.J. (1993) Acoustic reflectometry for airway measurements in man: implementation 
and validation. Physiol Meas. 14(2), 157-169. 
 
Marshall, I., Rogers, M. & Drummond, G. (1991) Acoustic reflectometry for airway measurement. 
Principles, limitations and previous work. Clin Phys Physiol Meas. 12(2), 131-141.  
 
Martin, S.E., Mathur, R., Marshall, I. & Douglas, N.J. (1997) The effect of age, sex, obesity and 
posture on upper airway size. Eur Respir J, 10(9), 2087-2090. 
 
May, K.R. (1973) The Collison nebulizer: Description, performance and application. Aerosol 
Science. 4, 235-243.  
 
McRobbie, D.W. & Pritchard, S. (2005) Studies of the human oropharyngeal airspaces using 
magnetic resonance imaging. III. The effects of device resistance with forced maneuver and tidal 
breathing on upper airway geometry. J Aerosol Med. 18(3), 325-336. 
 
Mehta, A., Qian, J., Petocz, P., Darendeliler, M.A. & Cistulli, P.A. (2001) A randomized, 
controlled study of a mandibular advancement splint for obstructive sleep apnea. Am J Respir Crit 
Care Med. 163(6), 1457-1461.  
 
Meier, R., Hall, G.L., Sennhauser, F.H. & Wildhaber, J.H. (2001) Wearing a noseclip improves 
nebulised aerosol delivery. Swiss Med Wkly. 131(33-34), 495-497. 
 
Merkus, P.J.F.M. (1993) Growth of lungs and airways in asthma. Den Haag, The Netherlands.  
 
Meurice, J.P., Marc, I., Carrier, G. & Sériès, F. (1996) Effects of mouth opening on upper airway 
collapsibility in normal sleeping subjects. Am J Respir Crit Care Med. 153(1), 255-259. 
 
Moeller, A.A.M. (1882) Thérapeutique Locale des Maladies de l’Appareil Respiratoire par les 
Inhalations Médicamenteuses et les Pratique Aérothérapiques. Librairie J.-B. Baillière et Fils, 
Paris. 
 
Molfino, N., Zamel, N., Hoffstein, V. & Fredberg, J.J. (1990) Artifacts in measuring airway areas 
by acoustic reflections. Am Rev Respir Dis. 142(6 Pt 1), 1465-1466.  
 
Monahan, K., Kirchner, H.L. & Redline, S. (2005) Oropharyngeal dimensions in adults: effect of 
ethnicity, gender, and sleep apnea. J Clin Sleep Med. 1(3), 257-263. 
 
Mostafiz, W., Dalci, O., Sutherland, K., Malhotra, A., Srinivasan, V., Darendeliler, M.A. & 
Cistulli, P.A. (2011) Influence of oral and craniofacial dimensions on mandibular advancement 
splint treatment outcome in patients with obstructive sleep apnea. Chest. 139(6), 1331-1339. 
 
 306 
  
 
Newman, S. with contributions from Anderson, P., Byron, P., Dalby, R. & Peart, J. (2009) 
Respiratory drug delivery: Essential theory and practice. Respiratory Drug Delivery Online. 
Richmond, VA, USA. 
 
Newman, S.P., Pitcairn, G.R., Hooper, G. & Knoch, M. (1994) Efficient drug delivery to the lungs 
from a continuously operated open-vent nebulizer and low pressure compressor system. Eur 
Respir J. 7(6), 1177-1181. 
 
Newman, S.P., Woodman, G. & Clarke, S.W. (1988) Deposition of carbenicillin aerosols in cystic 
fibrosis: effects of nebulizer system and breathing patterns. Thorax. 43(4), 318-322. 
 
Ng, A.T., Gotsopoulos, H., Qian, J. & Cistulli, P.A. (2003) Effect of oral appliance therapy on 
upper airway collapsibility in obstructive sleep apnea. Am J Respir Crit Care Med. 168(2), 238–
241.  
 
Nilsestuen, J., Fink, J.B., Stoller, J.K., Volpe, J. & Witek, T. Jr. (1994) Delivery of aerosols to the 
upper airway. AARC Clinical Practice Guidelines. Respir Care. 39(8), 803-807. 
 
Nikander, K. (1997) Adaptive aerosol delivery: the principles. Eur Respir Rev. 7: 51, 385–387.  
 
Nikander, K. (1994) Drug delivery systems. J Aerosol Med. 7 (Suppl 1), S19-24.   
Nikander, K., Agertoft, L. & Pedersen S. (2000a) Breath-synchronized nebulization diminishes 
the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized 
budesonide. J Asthma. 37(5), 451-459. 
 Nikander, K. & Bisgaard, H. (1999a) Impact of constant and breath-synchronized nebulization on 
inhaled mass of nebulized budesonide in infants and children. Pediatr Pulmonol. 28(3), 187-193. 
Nikander, K. & Denyer, J. (2000b) Breathing patterns. Eur Respir Rev. 10:76, 576–579.  
Nikander, K. & Denyer, J. (2008) Adaptive Aerosol Delivery (AAD) technology. In: Modified 
Release Drug Delivery Technology, Rathbone, M.J., editor. 2nd edition. Informa Healthcare USA, 
Inc., New York, NY, pp. 603–612.  
Nikander, K., Denyer, J., Dodd, M., Dyche, T., Webb, K., Weller, P. & Stableforth, D. (2010a) 
The Adaptive Aerosol Delivery system in a telehealth setting: patient acceptance, performance and 
feasibility. J Aerosol Med Pulm Drug Deliv. 23 (Suppl 1), S21–S27.  
Nikander, K., Petherbridge, I., Scarberry, E., Von Hollen, D., Viviano, J. & Chrystyn, H. (2010b) 
Mandibular advancement achieved through a stepped mouthpiece design can change the size of 
the upper airways. In: Respiratory drug delivery. Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., 
Farr, S.J. & Young, P.M., editors. Davis Healthcare Int. Publishing LLC, River Grove, IL, pp. 
747-751 
 307 
  
 
Nikander, K., Prince, I., Coughlin, S., Warren, S. & Taylor, G. (2010c) Mode of breathing - tidal 
or slow and deep - through the I-neb Adaptive Aerosol Delivery (AAD) System affects lung 
deposition of  99mTc-DTPA. J Aerosol Med Pulm Drug Deliv. 23 (Suppl 1), S37–S44.  
Nikander, K., Turpeinen, M. & Wollmer, P. (1999b) The conventional ultrasonic nebulizer proved 
inefficient in nebulizing a suspension. J Aerosol Med. 12(2), 47-53.  
Nikander, K., Turpeinen, M. & Wollmer, P. (2000c) Evaluation of pulsed and breath-synchronized 
nebulization of budesonide as a means of reducing nebulizer wastage of drug. Pediatr Pulmonol. 
29(2), 120-126.  
Nikolopoulou, M., Naeije, M., Aarab, G., Hamburger, H.L., Visscher, C.M. & Lobbezoo, F. 
(2011) The effect of raising the bite without mandibular protrusion on obstructive sleep apnoea. J 
Oral Rehabil. 38(9), 643-647. 
O'Callaghan, C. & Barry, P.W. (1997) The science of nebulised drug delivery. Thorax. 52 Suppl 
2, S31-44.  
Oliver, A., VanBuren, S., Allen, A., Hamilton, M., Tombs, L., Kempsford, R. & Qaqundah, P. 
(2014) Safety, tolerability, pharmacokinetics, and pharmacodynamics of vilanterol, a novel 
inhaled long-acting β-agonist, in children aged 5-11 years with persistent asthma: a randomized 
trial. Clin Pharmacol Drug Dev. 3(3), 215-221. 
Olschewski, H., Rohde, B., Behr, J., Ewert, R., Gessler, T., Ghofrani, H.A. & Schmehl, T. (2003) 
Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different 
devices, in severe pulmonary hypertension. Chest. 124(4), 1294-1304.  
Patel, S.R., Frame, J.M., Larkin, E.K. & Redline, S. (2008) Heritability of upper airway 
dimensions derived using acoustic pharyngometry. Eur Respir J. 32(5), 1304-1308. 
Persaud, N. (2010) APNEIC: an easy-to-use screening tool for obstructive sleep apnea. Can Fam 
Physician. 56(9), 904-905. 
Petri, N., Svanholt, P., Solow, B., Wildschiødtz, G. & Winkel, P. (2008) Mandibular advancement 
appliance for obstructive sleep apnoea: results of a randomized placebo controlled trial using 
parallel group design. J Sleep Res. 17(2), 221-229.  
Pitsis, A.J., Darendeliler, M.A., Gotsopoulos, H., Petocz, P. & Cistulli, P.A. (2002) Effect of 
vertical dimension on efficacy of oral appliance therapy in obstructive sleep apnea. Am J Respir 
Crit Care Med. 166(6), 860-864.  
Pritchard, S.E. & McRobbie, D.W. (2004) Studies of the human oropharyngeal airspaces using 
magnetic resonance imaging. II. The use of three-dimensional gated MRI to determine the 
influence of mouthpiece diameter and resistance of inhalation devices on the oropharyngeal 
airspace geometry. J Aerosol Med. 17(4), 310-324. 
 308 
  
 
Proctor, D.F. (1983) The naso-oro-pharyngo-laryngeal airway. Eur J Respir Dis Suppl. 128(Pt 1), 
89-96. 
Randerath, W.J., Verbraecken, J., Andreas, S., Bettega, G., Boudewyns, A., Hamans, E., Jalbert, 
F., Paoli, J.R., Sanner, B., Smith, I., Stuck, B.A., Lacassagne, L., Marklund, M., Maurer, J.T., 
Pepin, J.L., Valipour, A., Verse, T. & Fietze, I. (2011) Non-CPAP therapies on obstructive sleep 
apnoea. ERS Task Force Report. Eur Respir J. 37(5), 1000-1028.  
Raphael, D.T., Benbassat, M., Arnaudov, D., Bohorquez, A. & Nasseri, B. (2002) Validation study 
of two-microphone acoustic reflectometry for determination of breathing tube placement in 200 
adult patients. Anesthesiology. 97(6), 1371-1377. 
Respiratory System Upper Tracts available at: 
https://se.images.search.yahoo.com/images/view;_ylt=Az_6xdnCZLZVNAMAI2IVOAx.;_ylu=
X3oDMTIzbnNkMmg5BHNlYwNzcgRzbGsDaW1nBG9pZAMxNjMwMmNiZjY2ZjdmZDJh
NmYwZmM5MGVmMDU2OTYzOARncG9zAzIwBGl0A2Jpbmc-
?.origin=&back=https%3A%2F%2Fse.images.search.yahoo.com%2Fsearch%2Fimages%3Fp%3
DThe%2BAnatomy%2Bof%2Bthe%2BRespiratory%2BTract%26fr%3Dyset_ff_syc_oracle%26
tab%3Dorganic%26ri%3D20&w=401&h=538&imgurl=emptynosesyndrome.org%2Fwp-
content%2Fuploads%2F2013%2F02%2FRespiratory-
11.gif&rurl=http%3A%2F%2Fwww.emptynosesyndrome.org%2Frespiratory-
system%2Frespiratory-system-upper-
tracts%2F&size=52.7KB&name=%3Cb%3ERespiratory%3C%2Fb%3E+System+Upper+Tracts
&p=The+Anatomy+of+the+Respiratory+Tract&oid=16302cbf66f7fd2a6f0fc90ef0569638&fr2=
&fr=yset_ff_syc_oracle&tt=%3Cb%3ERespiratory%3C%2Fb%3E+System+Upper+Tracts&b=0
&ni=21&no=20&ts=&tab=organic&sigr=12kmib5rs&sigb=13vfckr4f&sigi=1231t02vn&sigt=11
69eqq4q&sign=1169eqq4q&.crumb=XCo6xe9BmwF&fr=yset_ff_syc_oracle. 
Rubinstein, I., McClean, P.A., Boucher, R., Zamel, N., Fredberg, J.J. & Hoffstein, V. (1987) Effect 
of mouthpiece, noseclips, and head position on airway area measured by acoustic reflections. J 
Appl Physiol. 63(4), 1469-1474.  
Ryan, C.F. & Love, L.L. (1996) Mechanical properties of the velopharynx in obese patients with 
obstructive sleep apnea. Am J Respir Crit Care Med. 154(3), 806-812. 
Ryan, C.F., Love, L.L., Peat, D., Fleetham, J.A. & Lowe, A.A. (1999) Mandibular advancement 
oral appliance therapy for obstructive sleep apnoea: effect on awake calibre of the velopharynx. 
Thorax. 54(11), 972–977.  
Sahin-Yilmaz, A. & Naclerio, R.M. (2011) Anatomy and physiology of the upper airway. Proc 
Am Thorac Soc. 8(1), 31-39.  
Sam, K., Lam, B., Ooi, C.G., Cooke, M. & Ip, M.S. (2006) Effect of a non-adjustable oral 
appliance on upper airway morphology in obstructive sleep apnea. Respir Med. 100(5), 897-902. 
Samsoon, G.L. & Young, J.R. (1987) Difficult tracheal intubation: a retrospective study. 
Anaesthesia. 42(5), 487-490.  
 309 
  
 
Sari, E. & Menillo, S. (2011) Comparison of titratable oral appliance and mandibular advancement 
splint in the treatment of patients with obstructive sleep apnea. ISRN Dent. 2011, 581692. 
Scheinherr, A., Bailly, L., Boiron, O., Lagier, A., Legou, T., Pichelin, M., Caillibotte, G. & 
Giovanni, A. (2015) Realistic glottal mortion and airflow rate during human breathing. Med Eng 
Physic. Epub ahead of print.  
Scheuch, G., Bennett, W., Borgström, L., Clark, A., Dalby, R., Dolovich, M., Eng, P., Fleming, J., 
Gehr, P., Gonda, I., O´Callaghan, C., Taylor, G. & Newman, S. (2010) Deposition, imaging, and 
clearance: what remains to be done? J Aerosol Med Pulm Drug Deliv. 23(Suppl 2), S39-S57. 
Schwab, R.J. (1998) Upper airway imaging. Clin Chest Med. 19(1) 33-54.  
Schwab, R.J., Gefter, W.B., Hoffman, E.A., Gupta, K.B. & Pack, A.I. (1993a) Dynamic upper 
airway imaging during awake respiration in normal subjects and patients with sleep disordered 
breathing. Am Rev Respir Dis. 148(5), 1385-1400.  
 
Schwab, R.J., Gefter, W.B., Pack, A.I. & Hoffman E.A. (1993b) Dynamic imaging of the upper 
airway during respiration in normal subjects. J Appl Physiol. 74(4), 1504-1514.  
 
Schwab, R.J., Gupta, K.B., Gefter, W.B., Metzger, L.J., Hoffman, E.A. & Pack, A.I. (1995) Upper 
airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. 
Significance of the lateral pharyngeal walls. Am J Respir Crit Care Med. 152(5), 1673-1689.  
 
Schwab, R.J., Pack, A.I., Gupta, K.B., Metzger, L.J., Oh, E., Getsy, J.E., Hoffman, E.A. & Gefter, 
W.B. (1996) Upper airway and soft tissue structural changes induced by CPAP in normal subjects. 
Am J Respir Crit Care Med. 154(4), 1106-1116.  
 
Shepard, J.W. Jr., Garrison, M. & Vas, W. (1990) Upper airway distensibility and collapsibility in 
patients with obstructive sleep apnea. Chest. 98(1), 84-91. 
 
Shiota, S., Ryan, C.M., Chiu, K.L., Ruttanaumpawan, P., Haight, J., Arzt, M., Floras, J.S., Chan, 
C. & Bradley, T.D. (2007) Alterations in upper airway cross-sectional area in response to lower 
body positive pressure in healthy subjects. Thorax. 62(10), 868-872.  
 
Simonds, A.K., Newman, S.P., Johnson, M.A., Talaee, N., Lee, C.A. & Clarke, S.W. (1990) 
Alveolar targeting of aerosol pentamidine. Toward a rational delivery system. Am Rev Respir Dis. 
141(4 Pt 1), 827-829. 
 
Sondhi, M.M. & Gopinath, B. (1971) Determination of vocal-tract shape from impulse response 
at the lips. J Acoust Soc Am. 49(6), 1867-1873. 
 
Straus, C., Louis, B., Isabey, D., Lemaire, F., Harf, A. & Brochard, L. (1998) Contribution of the 
endotracheal tube and the upper airway to breathing workload. Am J Respir Crit Care Med. 157(1), 
23-30. 
 
 310 
  
 
Strohl, K.P., Butler, J.P. & Malhotra, A. (2012) Mechanical properties of the upper airway. Compr 
Physiol. 2(3), 1853-1872.  
 
Suratt, P.M., Dee, P., Atkinson, R.L., Armstrong, P. & Wilhoit, S.C. (1983) Fluoroscopic and 
computed tomographic features of the pharyngeal airway in obstructive sleep apnea. Am Rev 
Respir Dis. 127(4), 487-492.  
 
Sutherland, K., Deane, S.A., Chan, A.S.L., Schwab, R.J., Ng, A.T., Darendeliler, M.A. & Cistulli, 
P.A. (2011) Comparative effects of two oral appliances on upper airway structure in obstructive 
sleep apnea. Sleep. 34(4), 469-477.  
 
Sutherland, K., Vanderveken, O.M., Tsuda, H., Marklund, M., Gagnadoux, F., Kushida, C.A. & 
Cistulli, P.A. (2014) Oral appliance treatment for obstructive sleep apnea: An update. J Clin Sleep 
Med. 10(2), 215-227.  
 
Svartengren, K., Anderson, M., Svartengren, M., Philipson, K. & Camner, P. (1996) 
Oropharyngeal deposition of 3.5 μm particles inhaled through an elongated mouthpiece. Eur 
Respir J. 9(7), 1556-1559. 
 
Svartengren, K., Lindestad, P.Å., Svartengren, M., Bylin, G., Philipson, K. & Camner, P. (1994) 
Deposition of inhaled particles in the mouth and throat of asthmatic subjects. Eur Respir J. 7(8), 
1467-1473. 
 
Swift, D.L. (1991) Inspiratory inertial deposition of aerosols in human nasal airway replicate casts: 
implication for the proposed NCRP lung model. Rad Prot Dosim, 38, 29-34. 
 
Swift, D.L., Cheng, Y.S., Su, Y.F. & Yeh, H.C. (1994) Ultrafine aerosol deposition in the human 
nasal and oral passages. Ann Occup Hyg. 38(1), 77-81. 
 
Tissier, P.L. (1903) Pneumotherapy including aerotherapy and inhalation methods and therapy. 
Volume X. In: A system of physiologic therapeutics. Cohen, S.S., editor. P. Blakiston’s son & Co, 
Philadelphia, USA.  
 
Tsai, W.H., Remmers, J.E., Brant, R., Flemons, W.W., Davies, J. & Macarthur, C. (2003) A 
decision rule for diagnostic testing in obstructive sleep apnea. Am J Respir Crit Care Med. 167(10), 
1427-1432.  
 
Tsuiki, S., Lowe, A.A., Almeida, F.R., Kawahata, N. & Fleetham, J.A. (2004) Effects of 
mandibular advancement on airway curvature and obstructive sleep apnoea severity. Eur Respir 
J. 23(2), 263-268. 
 
Tung, A. (2007) Upper airway anatomy. In: Obstructive sleep apnea: Pathophysiology, 
comorbidities and consequences. Kushida, C.A., editor. Stanford University, Stanford, CA, pp. 
81-92.  
 
Vanderveken, O.M. & Hoekema, A. (2010) How to treat patients that do not tolerate continuous 
positive airway pressure. Breathe. 7(2), 157-167.  
 311 
  
 
 
Van Holsbeke, C.S., Verhulst, S.L., Vos, W.G., De Backer, J.W., Vinchurkar, S.C., Verdonck, 
P.R., van Doorn, J.W., Nadjmi, N. & De Backer, W.A. (2014a) Change in upper airway geometry 
between upright and supine position during tidal nasal breathing. J Aerosol Med Pulm Drug Deliv. 
27(1), 51-57.  
 
Van Holsbeke, C., Vos, W., Hamilton, M., Claes, R., Prime, D., Vanhevel, F., De Backer, J., 
Nadjmi, N., Parizel, P. & De Backer, W. (2014b) Assessment of the effect of mouthpiece design 
on upper airway geometry using functional respiratory imaging. Eur Respir J. 44 (Suppl 58). 
 
Van Surell, C., Louis, B., Lofaso, F., Beydon, L., Brochard, L., Harf, A., Fredberg, J. & Isabey, 
D. (1994) Acoustic method to estimate the longitudinal area profile of endotracheal tubes. Am J 
Respir Crit Care Med. 149(1), 28-33. 
 
van Velzen, A.J., Uges, J.W.F., Le Brun, P.P.H., Shahbabai, P., Touw, D.J. & Heijerman, H.G.M. 
(2015) The influence of breathing mode on tobramycin serum levels using the I-neb AAD system 
in adults with cystic fibrosis. J Cyst Fibros. 14(6), 748-754.  
 
Viviano, J.S. (2002a) Acoustic reflection: Review and clinical applications for sleep-disordered 
breathing. Sleep Breath. 6(3), 129-149. 
 
Viviano, J.S. (2002b) Normalizing the pathological airway. Sleep Review. 3(1), 1-4. 
 
Viviano, J.S. (2004) Assessing orthotic normalization of pharyngeal dynamics. Cranio. 22(3), 
192-208. 
 
Vroegop, A.V., Vanderveken, O.M., Van de Heyning, P.H. & Braem, M.J. (2012) Effects of 
vertical opening on pharyngeal dimensions in patients with obstructive sleep apnoea. Sleep Med. 
13(3), 314-316. 
 
Waldenburg, L. (1864) Die Inhalationen der zerstäubten Flüssigkeiten sowie der Dämpfe und Gase 
in ihrer Wirkung auf die Krankenheiten der Athmungsorgane. Druck und Verlag von Georg 
Reimer, Berlin. 
 
Walker-Engström, M.L., Ringqvist, I., Vestling, O., Wilhelmsson, B. & Tegelberg, Å. (2003) A 
prospective randomized study comparing two different degrees of mandibular advancement with 
dental appliance in treatment of severe obstructive sleep apnea. Sleep Breath. 7(3), 119-130. 
 
Walker-Engström, M.L., Tegelberg, Å., Wilhelmsson, B. & Ringqvist, I. (2002) 4-year follow-up 
of treatment with dental appliance or uvulopalatopharyngoplasty in patients with obstructive sleep 
apnea. Chest. 121(3), 739-746. 
 
Walsh, J.H., Leigh, M.S., Paduch, A., Maddison, K.J., Armstrong, J.J., Sampson, D.D., Hillman, 
D.R. & Eastwood, P.R. (2008) Effect of body posture on pharyngeal shape and size in adults with 
and without obstructive sleep apnea. Sleep. 31(11), 1543-1549.  
 
 312 
  
 
Wee, A.G. (2012) Oral appliances in snoring and sleep apnea syndrome. In: Therapy in sleep 
medicine. Barkoukis, T.J., Matheson, J.K., Ferber, R. & Doghramji, K., editors. Elsevier Science, 
Chapter 18, pp. 230-242.  
 
Weiss, T.M., Atanasov, S. & Calhoun, K.H. (2005) The association of tongue scalloping with 
obstructive sleep apnea and related sleep pathology. Otolaryngol Head Neck Surg. 133(6), 966-
971.  
Weitzenblum, E., Chaouat, A., Kessler, R. & Canuet, M. (2008) Obstructive sleep apnea in patients 
with chronic obstructive pulmonary disease. Proc Am Thorac Soc. 5(2), 237-241. 
 
Zainudin, B.M., Tolfree, S.E., Short, M. & Spiro, S.G. (1988) Influence of breathing pattern on 
lung deposition and bronchodilator response to nebulised salbutamol in patients with stable 
asthma. Thorax. 43(12), 987-991. 
 
Zanen, P. (2003) Targetting aerosols to disease areas. In: Optimizing of aerosol drug delivery. 
Gradon., L & Marijnissen, J., editors. Kluwer Academic Publishers, Dortrecht, The Netherlands, 
pp. 234-276. 
 
Zhao, X., Liu, Y. & Gao, Y. (2008) Three-dimensional upper-airway changes associated with 
various amounts of mandibular advancement in awake apnea patients. Am J Orthod Dentofacial 
Orthop. 133(5), 661-668. 
 




1 
 
Appendix A-2 
Chapter 3, Individual pharyngograms  
The individual mean pharyngograms have been plotted for each of the 9 subjects (Figures 3.1 to 
3.9). Each plot covers 7 mean pharyngograms with legend “Measurement”: A, B, C, D20, D30, 
E20, E30 for the pharyngometry measurements without a nose clip, and 7 mean pharyngograms 
with legend “Measurement”: ANC, BNC, CNC, D20NC, D30NC, E20NC, E30NC for the 
pharyngometry measurements with a nose clip. In the plots the y-axis presents the cross-sectional 
area (CSA; in cm2) of the upper airway and the x-axis presents the length of the upper airway from 
the end of the pharyngometer wavetube (0) to the glottis (in cm). The position of the glottis is 
obviously different for different subjects and therefore not fixed at a certain point, for example 20 
cm. 
 
 
Figure 3.1: Subject 3, mean pharyngograms by measurement (measurements A to E without and 
with nose clip). 
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Figure 3.2: Subject 4, mean pharyngograms by measurement (measurements A to E without and 
with nose clip). 
. 
 
Figure 3.3: Subject 5, mean pharyngograms by measurement (measurements A to E without and 
with nose clip). 
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Figure 3.4: Subject 6, mean pharyngograms by measurement (measurements A to E without and 
with nose clip). 
 
 
Figure 3.5: Subject 8, mean pharyngograms by measurement (measurements A to E without and 
with nose clip). 
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Figure 3.6: Subject 9, mean pharyngograms by measurement (measurements A to E without and 
with nose clip). 
 
 
 
Figure 3.7: Subject 10, mean pharyngograms by measurement (measurements A to E without 
and with nose clip). 
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Figure 3.8: Subject 11, mean pharyngograms by measurement (measurements A to E without 
and with nose clip). 
 
 
 
Figure 3.9: Subject 12, mean pharyngograms by measurement (measurements A to E without 
and with nose clip). 
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APPENDIX B-1 
 
Chapter 4, Individual pharyngograms  
 
The individual mean pharyngograms have been plotted for each of the 4 subjects (Figures 4.1 to 
4.8). The plots in each figure cover 12 pharyngograms with separate legends for small (S = 10 mm 
orifice; -3 mm S, 0 mm S, 3 mm S, 6 mm S), medium (M = 15 mm orifice; -3 mm M, 0 mm M, 3 
mm M, 6 mm M) and large (L = 20 mm orifice; -3 mm L, 0 mm L, 3 mm L, 6 mm L) stepped 
mouthpieces. In the plots the y-axis presents the cross-sectional area (CSA; in cm2) of the upper 
airway and the x-axis presents the length of the upper airway from the end of the pharyngometer 
wavetube (0) to the glottis (in cm). 
 
 
Figure 4.1: The pharyngograms measured during exhalation have been plotted for subject A for 
each of the stepped mouthpieces. Each pharyngogram represents the means of two recordings.  
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Figure 4.2: The pharyngograms measured during inhalation have been plotted for subject A for 
each of the stepped mouthpieces. Each pharyngogram represents the means of two recordings.  
 
 
 
 
 
 
Figure 4.3: The pharyngograms measured during exhalation have been plotted for subject B for 
each of the stepped mouthpieces. Each pharyngogram represents the means of two recordings.  
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Figure 4.4: The pharyngograms measured during inhalation have been plotted for subject B for 
each of the stepped mouthpieces. Each pharyngogram represents the means of two recordings.  
 
 
 
 
 
 
Figure 4.5: The pharyngograms measured during exhalation have been plotted for subject C for 
each of the stepped mouthpieces. Each pharyngogram represents the means of two recordings.  
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Figure 4.6: The pharyngograms measured during inhalation have been plotted for subject C for 
each of the stepped mouthpieces. Each pharyngogram represents the means of two recordings.  
 
 
 
 
Figure 4.7: The pharyngograms measured during exhalation have been plotted for subject D for 
each of the stepped mouthpieces. Each pharyngogram represents the means of two recordings.  
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Figure 4.8: The pharyngograms measured during inhalation have been plotted for subject D for 
each of the stepped mouthpieces. Each pharyngogram represents the means of two recordings.  
 
 











APPENDIX C-2 
5.7.2. Landmarks 
For each subject the position of the oropharyngeal junction (OPJ), the epiglottis (EPI) and the 
glottis (GLO) was determined by the Investigator. This was performed before saving the four 
baseline measurements performed while the subjects exhaled on the hard disk of the acoustic 
pharyngometer. In Table 5.11 the individual landmarks for OPJ, EPI and GLO for all 60 subjects 
are presented as distance from the teeth. 
Table 5.11: Individual landmarks given as centimeters from the teeth for the 60 subjects. 
 
Subject # OPJ EPI GLO 
1 8.88 12.31 20.88 
2 8.88 12.31 20.88 
3 7.16 11.88 20.45 
4 9.31 12.74 18.74 
5 6.73 10.16 20.45 
6 6.30 9.31 19.60 
7 9.31 12.74 20.02 
8 9.31 12.31 20.02 
9 9.31 12.31 19.17 
10 9.31 13.16 20.45 
11 9.31 12.74 20.45 
12 9.31 13.16 21.74 
13 6.30 9.31 20.02 
14 8.88 12.74 20.88 
15 7.16 9.73 20.02 
16 8.45 12.31 21.31 
17 8.45 12.31 20.45 
18 8.88 12.74 23.02 
19 6.30 9.31 20.45 
20 9.31 12.74 20.45 
21 6.73 11.02 22.60 
22 8.45 12.31 20.88 
23 9.31 13.16 20.45 
24 9.31 13.59 23.45 
25 8.45 13.59 23.45 
26 9.31 12.74 22.60 
27 6.73 9.73 19.60 
28 8.88 13.16 19.17 
29 8.45 13.16 19.60 
30 8.88 12.31 18.74 
31 9.31 12.74 19.17 
32 9.31 13.59 23.02 
33 8.45 12.31 19.17 
34 8.88 12.74 22.17 
35 6.30 10.16 21.74 
36 8.88 12.74 20.45 
37 8.88 12.74 22.60 
38 7.16 12.31 19.60 
39 8.02 12.31 23.02 
40 8.88 12.31 20.88 
41 8.88 12.31 19.17 
42 9.31 13.16 20.02 
43 9.31 12.74 19.17 
44 8.02 12.74 20.02 
45 8.88 12.74 22.17 
46 6.30 10.16 20.02 
47 8.02 12.31 20.45 
48 8.45 12.74 22.60 
49 8.88 11.88 19.17 
50 8.88 12.74 22.60 
51 8.88 11.88 19.60 
52 8.88 12.31 20.88 
53 8.88 12.31 20.02 
54 8.45 12.74 19.60 
55 8.45 12.31 22.17 
56 8.88 12.74 22.60 
57 9.31 12.74 22.60 
58 8.88 12.74 20.02 
59 8.88 12.74 19.60 
60 8.88 12.31 19.17 
    
Mean 8.48 12.22 20.72 
SD 0.95 1.08 1.34 
Minimum 6.30 9.31 18.74 
Maximum 9.31 13.59 23.45 
Median 8.88 12.53 20.45 
RSD 11.20 8.85 6.45 
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5.7.3. Individual acoustic pharyngograms 
The individual acoustic pharyngograms are coded in each figure as outlined in Table 5.2 (from 
5.6.1. Data files).  
Table 5.2: Data files recorded in the study acoustic pharyngometer. 
Data files 
 
Explanations 
BFL0 BFL, in which B = Baseline, FRC = Functional Residual Capacity and L = 
Landmarks. Each BFL file contained four acoustic readings as follows:  
 1 – Functional Residual Capacity  
 2 -  Functional Residual Capacity  
 3 - Nasal breathing 
 4 - Coaching for glottal closure 
In the figures the following short forms were used: BFL = two measurements from 
FRC, BFL3 = one measurement during nasal breathing, and BFL4 = one 
measurement during glottal closure. 
BMI0 BMI, in which B = Baseline, M = Mid tidal inhalation and I = Inhalation. 
SMI0 SMI0, in which S = Stepped mouthpiece, M = Measurement at mid tidal 
inhalation, I = Inhalation and 0 = no advancement with stepped mouthpiece 
(baseline). 
SMI1 SMI1, as above with 1 = 1 mm advancement with stepped mouthpiece. 
SMI2 SMI2, as above with 2 = 2 mm advancement with stepped mouthpiece. 
SMI3 SMI3, as above with 3 = 3 mm advancement with stepped mouthpiece. 
SMI4 SMI4, as above with 4 = 4 mm advancement with stepped mouthpiece. 
SMI5 SMI5, as above with 5 = 5 mm advancement with stepped mouthpiece. 
SSI0 SSI0, in which S = Stepped mouthpiece, S = Measurement during slow prolonged 
inhalation, I = Inhalation and 0 = 0 mm advancement with stepped mouthpiece 
(baseline). 
SSI1 SSI1, as above with 1 = 1 mm advancement with stepped mouthpiece.  
SSI2 SSI2, as above with 2 = 2 mm advancement with stepped mouthpiece. 
SSI3 SSI3, as above with 3 = 3 mm advancement with stepped mouthpiece. 
SSI4 SSI4, as above with 4 = 4 mm advancement with stepped mouthpiece. 
SSI5 SSI5, as above with 5 = 5 mm advancement with stepped mouthpiece. 
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